 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_2.0  of_%logit_0.0  ant_%logit_0.0 if_%logit_0.0 ibr_%logit_2.0 ino_%logit_2.0 ly_%logit_0.0 tic_%logit_0.0  agents_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_1.0  CV_%logit_2.0 AD_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_1.0  these_%logit_1.0  agents_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  them_%logit_1.0  to_%logit_2.0  each_%logit_2.0  other_%logit_2.0  in_%logit_2.0  terms_%logit_0.0  of_%logit_1.0  cat_%logit_0.0 heter_%logit_2.0  function_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  trials_%logit_2.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  these_%logit_2.0  drugs_%logit_2.0  in_%logit_0.0  reducing_%logit_0.0  CV_%logit_1.0 AD_%logit_2.0  function_%logit_0.0  and_%logit_2.0  the_%logit_2.0  risk_%logit_0.0  of_%logit_2.0  infection_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  risks_%logit_0.0  of_%logit_0.0  infection_%logit_1.0  and_%logit_0.0  infection_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  also_%logit_0.0  to_%logit_2.0  compare_%logit_2.0  these_%logit_0.0  drugs_%logit_1.0  with_%logit_1.0  each_%logit_1.0  other_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  and_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  antim_%logit_0.0 icro_%logit_1.0 b_%logit_1.0 ials_%logit_0.0  in_%logit_0.0  improving_%logit_1.0  CV_%logit_1.0 AD_%logit_1.0  functions_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  draw_%logit_0.0  conclusions_%logit_1.0  about_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  cognitive_%logit_2.0  behavioral_%logit_0.0  therapy_%logit_1.0  for_%logit_1.0  depression_%logit_1.0  in_%logit_1.0  the_%logit_1.0  primary_%logit_1.0  care_%logit_0.0  setting_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  cognitive_%logit_0.0  behavioural_%logit_1.0  therapy_%logit_0.0  in_%logit_0.0  depression_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_2.0  cognitive_%logit_1.0  behavioral_%logit_0.0  therapies_%logit_0.0  to_%logit_1.0  other_%logit_1.0  types_%logit_0.0  of_%logit_2.0  psychological_%logit_1.0  therapy_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_2.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  of_%logit_0.0  cognitive_%logit_2.0  behaviour_%logit_0.0  therapy_%logit_2.0  in_%logit_0.0  depressive_%logit_0.0  disorders_%logit_0.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_0.0  cognitive_%logit_0.0  behavior_%logit_2.0  therapy_%logit_2.0  to_%logit_0.0  other_%logit_0.0  forms_%logit_0.0  of_%logit_2.0  mental_%logit_2.0  health_%logit_0.0  care_%logit_1.0 ,_%logit_0.0  including_%logit_1.0  psychological_%logit_1.0  therapies_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  other_%logit_2.0  psychological_%logit_1.0  therapies_%logit_1.0 ._%logit_1.0
 Ant_%logit_0.0 ib_%logit_0.0 iotic_%logit_0.0  pro_%logit_0.0 ph_%logit_0.0 yl_%logit_0.0 axis_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_1.0  reducing_%logit_1.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_0.0  per_%logit_0.0 ist_%logit_2.0 omal_%logit_1.0  infections_%logit_0.0  and_%logit_1.0  reducing_%logit_2.0  the_%logit_0.0  risk_%logit_0.0  of_%logit_0.0  death_%logit_0.0  and_%logit_2.0  infection_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  P_%logit_1.0 EG_%logit_2.0 ._%logit_0.0  Ant_%logit_0.0 ib_%logit_2.0 iotics_%logit_2.0  do_%logit_2.0  not_%logit_2.0  appear_%logit_2.0  to_%logit_0.0  have_%logit_0.0  a_%logit_0.0  significant_%logit_1.0  effect_%logit_1.0  on_%logit_2.0  mortality_%logit_1.0  or_%logit_1.0  infection_%logit_2.0 -_%logit_1.0 related_%logit_2.0  morbid_%logit_0.0 ity_%logit_0.0  in_%logit_1.0  patients_%logit_2.0  undergoing_%logit_0.0  P_%logit_0.0 EG_%logit_1.0  insertion_%logit_2.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_2.0  further_%logit_0.0  research_%logit_1.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotics_%logit_1.0  in_%logit_1.0  treating_%logit_2.0  P_%logit_1.0 EG_%logit_0.0  infections_%logit_2.0  and_%logit_2.0  the_%logit_2.0  risks_%logit_0.0  of_%logit_0.0  bacterial_%logit_2.0  contamination_%logit_0.0  in_%logit_0.0  the_%logit_2.0  early_%logit_1.0  post_%logit_2.0 -_%logit_0.0 trans_%logit_1.0 plant_%logit_1.0  period_%logit_2.0 ._%logit_2.0
 Cognitive_%logit_0.0  memory_%logit_2.0  training_%logit_0.0  appears_%logit_0.0  to_%logit_0.0  be_%logit_1.0  a_%logit_0.0  useful_%logit_0.0  adjunct_%logit_2.0  to_%logit_0.0  cognitive_%logit_1.0  memory_%logit_1.0  training_%logit_1.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  depressive_%logit_0.0  symptoms_%logit_0.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_1.0  it_%logit_0.0  is_%logit_0.0  not_%logit_2.0  clear_%logit_0.0  whether_%logit_0.0  it_%logit_0.0  is_%logit_0.0  a_%logit_2.0  worthwhile_%logit_2.0  adjunct_%logit_1.0  to_%logit_2.0  other_%logit_0.0  cognitive_%logit_0.0  rehabilitation_%logit_0.0  programmes_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_1.0  cognitive_%logit_1.0  memory_%logit_1.0 training_%logit_2.0  on_%logit_0.0  depressive_%logit_0.0  symptoms_%logit_1.0  in_%logit_1.0  people_%logit_0.0  with_%logit_2.0  depression_%logit_0.0  and_%logit_0.0  cognitive_%logit_2.0  impairment_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  on_%logit_0.0  cognitive_%logit_0.0  function_%logit_2.0  and_%logit_2.0  memory_%logit_2.0  training_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  cognitive_%logit_0.0  memory_%logit_0.0  rehabilitation_%logit_0.0  with_%logit_2.0  other_%logit_2.0  psychological_%logit_1.0  therapies_%logit_0.0 ,_%logit_0.0  including_%logit_2.0  cognitive_%logit_1.0  behavioural_%logit_1.0  rehabilitation_%logit_0.0  programmes_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  cognitive_%logit_0.0  behavioural_%logit_0.0  therapy_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_1.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_0.0 ,_%logit_0.0  well_%logit_2.0 -_%logit_0.0 conduct_%logit_2.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_0.0 ised_%logit_2.0  controlled_%logit_1.0  trial_%logit_0.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  cognitive_%logit_1.0 -_%logit_0.0 memory_%logit_2.0  training_%logit_2.0  for_%logit_2.0  depression_%logit_0.0 ,_%logit_2.0  cognitive_%logit_0.0  impairment_%logit_0.0  and_%logit_1.0  memory_%logit_0.0  rehabilitation_%logit_0.0 ._%logit_2.0
 Sodium_%logit_0.0  restriction_%logit_0.0  is_%logit_1.0  associated_%logit_2.0  with_%logit_2.0  a_%logit_1.0  reduction_%logit_1.0  in_%logit_1.0  blood_%logit_1.0  pressure_%logit_1.0  and_%logit_0.0  blood_%logit_1.0  pressure_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_0.0  hypertension_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  no_%logit_2.0  evidence_%logit_1.0  of_%logit_1.0  a_%logit_1.0  significant_%logit_1.0  difference_%logit_0.0  in_%logit_0.0  mortality_%logit_2.0 ,_%logit_0.0  cardiovascular_%logit_2.0  morbid_%logit_1.0 ity_%logit_1.0  or_%logit_0.0  morbid_%logit_0.0 ity_%logit_0.0  between_%logit_0.0  sodium_%logit_1.0  restriction_%logit_1.0  and_%logit_0.0  sodium_%logit_0.0  restriction_%logit_2.0 ,_%logit_0.0  or_%logit_0.0  between_%logit_2.0  sodium_%logit_1.0  and_%logit_0.0  potassium_%logit_1.0  restriction_%logit_1.0 ._%logit_2.0  Sodium_%logit_0.0  restriction_%logit_0.0  does_%logit_2.0  not_%logit_1.0  appear_%logit_0.0  to_%logit_0.0  have_%logit_0.0  a_%logit_0.0  significant_%logit_2.0  impact_%logit_1.0  on_%logit_0.0  blood_%logit_1.0  pressure_%logit_2.0  or_%logit_1.0  blood_%logit_1.0  pressure_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  may_%logit_1.0  have_%logit_0.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_1.0  on_%logit_1.0  cardiovascular_%logit_2.0  risk_%logit_0.0  factors_%logit_2.0 ,_%logit_1.0  such_%logit_1.0  as_%logit_2.0  cardiovascular_%logit_0.0  disease_%logit_0.0  and_%logit_0.0  diabetes_%logit_0.0  mell_%logit_2.0 itus_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  on_%logit_1.0  mortality_%logit_0.0  and_%logit_0.0  morbid_%logit_1.0 ity_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_1.0  use_%logit_0.0  of_%logit_2.0  defer_%logit_1.0 ox_%logit_0.0 amine_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  iron_%logit_0.0  overload_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_0.0  iron_%logit_0.0  overload_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_1.0 ,_%logit_1.0  duration_%logit_1.0  and_%logit_0.0  timing_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_0.0  best_%logit_2.0  way_%logit_1.0  to_%logit_2.0  deliver_%logit_1.0  defer_%logit_1.0 ox_%logit_0.0 amines_%logit_2.0  to_%logit_1.0  iron_%logit_0.0  overload_%logit_0.0  patients_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effects_%logit_0.0  on_%logit_1.0  other_%logit_2.0  iron_%logit_2.0  overload_%logit_2.0  conditions_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  dosage_%logit_0.0 ,_%logit_1.0  timing_%logit_1.0  and_%logit_1.0  duration_%logit_2.0 ,_%logit_2.0  the_%logit_1.0  best_%logit_1.0  dose_%logit_1.0  and_%logit_2.0  duration_%logit_1.0  of_%logit_2.0  defer_%logit_1.0 oxide_%logit_1.0 amine_%logit_0.0  for_%logit_2.0  iron_%logit_2.0  overload_%logit_0.0  and_%logit_0.0  iron_%logit_0.0  overload_%logit_1.0  is_%logit_2.0  needed_%logit_2.0 ._%logit_1.0  The_%logit_2.0  results_%logit_0.0  of_%logit_2.0  this_%logit_0.0  review_%logit_0.0  should_%logit_0.0  be_%logit_1.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  the_%logit_0.0  conclusions_%logit_0.0  of_%logit_2.0  the_%logit_2.0  review_%logit_2.0  were_%logit_2.0  based_%logit_1.0  on_%logit_1.0  a_%logit_0.0  small_%logit_1.0  number_%logit_1.0  of_%logit_0.0  patients_%logit_2.0 ,_%logit_0.0  with_%logit_1.0  a_%logit_2.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_0.0  bias_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_0.0  of_%logit_0.0  prog_%logit_0.0 est_%logit_2.0 ogen_%logit_0.0  as_%logit_0.0  a_%logit_1.0  supplement_%logit_0.0  to_%logit_1.0  LH_%logit_2.0 H_%logit_0.0  in_%logit_1.0  IV_%logit_2.0 F_%logit_2.0  cycles_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  whether_%logit_2.0  prog_%logit_1.0 est_%logit_1.0 ogens_%logit_0.0  are_%logit_2.0  beneficial_%logit_2.0  or_%logit_1.0  harmful_%logit_2.0  for_%logit_0.0  LH_%logit_0.0 H_%logit_2.0  or_%logit_1.0  LH_%logit_2.0 H_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_2.0  effects_%logit_2.0  on_%logit_2.0  pregnancy_%logit_2.0  rate_%logit_1.0  and_%logit_1.0  reproduction_%logit_1.0  rates_%logit_2.0  in_%logit_2.0  LH_%logit_1.0 H_%logit_1.0  and_%logit_0.0  LH_%logit_2.0 H_%logit_1.0  cycles_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  long_%logit_1.0 -_%logit_1.0 term_%logit_1.0  data_%logit_0.0  are_%logit_1.0  required_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_2.0  gon_%logit_0.0 ad_%logit_2.0 ot_%logit_0.0 roph_%logit_0.0 ins_%logit_0.0  on_%logit_0.0  pregnancy_%logit_1.0  rates_%logit_1.0  and_%logit_0.0  fertility_%logit_0.0  rates_%logit_0.0  in_%logit_2.0  RH_%logit_0.0 H_%logit_1.0  cycles_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  also_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  LH_%logit_0.0 H_%logit_2.0  as_%logit_1.0  a_%logit_1.0  complement_%logit_0.0  to_%logit_2.0  LH_%logit_0.0 RH_%logit_0.0 ._%logit_2.0
 Weight_%logit_0.0  loss_%logit_0.0  is_%logit_0.0  associated_%logit_0.0  with_%logit_0.0  a_%logit_0.0  significant_%logit_1.0  increase_%logit_2.0  in_%logit_2.0  weight_%logit_1.0  gain_%logit_1.0 ._%logit_2.0  Weight_%logit_0.0  loss_%logit_0.0  appears_%logit_0.0  to_%logit_2.0  be_%logit_1.0  associated_%logit_0.0  with_%logit_0.0  an_%logit_0.0  increase_%logit_2.0  in_%logit_1.0  depressive_%logit_0.0  symptoms_%logit_1.0 ,_%logit_0.0  but_%logit_2.0  there_%logit_2.0  is_%logit_1.0  no_%logit_2.0  clear_%logit_2.0  evidence_%logit_2.0  of_%logit_2.0  an_%logit_2.0  effect_%logit_2.0  on_%logit_0.0  weight_%logit_2.0  loss_%logit_0.0  in_%logit_2.0  the_%logit_2.0  short_%logit_2.0 -_%logit_1.0 term_%logit_0.0  or_%logit_0.0  longer_%logit_1.0  term_%logit_2.0 ._%logit_0.0  Weight_%logit_0.0  gain_%logit_0.0  appears_%logit_0.0  to_%logit_1.0  have_%logit_1.0  a_%logit_0.0  beneficial_%logit_0.0  effect_%logit_2.0  on_%logit_1.0  depressive_%logit_0.0  symptoms_%logit_1.0  and_%logit_1.0  on_%logit_2.0  self_%logit_1.0 -_%logit_2.0 reported_%logit_1.0  depressive_%logit_1.0  symptoms_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_0.0  weight_%logit_2.0  loss_%logit_1.0  is_%logit_1.0  not_%logit_2.0  a_%logit_0.0  significant_%logit_1.0  issue_%logit_1.0  for_%logit_0.0  people_%logit_2.0  with_%logit_2.0  borderline_%logit_1.0  personality_%logit_0.0  disorder_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  there_%logit_2.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0  studies_%logit_2.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_0.0  weight_%logit_0.0  loss_%logit_1.0  on_%logit_0.0  depressive_%logit_2.0  disorders_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  b_%logit_1.0 ron_%logit_1.0 ch_%logit_1.0 od_%logit_0.0 il_%logit_0.0 ator_%logit_1.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_2.0  P_%logit_1.0 IE_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_0.0  therapy_%logit_0.0  in_%logit_0.0  P_%logit_0.0 IE_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  profile_%logit_2.0  of_%logit_1.0  these_%logit_0.0  drugs_%logit_0.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_1.0  their_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  effectiveness_%logit_0.0  in_%logit_1.0  the_%logit_0.0  clinical_%logit_1.0  context_%logit_0.0  of_%logit_2.0  the_%logit_2.0  P_%logit_0.0 IE_%logit_0.0  treatment_%logit_1.0  group_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  B_%logit_0.0 ron_%logit_1.0 ch_%logit_1.0 oder_%logit_0.0  for_%logit_0.0  P_%logit_2.0 IE_%logit_2.0  and_%logit_2.0  its_%logit_1.0  safety_%logit_2.0  profile_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_0.0  as_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  these_%logit_0.0  drugs_%logit_1.0  to_%logit_2.0  each_%logit_0.0  other_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  bone_%logit_0.0  sc_%logit_2.0 int_%logit_1.0 igraph_%logit_1.0 y_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  L_%logit_0.0 BP_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_0.0  area_%logit_1.0 ,_%logit_0.0  particularly_%logit_0.0  in_%logit_1.0  the_%logit_2.0  areas_%logit_1.0  of_%logit_2.0  oste_%logit_1.0 op_%logit_2.0 or_%logit_1.0 osis_%logit_0.0 ,_%logit_0.0  bone_%logit_1.0  mineral_%logit_0.0 ization_%logit_1.0  and_%logit_1.0  bone_%logit_1.0  mineral_%logit_0.0 isation_%logit_2.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  in_%logit_0.0  areas_%logit_2.0  of_%logit_0.0  bone_%logit_2.0  mineral_%logit_1.0  density_%logit_1.0  and_%logit_0.0  thickness_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  in_%logit_1.0  areas_%logit_2.0  with_%logit_0.0  a_%logit_0.0  history_%logit_2.0  of_%logit_2.0  erosion_%logit_0.0  and_%logit_0.0  erosion_%logit_2.0 ._%logit_1.0  The_%logit_2.0  results_%logit_2.0  of_%logit_2.0  these_%logit_1.0  studies_%logit_1.0  should_%logit_0.0  be_%logit_1.0  interpreted_%logit_0.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  they_%logit_0.0  are_%logit_1.0  based_%logit_1.0  on_%logit_0.0  only_%logit_0.0  a_%logit_0.0  small_%logit_2.0  number_%logit_2.0  of_%logit_1.0  patients_%logit_2.0  and_%logit_0.0  are_%logit_1.0  subject_%logit_1.0  to_%logit_1.0  a_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_1.0  bias_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  bone_%logit_1.0  scaff_%logit_1.0 olding_%logit_2.0  for_%logit_2.0  L_%logit_2.0 BP_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  durability_%logit_1.0  of_%logit_2.0  these_%logit_0.0  scaff_%logit_2.0 olding_%logit_2.0  devices_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  continuum_%logit_1.0  of_%logit_1.0  surviv_%logit_1.0 orship_%logit_1.0  after_%logit_2.0  lap_%logit_0.0 ar_%logit_2.0 otomy_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  randomized_%logit_1.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  continuum_%logit_1.0  resusc_%logit_0.0 itation_%logit_0.0 ,_%logit_2.0  the_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  survival_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_0.0  extent_%logit_0.0  to_%logit_2.0  which_%logit_2.0  it_%logit_2.0  is_%logit_0.0  possible_%logit_2.0  to_%logit_0.0  achieve_%logit_0.0  this_%logit_2.0 ._%logit_2.0  Such_%logit_0.0  trials_%logit_1.0  are_%logit_0.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  durability_%logit_2.0  of_%logit_1.0  continuum_%logit_0.0  survival_%logit_0.0 ._%logit_1.0  Such_%logit_0.0  tests_%logit_2.0  are_%logit_2.0  also_%logit_1.0  required_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_2.0  durability_%logit_2.0  of_%logit_1.0  the_%logit_1.0  continuum_%logit_1.0  of_%logit_1.0 Surv_%logit_0.0 ival_%logit_0.0 ._%logit_2.0  They_%logit_2.0  are_%logit_2.0  also_%logit_2.0  necessary_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  whether_%logit_0.0  continuum_%logit_0.0  resusc_%logit_2.0 itative_%logit_0.0  techniques_%logit_0.0  are_%logit_1.0  more_%logit_1.0  or_%logit_0.0  less_%logit_2.0  effective_%logit_1.0  than_%logit_0.0  continuous_%logit_0.0  resusc_%logit_1.0 itation_%logit_2.0  techniques_%logit_0.0 ,_%logit_1.0  or_%logit_1.0  if_%logit_2.0  they_%logit_2.0  are_%logit_1.0  less_%logit_1.0  effective_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  difference_%logit_1.0  in_%logit_1.0  pat_%logit_0.0 ency_%logit_1.0  and_%logit_2.0  limb_%logit_0.0  salvage_%logit_2.0  rates_%logit_2.0  between_%logit_0.0  the_%logit_0.0  two_%logit_2.0  methods_%logit_1.0  of_%logit_0.0  bypass_%logit_2.0  graft_%logit_1.0 ing_%logit_2.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_1.0  optimal_%logit_1.0  technique_%logit_0.0  and_%logit_1.0  timing_%logit_2.0  of_%logit_0.0  this_%logit_2.0  procedure_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  different_%logit_0.0  techniques_%logit_0.0  of_%logit_2.0  graft_%logit_2.0 ing_%logit_0.0  and_%logit_1.0  plate_%logit_1.0 let_%logit_2.0  transf_%logit_0.0 usion_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  different_%logit_0.0  types_%logit_1.0  of_%logit_1.0  graft_%logit_0.0 s_%logit_1.0  and_%logit_2.0  types_%logit_2.0  of_%logit_0.0  plate_%logit_2.0 let_%logit_1.0  inf_%logit_1.0 usion_%logit_0.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  different_%logit_1.0  methods_%logit_1.0  of_%logit_1.0  graft_%logit_2.0  clamp_%logit_1.0 ing_%logit_1.0 ,_%logit_0.0  a_%logit_0.0  meta_%logit_2.0 -_%logit_1.0 analysis_%logit_1.0  is_%logit_0.0  required_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_2.0  there_%logit_0.0  are_%logit_1.0  any_%logit_0.0  differences_%logit_1.0  in_%logit_2.0  mortality_%logit_2.0 ,_%logit_0.0  pat_%logit_1.0 ency_%logit_1.0  or_%logit_1.0  pat_%logit_0.0 ency_%logit_2.0  between_%logit_0.0  these_%logit_0.0  methods_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  n_%logit_0.0 if_%logit_0.0 ed_%logit_2.0 ip_%logit_2.0 ine_%logit_0.0  as_%logit_0.0  a_%logit_0.0  mon_%logit_1.0 otherapy_%logit_2.0  in_%logit_2.0  Kle_%logit_1.0 bs_%logit_2.0 ie_%logit_2.0 lla_%logit_2.0  pneumonia_%logit_0.0 ,_%logit_2.0  or_%logit_0.0  to_%logit_2.0  support_%logit_0.0  its_%logit_0.0  use_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adj_%logit_0.0 u_%logit_1.0 vant_%logit_1.0  to_%logit_1.0  other_%logit_0.0  mon_%logit_0.0 otherapy_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_2.0  needed_%logit_2.0  to_%logit_1.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  this_%logit_0.0  mon_%logit_0.0 otherapy_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  other_%logit_1.0  mon_%logit_1.0 other_%logit_1.0 ap_%logit_0.0 ies_%logit_0.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_1.0  oral_%logit_1.0  antibiotics_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_1.0  efficacy_%logit_2.0  and_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  these_%logit_1.0  mon_%logit_1.0 other_%logit_0.0 aps_%logit_0.0 ies_%logit_0.0  with_%logit_0.0  each_%logit_1.0  other_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_1.0 os_%logit_1.0 ocial_%logit_2.0  interventions_%logit_2.0  for_%logit_2.0  retention_%logit_0.0  of_%logit_0.0  opioid_%logit_0.0  withdrawal_%logit_0.0  symptoms_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_2.0  interventions_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_1.0  efficacy_%logit_2.0  and_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  these_%logit_0.0  approaches_%logit_0.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_2.0  withdrawal_%logit_2.0  symptoms_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  also_%logit_0.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_0.0  efficacy_%logit_0.0  of_%logit_2.0  psych_%logit_1.0 oses_%logit_0.0  for_%logit_1.0  retention_%logit_1.0  in_%logit_1.0  treatment_%logit_0.0 ._%logit_2.0  Recommend_%logit_2.0 ations_%logit_2.0  for_%logit_1.0  future_%logit_0.0  research_%logit_2.0  should_%logit_0.0  be_%logit_0.0  made_%logit_2.0  regarding_%logit_2.0  the_%logit_1.0  efficacy_%logit_2.0 ,_%logit_2.0  safety_%logit_1.0  and_%logit_2.0  efficacy_%logit_2.0  of_%logit_2.0  psychological_%logit_0.0  therapies_%logit_2.0  for_%logit_0.0  withdrawal_%logit_0.0  symptoms_%logit_0.0  of_%logit_2.0  opioids_%logit_2.0  withdrawal_%logit_0.0  symptoms_%logit_2.0  and_%logit_0.0  for_%logit_2.0  the_%logit_0.0  management_%logit_0.0  of_%logit_2.0  retention_%logit_0.0  in_%logit_1.0  therapy_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  negative_%logit_2.0  feedback_%logit_1.0  loop_%logit_2.0  in_%logit_0.0  the_%logit_0.0  downward_%logit_0.0  direction_%logit_1.0  of_%logit_1.0  growth_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_2.0  or_%logit_0.0  not_%logit_2.0  this_%logit_0.0  feedback_%logit_2.0  loop_%logit_2.0  has_%logit_0.0  a_%logit_0.0  negative_%logit_2.0  effect_%logit_2.0  on_%logit_2.0  growth_%logit_2.0  or_%logit_0.0  injury_%logit_1.0  rates_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  whether_%logit_1.0  it_%logit_1.0  has_%logit_1.0  a_%logit_0.0  positive_%logit_1.0  effect_%logit_1.0  on_%logit_1.0  health_%logit_0.0  or_%logit_0.0  wellbeing_%logit_0.0 ,_%logit_0.0  or_%logit_2.0  on_%logit_2.0  health_%logit_0.0 -_%logit_0.0 related_%logit_2.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  on_%logit_1.0  productivity_%logit_2.0 ,_%logit_0.0  productivity_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  quality_%logit_1.0 -_%logit_2.0 of_%logit_1.0 -_%logit_2.0 life_%logit_0.0 ._%logit_0.0  Future_%logit_0.0  research_%logit_1.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_1.0  measuring_%logit_1.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  feedback_%logit_2.0  loop_%logit_1.0  feedback_%logit_1.0  on_%logit_0.0  health_%logit_2.0  and_%logit_0.0  wellbeing_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  on_%logit_1.0  productivity_%logit_2.0  and_%logit_2.0  wellbeing_%logit_2.0 ._%logit_2.0  Research_%logit_2.0  is_%logit_2.0  also_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  effects_%logit_2.0  on_%logit_2.0  health_%logit_1.0 ,_%logit_2.0  wellbeing_%logit_0.0  and_%logit_1.0  social_%logit_1.0  functioning_%logit_2.0 ._%logit_2.0
 Functional_%logit_0.0  assessment_%logit_2.0  is_%logit_0.0  a_%logit_1.0  useful_%logit_2.0  tool_%logit_1.0  for_%logit_2.0  improving_%logit_1.0  functional_%logit_0.0  outcome_%logit_0.0  and_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_0.0  in_%logit_0.0  stroke_%logit_0.0  patients_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_1.0  evidence_%logit_1.0  is_%logit_1.0  low_%logit_0.0  and_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_2.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0  studies_%logit_1.0  to_%logit_1.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  functional_%logit_1.0  assessment_%logit_0.0  and_%logit_0.0  social_%logit_2.0  support_%logit_1.0  services_%logit_2.0  for_%logit_0.0  stroke_%logit_1.0  patients_%logit_0.0  and_%logit_2.0  their_%logit_0.0  caregivers_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  functional_%logit_1.0  assessment_%logit_1.0  with_%logit_0.0  other_%logit_1.0  types_%logit_2.0  of_%logit_0.0  assessment_%logit_1.0  and_%logit_0.0  assessment_%logit_1.0 ._%logit_0.0  Future_%logit_0.0  research_%logit_2.0  should_%logit_1.0  focus_%logit_1.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  reliability_%logit_2.0  of_%logit_1.0  functional_%logit_0.0  assessments_%logit_1.0  and_%logit_0.0  assessing_%logit_2.0  functional_%logit_1.0  assessment_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  also_%logit_0.0  on_%logit_2.0  assessing_%logit_1.0  functional_%logit_1.0  outcome_%logit_2.0  measures_%logit_2.0 ,_%logit_1.0  such_%logit_2.0  as_%logit_0.0  mobility_%logit_0.0  function_%logit_0.0 ,_%logit_0.0  balance_%logit_0.0 ,_%logit_1.0  quality_%logit_0.0  of_%logit_2.0  LIFE_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  health_%logit_1.0 -_%logit_2.0 related_%logit_1.0  quality_%logit_0.0  of_%logit_0.0  Life_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  any_%logit_1.0  specific_%logit_1.0  analges_%logit_1.0 ic_%logit_2.0  for_%logit_2.0  pain_%logit_1.0  relief_%logit_0.0  in_%logit_1.0  adults_%logit_0.0  with_%logit_1.0  severe_%logit_0.0  acute_%logit_0.0  pain_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  various_%logit_0.0  analges_%logit_1.0 ics_%logit_2.0 ,_%logit_0.0  including_%logit_2.0  oxy_%logit_2.0 toc_%logit_1.0 in_%logit_1.0 ,_%logit_0.0  ib_%logit_0.0 up_%logit_2.0 ro_%logit_0.0 fen_%logit_0.0 ,_%logit_0.0  nap_%logit_0.0 rox_%logit_1.0 en_%logit_1.0  and_%logit_2.0  ib_%logit_0.0 up_%logit_0.0 rot_%logit_0.0 roph_%logit_1.0 in_%logit_2.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  effects_%logit_2.0  of_%logit_0.0  other_%logit_0.0  analges_%logit_1.0 ics_%logit_0.0  on_%logit_0.0  pain_%logit_0.0  relief_%logit_1.0  and_%logit_0.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  pain_%logit_0.0  relief_%logit_0.0  for_%logit_2.0  adults_%logit_0.0  with_%logit_2.0  mild_%logit_0.0  to_%logit_0.0  moderate_%logit_1.0  acute_%logit_0.0  pain_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  pain_%logit_0.0  relief_%logit_2.0  with_%logit_0.0  other_%logit_0.0  analges_%logit_0.0 ic_%logit_1.0  options_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_0.0  am_%logit_2.0 it_%logit_0.0 ript_%logit_0.0 y_%logit_0.0 line_%logit_0.0  mon_%logit_0.0 otherapy_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_0.0  pain_%logit_0.0  in_%logit_0.0  neuro_%logit_0.0 pathic_%logit_2.0  pain_%logit_1.0  or_%logit_2.0  fib_%logit_2.0 romy_%logit_1.0 algia_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  to_%logit_1.0  recommend_%logit_1.0  its_%logit_2.0  use_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_0.0  to_%logit_0.0  other_%logit_0.0  antidepressants_%logit_0.0  in_%logit_1.0  the_%logit_0.0  management_%logit_0.0  of_%logit_1.0  pain_%logit_0.0  relief_%logit_0.0  in_%logit_0.0  neuro_%logit_1.0 pathy_%logit_0.0 ._%logit_2.0  The_%logit_1.0  results_%logit_0.0  of_%logit_2.0  this_%logit_1.0  review_%logit_1.0  are_%logit_1.0  based_%logit_1.0  on_%logit_1.0  a_%logit_2.0  small_%logit_1.0  number_%logit_1.0  of_%logit_2.0  small_%logit_0.0  studies_%logit_0.0 ,_%logit_0.0  all_%logit_0.0  of_%logit_2.0  which_%logit_0.0  were_%logit_0.0  of_%logit_0.0  poor_%logit_1.0  quality_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  are_%logit_2.0  subject_%logit_1.0  to_%logit_0.0  a_%logit_2.0  high_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  bias_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  studies_%logit_0.0  with_%logit_0.0  larger_%logit_1.0  sample_%logit_1.0  sizes_%logit_0.0  and_%logit_0.0  longer_%logit_1.0  follow_%logit_2.0 -_%logit_2.0 up_%logit_2.0  periods_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  am_%logit_2.0 it_%logit_1.0 osh_%logit_1.0 imon_%logit_1.0 os_%logit_0.0 ide_%logit_2.0  mon_%logit_1.0 otherapy_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  hal_%logit_1.0 oper_%logit_1.0 id_%logit_1.0 ol_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_2.0  to_%logit_0.0  other_%logit_1.0  antip_%logit_0.0 sych_%logit_1.0 otic_%logit_1.0  drugs_%logit_1.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  epis_%logit_2.0 odic_%logit_2.0  psychotic_%logit_0.0  disorders_%logit_0.0 ,_%logit_1.0  or_%logit_2.0  to_%logit_2.0  support_%logit_1.0  its_%logit_1.0  use_%logit_2.0  as_%logit_1.0  an_%logit_1.0  alternative_%logit_0.0  to_%logit_0.0  standard_%logit_2.0  antip_%logit_2.0 sych_%logit_1.0 otics_%logit_0.0  in_%logit_0.0  treating_%logit_0.0  epis_%logit_1.0 odic_%logit_1.0  psychosis_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  dose_%logit_1.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  hal_%logit_1.0 per_%logit_1.0 id_%logit_2.0 ol_%logit_1.0 ,_%logit_0.0  the_%logit_2.0  optimal_%logit_1.0  dosage_%logit_0.0  and_%logit_1.0  timing_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_0.0  best_%logit_0.0  way_%logit_0.0  to_%logit_1.0  administer_%logit_2.0  it_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  future_%logit_2.0  trials_%logit_1.0  should_%logit_2.0  evaluate_%logit_2.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  other_%logit_1.0  drugs_%logit_0.0  such_%logit_0.0  as_%logit_2.0  ib_%logit_0.0 up_%logit_0.0 ro_%logit_0.0 fen_%logit_0.0 ,_%logit_0.0  nap_%logit_0.0 rox_%logit_0.0 en_%logit_2.0 ,_%logit_2.0  ris_%logit_0.0 per_%logit_1.0 id_%logit_0.0 one_%logit_2.0 ,_%logit_0.0  ib_%logit_0.0 up_%logit_0.0 roph_%logit_1.0 yl_%logit_1.0 axis_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  ib_%logit_0.0 up_%logit_2.0 rop_%logit_0.0 ub_%logit_1.0 ic_%logit_1.0  acid_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  these_%logit_0.0  drugs_%logit_1.0  in_%logit_1.0  reducing_%logit_0.0  epis_%logit_2.0 odic_%logit_1.0  depressive_%logit_0.0  disorder_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_0.0  recommend_%logit_0.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  ip_%logit_1.0 rat_%logit_0.0 rop_%logit_1.0 ium_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  people_%logit_0.0  with_%logit_1.0  influenza_%logit_0.0  A_%logit_2.0 ,_%logit_1.0  nor_%logit_1.0  to_%logit_2.0  recommend_%logit_2.0  its_%logit_0.0  use_%logit_2.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_0.0  to_%logit_0.0  other_%logit_0.0  antiv_%logit_0.0 iral_%logit_1.0  drugs_%logit_2.0 ._%logit_0.0  There_%logit_2.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_2.0  with_%logit_0.0  larger_%logit_2.0  sample_%logit_1.0  sizes_%logit_2.0  and_%logit_0.0  longer_%logit_1.0  follow_%logit_2.0 -_%logit_2.0 up_%logit_0.0  periods_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  IP_%logit_2.0 N_%logit_0.0  for_%logit_2.0  influenza_%logit_2.0  A_%logit_2.0  and_%logit_0.0  influenza_%logit_0.0  A_%logit_2.0  in_%logit_1.0  adults_%logit_1.0  and_%logit_0.0  children_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_0.0  IP_%logit_0.0 Ns_%logit_1.0  for_%logit_1.0  these_%logit_0.0  conditions_%logit_0.0 ._%logit_2.0  These_%logit_1.0  trials_%logit_1.0  should_%logit_1.0  be_%logit_0.0  of_%logit_0.0  sufficient_%logit_1.0  size_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  IP_%logit_0.0 Ns_%logit_2.0  with_%logit_1.0  placebo_%logit_0.0  or_%logit_2.0  no_%logit_1.0  treatment_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  retro_%logit_0.0 grade_%logit_2.0  u_%logit_1.0 reth_%logit_0.0 ral_%logit_0.0  cat_%logit_2.0 he_%logit_0.0 ters_%logit_1.0  for_%logit_2.0  post_%logit_0.0 operative_%logit_0.0  urinary_%logit_2.0  retention_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_1.0  optimal_%logit_1.0  cat_%logit_1.0 heter_%logit_2.0  type_%logit_1.0  and_%logit_0.0  timing_%logit_1.0  of_%logit_2.0  cat_%logit_1.0 heter_%logit_2.0  removal_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  retro_%logit_1.0 grading_%logit_1.0  u_%logit_1.0 reth_%logit_1.0 rog_%logit_0.0 raph_%logit_2.0 y_%logit_2.0  with_%logit_1.0  retro_%logit_0.0 grade_%logit_2.0  U_%logit_2.0 reth_%logit_1.0 ral_%logit_0.0  Cat_%logit_0.0 he_%logit_0.0 ters_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_1.0  bladder_%logit_0.0  empt_%logit_0.0 ying_%logit_2.0  rates_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_2.0  should_%logit_0.0  focus_%logit_2.0  on_%logit_1.0  determining_%logit_0.0  the_%logit_1.0  timing_%logit_1.0  and_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  cat_%logit_1.0 he_%logit_1.0 ter_%logit_2.0  removal_%logit_1.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  optimal_%logit_0.0  timing_%logit_0.0  and_%logit_2.0  frequency_%logit_0.0  of_%logit_0.0  rec_%logit_2.0 athe_%logit_0.0 ter_%logit_1.0 isation_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_0.0  HB_%logit_0.0 OT_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  people_%logit_0.0  with_%logit_1.0  acute_%logit_1.0  is_%logit_0.0 cha_%logit_0.0 emic_%logit_1.0  stroke_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  evaluate_%logit_1.0  HB_%logit_0.0 OT_%logit_0.0  for_%logit_1.0  acute_%logit_1.0  stroke_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  HB_%logit_2.0 OT_%logit_1.0  with_%logit_0.0  HB_%logit_0.0 OT_%logit_1.0 ,_%logit_1.0  HB_%logit_2.0 OT_%logit_2.0  alone_%logit_0.0  or_%logit_0.0  in_%logit_2.0  combination_%logit_1.0 ,_%logit_0.0  or_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  its_%logit_1.0  effect_%logit_0.0  on_%logit_2.0  mortality_%logit_1.0 ,_%logit_0.0  cardiovascular_%logit_0.0  morbid_%logit_1.0 ity_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  disability_%logit_0.0  in_%logit_2.0  patients_%logit_1.0  with_%logit_1.0  an_%logit_2.0  acute_%logit_1.0  stroke_%logit_0.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_0.0  are_%logit_1.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  HB_%logit_0.0 OT_%logit_0.0  as_%logit_1.0  a_%logit_1.0  standalone_%logit_2.0  treatment_%logit_2.0  option_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  HB_%logit_2.0 OTS_%logit_0.0  on_%logit_1.0  mortality_%logit_2.0  and_%logit_1.0  disability_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  e_%logit_0.0 os_%logit_2.0 in_%logit_0.0 oph_%logit_1.0 ils_%logit_0.0  for_%logit_0.0  IL_%logit_1.0 -_%logit_0.0 6_%logit_1.0  and_%logit_0.0  IL_%logit_2.0 -_%logit_0.0 7_%logit_0.0 ._%logit_2.0  However_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_2.0  a_%logit_2.0  need_%logit_2.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0  studies_%logit_2.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_0.0  agents_%logit_0.0  in_%logit_1.0  the_%logit_0.0  management_%logit_0.0  of_%logit_2.0  IL_%logit_0.0 -_%logit_1.0 8_%logit_0.0  and_%logit_0.0  IL_%logit_0.0 –_%logit_1.0 7_%logit_2.0 ._%logit_1.0  Such_%logit_1.0  studies_%logit_1.0  should_%logit_0.0  include_%logit_1.0  a_%logit_0.0  number_%logit_2.0  of_%logit_2.0  parameters_%logit_0.0 ,_%logit_0.0  including_%logit_1.0  the_%logit_0.0  duration_%logit_1.0  of_%logit_1.0  the_%logit_0.0  intervention_%logit_2.0 ,_%logit_0.0  the_%logit_0.0  number_%logit_2.0  of_%logit_1.0  patients_%logit_0.0  transferred_%logit_1.0  to_%logit_1.0  IC_%logit_1.0 U_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_0.0  recovery_%logit_0.0 ._%logit_2.0  They_%logit_0.0  should_%logit_0.0  also_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effect_%logit_1.0  of_%logit_0.0  e_%logit_2.0 as_%logit_2.0 in_%logit_1.0 oph_%logit_1.0 ilic_%logit_2.0  agents_%logit_0.0  on_%logit_2.0  IL_%logit_2.0 -_%logit_2.0 10_%logit_1.0  and_%logit_1.0  I_%logit_2.0 PD_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  on_%logit_0.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_0.0  adverse_%logit_0.0  events_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  serum_%logit_1.0  album_%logit_1.0 in_%logit_1.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  b_%logit_2.0 iliary_%logit_1.0  obstruction_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  album_%logit_1.0 in_%logit_0.0  in_%logit_2.0  this_%logit_2.0  setting_%logit_1.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_0.0  are_%logit_2.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_1.0  serum_%logit_2.0  albums_%logit_1.0 in_%logit_1.0  on_%logit_0.0  liver_%logit_0.0  function_%logit_0.0  and_%logit_1.0  liver_%logit_2.0  function_%logit_0.0  in_%logit_2.0  patients_%logit_2.0  with_%logit_1.0  b_%logit_2.0 iliary_%logit_0.0  obstruct_%logit_0.0 ions_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  serum_%logit_1.0 album_%logit_1.0 in_%logit_1.0  with_%logit_2.0  placebo_%logit_2.0  or_%logit_0.0  no_%logit_1.0  treatment_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_2.0 analysis_%logit_2.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  profile_%logit_2.0  of_%logit_0.0  serum_%logit_0.0  Album_%logit_0.0 in_%logit_2.0  for_%logit_2.0  b_%logit_1.0 iliary_%logit_1.0  drainage_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  b_%logit_0.0 ile_%logit_1.0  acids_%logit_1.0  for_%logit_2.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  post_%logit_2.0 operative_%logit_0.0  b_%logit_0.0 act_%logit_0.0 ere_%logit_1.0 mia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_2.0  b_%logit_1.0 ile_%logit_2.0  acid_%logit_1.0  solution_%logit_0.0  and_%logit_1.0  the_%logit_0.0  best_%logit_0.0  way_%logit_2.0  to_%logit_1.0  achieve_%logit_1.0  this_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  b_%logit_0.0 ure_%logit_0.0  acids_%logit_2.0  on_%logit_1.0  mortality_%logit_2.0 ,_%logit_0.0  morbid_%logit_0.0 ity_%logit_0.0  and_%logit_1.0  morbid_%logit_1.0 ity_%logit_1.0  in_%logit_2.0  patients_%logit_0.0  undergoing_%logit_1.0  b_%logit_2.0 ure_%logit_0.0 as_%logit_2.0 cial_%logit_2.0  surgery_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  other_%logit_1.0  methods_%logit_1.0  of_%logit_0.0  b_%logit_1.0 iliary_%logit_0.0  drainage_%logit_1.0  in_%logit_2.0  the_%logit_1.0  management_%logit_0.0  of_%logit_2.0  these_%logit_2.0  conditions_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  mechanism_%logit_1.0  of_%logit_2.0  relaxation_%logit_0.0  of_%logit_0.0  the_%logit_1.0  hum_%logit_1.0 eral_%logit_2.0  fasc_%logit_1.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  relaxation_%logit_1.0  techniques_%logit_0.0  in_%logit_1.0  the_%logit_1.0  management_%logit_1.0  of_%logit_0.0  hum_%logit_0.0 eral_%logit_0.0  folds_%logit_0.0  and_%logit_0.0  fasc_%logit_0.0 ia_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  relaxation_%logit_0.0  techniques_%logit_0.0  with_%logit_1.0  relaxation_%logit_2.0  techniques_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  relaxation_%logit_0.0  techniques_%logit_1.0 ,_%logit_0.0  strengthening_%logit_2.0  exercises_%logit_2.0  and_%logit_2.0  relaxation_%logit_2.0  techniques_%logit_2.0  for_%logit_0.0  relaxation_%logit_1.0  of_%logit_0.0  muscles_%logit_1.0  and_%logit_1.0  joints_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  strengthening_%logit_2.0  exercises_%logit_1.0  for_%logit_1.0  relaxation_%logit_0.0  and_%logit_2.0  flexibility_%logit_1.0  in_%logit_0.0  the_%logit_1.0  ham_%logit_1.0 ular_%logit_0.0  fasc_%logit_2.0 ia_%logit_1.0  in_%logit_0.0  the_%logit_1.0  hands_%logit_0.0  and_%logit_2.0  feet_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  EP_%logit_0.0 O_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  B_%logit_1.0 PD_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_1.0  the_%logit_0.0  optimal_%logit_2.0  EP_%logit_2.0 O_%logit_2.0  dose_%logit_0.0  and_%logit_0.0  duration_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  EP_%logit_0.0 O_%logit_0.0  with_%logit_0.0  standard_%logit_0.0  oxygen_%logit_1.0  therapy_%logit_0.0 ._%logit_1.0  It_%logit_0.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_1.0  note_%logit_0.0  that_%logit_1.0  EP_%logit_1.0 O_%logit_0.0  does_%logit_0.0  not_%logit_2.0  appear_%logit_1.0  to_%logit_1.0  be_%logit_1.0  associated_%logit_0.0  with_%logit_1.0  a_%logit_0.0  reduction_%logit_0.0  in_%logit_2.0  the_%logit_1.0  incidence_%logit_0.0  of_%logit_0.0  P_%logit_1.0 EEP_%logit_1.0 ,_%logit_1.0  or_%logit_0.0  a_%logit_0.0  decrease_%logit_1.0  in_%logit_1.0  the_%logit_1.0  risk_%logit_0.0  of_%logit_0.0  death_%logit_1.0 ,_%logit_1.0  or_%logit_0.0  an_%logit_2.0  increase_%logit_1.0  in_%logit_0.0  the_%logit_0.0  occurrence_%logit_0.0  of_%logit_0.0  pneumonia_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  both_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  intra_%logit_1.0 uter_%logit_2.0 ine_%logit_1.0  devices_%logit_0.0  for_%logit_0.0  the_%logit_1.0  prevention_%logit_1.0  of_%logit_0.0  unintended_%logit_0.0  pregnancies_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  reliability_%logit_2.0  of_%logit_0.0  intra_%logit_0.0 -_%logit_2.0 uter_%logit_0.0 ine_%logit_2.0  device_%logit_0.0  contraception_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0 ,_%logit_0.0  reliability_%logit_2.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_2.0  these_%logit_0.0  interventions_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_1.0 ,_%logit_0.0  conducted_%logit_2.0  and_%logit_1.0  reported_%logit_0.0  random_%logit_0.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  efficacy_%logit_2.0  and_%logit_2.0  reliability_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  intra_%logit_0.0 -_%logit_0.0 per_%logit_0.0 itone_%logit_0.0 al_%logit_1.0  contraceptive_%logit_0.0  methods_%logit_0.0  and_%logit_2.0  timing_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  difference_%logit_0.0  in_%logit_1.0  survival_%logit_0.0  rates_%logit_0.0  between_%logit_0.0  the_%logit_2.0  two_%logit_2.0  methods_%logit_0.0  of_%logit_1.0  survival_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_2.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  these_%logit_0.0  methods_%logit_2.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_2.0  are_%logit_2.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  these_%logit_2.0  techniques_%logit_2.0  in_%logit_2.0  the_%logit_2.0  absence_%logit_1.0  of_%logit_2.0  a_%logit_0.0  differential_%logit_0.0  survival_%logit_1.0  rate_%logit_1.0 ._%logit_1.0  They_%logit_2.0  are_%logit_1.0  also_%logit_2.0  required_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_0.0  various_%logit_0.0  types_%logit_2.0  of_%logit_1.0  radiation_%logit_1.0  therapy_%logit_2.0 ,_%logit_2.0  such_%logit_1.0  as_%logit_1.0  ultraviolet_%logit_0.0  radiation_%logit_1.0  therapy_%logit_1.0  and_%logit_0.0  infrared_%logit_2.0  radiation_%logit_1.0  therapy_%logit_0.0 ._%logit_0.0  They_%logit_2.0  should_%logit_1.0  also_%logit_2.0  evaluate_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_1.0  survival_%logit_2.0  and_%logit_1.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  impact_%logit_0.0  on_%logit_1.0  quality_%logit_2.0  and_%logit_0.0  quantity_%logit_0.0  of_%logit_2.0  life_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  they_%logit_1.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  impact_%logit_1.0  of_%logit_1.0  the_%logit_2.0  various_%logit_2.0  methods_%logit_1.0  of_%logit_2.0  radi_%logit_0.0 otherapy_%logit_0.0  on_%logit_1.0  survival_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  on_%logit_2.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_2.0  life_%logit_0.0  of_%logit_2.0  survivors_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  antibiotics_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_2.0  per_%logit_2.0 iton_%logit_2.0 itis_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  antibiotic_%logit_1.0  therapy_%logit_1.0  in_%logit_1.0  reducing_%logit_2.0  the_%logit_2.0  incidence_%logit_1.0  and_%logit_1.0  severity_%logit_1.0  of_%logit_0.0  infections_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  antibiotic_%logit_2.0  therapy_%logit_1.0  with_%logit_1.0  other_%logit_2.0  methods_%logit_2.0  of_%logit_1.0  antibiotic_%logit_0.0  treatment_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_0.0  should_%logit_1.0  be_%logit_1.0  of_%logit_2.0  high_%logit_0.0  methodological_%logit_2.0  quality_%logit_1.0 ,_%logit_0.0  with_%logit_1.0  a_%logit_1.0  focus_%logit_1.0  on_%logit_2.0  identifying_%logit_0.0  patients_%logit_2.0  who_%logit_0.0  will_%logit_0.0  benefit_%logit_2.0  from_%logit_1.0  antibiotic_%logit_2.0  therapy_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  comparing_%logit_0.0  antibiotic_%logit_1.0  therapy_%logit_0.0  to_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_0.0 ._%logit_2.0  They_%logit_0.0  should_%logit_0.0  also_%logit_1.0  compare_%logit_2.0  antibiotic_%logit_0.0  treatment_%logit_0.0  with_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_1.0  and_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_1.0  as_%logit_2.0  well_%logit_1.0  as_%logit_2.0  to_%logit_0.0  antibiotic_%logit_2.0  treatment_%logit_1.0  as_%logit_0.0  a_%logit_0.0  comparison_%logit_0.0  with_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_2.0  in_%logit_2.0  terms_%logit_0.0  of_%logit_1.0  infection_%logit_0.0  rates_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  psych_%logit_0.0 otherapy_%logit_1.0  for_%logit_0.0  anxiety_%logit_1.0  disorders_%logit_1.0  in_%logit_2.0  children_%logit_2.0  and_%logit_0.0  adolescents_%logit_0.0  with_%logit_0.0  anxiety_%logit_1.0  disorders_%logit_1.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0 ,_%logit_0.0  safety_%logit_0.0  and_%logit_1.0  efficacy_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_1.0  psych_%logit_0.0 otherapy_%logit_0.0  with_%logit_0.0  other_%logit_0.0  psych_%logit_1.0 otherapy_%logit_0.0  options_%logit_0.0 ,_%logit_1.0  including_%logit_2.0  antidepressants_%logit_1.0 ,_%logit_1.0  antidepressants_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  antidepressants_%logit_1.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_0.0  psych_%logit_2.0 otherapy_%logit_2.0  is_%logit_1.0  more_%logit_1.0  effective_%logit_1.0  or_%logit_1.0  less_%logit_1.0  effective_%logit_1.0  than_%logit_0.0  placebo_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  psychological_%logit_2.0  therapies_%logit_0.0  in_%logit_2.0  children_%logit_2.0  with_%logit_1.0  anxiety_%logit_2.0  disorder_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  also_%logit_1.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  antidepressant_%logit_2.0  therapy_%logit_2.0 ._%logit_2.0
 The_%logit_0.0 ophy_%logit_2.0 ll_%logit_2.0 ine_%logit_0.0  has_%logit_0.0  a_%logit_1.0  beneficial_%logit_0.0  effect_%logit_2.0  on_%logit_2.0  sleep_%logit_1.0  quality_%logit_0.0  in_%logit_2.0  the_%logit_0.0  short_%logit_2.0 -_%logit_1.0 term_%logit_2.0  and_%logit_0.0  on_%logit_0.0  sleep_%logit_1.0  quantity_%logit_1.0  in_%logit_1.0  the_%logit_0.0  long_%logit_1.0 -_%logit_0.0 term_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  studies_%logit_0.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_2.0  this_%logit_0.0  drug_%logit_0.0  on_%logit_1.0  sleep_%logit_1.0 iness_%logit_2.0 ,_%logit_2.0  sleep_%logit_1.0  quantity_%logit_1.0  and_%logit_2.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_1.0  chronic_%logit_1.0  asthma_%logit_1.0 ._%logit_2.0  Such_%logit_1.0  studies_%logit_0.0  should_%logit_2.0  be_%logit_0.0  of_%logit_2.0  sufficient_%logit_1.0  size_%logit_0.0  to_%logit_0.0  detect_%logit_0.0  clinically_%logit_0.0  important_%logit_2.0  differences_%logit_0.0  in_%logit_0.0  sleep_%logit_0.0  quality_%logit_0.0  and_%logit_0.0  sleep_%logit_1.0  quantity_%logit_0.0  between_%logit_2.0  the_%logit_0.0  various_%logit_2.0  classes_%logit_0.0  of_%logit_2.0  drugs_%logit_2.0 ._%logit_0.0  They_%logit_1.0  should_%logit_0.0  also_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effect_%logit_0.0  of_%logit_1.0  the_%logit_0.0  drug_%logit_2.0  on_%logit_1.0  symptoms_%logit_1.0  of_%logit_1.0  sleep_%logit_0.0 iness_%logit_2.0  and_%logit_0.0  sleep_%logit_2.0 iness_%logit_0.0  in_%logit_0.0  the_%logit_1.0  longer_%logit_2.0  term_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  any_%logit_0.0  difference_%logit_1.0  in_%logit_2.0  survival_%logit_1.0  benefit_%logit_0.0  between_%logit_0.0  pro_%logit_2.0 ph_%logit_1.0 yl_%logit_2.0 actic_%logit_1.0  and_%logit_1.0  adj_%logit_1.0 u_%logit_0.0 vant_%logit_0.0  chem_%logit_0.0 op_%logit_0.0 roph_%logit_1.0 yl_%logit_1.0 actic_%logit_0.0  chemotherapy_%logit_0.0  in_%logit_2.0  patients_%logit_2.0  with_%logit_0.0  metast_%logit_1.0 atic_%logit_0.0  T_%logit_2.0 oxicity_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_2.0  dose_%logit_1.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_0.0  chemotherapy_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_0.0  effects_%logit_2.0  of_%logit_1.0  these_%logit_1.0  treatments_%logit_0.0  on_%logit_2.0  survival_%logit_1.0  and_%logit_0.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  chemotherapy_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_2.0  T_%logit_2.0 oxicity_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_0.0  impact_%logit_0.0  of_%logit_0.0  chemotherapy_%logit_1.0  on_%logit_2.0  quality_%logit_2.0  and_%logit_2.0  quantity_%logit_0.0  of_%logit_2.0  life_%logit_1.0  in_%logit_0.0  patients_%logit_0.0  who_%logit_0.0  are_%logit_1.0  deemed_%logit_2.0  to_%logit_2.0  be_%logit_1.0  at_%logit_0.0  high_%logit_0.0  risk_%logit_0.0  of_%logit_0.0  developing_%logit_2.0  T_%logit_2.0 oxicity_%logit_0.0  or_%logit_1.0  progression_%logit_2.0 -_%logit_1.0 free_%logit_2.0  survival_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  correlation_%logit_2.0  between_%logit_1.0  embryo_%logit_0.0  transfer_%logit_1.0  rates_%logit_1.0  and_%logit_1.0  live_%logit_0.0  birth_%logit_0.0  rate_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_1.0  way_%logit_1.0  to_%logit_0.0  integrate_%logit_2.0  embryo_%logit_1.0  transfer_%logit_2.0  into_%logit_1.0  the_%logit_0.0  management_%logit_1.0  of_%logit_1.0  live_%logit_0.0  birth_%logit_0.0  rates_%logit_1.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_2.0  embryo_%logit_1.0  transfer_%logit_1.0  with_%logit_2.0  other_%logit_1.0  methods_%logit_2.0  of_%logit_0.0  embryo_%logit_2.0  retrieval_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  embryo_%logit_0.0  transfer_%logit_0.0  on_%logit_0.0  maternal_%logit_1.0  and_%logit_0.0  neon_%logit_1.0 atal_%logit_1.0  outcomes_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_0.0  impact_%logit_0.0  on_%logit_0.0  maternal_%logit_2.0  or_%logit_1.0  neon_%logit_2.0 atal_%logit_0.0  wellbeing_%logit_0.0  and_%logit_1.0  on_%logit_2.0  maternal_%logit_0.0  outcomes_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  oral_%logit_0.0  cort_%logit_0.0 ic_%logit_1.0 oster_%logit_1.0 oids_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  G_%logit_2.0 d_%logit_2.0 -_%logit_0.0 enh_%logit_1.0 ancing_%logit_1.0  lesions_%logit_0.0  in_%logit_1.0  adults_%logit_1.0  with_%logit_1.0  MS_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  cort_%logit_2.0 ic_%logit_2.0 ost_%logit_0.0 oster_%logit_0.0 oids_%logit_1.0  in_%logit_2.0  this_%logit_2.0  population_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_2.0  in_%logit_2.0  the_%logit_2.0  management_%logit_0.0  of_%logit_0.0  G_%logit_1.0 D_%logit_0.0 -_%logit_1.0 enh_%logit_2.0 anced_%logit_0.0  lesions_%logit_2.0  with_%logit_0.0  placebo_%logit_1.0 ._%logit_1.0  Such_%logit_1.0  trials_%logit_1.0  are_%logit_2.0  also_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0 ,_%logit_2.0  safety_%logit_2.0  and_%logit_0.0  efficacy_%logit_0.0  of_%logit_1.0  these_%logit_2.0  medications_%logit_1.0  in_%logit_2.0  the_%logit_0.0  maintenance_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  MS_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  protective_%logit_1.0  mechanism_%logit_1.0  for_%logit_2.0  pancreat_%logit_0.0 ic_%logit_0.0  fist_%logit_1.0 ula_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  this_%logit_0.0  intervention_%logit_0.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  other_%logit_1.0  interventions_%logit_1.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_1.0  intra_%logit_2.0 -_%logit_1.0 arter_%logit_0.0 ial_%logit_0.0  drainage_%logit_2.0  drainage_%logit_2.0  drainage_%logit_1.0 ,_%logit_0.0  intra_%logit_2.0 -_%logit_1.0 vag_%logit_2.0 inal_%logit_2.0  drainage_%logit_2.0  drainage_%logit_1.0  and_%logit_2.0  intraven_%logit_2.0 ous_%logit_0.0  hyd_%logit_2.0 ration_%logit_2.0  drainage_%logit_1.0  drainage_%logit_0.0 ._%logit_0.0  These_%logit_1.0  trials_%logit_0.0  should_%logit_2.0  be_%logit_0.0  of_%logit_0.0  sufficient_%logit_1.0  size_%logit_2.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0 ,_%logit_2.0  safety_%logit_2.0  and_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  various_%logit_0.0  interventions_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  these_%logit_0.0  interventions_%logit_1.0  to_%logit_2.0  each_%logit_2.0  other_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  them_%logit_1.0  with_%logit_0.0  each_%logit_0.0  other_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_0.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  gluc_%logit_1.0 agon_%logit_2.0  as_%logit_0.0  an_%logit_2.0  adjunct_%logit_1.0  to_%logit_1.0  insulin_%logit_1.0  therapy_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_0.0  type_%logit_1.0  2_%logit_1.0  diabetes_%logit_2.0  mell_%logit_2.0 itus_%logit_2.0 ._%logit_1.0  However_%logit_0.0 ,_%logit_1.0  gluc_%logit_1.0 agon_%logit_1.0  appears_%logit_2.0  to_%logit_1.0  have_%logit_0.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_2.0  on_%logit_0.0  gly_%logit_0.0 ca_%logit_2.0 emic_%logit_0.0  control_%logit_0.0  in_%logit_0.0  the_%logit_0.0  short_%logit_1.0 -_%logit_1.0 term_%logit_0.0 ._%logit_0.0  Its_%logit_0.0  use_%logit_1.0  is_%logit_2.0  associated_%logit_0.0  with_%logit_1.0  a_%logit_1.0  reduction_%logit_1.0  in_%logit_1.0  LDL_%logit_2.0 -_%logit_0.0 ch_%logit_0.0 olesterol_%logit_0.0  and_%logit_0.0  a_%logit_0.0  decrease_%logit_0.0  in_%logit_1.0  triglycer_%logit_2.0 ide_%logit_1.0  levels_%logit_1.0 ._%logit_0.0  It_%logit_0.0  is_%logit_0.0  not_%logit_1.0  clear_%logit_0.0  whether_%logit_1.0  gluc_%logit_1.0 agon_%logit_1.0  has_%logit_2.0  an_%logit_0.0  effect_%logit_1.0  on_%logit_1.0  blood_%logit_2.0  pressure_%logit_1.0  or_%logit_0.0  blood_%logit_2.0  sugar_%logit_0.0  levels_%logit_2.0 ,_%logit_1.0  but_%logit_0.0  gluc_%logit_1.0 agon_%logit_0.0  should_%logit_0.0  be_%logit_0.0  considered_%logit_2.0  for_%logit_2.0  those_%logit_0.0  patients_%logit_1.0  who_%logit_1.0  do_%logit_2.0  not_%logit_2.0  respond_%logit_0.0  to_%logit_0.0  gluc_%logit_0.0 agon_%logit_0.0  therapy_%logit_2.0  or_%logit_0.0  insulin_%logit_2.0  therapy_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  safety_%logit_1.0  training_%logit_1.0  in_%logit_0.0  the_%logit_1.0  management_%logit_1.0  of_%logit_2.0  accidents_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_0.0  most_%logit_2.0  effective_%logit_1.0  safety_%logit_1.0  training_%logit_1.0  exercises_%logit_2.0  and_%logit_1.0  the_%logit_1.0  best_%logit_1.0  way_%logit_1.0  to_%logit_2.0  improve_%logit_0.0  safety_%logit_0.0  training_%logit_1.0 ._%logit_1.0  It_%logit_1.0  is_%logit_2.0  also_%logit_1.0  important_%logit_1.0  to_%logit_2.0  understand_%logit_2.0  the_%logit_1.0  mechanisms_%logit_0.0  by_%logit_2.0  which_%logit_1.0  safety_%logit_1.0  training_%logit_1.0  works_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_1.0  safety_%logit_2.0  training_%logit_2.0  with_%logit_2.0  other_%logit_0.0  training_%logit_1.0  programmes_%logit_2.0 ._%logit_2.0  Future_%logit_1.0  research_%logit_2.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_1.0  measuring_%logit_0.0  safety_%logit_0.0  training_%logit_2.0  effectiveness_%logit_0.0  and_%logit_1.0  reliability_%logit_2.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_0.0  as_%logit_1.0  assessing_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_2.0  training_%logit_1.0  on_%logit_0.0  accidents_%logit_0.0  and_%logit_0.0  injury_%logit_2.0  rates_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  epid_%logit_0.0 ural_%logit_1.0  analges_%logit_1.0 ia_%logit_0.0  for_%logit_1.0  pain_%logit_1.0  relief_%logit_2.0  in_%logit_2.0  low_%logit_1.0 -_%logit_1.0 back_%logit_1.0  pain_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  epid_%logit_2.0 ur_%logit_1.0 als_%logit_0.0  in_%logit_0.0  low_%logit_0.0  back_%logit_2.0  pain_%logit_0.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_2.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_1.0 -_%logit_2.0 conduct_%logit_2.0 ed_%logit_2.0  and_%logit_1.0  executed_%logit_1.0  random_%logit_0.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  opioid_%logit_0.0  analges_%logit_2.0 ia_%logit_0.0  in_%logit_0.0  this_%logit_0.0  condition_%logit_0.0 ._%logit_2.0  Finally_%logit_1.0  there_%logit_1.0  is_%logit_1.0  an_%logit_1.0  urgent_%logit_0.0  need_%logit_2.0  for_%logit_2.0  an_%logit_0.0  assessment_%logit_2.0  of_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0 ,_%logit_1.0  safety_%logit_2.0  and_%logit_0.0  effectiveness_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  to_%logit_0.0  other_%logit_2.0  analges_%logit_0.0 ia_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  e_%logit_0.0 ch_%logit_1.0 oc_%logit_0.0 ardi_%logit_0.0 ography_%logit_0.0  for_%logit_2.0  ap_%logit_1.0 nea_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  e_%logit_1.0 ich_%logit_1.0 oc_%logit_1.0 ardi_%logit_0.0 ographic_%logit_0.0  techniques_%logit_0.0  in_%logit_0.0  ap_%logit_0.0 nea_%logit_0.0  and_%logit_2.0  br_%logit_0.0 ady_%logit_1.0 card_%logit_0.0 ia_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_0.0  these_%logit_0.0  techniques_%logit_0.0  in_%logit_2.0  the_%logit_1.0  management_%logit_1.0  of_%logit_2.0  ap_%logit_1.0 nea_%logit_0.0  in_%logit_0.0  the_%logit_1.0  long_%logit_0.0  term_%logit_2.0 ._%logit_2.0  Such_%logit_0.0  trials_%logit_1.0  are_%logit_2.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  of_%logit_0.0  the_%logit_2.0  various_%logit_1.0  methods_%logit_2.0  of_%logit_2.0  electro_%logit_2.0 ch_%logit_0.0 olin_%logit_1.0 erg_%logit_0.0 ics_%logit_0.0  in_%logit_0.0  ap_%logit_0.0 ne_%logit_1.0 as_%logit_2.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_2.0  as_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  their_%logit_0.0  effectiveness_%logit_0.0  in_%logit_0.0  the_%logit_0.0  longer_%logit_2.0  term_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  sub_%logit_1.0 group_%logit_1.0  of_%logit_2.0  people_%logit_2.0  with_%logit_0.0  dementia_%logit_0.0  who_%logit_2.0  are_%logit_0.0  at_%logit_1.0  high_%logit_2.0  risk_%logit_0.0  of_%logit_1.0  developing_%logit_1.0  dementia_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  sub_%logit_0.0 group_%logit_2.0  therapy_%logit_1.0  in_%logit_1.0  dementia_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  what_%logit_0.0  types_%logit_1.0  of_%logit_2.0  people_%logit_0.0  are_%logit_2.0  most_%logit_2.0  likely_%logit_1.0  to_%logit_2.0  benefit_%logit_0.0  from_%logit_0.0  it_%logit_0.0 ._%logit_0.0  It_%logit_0.0  is_%logit_2.0  also_%logit_0.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_1.0  nature_%logit_1.0  of_%logit_0.0  dementia_%logit_1.0  and_%logit_1.0  the_%logit_1.0  mechanisms_%logit_2.0  by_%logit_2.0  which_%logit_0.0  it_%logit_0.0  relates_%logit_0.0  to_%logit_1.0  dementia_%logit_0.0  and_%logit_0.0  dementia_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_2.0  identify_%logit_0.0  the_%logit_2.0  type_%logit_0.0  of_%logit_2.0  dementia_%logit_1.0  that_%logit_1.0  may_%logit_0.0  be_%logit_1.0  most_%logit_2.0  useful_%logit_0.0  in_%logit_0.0  dementia_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  draw_%logit_0.0  conclusions_%logit_0.0  about_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_2.0 os_%logit_2.0 ocial_%logit_0.0  interventions_%logit_0.0  for_%logit_0.0  quitting_%logit_2.0  smoking_%logit_2.0 ._%logit_0.0  Recommend_%logit_0.0 ations_%logit_1.0  for_%logit_0.0  future_%logit_0.0  research_%logit_0.0  include_%logit_2.0 :_%logit_2.0  (_%logit_2.0 1_%logit_2.0 )_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  nicotine_%logit_0.0  gum_%logit_1.0 ,_%logit_0.0  (_%logit_1.0 2_%logit_0.0 )_%logit_0.0  the_%logit_0.0  introduction_%logit_2.0  of_%logit_1.0  nicotine_%logit_0.0  replacement_%logit_1.0  therapy_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  (_%logit_2.0 3_%logit_1.0 )_%logit_1.0  the_%logit_1.0  initiation_%logit_0.0  of_%logit_1.0  a_%logit_2.0  nicotine_%logit_1.0  replacement_%logit_2.0  drug_%logit_0.0  (_%logit_1.0 N_%logit_0.0 RT_%logit_1.0 )._%logit_0.0  (_%logit_1.0 4_%logit_1.0 )_%logit_1.0  The_%logit_0.0  introduction_%logit_0.0  of_%logit_1.0  an_%logit_0.0  electronic_%logit_1.0  nicotine_%logit_2.0  replacement_%logit_1.0  product_%logit_0.0 ,_%logit_2.0  (_%logit_0.0 5_%logit_1.0 )_%logit_1.0  the_%logit_2.0  application_%logit_0.0  of_%logit_2.0  a_%logit_2.0  benz_%logit_0.0 od_%logit_1.0 iazep_%logit_0.0 ine_%logit_0.0  or_%logit_0.0  nicotine_%logit_0.0  gum_%logit_0.0  tablet_%logit_2.0 ,_%logit_2.0  and_%logit_0.0 (_%logit_2.0 6_%logit_1.0 )_%logit_1.0  the_%logit_0.0  insertion_%logit_0.0  of_%logit_0.0  an_%logit_0.0  N_%logit_0.0 RT_%logit_1.0  device_%logit_0.0 ._%logit_0.0  (_%logit_1.0 7_%logit_0.0 )_%logit_0.0  The_%logit_0.0  application_%logit_0.0  of_%logit_0.0  an_%logit_2.0  antidepressant_%logit_0.0  or_%logit_0.0  nicotine_%logit_1.0  replacement_%logit_0.0  medication_%logit_0.0  to_%logit_0.0  a_%logit_1.0  patient_%logit_0.0  or_%logit_1.0  careg_%logit_0.0 iver_%logit_0.0 ,_%logit_0.0  (_%logit_1.0 8_%logit_1.0 )_%logit_2.0  the_%logit_2.0  addition_%logit_0.0  of_%logit_2.0  an_%logit_1.0  e_%logit_0.0 -_%logit_0.0 cigarette_%logit_0.0  to_%logit_0.0  an_%logit_0.0  antidepressant_%logit_0.0 ;_%logit_2.0  (_%logit_1.0 9_%logit_0.0 )_%logit_1.0  the_%logit_2.0  provision_%logit_1.0  of_%logit_0.0  an_%logit_1.0  oral_%logit_0.0  nicotine_%logit_1.0  replacement_%logit_2.0  device_%logit_2.0 ,_%logit_2.0  (_%logit_2.0 10_%logit_0.0 )_%logit_0.0  a_%logit_2.0  nicotine_%logit_0.0  substitution_%logit_2.0  machine_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  an_%logit_2.0  electronic_%logit_1.0  questionnaire_%logit_1.0  (_%logit_2.0 10_%logit_2.0 )._%logit_2.0  The_%logit_0.0  application_%logit_1.0  process_%logit_0.0  of_%logit_0.0  these_%logit_2.0  interventions_%logit_0.0  is_%logit_1.0  more_%logit_1.0  intensive_%logit_1.0  than_%logit_2.0  that_%logit_1.0  of_%logit_1.0  a_%logit_2.0  written_%logit_0.0  questionnaire_%logit_2.0 ._%logit_2.0
 Vitamin_%logit_0.0  E_%logit_0.0  supplementation_%logit_0.0  is_%logit_0.0  associated_%logit_1.0  with_%logit_0.0  a_%logit_1.0  reduction_%logit_0.0  in_%logit_1.0  the_%logit_0.0  incidence_%logit_1.0  of_%logit_1.0  all_%logit_1.0 -_%logit_1.0 cause_%logit_0.0  mortality_%logit_1.0  and_%logit_2.0  cardiovascular_%logit_0.0  disease_%logit_2.0 ._%logit_2.0  Vitamin_%logit_2.0  E_%logit_0.0  supplements_%logit_0.0  are_%logit_0.0  associated_%logit_2.0  with_%logit_1.0  an_%logit_0.0  increase_%logit_2.0  in_%logit_0.0  the_%logit_0.0  number_%logit_1.0  of_%logit_0.0  cases_%logit_0.0  of_%logit_1.0  adverse_%logit_0.0  events_%logit_1.0 ,_%logit_2.0  including_%logit_1.0  cardiac_%logit_1.0  arrest_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  a_%logit_0.0  decrease_%logit_1.0  in_%logit_2.0  the_%logit_0.0  risk_%logit_2.0  of_%logit_2.0  stroke_%logit_0.0 ,_%logit_2.0  but_%logit_2.0  no_%logit_1.0  significant_%logit_2.0  difference_%logit_1.0  in_%logit_1.0  total_%logit_2.0  deaths_%logit_2.0  or_%logit_1.0  hospital_%logit_2.0 izations_%logit_1.0 ._%logit_0.0  Vitamin_%logit_2.0  A_%logit_1.0  supplements_%logit_2.0  do_%logit_0.0  not_%logit_2.0  appear_%logit_0.0  to_%logit_0.0  have_%logit_0.0  a_%logit_0.0  significant_%logit_1.0  impact_%logit_0.0  on_%logit_2.0  mortality_%logit_1.0  or_%logit_0.0  cardiovascular_%logit_0.0  disease_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  may_%logit_0.0  have_%logit_0.0  a_%logit_2.0  beneficial_%logit_2.0  effect_%logit_2.0  on_%logit_1.0  the_%logit_2.0  incidence_%logit_0.0  and_%logit_1.0  severity_%logit_1.0  of_%logit_0.0  these_%logit_0.0  adverse_%logit_0.0  events_%logit_0.0 ._%logit_0.0  Vit_%logit_0.0 amins_%logit_0.0  E_%logit_1.0  and_%logit_0.0  zinc_%logit_0.0  supplement_%logit_0.0 ing_%logit_0.0  supplements_%logit_2.0  may_%logit_0.0  reduce_%logit_2.0  mortality_%logit_2.0  and_%logit_0.0  morbid_%logit_1.0 ity_%logit_1.0 ,_%logit_2.0  but_%logit_2.0  further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  confirm_%logit_0.0  this_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_1.0 otherapy_%logit_1.0  for_%logit_1.0  t_%logit_1.0 ic_%logit_2.0 l_%logit_1.0 op_%logit_0.0 idine_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  ADHD_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  whether_%logit_0.0  psych_%logit_2.0 otherapy_%logit_1.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  what_%logit_2.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_2.0  and_%logit_2.0  intensity_%logit_0.0  of_%logit_1.0  therapy_%logit_0.0  is_%logit_0.0  most_%logit_1.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_1.0  the_%logit_1.0  severity_%logit_0.0  of_%logit_2.0  the_%logit_1.0  symptoms_%logit_0.0  of_%logit_2.0  ADHD_%logit_1.0  and_%logit_1.0  its_%logit_1.0  t_%logit_0.0 ic_%logit_0.0 -_%logit_2.0 related_%logit_1.0  symptoms_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_1.0  psychological_%logit_2.0  therapies_%logit_2.0  for_%logit_2.0  ADHD_%logit_2.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  psych_%logit_1.0 otherapy_%logit_2.0  with_%logit_0.0  other_%logit_0.0  treatments_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_1.0  use_%logit_0.0  of_%logit_2.0  creatine_%logit_0.0  for_%logit_2.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_1.0  ps_%logit_2.0 or_%logit_1.0 iasis_%logit_1.0  or_%logit_0.0  ps_%logit_0.0 ori_%logit_0.0 atic_%logit_2.0  arthritis_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  whether_%logit_1.0  creatine_%logit_1.0  has_%logit_0.0  a_%logit_0.0  beneficial_%logit_0.0  effect_%logit_2.0  on_%logit_2.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_1.0  pain_%logit_2.0  and_%logit_0.0  function_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  these_%logit_1.0  conditions_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  creatine_%logit_2.0  with_%logit_1.0  placebo_%logit_2.0  or_%logit_0.0  no_%logit_0.0  treatment_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  whether_%logit_2.0  creatine_%logit_2.0  is_%logit_0.0  more_%logit_0.0  effective_%logit_0.0  than_%logit_0.0  placebo_%logit_0.0  or_%logit_0.0  placebo_%logit_2.0  in_%logit_1.0  reducing_%logit_0.0  pain_%logit_2.0  and_%logit_2.0  stiffness_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  who_%logit_0.0  are_%logit_2.0  unable_%logit_1.0  to_%logit_0.0  tolerate_%logit_1.0  creatine_%logit_0.0  or_%logit_0.0  its_%logit_0.0  analog_%logit_1.0 ues_%logit_0.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  long_%logit_0.0 -_%logit_2.0 term_%logit_1.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  evaluate_%logit_2.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_1.0  creatine_%logit_0.0  on_%logit_0.0  pain_%logit_1.0 ,_%logit_1.0  stiffness_%logit_2.0  and_%logit_1.0  function_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  iron_%logit_0.0  supplements_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  iron_%logit_0.0  deficiency_%logit_1.0  ana_%logit_0.0 emia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_0.0  iron_%logit_1.0  supplements_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_1.0  harmful_%logit_0.0  for_%logit_0.0  this_%logit_0.0  condition_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  whether_%logit_0.0  iron_%logit_0.0  supplementation_%logit_0.0  is_%logit_0.0  beneficial_%logit_0.0  in_%logit_0.0  the_%logit_2.0  management_%logit_0.0  of_%logit_2.0  this_%logit_1.0  condition_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  iron_%logit_2.0  supplementation_%logit_2.0  on_%logit_2.0  iron_%logit_2.0  deficient_%logit_2.0  ana_%logit_2.0 emia_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  iron_%logit_1.0  supplementation_%logit_2.0  with_%logit_0.0  other_%logit_1.0  iron_%logit_1.0  supplements_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_0.0  long_%logit_2.0 -_%logit_2.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  iron_%logit_2.0  supplement_%logit_0.0 ing_%logit_2.0  iron_%logit_1.0  supplements_%logit_1.0  for_%logit_1.0  iron_%logit_2.0  deficiencies_%logit_1.0  in_%logit_1.0  ana_%logit_0.0 emia_%logit_0.0  patients_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  ib_%logit_1.0 up_%logit_1.0 ro_%logit_0.0 fen_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  acute_%logit_0.0  migraine_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  to_%logit_1.0  support_%logit_0.0  its_%logit_1.0  use_%logit_0.0  as_%logit_1.0  an_%logit_1.0  adjunct_%logit_0.0  to_%logit_2.0  other_%logit_0.0  anti_%logit_0.0 -_%logit_0.0 m_%logit_1.0 ig_%logit_1.0 raine_%logit_2.0  drugs_%logit_0.0 ,_%logit_0.0  or_%logit_1.0  as_%logit_0.0  an_%logit_0.0  adj_%logit_0.0 u_%logit_1.0 vant_%logit_1.0  to_%logit_2.0  other_%logit_0.0  treatments_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  identify_%logit_0.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_0.0  duration_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  best_%logit_1.0  dose_%logit_2.0  to_%logit_2.0  use_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_1.0  drugs_%logit_0.0  in_%logit_2.0  acute_%logit_2.0  migraine_%logit_1.0 ._%logit_0.0  Recommend_%logit_0.0 ations_%logit_0.0  for_%logit_1.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  be_%logit_0.0  made_%logit_0.0  in_%logit_1.0  light_%logit_2.0  of_%logit_1.0  the_%logit_0.0  increasing_%logit_0.0  prevalence_%logit_0.0  of_%logit_1.0  migraine_%logit_0.0 ,_%logit_2.0  the_%logit_0.0  increasing_%logit_1.0  frequency_%logit_2.0  of_%logit_1.0  adverse_%logit_1.0  events_%logit_1.0  and_%logit_1.0  the_%logit_0.0  increasing_%logit_2.0  number_%logit_0.0  of_%logit_0.0  patients_%logit_1.0  suffering_%logit_0.0  from_%logit_0.0  adverse_%logit_2.0  events_%logit_0.0 ._%logit_0.0
 The_%logit_0.0  results_%logit_0.0  of_%logit_0.0  this_%logit_1.0  review_%logit_2.0  support_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  aerobic_%logit_0.0  exercise_%logit_2.0  as_%logit_1.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_1.0  conventional_%logit_0.0  physical_%logit_1.0  activity_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_2.0  the_%logit_0.0  results_%logit_1.0  are_%logit_1.0  based_%logit_1.0  on_%logit_1.0  a_%logit_0.0  small_%logit_1.0  number_%logit_0.0  of_%logit_0.0  small_%logit_0.0  studies_%logit_0.0 ,_%logit_2.0  all_%logit_1.0  of_%logit_1.0  which_%logit_2.0  were_%logit_0.0  conducted_%logit_0.0  in_%logit_0.0  the_%logit_2.0  1990_%logit_2.0 s_%logit_0.0  and_%logit_2.0  2000_%logit_0.0 s_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_2.0  results_%logit_1.0  of_%logit_1.0  these_%logit_1.0  studies_%logit_1.0  are_%logit_1.0  still_%logit_1.0  the_%logit_0.0  same_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_0.0  whether_%logit_0.0  aerobic_%logit_2.0  exercise_%logit_0.0  is_%logit_0.0  more_%logit_0.0  effective_%logit_1.0  than_%logit_1.0  manual_%logit_0.0  exercise_%logit_1.0  as_%logit_2.0  a_%logit_0.0  supplement_%logit_0.0  to_%logit_1.0  physical_%logit_1.0  activity_%logit_2.0  or_%logit_0.0  as_%logit_1.0  a_%logit_2.0  substitute_%logit_0.0  for_%logit_1.0  aerobic_%logit_1.0  exercise_%logit_1.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_2.0  bone_%logit_0.0  mineral_%logit_1.0  density_%logit_2.0  and_%logit_1.0  muscle_%logit_1.0  strength_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_1.0  aerobic_%logit_2.0  exercise_%logit_1.0  with_%logit_2.0  manual_%logit_0.0  exercise_%logit_0.0 ._%logit_2.0
 Coun_%logit_0.0 selling_%logit_0.0  attendance_%logit_1.0  appears_%logit_0.0  to_%logit_0.0  have_%logit_2.0  a_%logit_0.0  positive_%logit_2.0  effect_%logit_2.0  on_%logit_1.0  retention_%logit_0.0  of_%logit_0.0  abstinence_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_1.0  it_%logit_0.0  is_%logit_0.0  not_%logit_1.0  clear_%logit_0.0  whether_%logit_0.0  it_%logit_0.0  has_%logit_0.0  an_%logit_0.0  effect_%logit_0.0  on_%logit_2.0  relapse_%logit_0.0  or_%logit_0.0  relapse_%logit_0.0  rates_%logit_1.0 ,_%logit_1.0  or_%logit_0.0  on_%logit_1.0  relapse_%logit_1.0  rates_%logit_0.0  or_%logit_0.0  relapse_%logit_0.0  rate_%logit_1.0 ,_%logit_0.0  or_%logit_2.0  whether_%logit_1.0  coun_%logit_0.0 selling_%logit_1.0  attendance_%logit_0.0  has_%logit_0.0  a_%logit_0.0  negative_%logit_1.0  impact_%logit_1.0  on_%logit_2.0  relapse_%logit_2.0  rate_%logit_0.0  and_%logit_0.0  relapse_%logit_2.0  rates_%logit_0.0 ._%logit_2.0  The_%logit_2.0  results_%logit_0.0  of_%logit_0.0  this_%logit_2.0  review_%logit_0.0  suggest_%logit_0.0  that_%logit_0.0  counselling_%logit_1.0  attendance_%logit_0.0  may_%logit_0.0  have_%logit_0.0  an_%logit_2.0  important_%logit_2.0  impact_%logit_0.0  on_%logit_2.0  retention_%logit_2.0  in_%logit_2.0  abstinence_%logit_0.0 ,_%logit_0.0  but_%logit_2.0  that_%logit_0.0  it_%logit_2.0  is_%logit_1.0  unlikely_%logit_2.0  that_%logit_1.0  it_%logit_0.0  will_%logit_1.0  have_%logit_0.0  a_%logit_1.0  significant_%logit_2.0  impact_%logit_0.0  on_%logit_2.0  quality_%logit_1.0  of_%logit_2.0  life_%logit_0.0  and_%logit_0.0  relapse_%logit_0.0  rate_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_1.0  counselling_%logit_1.0  attendance_%logit_1.0  on_%logit_1.0  relapse_%logit_0.0 ,_%logit_0.0  relapse_%logit_1.0  rates_%logit_0.0  and_%logit_0.0  relapse_%logit_1.0  severity_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_0.0  of_%logit_0.0  antibiotics_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  EB_%logit_0.0 V_%logit_2.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_1.0  in_%logit_0.0  EB_%logit_1.0 V_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  antibiotic_%logit_0.0  therapy_%logit_2.0  with_%logit_2.0  other_%logit_0.0  treatments_%logit_2.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_2.0  antibiotics_%logit_0.0  for_%logit_0.0  EB_%logit_1.0 V_%logit_0.0 -_%logit_0.0 related_%logit_0.0  symptoms_%logit_1.0 ,_%logit_2.0  or_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  antibiotics_%logit_0.0  with_%logit_1.0  other_%logit_1.0  anti_%logit_0.0 -_%logit_1.0 EB_%logit_1.0 V_%logit_1.0  treatments_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_2.0  efficacy_%logit_1.0  of_%logit_0.0  antibiotics_%logit_2.0 ,_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  the_%logit_0.0  impact_%logit_0.0  of_%logit_2.0  antibiotics_%logit_1.0  on_%logit_1.0  EB_%logit_1.0 V_%logit_2.0  symptoms_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  antibiotics_%logit_2.0  with_%logit_0.0  each_%logit_1.0  other_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  no_%logit_1.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_1.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_0.0  anti_%logit_0.0 hy_%logit_2.0 pert_%logit_0.0 ensive_%logit_0.0  drugs_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  album_%logit_1.0 in_%logit_2.0 uria_%logit_0.0  in_%logit_0.0  humans_%logit_0.0  with_%logit_1.0  CK_%logit_1.0 D_%logit_2.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_2.0 ised_%logit_2.0  controlled_%logit_0.0  trials_%logit_1.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_1.0  these_%logit_2.0  drugs_%logit_0.0  on_%logit_0.0  renal_%logit_0.0  function_%logit_1.0 ,_%logit_2.0  kidney_%logit_2.0  function_%logit_1.0  and_%logit_0.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_2.0  DK_%logit_0.0 D_%logit_0.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_2.0  of_%logit_0.0  high_%logit_0.0  quality_%logit_1.0 ,_%logit_1.0  with_%logit_0.0  a_%logit_1.0  focus_%logit_1.0  on_%logit_0.0  improving_%logit_0.0  quality_%logit_0.0  and_%logit_1.0  quantity_%logit_1.0  of_%logit_2.0  data_%logit_0.0 ._%logit_0.0  They_%logit_1.0  should_%logit_0.0  also_%logit_1.0  evaluate_%logit_1.0  the_%logit_2.0  effect_%logit_1.0  of_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  on_%logit_2.0  kidney_%logit_2.0  function_%logit_2.0 ._%logit_2.0
 Family_%logit_0.0  counselling_%logit_0.0  is_%logit_0.0  effective_%logit_2.0  in_%logit_2.0  reducing_%logit_0.0  relapse_%logit_0.0  rates_%logit_0.0  in_%logit_1.0  people_%logit_2.0  with_%logit_2.0  schizophrenia_%logit_0.0  and_%logit_0.0  family_%logit_1.0  distress_%logit_1.0 ._%logit_2.0  Family_%logit_2.0  counselling_%logit_1.0  may_%logit_0.0  reduce_%logit_0.0  relapse_%logit_1.0  rates_%logit_1.0 ,_%logit_0.0  but_%logit_2.0  it_%logit_0.0  is_%logit_0.0  not_%logit_1.0  clear_%logit_0.0  whether_%logit_0.0  it_%logit_0.0  has_%logit_0.0  an_%logit_2.0  impact_%logit_2.0  on_%logit_1.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_0.0 ._%logit_1.0  Family_%logit_0.0  counseling_%logit_1.0  is_%logit_1.0  effective_%logit_0.0  as_%logit_1.0  an_%logit_2.0  adjunct_%logit_2.0  to_%logit_1.0  other_%logit_0.0  psych_%logit_2.0 other_%logit_1.0 ape_%logit_1.0 utic_%logit_2.0  approaches_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  is_%logit_2.0  associated_%logit_2.0  with_%logit_2.0  a_%logit_0.0  higher_%logit_2.0  rate_%logit_2.0  of_%logit_0.0  psychological_%logit_1.0  distress_%logit_0.0  and_%logit_1.0  a_%logit_2.0  decreased_%logit_2.0  rate_%logit_1.0  of_%logit_2.0  depression_%logit_2.0 ._%logit_2.0  Family_%logit_0.0  therapy_%logit_2.0  may_%logit_2.0  be_%logit_2.0  effective_%logit_0.0  as_%logit_2.0  a_%logit_1.0  component_%logit_2.0  of_%logit_2.0  a_%logit_0.0  broader_%logit_1.0  range_%logit_1.0  of_%logit_1.0  psych_%logit_0.0 other_%logit_0.0 ap_%logit_0.0 ies_%logit_2.0 ,_%logit_2.0  but_%logit_0.0  its_%logit_2.0  effectiveness_%logit_0.0  is_%logit_0.0  unclear_%logit_0.0 ._%logit_2.0  Family_%logit_1.0  coun_%logit_0.0 sell_%logit_2.0 ors_%logit_1.0  may_%logit_0.0  have_%logit_0.0  a_%logit_1.0  role_%logit_2.0  to_%logit_0.0  play_%logit_1.0  in_%logit_0.0  the_%logit_0.0  management_%logit_0.0  of_%logit_2.0  relapse_%logit_0.0 ,_%logit_1.0  but_%logit_0.0  the_%logit_0.0  quality_%logit_2.0  of_%logit_2.0  the_%logit_0.0  evidence_%logit_2.0  is_%logit_0.0  low_%logit_0.0  and_%logit_0.0  the_%logit_0.0  number_%logit_0.0  of_%logit_2.0  studies_%logit_2.0  is_%logit_1.0  low_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  family_%logit_0.0  counselling_%logit_0.0  as_%logit_0.0  a_%logit_0.0  part_%logit_1.0  of_%logit_1.0  a_%logit_1.0  multif_%logit_1.0 acet_%logit_1.0 ed_%logit_2.0  approach_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  pro_%logit_0.0 ph_%logit_2.0 yl_%logit_2.0 actic_%logit_0.0  cort_%logit_0.0 ic_%logit_1.0 oster_%logit_2.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  NIC_%logit_0.0 U_%logit_1.0  neon_%logit_0.0 ates_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_1.0 ,_%logit_0.0  duration_%logit_1.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_1.0  treatment_%logit_2.0  and_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_1.0  effects_%logit_2.0  on_%logit_1.0  NIC_%logit_2.0 U_%logit_2.0  mortality_%logit_1.0  and_%logit_0.0  morbid_%logit_1.0 ity_%logit_2.0  in_%logit_1.0  neon_%logit_0.0 ates_%logit_2.0  who_%logit_0.0  are_%logit_0.0  at_%logit_1.0  risk_%logit_1.0  of_%logit_1.0  death_%logit_0.0  from_%logit_2.0  NIC_%logit_2.0 U_%logit_2.0  discharge_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_0.0  agents_%logit_0.0  in_%logit_1.0  neon_%logit_2.0 atal_%logit_0.0  resusc_%logit_0.0 itation_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  pro_%logit_0.0 ph_%logit_0.0 yl_%logit_0.0 actic_%logit_0.0  antibiotics_%logit_0.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  O_%logit_0.0 RT_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  best_%logit_1.0  antibiotic_%logit_2.0  for_%logit_1.0  O_%logit_0.0 RT_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_1.0  agents_%logit_0.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_2.0  survival_%logit_0.0  and_%logit_2.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_2.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  O_%logit_2.0 RT_%logit_1.0  who_%logit_0.0  are_%logit_0.0  at_%logit_1.0  high_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  relapse_%logit_2.0  or_%logit_0.0  relapse_%logit_1.0 ._%logit_1.0  It_%logit_1.0  is_%logit_1.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_2.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_1.0  in_%logit_0.0  this_%logit_0.0  area_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_2.0  evaluate_%logit_1.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_1.0  toxicity_%logit_0.0  profiles_%logit_0.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_2.0  in_%logit_1.0  particular_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_1.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  oxy_%logit_0.0 toc_%logit_1.0 in_%logit_1.0  as_%logit_0.0  an_%logit_2.0  induction_%logit_1.0  agent_%logit_2.0  for_%logit_1.0  ca_%logit_1.0 es_%logit_1.0 are_%logit_1.0 an_%logit_0.0  section_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  best_%logit_2.0  induction_%logit_2.0  agent_%logit_0.0  and_%logit_2.0  the_%logit_2.0  safest_%logit_2.0  induction_%logit_2.0  method_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_2.0  is_%logit_2.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  profiles_%logit_2.0  of_%logit_2.0  various_%logit_1.0  induction_%logit_2.0  methods_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_1.0  methods_%logit_0.0  to_%logit_2.0  other_%logit_2.0  induction_%logit_0.0  methods_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0  there_%logit_1.0  is_%logit_1.0  an_%logit_2.0  urgent_%logit_2.0  need_%logit_1.0  for_%logit_2.0  an_%logit_0.0  assessment_%logit_0.0  of_%logit_2.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  profile_%logit_0.0  of_%logit_0.0  induction_%logit_2.0  methods_%logit_2.0  and_%logit_2.0  the_%logit_2.0  risks_%logit_2.0  associated_%logit_2.0  with_%logit_2.0  them_%logit_1.0 ._%logit_1.0  This_%logit_1.0  should_%logit_1.0  be_%logit_1.0  done_%logit_2.0  in_%logit_0.0  accordance_%logit_0.0  with_%logit_0.0  the_%logit_1.0  recommendations_%logit_1.0  of_%logit_0.0  the_%logit_1.0  Coch_%logit_0.0 rane_%logit_0.0  Handbook_%logit_0.0  of_%logit_0.0  Obst_%logit_0.0 et_%logit_0.0 rics_%logit_0.0  and_%logit_0.0  Gy_%logit_0.0 nec_%logit_1.0 ology_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  ib_%logit_1.0 up_%logit_2.0 ro_%logit_0.0 fen_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_0.0  to_%logit_1.0  standard_%logit_2.0  analges_%logit_2.0 ia_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  acute_%logit_0.0  pain_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_1.0  of_%logit_1.0  ib_%logit_0.0 ip_%logit_2.0 ro_%logit_2.0 fen_%logit_1.0 ,_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  duration_%logit_1.0  of_%logit_0.0  analges_%logit_0.0 ia_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  dosage_%logit_1.0  and_%logit_2.0  timing_%logit_1.0  of_%logit_2.0  administration_%logit_2.0  in_%logit_0.0  acute_%logit_1.0  pain_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  other_%logit_1.0  analges_%logit_0.0 ia_%logit_2.0  types_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_1.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  other_%logit_0.0  NSA_%logit_1.0 IDs_%logit_2.0  in_%logit_1.0  pain_%logit_2.0  relief_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_0.0  safety_%logit_0.0  profiles_%logit_1.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_0.0 ._%logit_2.0
 Vigil_%logit_0.0 ant_%logit_0.0  vig_%logit_1.0 ab_%logit_2.0 at_%logit_2.0 rin_%logit_2.0  is_%logit_0.0  effective_%logit_2.0  in_%logit_2.0  reducing_%logit_1.0  the_%logit_1.0  number_%logit_1.0  of_%logit_0.0  seizures_%logit_0.0  and_%logit_0.0  the_%logit_0.0  frequency_%logit_0.0  of_%logit_1.0  adverse_%logit_2.0  events_%logit_2.0 ._%logit_1.0  Its_%logit_0.0  efficacy_%logit_2.0  appears_%logit_1.0  to_%logit_1.0  be_%logit_1.0  similar_%logit_2.0  to_%logit_2.0  that_%logit_2.0  of_%logit_1.0  g_%logit_1.0 ab_%logit_0.0 ap_%logit_1.0 entin_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  with_%logit_1.0  a_%logit_1.0  higher_%logit_1.0  incidence_%logit_0.0  of_%logit_1.0  adverse_%logit_1.0  effects_%logit_0.0 ._%logit_2.0  Its_%logit_1.0  effectiveness_%logit_1.0  is_%logit_0.0  similar_%logit_2.0  to_%logit_1.0  its_%logit_0.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_0.0  control_%logit_1.0  of_%logit_0.0  seizures_%logit_2.0  with_%logit_2.0  G_%logit_1.0 VG_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  it_%logit_1.0  is_%logit_1.0  not_%logit_2.0  clear_%logit_1.0  whether_%logit_1.0  it_%logit_1.0  is_%logit_1.0  more_%logit_2.0  effective_%logit_2.0  than_%logit_0.0  G_%logit_0.0 VG_%logit_0.0  in_%logit_1.0  reducing_%logit_1.0  seizures_%logit_1.0  with_%logit_1.0  or_%logit_2.0  without_%logit_1.0  G_%logit_0.0 VG_%logit_1.0 ._%logit_2.0  It_%logit_2.0  is_%logit_2.0  unclear_%logit_2.0  whether_%logit_1.0  it_%logit_0.0  has_%logit_1.0  an_%logit_1.0  effect_%logit_1.0  on_%logit_2.0  other_%logit_0.0  adverse_%logit_0.0  events_%logit_1.0 ,_%logit_2.0  such_%logit_1.0  as_%logit_2.0  nausea_%logit_1.0  or_%logit_1.0  vomiting_%logit_0.0 ,_%logit_0.0  or_%logit_2.0  on_%logit_2.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_2.0 ,_%logit_0.0  but_%logit_2.0  its_%logit_2.0  efficacy_%logit_0.0  appears_%logit_2.0  similar_%logit_1.0  to_%logit_2.0  G_%logit_0.0 VG_%logit_2.0  with_%logit_2.0  respect_%logit_1.0  to_%logit_2.0  frequency_%logit_0.0  and_%logit_2.0  severity_%logit_2.0  of_%logit_1.0  adverse_%logit_1.0  event_%logit_0.0  profiles_%logit_2.0 ._%logit_1.0  Vigil_%logit_0.0 ant_%logit_1.0  g_%logit_2.0 ab_%logit_2.0 av_%logit_1.0 at_%logit_0.0 rin_%logit_1.0  appears_%logit_0.0  to_%logit_0.0  have_%logit_0.0  a_%logit_0.0  similar_%logit_0.0  efficacy_%logit_0.0  to_%logit_0.0  G_%logit_0.0 GV_%logit_0.0 ,_%logit_1.0  but_%logit_1.0  has_%logit_1.0  a_%logit_1.0  higher_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  having_%logit_0.0  an_%logit_0.0  adverse_%logit_2.0  event_%logit_0.0  profile_%logit_0.0 ._%logit_0.0  Its_%logit_0.0  use_%logit_0.0  is_%logit_1.0  associated_%logit_1.0  with_%logit_0.0  an_%logit_0.0  increased_%logit_1.0  risk_%logit_0.0  of_%logit_1.0  nar_%logit_1.0 co_%logit_2.0 le_%logit_2.0 psy_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  a_%logit_2.0  decreased_%logit_1.0  risk_%logit_1.0  of_%logit_2.0  seizures_%logit_0.0  in_%logit_0.0  the_%logit_0.0  long_%logit_1.0  term_%logit_2.0 ._%logit_0.0  Its_%logit_0.0  adverse_%logit_0.0  effects_%logit_0.0  are_%logit_1.0  similar_%logit_1.0  to_%logit_1.0  those_%logit_1.0  of_%logit_1.0  G_%logit_0.0 VG_%logit_0.0  but_%logit_0.0  its_%logit_1.0  use_%logit_0.0  is_%logit_0.0  not_%logit_0.0  associated_%logit_1.0  with_%logit_1.0  a_%logit_1.0  reduction_%logit_0.0  in_%logit_2.0  seizures_%logit_0.0  in_%logit_0.0  G_%logit_0.0 VG_%logit_0.0  or_%logit_0.0  G_%logit_0.0 VG_%logit_0.0  alone_%logit_0.0 ._%logit_2.0  Its_%logit_1.0  duration_%logit_1.0  is_%logit_1.0  longer_%logit_2.0  than_%logit_1.0  that_%logit_1.0  of_%logit_1.0  other_%logit_0.0  G_%logit_0.0 VG_%logit_0.0  agon_%logit_1.0 ist_%logit_1.0  drugs_%logit_0.0 ._%logit_2.0  It_%logit_0.0  appears_%logit_1.0  that_%logit_0.0  Vigil_%logit_2.0 ant_%logit_2.0  G_%logit_2.0 GB_%logit_0.0  is_%logit_0.0  more_%logit_0.0  likely_%logit_0.0  to_%logit_0.0  have_%logit_0.0  an_%logit_1.0  adverse_%logit_1.0  effect_%logit_1.0  on_%logit_1.0  G_%logit_0.0 VG_%logit_1.0  and_%logit_0.0  G_%logit_0.0 VG_%logit_2.0  compared_%logit_0.0  to_%logit_2.0  G_%logit_1.0 GB_%logit_1.0 ,_%logit_2.0  but_%logit_1.0  the_%logit_0.0  exact_%logit_2.0  duration_%logit_2.0  of_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  is_%logit_1.0  unclear_%logit_1.0 ._%logit_1.0  Vigil_%logit_2.0 ante_%logit_2.0  G_%logit_1.0 GB_%logit_1.0  has_%logit_1.0  a_%logit_2.0  longer_%logit_2.0  duration_%logit_2.0  and_%logit_2.0  is_%logit_1.0  less_%logit_1.0  likely_%logit_1.0  to_%logit_2.0  cause_%logit_0.0  adverse_%logit_0.0  events_%logit_1.0  in_%logit_2.0  the_%logit_2.0  short_%logit_2.0  term_%logit_0.0 ._%logit_0.0  It_%logit_0.0  has_%logit_1.0  a_%logit_0.0  shorter_%logit_0.0  duration_%logit_0.0  and_%logit_1.0  has_%logit_1.0  a_%logit_2.0  lower_%logit_0.0  risk_%logit_2.0  of_%logit_2.0  relapse_%logit_1.0 ,_%logit_2.0  but_%logit_2.0  a_%logit_1.0  higher_%logit_1.0  rate_%logit_0.0  of_%logit_2.0  relapse_%logit_0.0  in_%logit_0.0  the_%logit_0.0  longer_%logit_2.0  term_%logit_0.0 ,_%logit_1.0  but_%logit_1.0  is_%logit_1.0  not_%logit_2.0  significantly_%logit_2.0  different_%logit_1.0  from_%logit_1.0  that_%logit_0.0  of_%logit_0.0  G_%logit_0.0 GB_%logit_0.0  with_%logit_2.0  G_%logit_2.0 GB_%logit_2.0 ._%logit_2.0  Its_%logit_0.0  long_%logit_0.0 -_%logit_0.0 term_%logit_1.0  efficacy_%logit_0.0  is_%logit_0.0  unknown_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  its_%logit_2.0  duration_%logit_2.0  is_%logit_1.0  unclear_%logit_1.0  due_%logit_1.0  to_%logit_2.0  the_%logit_2.0  rarity_%logit_1.0  of_%logit_0.0  the_%logit_1.0  adverse_%logit_1.0  events_%logit_2.0  reported_%logit_0.0  in_%logit_2.0  this_%logit_2.0  review_%logit_1.0 ._%logit_1.0  Vigil_%logit_1.0 antes_%logit_1.0  G_%logit_0.0 GB_%logit_0.0  appear_%logit_0.0  to_%logit_0.0  have_%logit_2.0  similar_%logit_0.0  efficacy_%logit_1.0  as_%logit_0.0  G_%logit_0.0 GB_%logit_0.0  and_%logit_0.0  G_%logit_0.0 GB_%logit_1.0  in_%logit_1.0  terms_%logit_0.0  of_%logit_1.0  seizure_%logit_0.0  frequency_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  have_%logit_2.0  a_%logit_0.0  longer_%logit_1.0  course_%logit_1.0  of_%logit_2.0  action_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  recommend_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  sal_%logit_0.0 but_%logit_0.0 am_%logit_1.0 ol_%logit_0.0  as_%logit_2.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_1.0  sal_%logit_1.0 but_%logit_0.0 af_%logit_0.0 il_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  asthma_%logit_2.0  who_%logit_1.0  are_%logit_1.0  unable_%logit_2.0  to_%logit_0.0  tolerate_%logit_0.0  or_%logit_0.0  tolerate_%logit_2.0  sal_%logit_1.0 but_%logit_2.0 amin_%logit_1.0 ophen_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_2.0  confirm_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  sal_%logit_2.0 ut_%logit_0.0 am_%logit_2.0 ol_%logit_2.0  in_%logit_1.0  reducing_%logit_2.0  the_%logit_1.0  number_%logit_1.0  of_%logit_2.0  exacerb_%logit_0.0 ations_%logit_0.0  and_%logit_0.0  the_%logit_1.0  severity_%logit_2.0  of_%logit_0.0  adverse_%logit_0.0  events_%logit_0.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_1.0  sal_%logit_0.0 ut_%logit_0.0 amin_%logit_0.0 ophen_%logit_1.0  with_%logit_2.0  sal_%logit_0.0 ut_%logit_2.0 amide_%logit_1.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_2.0  long_%logit_1.0 -_%logit_1.0 term_%logit_0.0  data_%logit_0.0  are_%logit_2.0  needed_%logit_2.0  in_%logit_0.0  order_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  sal_%logit_0.0 uting_%logit_0.0  sal_%logit_0.0 ut_%logit_0.0 amy_%logit_0.0 ol_%logit_2.0  as_%logit_2.0  an_%logit_0.0  alternative_%logit_2.0  to_%logit_0.0  sal_%logit_1.0 but_%logit_1.0 amide_%logit_2.0  as_%logit_2.0  a_%logit_2.0  mon_%logit_0.0 otherapy_%logit_0.0  for_%logit_0.0  patients_%logit_1.0  who_%logit_2.0  are_%logit_2.0  able_%logit_1.0  to_%logit_1.0  tolerate_%logit_2.0  Sal_%logit_2.0 ut_%logit_2.0 amide_%logit_1.0  as_%logit_2.0  mon_%logit_2.0 otherapy_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  hyd_%logit_0.0 roc_%logit_0.0 oll_%logit_2.0 oid_%logit_0.0  gel_%logit_0.0  gel_%logit_1.0  as_%logit_1.0  a_%logit_2.0  substitute_%logit_2.0  for_%logit_0.0  saline_%logit_2.0  gel_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_1.0  successful_%logit_1.0  eruption_%logit_1.0  of_%logit_2.0  an_%logit_0.0  erupt_%logit_0.0 ing_%logit_1.0  volcano_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  formulation_%logit_2.0  and_%logit_1.0  timing_%logit_2.0  of_%logit_2.0  hyd_%logit_2.0 oc_%logit_0.0 oll_%logit_1.0 oid_%logit_2.0  fluid_%logit_2.0  gel_%logit_2.0  gel_%logit_1.0  gel_%logit_0.0  and_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  its_%logit_0.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_2.0  management_%logit_0.0  of_%logit_2.0  successful_%logit_1.0  eru_%logit_0.0 ptions_%logit_2.0 ._%logit_0.0  It_%logit_0.0  is_%logit_1.0  also_%logit_2.0  important_%logit_2.0  to_%logit_1.0  understand_%logit_0.0  the_%logit_2.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_0.0  Hyd_%logit_2.0 roc_%logit_0.0 oll_%logit_2.0 oids_%logit_1.0  gel_%logit_0.0  gel_%logit_0.0  works_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_2.0  various_%logit_1.0  types_%logit_0.0  of_%logit_2.0  gel_%logit_1.0  gel_%logit_2.0  in_%logit_2.0  different_%logit_1.0  settings_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  dietary_%logit_0.0  fibre_%logit_1.0  supplements_%logit_1.0  for_%logit_0.0  weight_%logit_2.0  loss_%logit_0.0  in_%logit_0.0  NJ_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_2.0  fibre_%logit_2.0  supplements_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_1.0  for_%logit_0.0  weight_%logit_0.0  gain_%logit_1.0  in_%logit_1.0  NJ_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_1.0  effects_%logit_2.0  of_%logit_1.0  fibre_%logit_1.0  supplements_%logit_1.0  on_%logit_0.0  mortality_%logit_0.0  and_%logit_0.0  morbid_%logit_1.0 ity_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effect_%logit_0.0  of_%logit_0.0  fibre_%logit_2.0  supplementation_%logit_1.0  on_%logit_1.0  mortality_%logit_0.0 ,_%logit_2.0  morbid_%logit_2.0 ity_%logit_1.0  and_%logit_2.0  mortality_%logit_0.0  in_%logit_1.0  NJ_%logit_0.0  and_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  effects_%logit_2.0  on_%logit_1.0  morbid_%logit_1.0 ity_%logit_1.0  or_%logit_0.0  mortality_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  long_%logit_0.0 -_%logit_1.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  required_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_0.0  fibre_%logit_1.0  supplement_%logit_0.0 ing_%logit_2.0  diets_%logit_2.0  in_%logit_1.0  NJ_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  fibre_%logit_0.0  supplements_%logit_0.0  with_%logit_0.0  fibre_%logit_2.0  supplements_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  nicotine_%logit_1.0  replacement_%logit_2.0  therapy_%logit_0.0  for_%logit_0.0  quitting_%logit_2.0  tobacco_%logit_2.0  use_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  establish_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  this_%logit_0.0  therapy_%logit_0.0 ._%logit_2.0  It_%logit_2.0  is_%logit_2.0  also_%logit_1.0  important_%logit_2.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_2.0  by_%logit_0.0  which_%logit_0.0  nicotine_%logit_0.0  replacement_%logit_0.0  has_%logit_0.0  been_%logit_1.0  used_%logit_0.0  to_%logit_1.0  improve_%logit_1.0  quitting_%logit_2.0  behaviour_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  how_%logit_2.0  nicotine_%logit_0.0  replacement_%logit_1.0  is_%logit_2.0  used_%logit_2.0  in_%logit_2.0  the_%logit_2.0  context_%logit_0.0  of_%logit_0.0  a_%logit_0.0  reduction_%logit_0.0  in_%logit_2.0  smoking_%logit_1.0  frequency_%logit_1.0  and_%logit_2.0  duration_%logit_0.0  of_%logit_2.0  abstinence_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  other_%logit_2.0  nicotine_%logit_1.0  replacement_%logit_1.0  therapies_%logit_2.0 ,_%logit_1.0  such_%logit_2.0  as_%logit_2.0  oral_%logit_2.0  meth_%logit_1.0 ad_%logit_1.0 one_%logit_2.0  and_%logit_0.0  nicotine_%logit_0.0  replacement_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  th_%logit_0.0 rom_%logit_0.0 bo_%logit_0.0 ly_%logit_0.0 tic_%logit_0.0  agents_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  recurrent_%logit_2.0  DV_%logit_1.0 T_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  th_%logit_1.0 ro_%logit_0.0 bo_%logit_2.0 ly_%logit_2.0 tics_%logit_2.0  in_%logit_2.0  reducing_%logit_1.0  the_%logit_2.0  incidence_%logit_1.0  of_%logit_0.0  DV_%logit_2.0 T_%logit_0.0  rec_%logit_0.0 urrence_%logit_0.0  and_%logit_0.0  mortality_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  these_%logit_2.0  agents_%logit_0.0  with_%logit_0.0  placebo_%logit_0.0  or_%logit_1.0  no_%logit_1.0  treatment_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  also_%logit_0.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_1.0  and_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  these_%logit_0.0  drugs_%logit_1.0  in_%logit_0.0  reducing_%logit_1.0  total_%logit_0.0  mortality_%logit_0.0  and_%logit_1.0  morbid_%logit_0.0 ity_%logit_0.0  in_%logit_2.0  patients_%logit_2.0  with_%logit_1.0  DV_%logit_0.0 T_%logit_0.0 ,_%logit_0.0  including_%logit_1.0  in_%logit_1.0  those_%logit_1.0  with_%logit_2.0  a_%logit_0.0  history_%logit_2.0  of_%logit_0.0  major_%logit_0.0  bleeding_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  any_%logit_0.0  difference_%logit_2.0  in_%logit_1.0  mortality_%logit_1.0  rates_%logit_1.0  between_%logit_1.0  orth_%logit_2.0 op_%logit_2.0 aed_%logit_2.0 ic_%logit_0.0  and_%logit_0.0  robotic_%logit_0.0  hip_%logit_0.0  replacements_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  best_%logit_0.0  way_%logit_2.0  to_%logit_0.0  minim_%logit_0.0 ise_%logit_2.0  the_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_1.0  in_%logit_2.0  this_%logit_2.0  review_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  robotic_%logit_1.0  hip_%logit_0.0  replacement_%logit_0.0  as_%logit_1.0  a_%logit_2.0  replacement_%logit_1.0  for_%logit_1.0  traditional_%logit_0.0  hip_%logit_2.0  replacement_%logit_2.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  well_%logit_1.0 -_%logit_1.0 designed_%logit_2.0 ,_%logit_2.0  well_%logit_0.0 -_%logit_1.0 conduct_%logit_1.0 ed_%logit_0.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_1.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_2.0  robotic_%logit_1.0  replacement_%logit_0.0  on_%logit_1.0  mortality_%logit_2.0  rates_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  robotic_%logit_2.0  replacement_%logit_1.0  with_%logit_0.0  robotic_%logit_2.0  replacement_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_1.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  hyd_%logit_0.0 roc_%logit_0.0 ort_%logit_0.0 is_%logit_2.0 one_%logit_0.0  in_%logit_2.0  reducing_%logit_2.0  blood_%logit_2.0  pressure_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_0.0  hypertension_%logit_1.0 ._%logit_1.0  However_%logit_1.0 ,_%logit_0.0  the_%logit_1.0  amount_%logit_1.0  of_%logit_2.0  blood_%logit_1.0  pressure_%logit_0.0  reduction_%logit_0.0  achieved_%logit_0.0  was_%logit_2.0  not_%logit_2.0  significantly_%logit_1.0  different_%logit_2.0  from_%logit_2.0  that_%logit_1.0  achieved_%logit_1.0  in_%logit_0.0  the_%logit_0.0  control_%logit_0.0  group_%logit_1.0 ._%logit_1.0  There_%logit_0.0  is_%logit_1.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_1.0 -_%logit_2.0 conduct_%logit_1.0 ed_%logit_1.0  and_%logit_1.0  reported_%logit_2.0  random_%logit_1.0 ised_%logit_1.0  controlled_%logit_1.0  trials_%logit_1.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_1.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  hyd_%logit_0.0 oc_%logit_2.0 ort_%logit_1.0 is_%logit_0.0 ones_%logit_1.0  in_%logit_2.0  hypertension_%logit_0.0  patients_%logit_1.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_2.0  undertaken_%logit_1.0  in_%logit_1.0  areas_%logit_1.0  with_%logit_1.0  high_%logit_0.0  blood_%logit_1.0  pressure_%logit_1.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_2.0  in_%logit_0.0  areas_%logit_1.0  where_%logit_2.0  blood_%logit_0.0  pressure_%logit_0.0  is_%logit_1.0  low_%logit_1.0 ._%logit_0.0
 Psych_%logit_0.0 otherapy_%logit_0.0  appears_%logit_0.0  to_%logit_1.0  be_%logit_1.0  a_%logit_2.0  useful_%logit_0.0  tool_%logit_2.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  PTSD_%logit_2.0  and_%logit_1.0  its_%logit_0.0  aftermath_%logit_2.0 ._%logit_2.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_0.0  its_%logit_1.0  use_%logit_1.0  as_%logit_2.0  an_%logit_2.0  adjunct_%logit_0.0  to_%logit_0.0  other_%logit_2.0  psych_%logit_2.0 otherapy_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_0.0 otherapy_%logit_0.0  for_%logit_0.0  PTSD_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  psych_%logit_0.0 otherapy_%logit_2.0  with_%logit_0.0  other_%logit_1.0  psychological_%logit_1.0  therapies_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_2.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  its_%logit_0.0  effectiveness_%logit_1.0  in_%logit_2.0  other_%logit_0.0  conditions_%logit_0.0 ,_%logit_0.0  such_%logit_2.0  as_%logit_1.0  sleep_%logit_1.0  deprivation_%logit_0.0 ,_%logit_0.0  depression_%logit_1.0 ,_%logit_1.0  insomnia_%logit_1.0 ,_%logit_1.0  fatigue_%logit_2.0 ,_%logit_2.0  sleep_%logit_0.0  deprivation_%logit_2.0  and_%logit_2.0  sleep_%logit_1.0  deprivation_%logit_2.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_1.0  future_%logit_1.0  research_%logit_0.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  of_%logit_1.0  psychological_%logit_1.0  therapies_%logit_0.0  for_%logit_1.0  PTSD_%logit_0.0  and_%logit_1.0  other_%logit_1.0  psychological_%logit_1.0  disorders_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  also_%logit_2.0  examine_%logit_2.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  psychological_%logit_2.0  therapy_%logit_2.0  on_%logit_1.0  sleep_%logit_1.0  deprivation_%logit_1.0  in_%logit_0.0  particular_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  on_%logit_1.0  depression_%logit_2.0  and_%logit_0.0  anxiety_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  recommend_%logit_0.0  pro_%logit_2.0 ph_%logit_0.0 yl_%logit_0.0 actic_%logit_0.0  antibiotic_%logit_0.0  use_%logit_0.0  in_%logit_1.0  UT_%logit_2.0 I_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  antibiotic_%logit_2.0  use_%logit_1.0  for_%logit_1.0  UT_%logit_0.0 I_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  antibiotic_%logit_2.0  administration_%logit_2.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  UT_%logit_1.0 I_%logit_1.0  in_%logit_1.0  women_%logit_2.0  with_%logit_1.0  a_%logit_2.0  history_%logit_1.0  of_%logit_1.0  bacter_%logit_2.0 i_%logit_1.0 uria_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_2.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  of_%logit_0.0  antibiotics_%logit_1.0  in_%logit_2.0  UT_%logit_1.0 Is_%logit_1.0  in_%logit_1.0  women_%logit_2.0  who_%logit_1.0  are_%logit_1.0  undergoing_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_1.0  for_%logit_1.0  py_%logit_1.0 el_%logit_2.0 one_%logit_0.0 ph_%logit_0.0 ritis_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  for_%logit_0.0  those_%logit_0.0  who_%logit_0.0  are_%logit_1.0  unable_%logit_2.0  to_%logit_2.0  tolerate_%logit_0.0  antibiotic_%logit_0.0  treatment_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  oxy_%logit_0.0 toc_%logit_0.0 in_%logit_2.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  menstrual_%logit_1.0  bleeding_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_0.0  drug_%logit_0.0  for_%logit_2.0  menstrual_%logit_2.0  bleeding_%logit_2.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  its_%logit_1.0  effectiveness_%logit_2.0  to_%logit_1.0  other_%logit_1.0  drugs_%logit_1.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_1.0  oxy_%logit_2.0 toc_%logit_2.0 ins_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  its_%logit_2.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  other_%logit_1.0  menstrual_%logit_1.0  bleeding_%logit_0.0  conditions_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_1.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  other_%logit_2.0  drugs_%logit_1.0  for_%logit_2.0  menstrual_%logit_2.0  blood_%logit_1.0  loss_%logit_0.0  and_%logit_0.0  fertility_%logit_0.0 ._%logit_0.0
 Vitamin_%logit_0.0  E_%logit_2.0  supplementation_%logit_1.0  is_%logit_0.0  associated_%logit_2.0  with_%logit_0.0  a_%logit_0.0  reduction_%logit_1.0  in_%logit_1.0  mortality_%logit_0.0  and_%logit_1.0  disability_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  hepatitis_%logit_0.0  C_%logit_2.0  virus_%logit_0.0  infection_%logit_0.0 ._%logit_0.0  Vitamin_%logit_1.0  E_%logit_0.0  supplements_%logit_2.0  are_%logit_1.0  associated_%logit_2.0  with_%logit_0.0  an_%logit_0.0  increase_%logit_0.0  in_%logit_0.0  mortality_%logit_0.0 ,_%logit_1.0  disability_%logit_0.0 ,_%logit_1.0  liver_%logit_1.0  function_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  disability_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  there_%logit_2.0  is_%logit_0.0  no_%logit_1.0  evidence_%logit_1.0  of_%logit_2.0  an_%logit_0.0  improvement_%logit_0.0  in_%logit_0.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_1.0  or_%logit_0.0  health_%logit_0.0 -_%logit_1.0 related_%logit_1.0  quality_%logit_0.0  or_%logit_0.0  quantity_%logit_0.0  of_%logit_1.0  life_%logit_0.0  in_%logit_1.0  patients_%logit_0.0  treated_%logit_1.0  with_%logit_1.0  vitamin_%logit_1.0  E_%logit_0.0  supplements_%logit_0.0 ._%logit_1.0  Treatment_%logit_0.0  with_%logit_0.0  Vitamin_%logit_0.0  E_%logit_0.0  has_%logit_2.0  a_%logit_0.0  beneficial_%logit_1.0  effect_%logit_1.0  on_%logit_2.0  liver_%logit_2.0  function_%logit_0.0  and_%logit_1.0  liver_%logit_1.0  function_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  who_%logit_1.0  are_%logit_0.0  not_%logit_0.0  receiving_%logit_1.0  vitamin_%logit_2.0  E_%logit_1.0  supplementation_%logit_2.0 ,_%logit_0.0  but_%logit_0.0  this_%logit_0.0  is_%logit_1.0  not_%logit_2.0  clear_%logit_1.0  from_%logit_0.0  this_%logit_2.0  review_%logit_2.0 ._%logit_0.0  The_%logit_0.0  number_%logit_0.0  of_%logit_0.0  patients_%logit_0.0  in_%logit_0.0  the_%logit_0.0  study_%logit_2.0  was_%logit_2.0  too_%logit_1.0  small_%logit_1.0  to_%logit_1.0  draw_%logit_1.0  conclusions_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  hyd_%logit_0.0 roc_%logit_2.0 ort_%logit_1.0 is_%logit_0.0 one_%logit_2.0  in_%logit_0.0  the_%logit_2.0  management_%logit_2.0  of_%logit_1.0  breast_%logit_0.0  milk_%logit_0.0  loss_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_0.0  hyd_%logit_1.0 roc_%logit_0.0 ORT_%logit_2.0 is_%logit_2.0 one_%logit_2.0  solution_%logit_2.0 ,_%logit_1.0  the_%logit_1.0  safest_%logit_2.0  solution_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  the_%logit_1.0  best_%logit_0.0  way_%logit_1.0  to_%logit_1.0  administer_%logit_0.0  it_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_2.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_2.0 ised_%logit_2.0  controlled_%logit_0.0  trial_%logit_1.0  to_%logit_2.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  this_%logit_0.0  solution_%logit_0.0 ._%logit_1.0  Such_%logit_2.0  a_%logit_1.0  trial_%logit_1.0  is_%logit_0.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_1.0  best_%logit_2.0  solution_%logit_1.0 ._%logit_2.0  It_%logit_2.0  is_%logit_1.0  also_%logit_2.0  important_%logit_1.0  to_%logit_0.0  note_%logit_0.0  that_%logit_2.0  the_%logit_0.0  data_%logit_1.0  in_%logit_1.0  this_%logit_2.0  review_%logit_2.0  are_%logit_2.0  based_%logit_2.0  on_%logit_0.0  only_%logit_0.0  a_%logit_0.0  small_%logit_2.0  number_%logit_2.0  of_%logit_1.0  cases_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  therefore_%logit_2.0  the_%logit_0.0  conclusions_%logit_0.0  of_%logit_0.0  this_%logit_1.0  review_%logit_1.0  should_%logit_0.0  be_%logit_0.0  interpreted_%logit_0.0  with_%logit_0.0  caution_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  digital_%logit_2.0  scales_%logit_2.0  for_%logit_1.0  measuring_%logit_1.0  health_%logit_1.0  expenditure_%logit_0.0  in_%logit_0.0  health_%logit_2.0  care_%logit_1.0  settings_%logit_2.0 ._%logit_2.0  There_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_2.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_0.0 ised_%logit_2.0  controlled_%logit_2.0  trials_%logit_1.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  on_%logit_1.0  health_%logit_1.0  expenditure_%logit_2.0  and_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_1.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_2.0  should_%logit_2.0  be_%logit_0.0  conducted_%logit_1.0  in_%logit_2.0  health_%logit_2.0  settings_%logit_0.0  with_%logit_0.0  low_%logit_0.0  risk_%logit_2.0  of_%logit_0.0  bias_%logit_0.0  and_%logit_0.0  with_%logit_1.0  a_%logit_1.0  focus_%logit_2.0  on_%logit_2.0  measuring_%logit_2.0  health_%logit_0.0  expenditures_%logit_0.0  in_%logit_0.0  health_%logit_2.0  services_%logit_1.0  settings_%logit_2.0 ._%logit_2.0  They_%logit_0.0  should_%logit_1.0  also_%logit_2.0  assess_%logit_0.0  health_%logit_2.0  expenditure_%logit_0.0 ,_%logit_1.0  quality_%logit_2.0 -_%logit_2.0 of_%logit_2.0 -_%logit_1.0 life_%logit_1.0  and_%logit_1.0  cost_%logit_2.0 -_%logit_0.0 effect_%logit_1.0 iveness_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  compare_%logit_2.0  digital_%logit_1.0  scales_%logit_1.0  with_%logit_1.0  digital_%logit_0.0  scales_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  electro_%logit_2.0 stim_%logit_0.0 ulation_%logit_0.0  as_%logit_1.0  an_%logit_2.0  adjunct_%logit_0.0  to_%logit_2.0  standard_%logit_0.0  IC_%logit_2.0 U_%logit_0.0  care_%logit_2.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_2.0  acute_%logit_0.0  stroke_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  establish_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  Electro_%logit_2.0 stim_%logit_0.0 ulation_%logit_1.0  in_%logit_0.0  acute_%logit_1.0  stroke_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_1.0  its_%logit_0.0  effects_%logit_0.0  on_%logit_0.0  other_%logit_0.0  outcomes_%logit_0.0 ,_%logit_1.0  including_%logit_2.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_2.0  and_%logit_1.0  cost_%logit_0.0 ._%logit_0.0  It_%logit_2.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  the_%logit_0.0  results_%logit_1.0  of_%logit_1.0  this_%logit_0.0  review_%logit_0.0  are_%logit_2.0  based_%logit_1.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_2.0  of_%logit_0.0  patients_%logit_1.0 ,_%logit_0.0  all_%logit_1.0  of_%logit_2.0  whom_%logit_1.0  were_%logit_0.0  discharged_%logit_2.0  from_%logit_1.0  IC_%logit_2.0 U_%logit_1.0  earlier_%logit_1.0  than_%logit_1.0  expected_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  that_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  correlation_%logit_1.0  between_%logit_1.0  involuntary_%logit_2.0  falls_%logit_2.0  and_%logit_2.0  mortality_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  establish_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  involuntary_%logit_1.0  falls_%logit_2.0  as_%logit_0.0  a_%logit_2.0  measure_%logit_0.0  of_%logit_1.0  mortality_%logit_1.0  and_%logit_1.0  morbid_%logit_2.0 ity_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  on_%logit_2.0  bodily_%logit_0.0  function_%logit_1.0 ,_%logit_0.0  balance_%logit_1.0 ,_%logit_2.0  g_%logit_0.0 ait_%logit_2.0 ,_%logit_0.0  reflex_%logit_0.0 ivity_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  function_%logit_0.0  of_%logit_0.0  involuntary_%logit_2.0  falling_%logit_0.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_0.0  involuntary_%logit_2.0  fall_%logit_0.0  on_%logit_0.0  bodily_%logit_2.0  functions_%logit_1.0 ,_%logit_2.0  balance_%logit_1.0  and_%logit_1.0  function_%logit_2.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_1.0  on_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0  and_%logit_0.0  injury_%logit_1.0  rates_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  on_%logit_1.0  the_%logit_0.0  impact_%logit_0.0  on_%logit_2.0  physical_%logit_0.0  function_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  oxy_%logit_0.0 toc_%logit_0.0 in_%logit_1.0  gel_%logit_0.0  as_%logit_0.0  a_%logit_2.0  substitute_%logit_2.0  for_%logit_1.0  vaginal_%logit_2.0  gel_%logit_2.0  in_%logit_2.0  terms_%logit_1.0  of_%logit_1.0  cervical_%logit_0.0  rip_%logit_1.0 ening_%logit_2.0  time_%logit_0.0 ,_%logit_1.0  cervical_%logit_1.0  thickness_%logit_1.0 ,_%logit_1.0  per_%logit_0.0 in_%logit_0.0 atal_%logit_1.0  outcome_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  cervical_%logit_1.0  thickness_%logit_2.0 ._%logit_0.0  There_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_2.0  treatment_%logit_0.0 ._%logit_2.0  In_%logit_2.0  addition_%logit_1.0 ,_%logit_2.0  there_%logit_2.0  is_%logit_1.0  an_%logit_1.0  urgent_%logit_2.0  need_%logit_2.0  for_%logit_0.0  an_%logit_0.0  assessment_%logit_2.0  of_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  uter_%logit_2.0 oton_%logit_1.0 ics_%logit_1.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_0.0  to_%logit_2.0  vaginal_%logit_2.0  gel_%logit_0.0  administration_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  vaginal_%logit_1.0  fib_%logit_1.0 ro_%logit_2.0 ids_%logit_2.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_1.0  as_%logit_2.0  a_%logit_0.0  review_%logit_0.0  of_%logit_2.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  profiles_%logit_1.0  of_%logit_1.0  oxy_%logit_1.0 cod_%logit_2.0 one_%logit_0.0  gel_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  male_%logit_0.0  hormones_%logit_1.0  in_%logit_1.0  the_%logit_2.0  management_%logit_0.0  of_%logit_1.0  s_%logit_1.0 per_%logit_2.0 mat_%logit_1.0 ogenesis_%logit_0.0 ._%logit_0.0  Men_%logit_2.0  using_%logit_2.0  male_%logit_2.0  hormones_%logit_2.0  should_%logit_0.0  be_%logit_1.0  encouraged_%logit_2.0  to_%logit_0.0  take_%logit_0.0  part_%logit_1.0  in_%logit_0.0  this_%logit_0.0  review_%logit_1.0 ._%logit_2.0  Men_%logit_0.0  should_%logit_0.0  be_%logit_2.0  advised_%logit_2.0  that_%logit_1.0  male_%logit_2.0  hormones_%logit_2.0  do_%logit_0.0  not_%logit_0.0  appear_%logit_1.0  to_%logit_2.0  have_%logit_2.0  a_%logit_2.0  significant_%logit_0.0  impact_%logit_0.0  on_%logit_1.0  sperm_%logit_1.0  production_%logit_1.0 ._%logit_0.0  Men_%logit_1.0  taking_%logit_2.0  male_%logit_2.0  hormones_%logit_1.0  are_%logit_0.0  unlikely_%logit_2.0  to_%logit_0.0  have_%logit_0.0  an_%logit_1.0  adverse_%logit_2.0  effect_%logit_0.0  on_%logit_0.0  their_%logit_2.0  sperm_%logit_0.0  production_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  men_%logit_0.0  taking_%logit_1.0  female_%logit_0.0  hormones_%logit_2.0  may_%logit_0.0  have_%logit_0.0  an_%logit_1.0  increased_%logit_0.0  risk_%logit_0.0  of_%logit_2.0  developing_%logit_2.0  prostate_%logit_0.0  cancer_%logit_2.0 ._%logit_0.0  Men_%logit_0.0  who_%logit_0.0  take_%logit_0.0  male_%logit_1.0  hormones_%logit_1.0  will_%logit_2.0  have_%logit_0.0  a_%logit_1.0  decreased_%logit_1.0  risk_%logit_0.0  of_%logit_0.0  prostate_%logit_0.0  cancer_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  the_%logit_0.0  number_%logit_1.0  of_%logit_0.0  men_%logit_2.0  who_%logit_2.0  develop_%logit_2.0  prostate_%logit_0.0  cancer_%logit_0.0  will_%logit_0.0  be_%logit_0.0  reduced_%logit_0.0  by_%logit_0.0  male_%logit_0.0  hormones_%logit_1.0 ._%logit_0.0  Women_%logit_0.0  should_%logit_0.0  be_%logit_0.0  informed_%logit_1.0  of_%logit_2.0  the_%logit_0.0  risks_%logit_0.0  and_%logit_0.0  benefits_%logit_2.0  of_%logit_0.0  male_%logit_0.0  hormonal_%logit_0.0  supplements_%logit_1.0  and_%logit_1.0  the_%logit_0.0  possibility_%logit_2.0  that_%logit_0.0  male_%logit_1.0  hormone_%logit_2.0  supplements_%logit_2.0  may_%logit_1.0  have_%logit_2.0  a_%logit_0.0  negative_%logit_2.0  effect_%logit_0.0  on_%logit_2.0  the_%logit_2.0  sperm_%logit_0.0  production_%logit_2.0  of_%logit_1.0  sperm_%logit_0.0  producing_%logit_0.0  men_%logit_2.0 ,_%logit_2.0  but_%logit_0.0  this_%logit_2.0  is_%logit_0.0  unlikely_%logit_0.0  to_%logit_0.0  be_%logit_0.0  a_%logit_0.0  significant_%logit_1.0  issue_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  manual_%logit_1.0  labour_%logit_0.0  as_%logit_1.0  an_%logit_1.0  integral_%logit_2.0  part_%logit_2.0  of_%logit_1.0  the_%logit_0.0  management_%logit_0.0  of_%logit_0.0  human_%logit_0.0  resource_%logit_0.0  problems_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  identify_%logit_1.0  the_%logit_0.0  best_%logit_1.0  manual_%logit_0.0  labour_%logit_2.0  technique_%logit_2.0  and_%logit_2.0  the_%logit_2.0  best_%logit_0.0  way_%logit_0.0  to_%logit_0.0  integrate_%logit_0.0  manual_%logit_1.0  labour_%logit_1.0  into_%logit_0.0  management_%logit_0.0  of_%logit_1.0  resource_%logit_1.0  problems_%logit_1.0  in_%logit_1.0  human_%logit_1.0  resource_%logit_0.0  management_%logit_0.0  problems_%logit_2.0 ._%logit_1.0  It_%logit_1.0  is_%logit_1.0  also_%logit_2.0  important_%logit_2.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_1.0  manual_%logit_1.0  labour_%logit_2.0  works_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  how_%logit_2.0  it_%logit_0.0  relates_%logit_1.0  to_%logit_1.0  human_%logit_0.0  resource_%logit_0.0  util_%logit_0.0 isation_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  manual_%logit_2.0  labour_%logit_1.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_1.0  of_%logit_1.0  labour_%logit_1.0  management_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  any_%logit_1.0  specific_%logit_1.0  analges_%logit_1.0 ic_%logit_0.0  for_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  post_%logit_2.0 -_%logit_2.0 ext_%logit_2.0 raction_%logit_2.0  pain_%logit_1.0  in_%logit_0.0  people_%logit_0.0  with_%logit_2.0  orth_%logit_2.0 od_%logit_2.0 ont_%logit_0.0 ic_%logit_1.0  pain_%logit_1.0 ._%logit_2.0  There_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0 ,_%logit_0.0  conducted_%logit_0.0  and_%logit_1.0  reported_%logit_1.0  random_%logit_0.0 ised_%logit_1.0  controlled_%logit_1.0  trials_%logit_2.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  various_%logit_0.0  analges_%logit_1.0 ics_%logit_0.0  for_%logit_0.0  post_%logit_2.0 -_%logit_1.0 operative_%logit_0.0  pain_%logit_2.0  relief_%logit_1.0  in_%logit_0.0  adults_%logit_1.0  and_%logit_0.0  children_%logit_2.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_0.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_2.0  optimal_%logit_2.0  analges_%logit_0.0 ic_%logit_0.0  regime_%logit_0.0  and_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  dosage_%logit_0.0  and_%logit_0.0  duration_%logit_1.0  of_%logit_2.0  analges_%logit_0.0 ia_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  different_%logit_0.0  analges_%logit_1.0 ic_%logit_2.0  reg_%logit_2.0 imens_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  erg_%logit_1.0 onomic_%logit_0.0  tools_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_2.0  K_%logit_1.0 nee_%logit_2.0  pain_%logit_1.0  and_%logit_0.0  disability_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  best_%logit_0.0  erg_%logit_1.0 onomic_%logit_2.0  tool_%logit_2.0  to_%logit_0.0  implement_%logit_2.0  erg_%logit_1.0 onomic_%logit_2.0  techniques_%logit_1.0  in_%logit_0.0  K_%logit_2.0 nee_%logit_2.0  Pain_%logit_0.0  Pain_%logit_0.0  and_%logit_0.0  Disability_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  erg_%logit_0.0 onomic_%logit_0.0  technologies_%logit_0.0  to_%logit_2.0  erg_%logit_2.0 onomic_%logit_2.0  methods_%logit_0.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  erg_%logit_1.0 onomic_%logit_0.0  devices_%logit_0.0  for_%logit_2.0  K_%logit_1.0 nee_%logit_1.0 Pain_%logit_0.0  and_%logit_1.0  Disability_%logit_1.0 ._%logit_2.0  These_%logit_0.0  findings_%logit_2.0  should_%logit_2.0  be_%logit_0.0  interpreted_%logit_0.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  they_%logit_0.0  are_%logit_0.0  based_%logit_1.0  on_%logit_2.0  a_%logit_0.0  small_%logit_2.0  number_%logit_1.0  of_%logit_1.0  studies_%logit_2.0  with_%logit_0.0  a_%logit_0.0  high_%logit_2.0  risk_%logit_0.0  of_%logit_1.0  bias_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  are_%logit_1.0  subject_%logit_1.0  to_%logit_1.0  considerable_%logit_0.0  variation_%logit_1.0  in_%logit_2.0  outcome_%logit_2.0  measures_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  antidepressants_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  AM_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  most_%logit_2.0  effective_%logit_2.0  antidepressant_%logit_0.0  for_%logit_1.0  AM_%logit_0.0 ._%logit_2.0  It_%logit_2.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_1.0  understand_%logit_0.0  the_%logit_1.0  mechanisms_%logit_1.0  by_%logit_0.0  which_%logit_0.0  antidepressants_%logit_0.0  are_%logit_0.0  used_%logit_1.0  to_%logit_0.0  treat_%logit_1.0  AM_%logit_0.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  the_%logit_0.0  mechanism_%logit_2.0  by_%logit_0.0  which_%logit_1.0  they_%logit_0.0  are_%logit_0.0  used_%logit_2.0  in_%logit_0.0  the_%logit_2.0  management_%logit_1.0  of_%logit_1.0  AM_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  antidepressants_%logit_2.0  with_%logit_1.0  placebo_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  of_%logit_1.0  antidepressants_%logit_2.0  for_%logit_0.0  AM_%logit_1.0 ,_%logit_0.0  which_%logit_1.0  is_%logit_2.0  currently_%logit_2.0  in_%logit_0.0  its_%logit_0.0  infancy_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  intraven_%logit_0.0 ous_%logit_2.0  antibiotics_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  forced_%logit_2.0  exp_%logit_0.0 ir_%logit_0.0 atory_%logit_0.0  flow_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  intraven_%logit_2.0 ous_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_1.0  is_%logit_2.0  more_%logit_1.0  effective_%logit_0.0  than_%logit_1.0  oral_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_2.0  in_%logit_1.0  improving_%logit_1.0  lung_%logit_0.0  function_%logit_1.0  and_%logit_1.0  improving_%logit_2.0  pulmonary_%logit_0.0  function_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  admitted_%logit_1.0  to_%logit_2.0  intensive_%logit_1.0  care_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_1.0  intraven_%logit_2.0 ous_%logit_2.0  and_%logit_0.0  oral_%logit_1.0  antibiotics_%logit_2.0  with_%logit_2.0  oral_%logit_2.0  antibiotics_%logit_2.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_1.0  pulmonary_%logit_0.0  function_%logit_0.0  and_%logit_0.0  lung_%logit_1.0  function_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_1.0 conduct_%logit_2.0 ed_%logit_1.0  and_%logit_2.0  executed_%logit_0.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_1.0  trial_%logit_0.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_1.0  intraven_%logit_1.0 ously_%logit_1.0  antibiotic_%logit_2.0  therapy_%logit_2.0  on_%logit_1.0  pulmonary_%logit_0.0  function_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  also_%logit_2.0  to_%logit_2.0  compare_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  antibiotic_%logit_2.0  therapy_%logit_1.0  to_%logit_2.0  oral_%logit_1.0  antibiotics_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  any_%logit_0.0  particular_%logit_2.0  surgical_%logit_1.0  technique_%logit_2.0  for_%logit_1.0  removing_%logit_1.0  surgical_%logit_1.0  s_%logit_0.0 ut_%logit_0.0 ures_%logit_1.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_0.0  sin_%logit_0.0 us_%logit_1.0  infections_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_0.0  surgical_%logit_0.0  technique_%logit_0.0  and_%logit_2.0  the_%logit_2.0  best_%logit_2.0  way_%logit_1.0  to_%logit_2.0  minim_%logit_2.0 ise_%logit_0.0  rec_%logit_0.0 urrence_%logit_0.0  and_%logit_1.0  minim_%logit_0.0 ise_%logit_1.0  the_%logit_0.0  risk_%logit_0.0  of_%logit_1.0  rec_%logit_1.0 urrence_%logit_0.0  in_%logit_1.0  these_%logit_2.0  patients_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  other_%logit_0.0  surgical_%logit_0.0  techniques_%logit_0.0 ,_%logit_1.0  such_%logit_1.0  as_%logit_0.0  wound_%logit_0.0  dressing_%logit_1.0 ,_%logit_2.0  s_%logit_2.0 ut_%logit_2.0 uring_%logit_1.0  devices_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  wound_%logit_2.0  dressing_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_1.0  is_%logit_2.0  required_%logit_0.0  to_%logit_0.0  investigate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  durability_%logit_0.0  of_%logit_1.0  various_%logit_0.0  surgical_%logit_0.0  techniques_%logit_0.0  for_%logit_2.0  treating_%logit_2.0  sin_%logit_0.0 us_%logit_1.0  infection_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  also_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  surgical_%logit_0.0  techniques_%logit_2.0  to_%logit_2.0  other_%logit_2.0  surgical_%logit_2.0  methods_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  any_%logit_1.0  of_%logit_1.0  the_%logit_0.0  interventions_%logit_0.0  reviewed_%logit_0.0  in_%logit_1.0  this_%logit_2.0  review_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  large_%logit_0.0 ,_%logit_1.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_1.0  and_%logit_0.0  reported_%logit_0.0  systematic_%logit_1.0  review_%logit_1.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  the_%logit_0.0  various_%logit_1.0  approaches_%logit_1.0  to_%logit_1.0  managing_%logit_2.0  compliance_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  a_%logit_0.0  review_%logit_1.0  should_%logit_1.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_0.0  the_%logit_2.0  context_%logit_2.0  of_%logit_0.0  a_%logit_0.0  large_%logit_0.0  scale_%logit_2.0 ,_%logit_0.0  multi_%logit_1.0 -_%logit_2.0 cent_%logit_0.0 re_%logit_0.0 ,_%logit_1.0  mult_%logit_0.0 icent_%logit_2.0 re_%logit_0.0 ,_%logit_1.0  placebo_%logit_0.0 -_%logit_0.0 controlled_%logit_1.0 ,_%logit_0.0  double_%logit_0.0 -_%logit_2.0 blind_%logit_0.0  controlled_%logit_0.0  trial_%logit_0.0  with_%logit_1.0  a_%logit_2.0  focus_%logit_2.0  on_%logit_1.0  compliance_%logit_0.0  with_%logit_0.0  standard_%logit_0.0  medication_%logit_2.0  and_%logit_2.0  adherence_%logit_2.0  to_%logit_1.0  standard_%logit_0.0  medication_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  any_%logit_0.0  specific_%logit_0.0  type_%logit_1.0  of_%logit_2.0  ant_%logit_0.0 ich_%logit_1.0 olin_%logit_0.0 erg_%logit_1.0 ics_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  sensory_%logit_0.0  nerve_%logit_1.0  block_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_0.0  duration_%logit_1.0  of_%logit_2.0  ant_%logit_1.0 ico_%logit_1.0 ag_%logit_1.0 ulation_%logit_1.0 ,_%logit_1.0  the_%logit_1.0  optimal_%logit_1.0  timing_%logit_0.0  and_%logit_1.0  timing_%logit_0.0  of_%logit_2.0  analges_%logit_0.0 ia_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_0.0  optimal_%logit_0.0  dosage_%logit_2.0  and_%logit_1.0  timing_%logit_2.0  for_%logit_0.0  analges_%logit_2.0 ia_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  future_%logit_2.0  trials_%logit_1.0  should_%logit_2.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  various_%logit_0.0  types_%logit_0.0  of_%logit_0.0  nerve_%logit_1.0  stimulation_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  also_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  different_%logit_1.0  types_%logit_1.0  of_%logit_2.0  anti_%logit_0.0 em_%logit_0.0 etic_%logit_2.0  agents_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  their_%logit_1.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_1.0  management_%logit_2.0  of_%logit_2.0  pain_%logit_0.0 ,_%logit_1.0  function_%logit_1.0  and_%logit_0.0  function_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  positive_%logit_0.0  effect_%logit_2.0  of_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_1.0  on_%logit_2.0  hand_%logit_1.0  function_%logit_1.0  and_%logit_0.0  independence_%logit_1.0  in_%logit_0.0  people_%logit_1.0  with_%logit_2.0  impaired_%logit_1.0  limb_%logit_0.0  function_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  relaxation_%logit_0.0  exercises_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  whether_%logit_2.0  relaxing_%logit_2.0  exercises_%logit_2.0  may_%logit_0.0  be_%logit_0.0  beneficial_%logit_1.0  or_%logit_0.0  detrimental_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  studies_%logit_2.0  are_%logit_2.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_1.0  for_%logit_0.0  impaired_%logit_2.0  limb_%logit_2.0  functions_%logit_1.0  and_%logit_1.0  independence_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  relaxation_%logit_1.0  exercises_%logit_0.0  with_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  studies_%logit_2.0  are_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  assess_%logit_1.0  relaxation_%logit_0.0  exercises_%logit_0.0  and_%logit_0.0  relaxation_%logit_2.0  exercises_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_2.0  relaxation_%logit_0.0  exercise_%logit_0.0  on_%logit_1.0  muscle_%logit_1.0  strength_%logit_1.0  and_%logit_1.0  flexibility_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  digital_%logit_1.0  media_%logit_2.0  editing_%logit_2.0  as_%logit_0.0  a_%logit_1.0  tool_%logit_0.0  to_%logit_1.0  improve_%logit_1.0  journalistic_%logit_1.0  integrity_%logit_2.0  and_%logit_0.0  journalistic_%logit_2.0  integrity_%logit_1.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_2.0  most_%logit_1.0  effective_%logit_1.0  media_%logit_1.0  editing_%logit_1.0  techniques_%logit_2.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  reliability_%logit_2.0  of_%logit_1.0  such_%logit_0.0  techniques_%logit_2.0 ._%logit_1.0  It_%logit_2.0  is_%logit_2.0  also_%logit_0.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_2.0  mechanisms_%logit_2.0  by_%logit_0.0  which_%logit_0.0  media_%logit_0.0  editing_%logit_2.0  works_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  how_%logit_1.0  they_%logit_1.0  are_%logit_1.0  used_%logit_0.0  in_%logit_0.0  the_%logit_2.0  context_%logit_2.0  of_%logit_2.0  a_%logit_1.0  multif_%logit_1.0 acet_%logit_2.0 ed_%logit_2.0  media_%logit_2.0  editing_%logit_0.0  programme_%logit_0.0 ._%logit_0.0  Future_%logit_0.0  research_%logit_0.0  should_%logit_1.0  focus_%logit_2.0  on_%logit_0.0  measuring_%logit_0.0  journalistic_%logit_0.0  integrity_%logit_0.0 ,_%logit_1.0  transparency_%logit_2.0  and_%logit_2.0  accuracy_%logit_2.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  on_%logit_1.0  assessing_%logit_0.0  the_%logit_1.0  impact_%logit_2.0  of_%logit_2.0  media_%logit_0.0  editing_%logit_2.0  on_%logit_2.0  journalistic_%logit_1.0  integrity_%logit_1.0  in_%logit_0.0  journalism_%logit_2.0  and_%logit_1.0  journalism_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_1.0  on_%logit_0.0  journalistic_%logit_2.0  ethics_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  cort_%logit_1.0 ic_%logit_1.0 oster_%logit_0.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  As_%logit_0.0 per_%logit_2.0 g_%logit_2.0 illus_%logit_0.0  f_%logit_0.0 um_%logit_0.0 ig_%logit_0.0 atus_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  confirm_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  cort_%logit_0.0 ico_%logit_1.0 ag_%logit_1.0 ulation_%logit_0.0  in_%logit_2.0  the_%logit_1.0  management_%logit_0.0  of_%logit_1.0  AS_%logit_1.0 F_%logit_0.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_1.0  undertaken_%logit_0.0  in_%logit_0.0  the_%logit_2.0  context_%logit_0.0  of_%logit_1.0  a_%logit_1.0  large_%logit_0.0  scale_%logit_1.0  randomized_%logit_2.0  controlled_%logit_2.0  trial_%logit_2.0 ,_%logit_0.0  preferably_%logit_0.0  with_%logit_1.0  a_%logit_1.0  long_%logit_0.0 -_%logit_1.0 term_%logit_0.0  duration_%logit_0.0  of_%logit_0.0  follow_%logit_0.0 -_%logit_0.0 up_%logit_0.0 ._%logit_0.0  They_%logit_0.0  should_%logit_0.0  include_%logit_2.0  patients_%logit_2.0  with_%logit_2.0  a_%logit_2.0  high_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  hyp_%logit_0.0 ogly_%logit_0.0 ca_%logit_0.0 emia_%logit_0.0  and_%logit_0.0  a_%logit_0.0  low_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  pneum_%logit_2.0 oth_%logit_0.0 or_%logit_0.0 ax_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  no_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  prog_%logit_0.0 est_%logit_0.0 ogens_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  PC_%logit_0.0 OS_%logit_1.0 ._%logit_2.0  However_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_2.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_1.0 ,_%logit_0.0  conducted_%logit_0.0  and_%logit_2.0  reported_%logit_1.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_2.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  efficacy_%logit_2.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_0.0  in_%logit_2.0  PC_%logit_2.0 OS_%logit_1.0  patients_%logit_0.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_2.0  should_%logit_0.0  be_%logit_2.0  of_%logit_1.0  high_%logit_1.0  methodological_%logit_1.0  quality_%logit_0.0 ,_%logit_0.0  with_%logit_1.0  appropriate_%logit_1.0  attention_%logit_1.0  paid_%logit_0.0  to_%logit_2.0  outcome_%logit_2.0  measures_%logit_2.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_2.0  follow_%logit_1.0 -_%logit_0.0 up_%logit_1.0 ._%logit_0.0  They_%logit_0.0  should_%logit_0.0  also_%logit_1.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  the_%logit_0.0  prog_%logit_1.0 est_%logit_2.0 ogen_%logit_0.0  as_%logit_1.0  an_%logit_1.0  adj_%logit_0.0 u_%logit_2.0 vant_%logit_2.0  treatment_%logit_0.0  for_%logit_0.0  PC_%logit_2.0 OS_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0  of_%logit_1.0  the_%logit_1.0  patients_%logit_1.0  treated_%logit_0.0 ._%logit_2.0
 Cond_%logit_0.0 oms_%logit_0.0  are_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  sexual_%logit_0.0  risk_%logit_1.0  behaviors_%logit_0.0  and_%logit_0.0  enhancing_%logit_2.0  condom_%logit_0.0  usage_%logit_0.0 ._%logit_0.0  Cond_%logit_0.0 oms_%logit_2.0  appear_%logit_0.0  to_%logit_0.0  reduce_%logit_0.0  sexual_%logit_2.0  risk_%logit_0.0  behaviours_%logit_0.0  and_%logit_1.0  enhance_%logit_1.0  condom_%logit_1.0  usage_%logit_1.0 ,_%logit_0.0  but_%logit_1.0  they_%logit_1.0  do_%logit_2.0  not_%logit_2.0  appear_%logit_0.0  to_%logit_2.0  have_%logit_0.0  a_%logit_0.0  significant_%logit_2.0  impact_%logit_2.0  on_%logit_2.0  sexual_%logit_1.0  risk_%logit_1.0  behaviour_%logit_2.0 ._%logit_0.0  The_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  Cond_%logit_0.0 oms_%logit_0.0  is_%logit_0.0  unclear_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  there_%logit_0.0  is_%logit_2.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_2.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  condoms_%logit_2.0  and_%logit_2.0  condoms_%logit_1.0  for_%logit_2.0  sexual_%logit_2.0  risk_%logit_0.0  behavior_%logit_2.0  and_%logit_2.0  sexual_%logit_1.0  risks_%logit_1.0  behaviors_%logit_1.0  in_%logit_1.0  women_%logit_1.0  and_%logit_2.0  their_%logit_2.0  partners_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  in_%logit_0.0  developing_%logit_0.0  countries_%logit_0.0 ,_%logit_0.0  where_%logit_0.0  condoms_%logit_2.0  are_%logit_0.0  widely_%logit_2.0  available_%logit_2.0 ._%logit_1.0  Cond_%logit_0.0 om_%logit_1.0  training_%logit_2.0  may_%logit_0.0  improve_%logit_0.0  condom_%logit_0.0  usage_%logit_1.0  and_%logit_1.0  reduce_%logit_1.0  sexual_%logit_0.0  risks_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  there_%logit_2.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_1.0  of_%logit_2.0  a_%logit_1.0  significant_%logit_1.0  difference_%logit_0.0  in_%logit_2.0  sexual_%logit_1.0  risks_%logit_1.0  or_%logit_2.0  STD_%logit_2.0  rates_%logit_0.0  between_%logit_2.0  the_%logit_1.0  two_%logit_1.0  types_%logit_2.0  of_%logit_0.0  condoms_%logit_0.0  or_%logit_1.0  the_%logit_1.0  same_%logit_1.0  type_%logit_2.0  of_%logit_1.0  condoms_%logit_2.0 ._%logit_1.0  Cond_%logit_2.0 o_%logit_0.0  training_%logit_1.0  may_%logit_0.0  also_%logit_0.0  improve_%logit_2.0  condom_%logit_0.0  use_%logit_1.0 ,_%logit_1.0  but_%logit_1.0  it_%logit_2.0  is_%logit_2.0  not_%logit_2.0  clear_%logit_2.0  what_%logit_0.0  type_%logit_0.0  of_%logit_2.0  training_%logit_0.0  is_%logit_0.0  most_%logit_0.0  effective_%logit_0.0 ._%logit_0.0  Cond_%logit_0.0 os_%logit_1.0  should_%logit_1.0  not_%logit_1.0  be_%logit_2.0  used_%logit_0.0  for_%logit_0.0  sexual_%logit_0.0  risks_%logit_1.0  and_%logit_2.0  sexual_%logit_0.0  behaviors_%logit_0.0  in_%logit_2.0  the_%logit_2.0  context_%logit_1.0  of_%logit_2.0  condom_%logit_0.0  use_%logit_0.0  and_%logit_0.0  condom_%logit_0.0  usage_%logit_2.0  in_%logit_2.0  developing_%logit_1.0  nations_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  beta_%logit_0.0 -_%logit_1.0 block_%logit_1.0 ers_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  HELL_%logit_0.0 P_%logit_0.0  syndrome_%logit_0.0 ._%logit_1.0  There_%logit_1.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_0.0  area_%logit_1.0 ,_%logit_0.0  particularly_%logit_0.0  in_%logit_0.0  the_%logit_1.0  context_%logit_1.0  of_%logit_2.0  the_%logit_2.0  introduction_%logit_2.0  of_%logit_0.0  anti_%logit_0.0 plate_%logit_0.0 let_%logit_2.0  agents_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  in_%logit_0.0  the_%logit_0.0  development_%logit_0.0  of_%logit_2.0  a_%logit_2.0  more_%logit_0.0  efficient_%logit_0.0  treatment_%logit_2.0  strategy_%logit_0.0 ._%logit_1.0  In_%logit_2.0  addition_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_0.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_1.0 conduct_%logit_1.0 ed_%logit_0.0 ,_%logit_1.0  transparent_%logit_1.0  and_%logit_2.0  reported_%logit_2.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_1.0  beta_%logit_1.0  -_%logit_0.0 block_%logit_1.0 ers_%logit_1.0  on_%logit_1.0  mortality_%logit_0.0  and_%logit_0.0  morbid_%logit_1.0 ity_%logit_1.0  in_%logit_0.0  these_%logit_2.0  patients_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_0.0  of_%logit_2.0  any_%logit_1.0  of_%logit_0.0  the_%logit_0.0  treatments_%logit_1.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  oral_%logit_0.0  le_%logit_2.0 uk_%logit_2.0 opl_%logit_2.0 akia_%logit_2.0 ._%logit_2.0  There_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_1.0  these_%logit_1.0  treatments_%logit_2.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_0.0  reducing_%logit_0.0  the_%logit_1.0  number_%logit_0.0  and_%logit_1.0  severity_%logit_1.0  of_%logit_0.0  lesions_%logit_0.0  and_%logit_0.0  improving_%logit_0.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_1.0  of_%logit_1.0  patients_%logit_2.0  with_%logit_0.0  this_%logit_1.0  condition_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_0.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_2.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_2.0  trial_%logit_1.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_0.0  of_%logit_1.0  the_%logit_2.0  various_%logit_0.0  treatments_%logit_2.0  in_%logit_0.0  this_%logit_2.0  population_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  laser_%logit_1.0  phot_%logit_2.0 oco_%logit_1.0 ag_%logit_2.0 ulation_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  BC_%logit_0.0 VA_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  identify_%logit_0.0  the_%logit_1.0  best_%logit_2.0  way_%logit_2.0  to_%logit_1.0  achieve_%logit_2.0  this_%logit_2.0  goal_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  laser_%logit_0.0  phot_%logit_1.0 o_%logit_0.0 ag_%logit_0.0 ulation_%logit_1.0  with_%logit_2.0  other_%logit_0.0  methods_%logit_2.0  of_%logit_1.0  optical_%logit_2.0  manipulation_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_2.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  the_%logit_0.0  results_%logit_2.0  of_%logit_0.0  the_%logit_2.0  two_%logit_0.0  trials_%logit_2.0 ,_%logit_0.0  which_%logit_1.0  are_%logit_2.0  currently_%logit_2.0  in_%logit_0.0  progress_%logit_0.0 ._%logit_1.0  The_%logit_0.0  results_%logit_0.0  of_%logit_1.0  these_%logit_2.0  trials_%logit_1.0  should_%logit_0.0  be_%logit_1.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  they_%logit_0.0  are_%logit_0.0  based_%logit_1.0  on_%logit_0.0  only_%logit_0.0  a_%logit_0.0  small_%logit_1.0  number_%logit_1.0  of_%logit_1.0  patients_%logit_0.0  and_%logit_2.0  are_%logit_2.0  subject_%logit_2.0  to_%logit_0.0  a_%logit_0.0  high_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  therefore_%logit_0.0  should_%logit_2.0  be_%logit_1.0  viewed_%logit_0.0  with_%logit_1.0  caution_%logit_2.0 ._%logit_0.0
 Cognitive_%logit_0.0  behavioural_%logit_0.0  therapy_%logit_0.0  is_%logit_1.0  effective_%logit_1.0  in_%logit_1.0  reducing_%logit_0.0  the_%logit_0.0  severity_%logit_0.0  of_%logit_2.0  depression_%logit_0.0  and_%logit_0.0  reducing_%logit_0.0  the_%logit_0.0  frequency_%logit_0.0  of_%logit_0.0  depressive_%logit_0.0  symptoms_%logit_0.0 ._%logit_1.0  Positive_%logit_1.0  effects_%logit_2.0  of_%logit_1.0  cognitive_%logit_1.0  behavioural_%logit_0.0  therapy_%logit_2.0  are_%logit_0.0  similar_%logit_0.0  to_%logit_1.0  those_%logit_0.0  seen_%logit_0.0  in_%logit_1.0  other_%logit_2.0  types_%logit_0.0  of_%logit_2.0  psychiatric_%logit_2.0  therapy_%logit_2.0 ,_%logit_1.0  but_%logit_1.0  are_%logit_2.0  associated_%logit_2.0  with_%logit_0.0  a_%logit_2.0  higher_%logit_1.0  incidence_%logit_1.0  of_%logit_1.0  depression_%logit_1.0 ._%logit_2.0  Cognitive_%logit_2.0  behavioral_%logit_2.0  therapy_%logit_0.0  is_%logit_1.0  less_%logit_1.0  effective_%logit_1.0  than_%logit_0.0  behavioural_%logit_2.0  therapy_%logit_2.0 ._%logit_0.0  Cognitive_%logit_1.0  behavioural_%logit_0.0  counselling_%logit_0.0  is_%logit_1.0  more_%logit_0.0  effective_%logit_1.0  than_%logit_0.0  no_%logit_0.0  treatment_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  is_%logit_1.0  associated_%logit_1.0  with_%logit_2.0  an_%logit_1.0  increased_%logit_1.0  risk_%logit_0.0  of_%logit_2.0  relapse_%logit_0.0 ._%logit_1.0  Cognitive_%logit_1.0  behaviour_%logit_0.0  therapy_%logit_0.0  is_%logit_0.0  more_%logit_0.0  likely_%logit_0.0  to_%logit_2.0  result_%logit_2.0  in_%logit_0.0  an_%logit_0.0  improvement_%logit_0.0  in_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  its_%logit_2.0  effectiveness_%logit_2.0  is_%logit_2.0  not_%logit_1.0  clear_%logit_0.0 ._%logit_1.0  Cognitive_%logit_1.0  behavior_%logit_1.0  therapy_%logit_2.0  may_%logit_1.0  be_%logit_2.0  more_%logit_2.0  effective_%logit_1.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_2.0  depression_%logit_2.0  or_%logit_0.0  anxiety_%logit_0.0  symptoms_%logit_1.0  than_%logit_1.0  behavioural_%logit_2.0  counselling_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  there_%logit_1.0  is_%logit_1.0  no_%logit_2.0  clear_%logit_1.0  evidence_%logit_1.0  of_%logit_0.0  an_%logit_2.0  effect_%logit_0.0  on_%logit_2.0  severity_%logit_1.0  or_%logit_1.0  duration_%logit_0.0  of_%logit_2.0  depression_%logit_1.0  in_%logit_2.0  people_%logit_0.0  with_%logit_2.0  epilepsy_%logit_2.0 ._%logit_0.0  Positive_%logit_0.0  findings_%logit_0.0  of_%logit_1.0  cognitive_%logit_0.0  behaviour_%logit_1.0  therapy_%logit_1.0  are_%logit_1.0  consistent_%logit_2.0  with_%logit_1.0  those_%logit_0.0  of_%logit_2.0  the_%logit_2.0  previous_%logit_2.0  review_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  more_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  confirm_%logit_1.0  these_%logit_0.0  findings_%logit_0.0 ._%logit_1.0
 Screen_%logit_0.0 ing_%logit_0.0  mamm_%logit_0.0 ography_%logit_0.0  results_%logit_0.0  in_%logit_0.0  a_%logit_1.0  significant_%logit_0.0  reduction_%logit_1.0  in_%logit_1.0  the_%logit_0.0  incidence_%logit_1.0  of_%logit_0.0  pap_%logit_1.0  sm_%logit_0.0 ears_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  a_%logit_1.0  significant_%logit_0.0  increase_%logit_2.0  in_%logit_1.0  the_%logit_0.0  risk_%logit_0.0  of_%logit_2.0  breast_%logit_2.0  cancer_%logit_1.0 ._%logit_0.0  Screen_%logit_1.0 ing_%logit_1.0  results_%logit_0.0  in_%logit_0.0  an_%logit_2.0  increase_%logit_1.0  in_%logit_2.0  breast_%logit_0.0  cancer_%logit_1.0  screening_%logit_0.0  rates_%logit_0.0 ,_%logit_1.0  but_%logit_2.0  no_%logit_1.0  significant_%logit_1.0  difference_%logit_1.0  in_%logit_1.0  overall_%logit_0.0  survival_%logit_0.0 ._%logit_1.0  Screen_%logit_1.0 ings_%logit_0.0  are_%logit_1.0  also_%logit_1.0  associated_%logit_2.0  with_%logit_0.0  a_%logit_1.0  significant_%logit_0.0  decrease_%logit_1.0  in_%logit_0.0  the_%logit_0.0  number_%logit_0.0  of_%logit_1.0  smear_%logit_1.0 -_%logit_2.0 related_%logit_2.0  deaths_%logit_2.0 ,_%logit_0.0  but_%logit_0.0  this_%logit_1.0  is_%logit_2.0  based_%logit_2.0  on_%logit_1.0  a_%logit_1.0  small_%logit_2.0  number_%logit_1.0  of_%logit_1.0  studies_%logit_2.0  with_%logit_0.0  short_%logit_1.0 -_%logit_2.0 term_%logit_0.0  follow_%logit_2.0 -_%logit_2.0 up_%logit_0.0  and_%logit_0.0  a_%logit_0.0  very_%logit_1.0  low_%logit_1.0  risk_%logit_2.0  of_%logit_0.0  bias_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_0.0  screening_%logit_0.0  mamm_%logit_1.0 ography_%logit_0.0  on_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_0.0  and_%logit_0.0  health_%logit_0.0  behaviours_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_0.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  screening_%logit_2.0  mamm_%logit_0.0 ograms_%logit_0.0  with_%logit_1.0  other_%logit_1.0  screening_%logit_0.0  methods_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  relaxation_%logit_0.0  exercises_%logit_2.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  f_%logit_0.0 ec_%logit_0.0 al_%logit_2.0  inc_%logit_0.0 ont_%logit_0.0 inence_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  whether_%logit_2.0  relaxation_%logit_0.0  exercises_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_1.0  for_%logit_0.0  patients_%logit_2.0  with_%logit_2.0  F_%logit_1.0 ec_%logit_1.0 al_%logit_1.0  Inc_%logit_1.0 ont_%logit_0.0 inence_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_2.0  relaxation_%logit_0.0  exercises_%logit_2.0  as_%logit_2.0  an_%logit_0.0  adjunct_%logit_2.0  to_%logit_1.0  relaxation_%logit_0.0  exercises_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  relaxation_%logit_1.0  exercises_%logit_2.0  for_%logit_0.0  patients_%logit_0.0  who_%logit_0.0  are_%logit_1.0  struggling_%logit_2.0  with_%logit_2.0  relaxation_%logit_1.0 ._%logit_1.0  This_%logit_2.0  is_%logit_2.0  particularly_%logit_2.0  important_%logit_2.0  in_%logit_1.0  areas_%logit_2.0  where_%logit_0.0  relaxation_%logit_2.0  exercises_%logit_1.0  do_%logit_0.0  not_%logit_0.0  seem_%logit_2.0  to_%logit_2.0  be_%logit_1.0  beneficial_%logit_0.0  or_%logit_0.0  detrimental_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  acoustic_%logit_1.0  stimulation_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  s_%logit_2.0 ut_%logit_2.0 ured_%logit_2.0  vul_%logit_1.0 var_%logit_1.0  tears_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_0.0  acoustic_%logit_2.0  stimulating_%logit_2.0  stimulation_%logit_1.0  in_%logit_0.0  this_%logit_2.0  population_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_1.0  acoustic_%logit_1.0  stimulation_%logit_2.0  with_%logit_1.0  other_%logit_0.0  forms_%logit_1.0  of_%logit_0.0  stimulation_%logit_1.0 ,_%logit_1.0  such_%logit_0.0  as_%logit_2.0  vibration_%logit_0.0  stimulation_%logit_0.0 ,_%logit_0.0  vibration_%logit_1.0  stimulation_%logit_2.0  and_%logit_0.0  vibration_%logit_1.0  stimulation_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  acoustic_%logit_0.0  stimulation_%logit_1.0  for_%logit_0.0  s_%logit_2.0 ut_%logit_0.0 ures_%logit_0.0  vul_%logit_2.0 va_%logit_0.0  tears_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0 ,_%logit_1.0  safety_%logit_0.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  electromagnetic_%logit_0.0  stimulation_%logit_0.0  in_%logit_2.0  these_%logit_0.0  populations_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0  there_%logit_0.0  is_%logit_2.0  an_%logit_1.0  urgent_%logit_1.0  need_%logit_1.0  for_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  vibration_%logit_1.0  stimulation_%logit_2.0  on_%logit_2.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_1.0 ._%logit_2.0
 The_%logit_0.0  results_%logit_0.0  of_%logit_2.0  this_%logit_2.0  review_%logit_1.0  support_%logit_0.0  the_%logit_1.0  use_%logit_1.0  of_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_1.0  as_%logit_0.0  a_%logit_1.0  measure_%logit_1.0  of_%logit_1.0  quality_%logit_2.0  of_%logit_2.0  life_%logit_1.0 ._%logit_2.0  Relax_%logit_2.0 ation_%logit_1.0  exercises_%logit_0.0  appear_%logit_0.0  to_%logit_0.0  have_%logit_1.0  a_%logit_1.0  beneficial_%logit_0.0  effect_%logit_0.0  on_%logit_0.0  relaxation_%logit_1.0  exercises_%logit_0.0 ,_%logit_1.0  although_%logit_1.0  results_%logit_2.0  were_%logit_2.0  not_%logit_2.0  statistically_%logit_1.0  significant_%logit_1.0  in_%logit_1.0  the_%logit_2.0  short_%logit_2.0 -_%logit_2.0 term_%logit_0.0 ._%logit_1.0  Exercise_%logit_2.0  exercises_%logit_0.0  may_%logit_1.0  have_%logit_0.0  a_%logit_2.0  positive_%logit_0.0  effect_%logit_1.0  on_%logit_0.0  fatigue_%logit_2.0 ,_%logit_0.0  but_%logit_1.0  further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_1.0  relaxation_%logit_1.0  exercises_%logit_1.0  are_%logit_2.0  beneficial_%logit_0.0  in_%logit_0.0  the_%logit_0.0  long_%logit_1.0 -_%logit_1.0 term_%logit_2.0  or_%logit_0.0  in_%logit_1.0  the_%logit_2.0  longer_%logit_0.0  term_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  also_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  relaxation_%logit_2.0  exercises_%logit_1.0  and_%logit_1.0  relaxation_%logit_0.0  exercises_%logit_1.0  for_%logit_0.0  relaxation_%logit_2.0  exercises_%logit_1.0  after_%logit_2.0  surgery_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  difference_%logit_1.0  in_%logit_1.0  mortality_%logit_0.0  or_%logit_0.0  morbid_%logit_0.0 ity_%logit_2.0  in_%logit_2.0  acute_%logit_0.0  b_%logit_2.0 iliary_%logit_2.0  pancreat_%logit_0.0 itis_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  randomized_%logit_2.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  whether_%logit_0.0  there_%logit_1.0  are_%logit_1.0  differences_%logit_1.0  in_%logit_2.0  mortality_%logit_0.0  and_%logit_2.0  morbid_%logit_1.0 ity_%logit_0.0  between_%logit_1.0  the_%logit_0.0  two_%logit_1.0  approaches_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_2.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  the_%logit_1.0  various_%logit_2.0  methods_%logit_2.0  of_%logit_1.0  intra_%logit_0.0 -_%logit_0.0 oral_%logit_0.0  drainage_%logit_0.0  and_%logit_1.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_2.0  these_%logit_0.0  methods_%logit_1.0  on_%logit_2.0  morbid_%logit_1.0 ity_%logit_0.0  and_%logit_1.0  mortality_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_2.0  approaches_%logit_0.0  to_%logit_2.0  other_%logit_0.0  types_%logit_1.0  of_%logit_2.0  drainage_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_1.0  use_%logit_0.0  of_%logit_2.0  _%logit_1.0 ery_%logit_1.0 throp_%logit_2.0 o_%logit_0.0 iet_%logit_0.0 in_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  RA_%logit_2.0 ._%logit_2.0  Further_%logit_1.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  _%logit_0.0 ary_%logit_0.0 throp_%logit_0.0 o_%logit_2.0 iat_%logit_2.0 in_%logit_0.0  for_%logit_1.0  RA_%logit_2.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_1.0  should_%logit_1.0  include_%logit_2.0  patients_%logit_0.0  with_%logit_0.0  a_%logit_0.0  history_%logit_2.0  of_%logit_0.0  RA_%logit_0.0  who_%logit_2.0  are_%logit_2.0  at_%logit_0.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_0.0  relapse_%logit_0.0  and_%logit_0.0  those_%logit_0.0  with_%logit_2.0  severe_%logit_1.0  ana_%logit_1.0 emia_%logit_0.0 ._%logit_0.0  They_%logit_1.0  should_%logit_0.0  also_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_0.0  other_%logit_0.0  treatments_%logit_0.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_1.0  gluc_%logit_0.0 oc_%logit_0.0 ort_%logit_2.0 ic_%logit_0.0 oid_%logit_0.0  therapy_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_0.0  as_%logit_2.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_0.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0  and_%logit_2.0  health_%logit_1.0 -_%logit_1.0 related_%logit_2.0  productivity_%logit_1.0 ._%logit_0.0
 Manual_%logit_0.0  removal_%logit_0.0  of_%logit_1.0  the_%logit_0.0  pl_%logit_0.0 acent_%logit_0.0 a_%logit_0.0  reduces_%logit_0.0  the_%logit_0.0  risk_%logit_1.0  of_%logit_0.0  post_%logit_0.0 part_%logit_2.0 um_%logit_2.0  ha_%logit_0.0 em_%logit_1.0 or_%logit_0.0 rh_%logit_0.0 age_%logit_0.0  and_%logit_0.0  the_%logit_1.0  need_%logit_1.0  for_%logit_2.0  blood_%logit_2.0  transf_%logit_1.0 usion_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  there_%logit_1.0  is_%logit_1.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_2.0  recommend_%logit_1.0  the_%logit_2.0  use_%logit_0.0  of_%logit_1.0  this_%logit_1.0  procedure_%logit_2.0  as_%logit_1.0  a_%logit_1.0  substitute_%logit_0.0  for_%logit_2.0  manual_%logit_1.0  removal_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  best_%logit_1.0  method_%logit_2.0  of_%logit_0.0  manual_%logit_1.0  removal_%logit_1.0  and_%logit_2.0  the_%logit_0.0  best_%logit_2.0  way_%logit_1.0  to_%logit_1.0  administer_%logit_0.0  it_%logit_0.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_2.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  an_%logit_0.0  assessment_%logit_0.0  of_%logit_0.0  the_%logit_2.0  risks_%logit_0.0  and_%logit_1.0  benefits_%logit_1.0  of_%logit_0.0  using_%logit_0.0  manual_%logit_0.0  removal_%logit_2.0  as_%logit_0.0  an_%logit_1.0  alternative_%logit_0.0  to_%logit_0.0  manual_%logit_2.0  removal_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_1.0  manual_%logit_2.0  removal_%logit_2.0  with_%logit_0.0  manual_%logit_0.0  removal_%logit_2.0  of_%logit_0.0  pl_%logit_2.0 acent_%logit_0.0 as_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_1.0  correlation_%logit_1.0  between_%logit_1.0  prenatal_%logit_2.0  abstinence_%logit_2.0  and_%logit_0.0  maternal_%logit_2.0  alcohol_%logit_1.0  use_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  prenatal_%logit_2.0  abstinence_%logit_0.0  as_%logit_2.0  a_%logit_1.0  measure_%logit_0.0  of_%logit_1.0  maternal_%logit_1.0  abstinence_%logit_1.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  prenatal_%logit_1.0  abstinence_%logit_1.0  with_%logit_0.0  prenatal_%logit_0.0  abstinence_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_0.0  prenatal_%logit_2.0  alcohol_%logit_0.0  use_%logit_1.0  on_%logit_0.0  maternal_%logit_2.0  alcohol_%logit_2.0  intake_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_0.0  effect_%logit_0.0  on_%logit_2.0  maternal_%logit_1.0  and_%logit_0.0  neon_%logit_1.0 atal_%logit_2.0  mortality_%logit_2.0 ,_%logit_0.0  a_%logit_2.0  meta_%logit_1.0 -_%logit_2.0 analysis_%logit_0.0  should_%logit_0.0  be_%logit_0.0  undertaken_%logit_2.0  to_%logit_2.0  determine_%logit_0.0  its_%logit_1.0  role_%logit_2.0  in_%logit_2.0  prenatal_%logit_1.0  abstinence_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  difference_%logit_2.0  in_%logit_2.0  healing_%logit_0.0  rates_%logit_2.0  between_%logit_1.0  the_%logit_0.0  two_%logit_0.0  types_%logit_2.0  of_%logit_2.0  anti_%logit_2.0 em_%logit_0.0 etic_%logit_0.0  drugs_%logit_2.0  for_%logit_0.0  cor_%logit_1.0 ne_%logit_2.0 al_%logit_1.0  abras_%logit_1.0 ions_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  these_%logit_0.0  drugs_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  these_%logit_1.0  conditions_%logit_2.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_2.0  them_%logit_1.0  to_%logit_0.0  each_%logit_2.0  other_%logit_0.0  in_%logit_1.0  terms_%logit_0.0  of_%logit_0.0  healing_%logit_0.0  rates_%logit_0.0 ,_%logit_0.0  pain_%logit_2.0  relief_%logit_0.0  and_%logit_0.0  satisfaction_%logit_1.0  with_%logit_1.0  treatment_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  an_%logit_0.0  assessment_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  these_%logit_1.0  medications_%logit_1.0  on_%logit_0.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_1.0  and_%logit_0.0  pain_%logit_1.0  relief_%logit_0.0  in_%logit_2.0  the_%logit_1.0  long_%logit_0.0  term_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  no_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_1.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  anti_%logit_0.0 plate_%logit_0.0 let_%logit_1.0  agents_%logit_1.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_2.0  transf_%logit_0.0 usion_%logit_0.0  reactions_%logit_0.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_1.0  a_%logit_2.0  need_%logit_2.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  anti_%logit_2.0  plate_%logit_1.0 let_%logit_0.0  agents_%logit_0.0  on_%logit_0.0  transf_%logit_1.0 usion_%logit_1.0  response_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  these_%logit_0.0  agents_%logit_1.0  with_%logit_2.0  placebo_%logit_0.0  or_%logit_2.0  no_%logit_1.0  treatment_%logit_2.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_0.0  of_%logit_2.0  high_%logit_0.0  quality_%logit_1.0 ,_%logit_1.0  preferably_%logit_0.0  with_%logit_2.0  low_%logit_0.0  risk_%logit_1.0  of_%logit_0.0  bias_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  should_%logit_2.0  include_%logit_2.0  patients_%logit_0.0  with_%logit_1.0  a_%logit_2.0  history_%logit_1.0  of_%logit_0.0  allergic_%logit_0.0  reactions_%logit_1.0 ._%logit_1.0  They_%logit_0.0  should_%logit_2.0  also_%logit_1.0  include_%logit_1.0  patients_%logit_2.0  who_%logit_1.0  are_%logit_1.0  at_%logit_1.0  high_%logit_1.0  risk_%logit_0.0  of_%logit_0.0  infection_%logit_0.0 ,_%logit_0.0  such_%logit_2.0  as_%logit_2.0  those_%logit_0.0  who_%logit_0.0  are_%logit_0.0  allergic_%logit_1.0  to_%logit_0.0  plate_%logit_1.0 let_%logit_1.0  products_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  those_%logit_1.0  who_%logit_0.0  do_%logit_1.0  not_%logit_1.0  have_%logit_0.0  an_%logit_0.0  allergy_%logit_0.0  to_%logit_1.0  these_%logit_0.0  products_%logit_0.0 ._%logit_0.0
 Parent_%logit_0.0 ing_%logit_0.0  skills_%logit_2.0  are_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  sexual_%logit_0.0  risk_%logit_2.0  behaviours_%logit_0.0 ,_%logit_0.0  reducing_%logit_2.0  sexual_%logit_1.0  initiation_%logit_0.0  rates_%logit_1.0 ,_%logit_2.0  reducing_%logit_2.0  violence_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  reducing_%logit_1.0  violence_%logit_0.0 ._%logit_1.0  They_%logit_2.0  are_%logit_0.0  also_%logit_2.0  effective_%logit_2.0  in_%logit_1.0  preventing_%logit_0.0  sexual_%logit_1.0  initiation_%logit_1.0  and_%logit_0.0  sexual_%logit_2.0  initiation_%logit_0.0 ,_%logit_0.0  reducing_%logit_1.0  violent_%logit_0.0  initiation_%logit_0.0  rates_%logit_2.0  and_%logit_0.0  decreasing_%logit_0.0  violence_%logit_0.0  rates_%logit_0.0 ._%logit_2.0  Parent_%logit_0.0 ing_%logit_1.0  Skills_%logit_0.0  are_%logit_2.0  effective_%logit_2.0  as_%logit_0.0  a_%logit_1.0  tool_%logit_2.0  to_%logit_0.0  reduce_%logit_0.0  sexual_%logit_1.0  initiation_%logit_0.0  rate_%logit_0.0 ,_%logit_1.0  but_%logit_2.0  they_%logit_1.0  are_%logit_2.0  also_%logit_2.0  associated_%logit_0.0  with_%logit_2.0  a_%logit_1.0  reduction_%logit_0.0  in_%logit_2.0  violence_%logit_1.0  rates_%logit_0.0  and_%logit_1.0  violence_%logit_1.0  rates_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  a_%logit_1.0  decreased_%logit_1.0  risk_%logit_1.0  of_%logit_2.0  sexual_%logit_1.0  initiation_%logit_2.0 ._%logit_1.0  Parents_%logit_1.0  and_%logit_1.0  their_%logit_1.0  children_%logit_0.0  are_%logit_0.0  more_%logit_0.0  likely_%logit_2.0  to_%logit_2.0  report_%logit_0.0  positive_%logit_0.0  results_%logit_2.0 ,_%logit_2.0  but_%logit_0.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_1.0  the_%logit_2.0  evidence_%logit_0.0  is_%logit_1.0  low_%logit_1.0 ._%logit_2.0  Parents_%logit_2.0  should_%logit_0.0  be_%logit_0.0  encouraged_%logit_2.0  to_%logit_1.0  take_%logit_2.0  part_%logit_1.0  in_%logit_2.0  the_%logit_0.0  evaluation_%logit_1.0  of_%logit_0.0  parent_%logit_1.0 -_%logit_1.0 child_%logit_1.0  relationship_%logit_0.0  skills_%logit_1.0  as_%logit_0.0  a_%logit_2.0  core_%logit_0.0  component_%logit_1.0  of_%logit_1.0  their_%logit_2.0  parenting_%logit_0.0  skills_%logit_0.0 ._%logit_0.0  Parents_%logit_0.0  need_%logit_0.0  to_%logit_2.0  be_%logit_2.0  aware_%logit_0.0  of_%logit_0.0  the_%logit_0.0  risks_%logit_1.0  and_%logit_0.0  benefits_%logit_2.0  of_%logit_0.0  parenting_%logit_0.0  skills_%logit_0.0  as_%logit_0.0  an_%logit_0.0  integral_%logit_2.0  part_%logit_1.0  of_%logit_2.0  the_%logit_1.0  parenting_%logit_0.0  skills_%logit_0.0  programme_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  of_%logit_1.0  the_%logit_0.0  role_%logit_0.0  of_%logit_0.0  parent_%logit_0.0  training_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  violence_%logit_0.0  and_%logit_0.0  violence_%logit_0.0 ._%logit_1.0  Parents_%logit_2.0  also_%logit_0.0  need_%logit_0.0  to_%logit_0.0  take_%logit_0.0  into_%logit_0.0  account_%logit_2.0  the_%logit_2.0  fact_%logit_0.0  that_%logit_0.0  parents_%logit_0.0  and_%logit_1.0  children_%logit_2.0  are_%logit_0.0  likely_%logit_2.0  to_%logit_0.0  respond_%logit_0.0  negatively_%logit_1.0  to_%logit_2.0  parenting_%logit_1.0  skills_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  that_%logit_1.0  they_%logit_0.0  may_%logit_0.0  have_%logit_2.0  a_%logit_2.0  role_%logit_2.0  to_%logit_1.0  play_%logit_0.0  in_%logit_0.0  helping_%logit_0.0  parents_%logit_0.0  to_%logit_2.0  improve_%logit_2.0  their_%logit_2.0  own_%logit_0.0  parenting_%logit_1.0  skills_%logit_2.0  and_%logit_1.0  behaviours_%logit_2.0 ._%logit_1.0  Parents_%logit_0.0 ,_%logit_2.0  children_%logit_1.0  and_%logit_1.0  parents_%logit_0.0  need_%logit_1.0  to_%logit_1.0  weigh_%logit_0.0  the_%logit_2.0  potential_%logit_2.0  benefits_%logit_0.0  and_%logit_0.0  drawbacks_%logit_2.0  of_%logit_0.0  parenting_%logit_0.0  Skills_%logit_1.0  as_%logit_0.0  a_%logit_0.0  standalone_%logit_2.0  component_%logit_2.0  of_%logit_2.0  the_%logit_2.0  programme_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  potential_%logit_0.0  drawbacks_%logit_2.0  and_%logit_0.0  drawbacks_%logit_1.0 ._%logit_2.0  Parents_%logit_2.0  can_%logit_0.0  expect_%logit_0.0  to_%logit_2.0  be_%logit_2.0  disappointed_%logit_0.0  with_%logit_1.0  the_%logit_0.0  results_%logit_1.0  of_%logit_1.0  this_%logit_0.0  review_%logit_2.0 ._%logit_1.0  Parents_%logit_0.0  deserve_%logit_1.0  to_%logit_2.0  be_%logit_0.0  informed_%logit_0.0  of_%logit_0.0  the_%logit_0.0  potential_%logit_0.0  pitfalls_%logit_0.0  and_%logit_0.0  pitfalls_%logit_2.0  of_%logit_1.0  coaching_%logit_2.0  skills_%logit_0.0  as_%logit_1.0  part_%logit_2.0  of_%logit_0.0  their_%logit_0.0  role_%logit_0.0  in_%logit_0.0  parenting_%logit_1.0  skills_%logit_1.0  programmes_%logit_1.0 ._%logit_0.0  Parents_%logit_0.0  may_%logit_0.0  also_%logit_2.0  expect_%logit_2.0  to_%logit_2.0  find_%logit_2.0  satisfaction_%logit_0.0  with_%logit_0.0  coaching_%logit_2.0  skills_%logit_0.0 ,_%logit_2.0  but_%logit_2.0  this_%logit_1.0  is_%logit_0.0  unlikely_%logit_1.0  to_%logit_0.0  be_%logit_0.0  sustained_%logit_1.0 ._%logit_1.0  Parents_%logit_2.0  are_%logit_0.0  also_%logit_0.0  likely_%logit_0.0  to_%logit_1.0  have_%logit_2.0  an_%logit_0.0  easier_%logit_2.0  time_%logit_1.0  with_%logit_2.0  parenting_%logit_1.0  skills_%logit_2.0  than_%logit_0.0  their_%logit_1.0  children_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  will_%logit_1.0  have_%logit_0.0  a_%logit_1.0  better_%logit_1.0  understanding_%logit_0.0  of_%logit_2.0  the_%logit_1.0  mechanisms_%logit_2.0  by_%logit_0.0  which_%logit_1.0  parenting_%logit_1.0  skills_%logit_1.0  work_%logit_1.0 ._%logit_0.0  Parents_%logit_0.0  have_%logit_1.0  a_%logit_2.0  greater_%logit_2.0  chance_%logit_0.0  of_%logit_0.0  being_%logit_0.0  disappointed_%logit_1.0  with_%logit_1.0  their_%logit_1.0  child_%logit_1.0 's_%logit_1.0  behaviour_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  may_%logit_1.0  have_%logit_2.0  more_%logit_2.0  opportunities_%logit_0.0  to_%logit_1.0  seek_%logit_0.0  support_%logit_1.0  from_%logit_1.0  parents_%logit_1.0  and_%logit_1.0  their_%logit_0.0  care_%logit_2.0 rs_%logit_0.0 ._%logit_0.0  Parent_%logit_0.0  training_%logit_0.0  may_%logit_2.0  also_%logit_0.0  have_%logit_0.0  an_%logit_0.0  impact_%logit_0.0  on_%logit_1.0  behaviour_%logit_0.0  change_%logit_1.0 ,_%logit_1.0  but_%logit_1.0  it_%logit_1.0  is_%logit_2.0  unclear_%logit_0.0  whether_%logit_2.0  this_%logit_1.0  will_%logit_0.0  translate_%logit_0.0  into_%logit_0.0  a_%logit_0.0  greater_%logit_0.0  proportion_%logit_2.0  of_%logit_2.0  successful_%logit_2.0  parenting_%logit_0.0  skills_%logit_2.0  being_%logit_0.0  employed_%logit_1.0  as_%logit_1.0  a_%logit_1.0  part_%logit_1.0  of_%logit_1.0  a_%logit_0.0  parenting_%logit_1.0  programme_%logit_0.0 ._%logit_0.0  Parents_%logit_2.0 '_%logit_0.0  satisfaction_%logit_0.0  with_%logit_1.0  parenting_%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  SC_%logit_0.0 S_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_0.0  for_%logit_1.0  SC_%logit_1.0 S_%logit_0.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_0.0  limb_%logit_2.0  survival_%logit_2.0 ,_%logit_2.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_0.0 ,_%logit_0.0  pain_%logit_0.0  relief_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  function_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_1.0  optimal_%logit_2.0  SC_%logit_2.0 S_%logit_0.0  dose_%logit_0.0  and_%logit_0.0  duration_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  SC_%logit_2.0 S_%logit_1.0  with_%logit_2.0  SC_%logit_0.0 S_%logit_1.0 ,_%logit_0.0  SC_%logit_1.0 S_%logit_1.0  and_%logit_1.0  SC_%logit_0.0 S_%logit_0.0  at_%logit_0.0  different_%logit_1.0  doses_%logit_1.0  and_%logit_0.0  times_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  also_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  optimal_%logit_2.0  dosage_%logit_2.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_1.0  sc_%logit_2.0 S_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_0.0  to_%logit_1.0  determine_%logit_0.0  whether_%logit_0.0  SC_%logit_1.0 S_%logit_0.0  is_%logit_0.0  better_%logit_0.0  than_%logit_1.0  SC_%logit_2.0 S_%logit_2.0  or_%logit_0.0  SC_%logit_1.0 S_%logit_0.0  alone_%logit_0.0  or_%logit_1.0  in_%logit_2.0  combination_%logit_0.0 ,_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  both_%logit_2.0  methods_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_0.0  methods_%logit_2.0 ,_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  them_%logit_2.0  to_%logit_1.0  SC_%logit_1.0 S_%logit_0.0  using_%logit_2.0  SC_%logit_0.0 S_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  hyd_%logit_1.0 roc_%logit_1.0 oll_%logit_2.0 oid_%logit_1.0  tablets_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  Cro_%logit_1.0 hn_%logit_2.0 's_%logit_2.0  disease_%logit_2.0 ._%logit_2.0  Further_%logit_1.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  efficacy_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  hyd_%logit_2.0 oc_%logit_1.0 oll_%logit_2.0 oid_%logit_1.0  cream_%logit_0.0  in_%logit_2.0  Cro_%logit_2.0 hn_%logit_2.0 �_%logit_0.0 �_%logit_1.0 s_%logit_2.0  disease_%logit_1.0 ._%logit_1.0  Such_%logit_1.0  trials_%logit_1.0  should_%logit_1.0  be_%logit_1.0  undertaken_%logit_2.0  in_%logit_2.0  the_%logit_0.0  context_%logit_0.0  of_%logit_0.0  a_%logit_2.0  large_%logit_0.0  scale_%logit_1.0  randomized_%logit_2.0  controlled_%logit_0.0  trial_%logit_0.0 ,_%logit_0.0  preferably_%logit_2.0  with_%logit_2.0  a_%logit_2.0  long_%logit_0.0 -_%logit_1.0 term_%logit_1.0  duration_%logit_0.0  of_%logit_0.0  follow_%logit_2.0 -_%logit_0.0 up_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  with_%logit_0.0  a_%logit_0.0  focus_%logit_0.0  on_%logit_2.0  efficacy_%logit_2.0  and_%logit_0.0  toler_%logit_2.0 ability_%logit_2.0 ._%logit_1.0  They_%logit_1.0  should_%logit_0.0  also_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_0.0  hyd_%logit_0.0 rop_%logit_1.0 oll_%logit_1.0 oid_%logit_1.0  therapy_%logit_2.0  on_%logit_1.0  relapse_%logit_0.0  and_%logit_1.0  relapse_%logit_1.0  severity_%logit_2.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  on_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  life_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  any_%logit_1.0  of_%logit_0.0  the_%logit_0.0  interventions_%logit_0.0  reviewed_%logit_2.0  in_%logit_0.0  this_%logit_2.0  review_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  various_%logit_2.0  interventions_%logit_1.0  in_%logit_0.0  the_%logit_1.0  management_%logit_1.0  of_%logit_1.0  pain_%logit_1.0  and_%logit_0.0  function_%logit_2.0  of_%logit_0.0  people_%logit_1.0  with_%logit_1.0  chronic_%logit_2.0  pain_%logit_2.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_0.0  their_%logit_1.0  effectiveness_%logit_0.0  in_%logit_1.0  various_%logit_2.0  settings_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_2.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_1.0  in_%logit_2.0  this_%logit_2.0  area_%logit_2.0 ,_%logit_0.0  particularly_%logit_0.0  in_%logit_1.0  areas_%logit_1.0  with_%logit_0.0  a_%logit_1.0  high_%logit_2.0  incidence_%logit_1.0  of_%logit_0.0  chronic_%logit_0.0  pain_%logit_0.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_1.0  hospitals_%logit_1.0  and_%logit_1.0  clinics_%logit_2.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  in_%logit_0.0  regions_%logit_0.0  with_%logit_0.0  a_%logit_2.0  low_%logit_2.0  incidence_%logit_2.0  of_%logit_2.0  acute_%logit_0.0  pain_%logit_2.0  and_%logit_0.0  chronic_%logit_0.0  pain_%logit_1.0 ._%logit_2.0
 Breat_%logit_0.0 hing_%logit_2.0  oxygen_%logit_0.0  is_%logit_0.0  effective_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  breath_%logit_1.0 lessness_%logit_2.0  and_%logit_2.0  improving_%logit_0.0  lung_%logit_0.0  function_%logit_1.0  in_%logit_0.0  people_%logit_2.0  with_%logit_1.0  COP_%logit_1.0 D_%logit_1.0 ._%logit_2.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_1.0  recommend_%logit_0.0  the_%logit_1.0  use_%logit_1.0  of_%logit_0.0  breathing_%logit_2.0  oxygen_%logit_1.0  as_%logit_0.0  a_%logit_1.0  substitute_%logit_2.0  for_%logit_2.0  oxygen_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_2.0  breath_%logit_1.0 lessness_%logit_1.0  or_%logit_1.0  dys_%logit_2.0 pn_%logit_1.0 oe_%logit_0.0 a_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_0.0  duration_%logit_1.0  of_%logit_2.0  breathing_%logit_1.0  gas_%logit_1.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_1.0  breathing_%logit_0.0  oxygen_%logit_0.0  with_%logit_2.0  oxygen_%logit_0.0 ,_%logit_0.0  oxygen_%logit_0.0  and_%logit_2.0  oxygen_%logit_2.0  therapy_%logit_2.0  in_%logit_0.0  patients_%logit_0.0  who_%logit_1.0  are_%logit_1.0  at_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  developing_%logit_1.0  hyp_%logit_1.0 ox_%logit_2.0 a_%logit_0.0 emia_%logit_0.0  or_%logit_0.0  developing_%logit_0.0  hyp_%logit_0.0 oxic_%logit_1.0  symptoms_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  future_%logit_1.0  research_%logit_0.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  oxygen_%logit_2.0  inhal_%logit_1.0 ation_%logit_2.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_1.0  oxygen_%logit_0.0  therapy_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  ant_%logit_0.0 imal_%logit_0.0 arial_%logit_1.0  drugs_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  people_%logit_0.0  with_%logit_0.0  malaria_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  establish_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_0.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_0.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_0.0  reducing_%logit_1.0  mortality_%logit_1.0  and_%logit_1.0  disability_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  malaria_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_1.0  them_%logit_2.0  with_%logit_0.0  each_%logit_0.0  other_%logit_0.0 ._%logit_0.0  In_%logit_0.0  addition_%logit_0.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_1.0  should_%logit_2.0  focus_%logit_0.0  on_%logit_1.0  assessing_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_1.0  safety_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  on_%logit_2.0  identifying_%logit_0.0  the_%logit_2.0  most_%logit_2.0  effective_%logit_1.0  drugs_%logit_1.0  to_%logit_1.0  use_%logit_0.0  in_%logit_1.0  these_%logit_2.0  patients_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_1.0  as_%logit_2.0  assessing_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  these_%logit_0.0  medications_%logit_0.0  in_%logit_1.0  reducing_%logit_2.0  mortality_%logit_2.0 ,_%logit_1.0  disability_%logit_2.0  and_%logit_1.0  disability_%logit_1.0 ._%logit_0.0
 Exercise_%logit_0.0  training_%logit_0.0  may_%logit_2.0  improve_%logit_2.0  lung_%logit_2.0  function_%logit_0.0  in_%logit_0.0  people_%logit_2.0  with_%logit_2.0  dys_%logit_0.0 p_%logit_1.0 nea_%logit_1.0 ,_%logit_0.0  but_%logit_2.0  there_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_2.0  exercise_%logit_0.0  training_%logit_1.0  as_%logit_1.0  an_%logit_2.0  exercise_%logit_2.0  training_%logit_1.0  exercise_%logit_2.0  programme_%logit_2.0 ._%logit_2.0  Exercise_%logit_2.0  training_%logit_2.0  appears_%logit_2.0  to_%logit_1.0  have_%logit_2.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_1.0  on_%logit_0.0  lung_%logit_1.0  function_%logit_2.0  and_%logit_2.0  fitness_%logit_2.0  capacity_%logit_0.0 ,_%logit_2.0  but_%logit_1.0  its_%logit_1.0  effects_%logit_2.0  on_%logit_2.0  health_%logit_2.0 -_%logit_0.0 related_%logit_1.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_2.0  are_%logit_0.0  unclear_%logit_0.0 ._%logit_2.0  Exercise_%logit_1.0  programs_%logit_0.0  appear_%logit_1.0  to_%logit_2.0  be_%logit_0.0  beneficial_%logit_2.0  in_%logit_2.0  improving_%logit_1.0  lung_%logit_0.0  function_%logit_1.0 ,_%logit_0.0  but_%logit_1.0  their_%logit_1.0  effect_%logit_1.0  on_%logit_2.0  fitness_%logit_1.0  capacity_%logit_1.0  is_%logit_2.0  not_%logit_2.0  clear_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_0.0  exercise_%logit_0.0  training_%logit_0.0  on_%logit_0.0  fitness_%logit_0.0  performance_%logit_0.0  and_%logit_1.0  fitness_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  exercise_%logit_2.0  training_%logit_1.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_1.0  of_%logit_0.0  exercise_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  any_%logit_0.0  particular_%logit_0.0  type_%logit_0.0  of_%logit_1.0  tooth_%logit_2.0 paste_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  tooth_%logit_2.0  decay_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  most_%logit_2.0  effective_%logit_2.0  tooth_%logit_0.0 paste_%logit_1.0  and_%logit_2.0  the_%logit_0.0  best_%logit_0.0  way_%logit_0.0  to_%logit_0.0  apply_%logit_0.0  it_%logit_0.0  to_%logit_0.0  tooth_%logit_1.0  decay_%logit_1.0  in_%logit_0.0  tooth_%logit_0.0  decay_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  different_%logit_1.0  types_%logit_2.0  and_%logit_1.0  methods_%logit_0.0  of_%logit_0.0  tooth_%logit_2.0  extraction_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  durability_%logit_2.0  of_%logit_1.0  tooth_%logit_0.0 past_%logit_0.0 es_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  tooth_%logit_0.0 paste_%logit_2.0  with_%logit_0.0  other_%logit_0.0  tooth_%logit_0.0 paste_%logit_2.0  products_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_2.0  of_%logit_1.0  a_%logit_0.0  protective_%logit_2.0  effect_%logit_1.0  of_%logit_1.0  hyd_%logit_2.0 roc_%logit_2.0 ort_%logit_2.0 is_%logit_1.0 one_%logit_1.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  L_%logit_2.0 UT_%logit_1.0 S_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  hyd_%logit_1.0 oc_%logit_1.0 ort_%logit_0.0 is_%logit_0.0 ones_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  the_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  over_%logit_1.0 active_%logit_0.0  bladder_%logit_0.0  syndrome_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_1.0  hyd_%logit_2.0 rop_%logit_1.0 ort_%logit_2.0 is_%logit_1.0 ole_%logit_0.0  in_%logit_2.0  the_%logit_1.0  management_%logit_0.0  of_%logit_2.0  bladder_%logit_1.0  dys_%logit_2.0 pl_%logit_0.0 asia_%logit_0.0  and_%logit_0.0  residual_%logit_0.0  urine_%logit_1.0  volume_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  long_%logit_0.0 -_%logit_0.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_0.0  effectiveness_%logit_1.0  in_%logit_1.0  bladder_%logit_1.0  function_%logit_2.0  and_%logit_2.0  quality_%logit_2.0  of_%logit_1.0  life_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_0.0  of_%logit_0.0  digital_%logit_0.0 -_%logit_1.0 sy_%logit_0.0 mbol_%logit_1.0  substitution_%logit_0.0  tests_%logit_0.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_2.0  anxiety_%logit_0.0  or_%logit_0.0  distress_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_0.0  establish_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_2.0  reliability_%logit_1.0  of_%logit_2.0  these_%logit_0.0  tests_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_2.0  digital_%logit_2.0  substitution_%logit_0.0  with_%logit_2.0  other_%logit_0.0  types_%logit_2.0  of_%logit_2.0  electro_%logit_2.0 stim_%logit_0.0 ulation_%logit_1.0  in_%logit_0.0  the_%logit_2.0  management_%logit_1.0  of_%logit_2.0  anxiety_%logit_1.0  and_%logit_0.0  distress_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  ana_%logit_2.0 esthesia_%logit_0.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_2.0  for_%logit_0.0  an_%logit_0.0  assessment_%logit_0.0  of_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0 ,_%logit_1.0  reliability_%logit_2.0  and_%logit_2.0  durability_%logit_2.0  of_%logit_0.0  digital_%logit_2.0  symbols_%logit_1.0  substitution_%logit_2.0  tests_%logit_1.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  a_%logit_0.0  comparison_%logit_1.0  of_%logit_0.0  digital_%logit_0.0  and_%logit_0.0  analog_%logit_1.0  substitution_%logit_0.0  tests_%logit_2.0  with_%logit_1.0  each_%logit_1.0  other_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  mineral_%logit_0.0  baths_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  verte_%logit_1.0 bral_%logit_0.0  fractures_%logit_0.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_0.0  mineral_%logit_0.0  baths_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0  for_%logit_0.0  verte_%logit_2.0 bral_%logit_2.0  fracture_%logit_0.0  prevention_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  whether_%logit_2.0  they_%logit_0.0  are_%logit_2.0  beneficial_%logit_2.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_1.0  bone_%logit_1.0  mineral_%logit_0.0  density_%logit_0.0 ,_%logit_0.0  bone_%logit_2.0  integrity_%logit_0.0 ,_%logit_0.0  bone_%logit_2.0  density_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  bone_%logit_1.0  density_%logit_1.0  in_%logit_1.0  particular_%logit_2.0  in_%logit_1.0  patients_%logit_1.0  with_%logit_0.0  non_%logit_2.0 -_%logit_1.0 ver_%logit_2.0 te_%logit_0.0 bral_%logit_1.0  fractures_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  those_%logit_1.0  with_%logit_1.0  oste_%logit_0.0 op_%logit_1.0 or_%logit_0.0 osis_%logit_2.0  or_%logit_0.0  bone_%logit_2.0  frag_%logit_1.0 ility_%logit_2.0 ,_%logit_2.0  or_%logit_0.0  whether_%logit_2.0  bone_%logit_2.0  density_%logit_0.0  is_%logit_2.0  reduced_%logit_1.0  in_%logit_1.0  these_%logit_0.0  patients_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  intraven_%logit_0.0 ous_%logit_1.0  immun_%logit_0.0 ogl_%logit_0.0 ob_%logit_0.0 ulin_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  S_%logit_0.0 MA_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  this_%logit_2.0  therapy_%logit_2.0  in_%logit_2.0  reducing_%logit_0.0  blood_%logit_0.0  pressure_%logit_0.0  and_%logit_0.0  blood_%logit_2.0  pressure_%logit_2.0  in_%logit_1.0  S_%logit_0.0 MA_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_1.0  this_%logit_0.0  treatment_%logit_2.0  with_%logit_1.0  other_%logit_1.0  treatments_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  long_%logit_2.0 -_%logit_2.0 term_%logit_2.0  follow_%logit_0.0 -_%logit_0.0 up_%logit_0.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  this_%logit_1.0  intervention_%logit_0.0  on_%logit_2.0  S_%logit_1.0 MA_%logit_1.0  and_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  its_%logit_1.0  effectiveness_%logit_1.0  in_%logit_0.0  the_%logit_1.0  long_%logit_0.0  term_%logit_2.0 ._%logit_1.0  Long_%logit_1.0 -_%logit_1.0 term_%logit_2.0  data_%logit_0.0  are_%logit_1.0  also_%logit_2.0  required_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  its_%logit_0.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_2.0  and_%logit_0.0  effectiveness_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  vas_%logit_0.0 op_%logit_1.0 ressor_%logit_1.0  systems_%logit_0.0  for_%logit_1.0  reducing_%logit_0.0  blood_%logit_2.0  loss_%logit_0.0  or_%logit_2.0  blood_%logit_1.0  transf_%logit_0.0 usion_%logit_2.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  acute_%logit_0.0  hem_%logit_2.0 odynamic_%logit_2.0  hypertension_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_1.0  best_%logit_1.0  method_%logit_1.0  of_%logit_2.0  pumping_%logit_0.0  blood_%logit_0.0  into_%logit_1.0  veins_%logit_1.0 ,_%logit_1.0  the_%logit_1.0  best_%logit_1.0  way_%logit_0.0  to_%logit_0.0  reduce_%logit_0.0  blood_%logit_2.0  loss_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  the_%logit_1.0  most_%logit_1.0  effective_%logit_1.0  way_%logit_2.0  to_%logit_1.0  achieve_%logit_2.0  this_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_2.0  area_%logit_1.0 ._%logit_0.0  The_%logit_0.0  results_%logit_2.0  of_%logit_1.0  this_%logit_0.0  review_%logit_2.0  should_%logit_1.0  be_%logit_2.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  the_%logit_0.0  conclusions_%logit_1.0  are_%logit_0.0  based_%logit_0.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_2.0  of_%logit_0.0  patients_%logit_0.0  and_%logit_0.0  are_%logit_1.0  subject_%logit_1.0  to_%logit_1.0  considerable_%logit_2.0  variation_%logit_2.0  in_%logit_1.0  outcome_%logit_0.0  measures_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  intra_%logit_0.0 uter_%logit_2.0 ine_%logit_0.0  exc_%logit_1.0 ision_%logit_2.0 ing_%logit_1.0  as_%logit_1.0  a_%logit_2.0  contraceptive_%logit_2.0  strategy_%logit_1.0  in_%logit_0.0  women_%logit_1.0  with_%logit_2.0  a_%logit_1.0  history_%logit_2.0  of_%logit_0.0  recurrent_%logit_0.0  menstrual_%logit_0.0  bleeding_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_2.0  treatment_%logit_0.0  option_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  it_%logit_1.0  with_%logit_1.0  other_%logit_1.0  hormonal_%logit_2.0  contraception_%logit_1.0  options_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_1.0  best_%logit_2.0  way_%logit_1.0  to_%logit_2.0  administer_%logit_0.0  exc_%logit_2.0 ision_%logit_2.0 ation_%logit_2.0  as_%logit_2.0  a_%logit_0.0  hormonal_%logit_2.0  contraceptive_%logit_2.0  strategy_%logit_0.0 ,_%logit_0.0  a_%logit_0.0  meta_%logit_2.0 -_%logit_0.0 analysis_%logit_1.0  should_%logit_0.0  be_%logit_0.0  undertaken_%logit_1.0  to_%logit_1.0  determine_%logit_0.0  its_%logit_0.0  effectiveness_%logit_2.0  and_%logit_1.0  cost_%logit_1.0 -_%logit_2.0 effect_%logit_2.0 iveness_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  phen_%logit_0.0 obar_%logit_1.0 b_%logit_2.0 ital_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  SE_%logit_0.0 /_%logit_0.0 IV_%logit_0.0 H_%logit_0.0 ._%logit_2.0  Further_%logit_2.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_1.0  and_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  phen_%logit_0.0 y_%logit_2.0 to_%logit_2.0 in_%logit_1.0  therapy_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_0.0  the_%logit_2.0  various_%logit_0.0  methods_%logit_2.0  of_%logit_2.0  administration_%logit_1.0  in_%logit_1.0  this_%logit_0.0  population_%logit_2.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_1.0  are_%logit_2.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_0.0  phen_%logit_2.0 oxy_%logit_1.0 cycl_%logit_1.0 ine_%logit_0.0  on_%logit_0.0  mortality_%logit_2.0  and_%logit_0.0  morbid_%logit_0.0 ity_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  phen_%logit_0.0 oxy_%logit_0.0 cl_%logit_0.0 onic_%logit_0.0  acid_%logit_0.0  with_%logit_1.0  other_%logit_0.0  treatments_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  for_%logit_2.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  ak_%logit_2.0 ath_%logit_2.0 is_%logit_0.0 ia_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  acupuncture_%logit_2.0  in_%logit_1.0  this_%logit_1.0  population_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_2.0  efficacy_%logit_0.0  of_%logit_1.0  acupuncture_%logit_1.0  as_%logit_0.0  a_%logit_0.0  standalone_%logit_1.0  treatment_%logit_2.0  for_%logit_2.0  ak_%logit_2.0 ath_%logit_0.0 ias_%logit_0.0 ia_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  acupuncture_%logit_0.0  with_%logit_1.0  other_%logit_0.0  treatments_%logit_2.0 ,_%logit_1.0  such_%logit_0.0  as_%logit_2.0  chirop_%logit_0.0 ract_%logit_1.0 ic_%logit_1.0  treatment_%logit_0.0 ,_%logit_0.0  or_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  its_%logit_0.0  effectiveness_%logit_1.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_2.0  to_%logit_2.0  other_%logit_0.0  treatments_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_0.0  is_%logit_0.0  required_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  whether_%logit_1.0  acupuncture_%logit_0.0  has_%logit_2.0  an_%logit_2.0  effect_%logit_2.0  on_%logit_1.0  the_%logit_2.0  quality_%logit_1.0  of_%logit_2.0  life_%logit_0.0  of_%logit_1.0  people_%logit_1.0  with_%logit_0.0  ak_%logit_1.0 ath_%logit_0.0 ia_%logit_0.0 ,_%logit_2.0  or_%logit_2.0  on_%logit_1.0  the_%logit_0.0  severity_%logit_0.0  of_%logit_1.0  its_%logit_2.0  symptoms_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  ip_%logit_1.0 rat_%logit_0.0 rop_%logit_2.0 ium_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  rel_%logit_0.0 apsed_%logit_1.0  or_%logit_1.0  ref_%logit_0.0 ract_%logit_0.0 ory_%logit_0.0  RR_%logit_0.0 MS_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  ip_%logit_0.0 at_%logit_2.0 rop_%logit_2.0 ium_%logit_2.0  in_%logit_1.0  treating_%logit_2.0  rel_%logit_2.0 apses_%logit_2.0  and_%logit_2.0  relapse_%logit_0.0  in_%logit_2.0  patients_%logit_0.0  with_%logit_1.0  RR_%logit_1.0 MS_%logit_0.0  who_%logit_0.0  are_%logit_0.0  unable_%logit_2.0  to_%logit_1.0  tolerate_%logit_1.0  it_%logit_0.0  or_%logit_2.0  who_%logit_0.0  are_%logit_1.0  unwilling_%logit_1.0  or_%logit_1.0  unable_%logit_1.0  to_%logit_2.0  accept_%logit_0.0  it_%logit_1.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_0.0  should_%logit_1.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_0.0  the_%logit_1.0  absence_%logit_2.0  of_%logit_0.0  evidence_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_1.0  this_%logit_2.0  drug_%logit_0.0 ._%logit_2.0
 R_%logit_0.0 uf_%logit_2.0 in_%logit_1.0 amide_%logit_1.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  the_%logit_1.0  frequency_%logit_1.0  of_%logit_1.0  drop_%logit_0.0  attacks_%logit_1.0  and_%logit_0.0  reducing_%logit_1.0  the_%logit_1.0  number_%logit_2.0  of_%logit_0.0  drop_%logit_0.0 outs_%logit_0.0 ._%logit_0.0  It_%logit_2.0  is_%logit_2.0  also_%logit_0.0  associated_%logit_0.0  with_%logit_2.0  a_%logit_0.0  reduction_%logit_2.0  in_%logit_0.0  the_%logit_0.0  severity_%logit_0.0  of_%logit_0.0  the_%logit_2.0  drop_%logit_0.0  attacks_%logit_2.0 ,_%logit_0.0  but_%logit_1.0  this_%logit_1.0  is_%logit_0.0  based_%logit_1.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_1.0  of_%logit_2.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_0.0  a_%logit_2.0  high_%logit_1.0  risk_%logit_2.0  of_%logit_0.0  bias_%logit_0.0  and_%logit_0.0  a_%logit_0.0  low_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  random_%logit_0.0  errors_%logit_0.0 ._%logit_1.0  Its_%logit_0.0  efficacy_%logit_0.0  is_%logit_1.0  similar_%logit_1.0  to_%logit_1.0  that_%logit_1.0  of_%logit_2.0  other_%logit_0.0  drugs_%logit_1.0 ,_%logit_0.0  but_%logit_1.0  with_%logit_1.0  a_%logit_1.0  higher_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  adverse_%logit_0.0  events_%logit_0.0  and_%logit_2.0  a_%logit_2.0  lower_%logit_0.0  risk_%logit_0.0  of_%logit_2.0  seizure_%logit_2.0  frequency_%logit_1.0 ._%logit_0.0  Its_%logit_0.0  use_%logit_2.0  is_%logit_2.0  associated_%logit_2.0  with_%logit_0.0  an_%logit_2.0  increased_%logit_1.0  risk_%logit_0.0  of_%logit_0.0  seizures_%logit_0.0  and_%logit_1.0  a_%logit_1.0  decreased_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  death_%logit_2.0 ._%logit_0.0  Its_%logit_0.0  effectiveness_%logit_2.0  is_%logit_2.0  similar_%logit_2.0  with_%logit_1.0  other_%logit_2.0  drugs_%logit_2.0 ._%logit_2.0  Its_%logit_0.0  safety_%logit_2.0  is_%logit_2.0  similar_%logit_0.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_0.0  efficacy_%logit_2.0  and_%logit_0.0  safety_%logit_2.0 ._%logit_1.0  Its_%logit_1.0  long_%logit_1.0 -_%logit_2.0 term_%logit_2.0  safety_%logit_1.0  is_%logit_1.0  unknown_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  any_%logit_0.0  difference_%logit_2.0  in_%logit_2.0  accuracy_%logit_2.0  between_%logit_0.0  Brooks_%logit_1.0  and_%logit_1.0  Kir_%logit_2.0 i_%logit_2.0 uchi_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_2.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  whether_%logit_0.0  or_%logit_0.0  not_%logit_2.0  Brooks_%logit_0.0  is_%logit_1.0  better_%logit_0.0  suited_%logit_0.0  to_%logit_1.0  the_%logit_2.0  position_%logit_1.0  of_%logit_0.0  Brooks_%logit_1.0  in_%logit_1.0  the_%logit_1.0  orth_%logit_1.0 op_%logit_0.0 aed_%logit_0.0 ic_%logit_2.0  field_%logit_2.0 ,_%logit_0.0  or_%logit_0.0  whether_%logit_0.0  he_%logit_1.0  is_%logit_1.0  worse_%logit_0.0  suited_%logit_0.0  for_%logit_1.0  the_%logit_0.0  role_%logit_2.0  of_%logit_0.0  a_%logit_1.0  surgeon_%logit_1.0  in_%logit_1.0  this_%logit_2.0  field_%logit_1.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_2.0  Brooks_%logit_2.0  on_%logit_1.0  accuracy_%logit_0.0  and_%logit_0.0  accuracy_%logit_2.0  of_%logit_0.0  Brooks_%logit_1.0 '_%logit_1.0  position_%logit_1.0  in_%logit_1.0  orth_%logit_0.0 oped_%logit_0.0 ic_%logit_0.0  surgery_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  Brooks_%logit_0.0  with_%logit_0.0  other_%logit_0.0  surgical_%logit_1.0  procedures_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_2.0 otherapy_%logit_1.0  for_%logit_0.0  psychological_%logit_1.0  distress_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  psychological_%logit_2.0  therapy_%logit_0.0  for_%logit_2.0  psychological_%logit_1.0  stress_%logit_2.0  disorder_%logit_2.0 ._%logit_2.0  It_%logit_2.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_0.0  by_%logit_0.0  which_%logit_0.0  psych_%logit_0.0 otherapy_%logit_0.0  works_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  how_%logit_2.0  it_%logit_1.0  relates_%logit_1.0  to_%logit_2.0  psychological_%logit_0.0  distress_%logit_0.0  disorder_%logit_0.0  and_%logit_1.0  coping_%logit_2.0  skills_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_0.0  as_%logit_1.0  how_%logit_0.0  it_%logit_2.0  compares_%logit_1.0  to_%logit_2.0  other_%logit_2.0  psychological_%logit_1.0  therapies_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  psych_%logit_0.0 otherapy_%logit_1.0  with_%logit_2.0  other_%logit_0.0  psychological_%logit_1.0  treatments_%logit_0.0 ,_%logit_1.0  including_%logit_2.0  antidepressant_%logit_2.0  drugs_%logit_0.0  and_%logit_2.0  psychological_%logit_1.0  therapies_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  t_%logit_2.0 af_%logit_1.0 en_%logit_2.0 oqu_%logit_1.0 ine_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_1.0  P_%logit_1.0 ._%logit_0.0  v_%logit_1.0 iv_%logit_1.0 ax_%logit_1.0  malaria_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  treatment_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  t_%logit_2.0 aff_%logit_2.0 en_%logit_1.0 oqu_%logit_2.0 ines_%logit_2.0  in_%logit_1.0  the_%logit_2.0  management_%logit_2.0  of_%logit_2.0  this_%logit_1.0  condition_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_1.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  long_%logit_0.0 -_%logit_0.0 acting_%logit_1.0  beta_%logit_1.0 -_%logit_1.0 l_%logit_0.0 act_%logit_0.0 ams_%logit_2.0 ,_%logit_0.0  particularly_%logit_1.0  in_%logit_1.0  combination_%logit_1.0  with_%logit_0.0  chlor_%logit_1.0 oqu_%logit_0.0 ine_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0 ,_%logit_1.0  safety_%logit_1.0  and_%logit_1.0  efficacy_%logit_0.0  of_%logit_0.0  these_%logit_1.0  drugs_%logit_1.0  in_%logit_2.0  the_%logit_1.0  control_%logit_1.0  group_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_1.0  of_%logit_2.0  thermal_%logit_1.0  baths_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  tear_%logit_1.0 -_%logit_1.0 up_%logit_1.0  conditions_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_2.0  thermal_%logit_0.0  baths_%logit_1.0  are_%logit_0.0  more_%logit_0.0  effective_%logit_0.0  than_%logit_1.0  thermal_%logit_1.0  baths_%logit_0.0  for_%logit_0.0  tearing_%logit_1.0 -_%logit_0.0 up_%logit_2.0  periods_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  whether_%logit_2.0  thermal_%logit_1.0  bathing_%logit_0.0  is_%logit_2.0  more_%logit_1.0  effective_%logit_1.0  or_%logit_1.0  safer_%logit_1.0  than_%logit_1.0  thermal_%logit_0.0  bathing_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_2.0  reducing_%logit_0.0  tear_%logit_0.0 -_%logit_1.0 ups_%logit_0.0  conditions_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  thermal_%logit_1.0  baths_%logit_2.0  with_%logit_0.0  thermal_%logit_0.0  baths_%logit_2.0  or_%logit_0.0  thermal_%logit_1.0  baths_%logit_1.0  alone_%logit_0.0  or_%logit_0.0  in_%logit_2.0  combination_%logit_1.0  with_%logit_0.0  a_%logit_0.0  thermal_%logit_1.0  bath_%logit_2.0  or_%logit_1.0  thermal_%logit_1.0  bath_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  studies_%logit_1.0  are_%logit_2.0  also_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  thermal_%logit_2.0  bathing_%logit_0.0 ,_%logit_1.0  thermal_%logit_2.0  baths_%logit_1.0  and_%logit_1.0  thermal_%logit_1.0  baths_%logit_0.0  compared_%logit_1.0  to_%logit_1.0  thermal_%logit_0.0  bathing_%logit_1.0  alone_%logit_2.0  or_%logit_0.0  with_%logit_1.0  thermal_%logit_0.0  bathing_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  tooth_%logit_1.0  alignment_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  cav_%logit_0.0 ities_%logit_1.0  in_%logit_2.0  tooth_%logit_0.0 br_%logit_0.0 ushes_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_0.0  tooth_%logit_1.0 br_%logit_2.0 ushing_%logit_2.0  for_%logit_2.0  cav_%logit_1.0 ities_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  other_%logit_2.0  types_%logit_1.0  of_%logit_2.0  dental_%logit_2.0  cleaning_%logit_2.0  products_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  to_%logit_0.0  other_%logit_0.0  forms_%logit_2.0  of_%logit_1.0  cleaning_%logit_2.0  products_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_2.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_0.0  the_%logit_0.0  evaluation_%logit_2.0  of_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  efficacy_%logit_1.0  of_%logit_1.0  various_%logit_0.0  cleaning_%logit_2.0  products_%logit_2.0  for_%logit_2.0  cav_%logit_2.0 ions_%logit_0.0  in_%logit_0.0  teeth_%logit_2.0 br_%logit_1.0 ushing_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  mic_%logit_1.0 ron_%logit_2.0 ut_%logit_0.0 rient_%logit_0.0  supplements_%logit_1.0  in_%logit_0.0  the_%logit_0.0  management_%logit_1.0  of_%logit_2.0  physical_%logit_0.0  fitness_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  mic_%logit_1.0 rone_%logit_1.0 ut_%logit_1.0 rient_%logit_0.0  supplementation_%logit_0.0  in_%logit_1.0  improving_%logit_0.0  physical_%logit_1.0  fitness_%logit_2.0  and_%logit_1.0  improving_%logit_1.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_1.0  HIV_%logit_1.0 /_%logit_0.0 AIDS_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  on_%logit_1.0  health_%logit_1.0 -_%logit_1.0 related_%logit_0.0  quality_%logit_2.0  and_%logit_0.0  quantity_%logit_0.0  of_%logit_1.0  life_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_2.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_2.0  mic_%logit_1.0 rot_%logit_0.0 rient_%logit_2.0  supplements_%logit_2.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_0.0  durability_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  also_%logit_0.0  to_%logit_0.0  assess_%logit_2.0  their_%logit_0.0  effectiveness_%logit_2.0  in_%logit_1.0  other_%logit_2.0  areas_%logit_0.0  of_%logit_2.0  fitness_%logit_1.0  and_%logit_1.0  health_%logit_2.0 -_%logit_0.0 associated_%logit_0.0  quality_%logit_2.0  of_%logit_2.0  Life_%logit_0.0 ._%logit_0.0
 Pro_%logit_0.0 pr_%logit_2.0 anol_%logit_0.0 ol_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  blood_%logit_0.0  pressure_%logit_0.0  in_%logit_0.0  pre_%logit_1.0 term_%logit_0.0  or_%logit_0.0  newborn_%logit_2.0  patients_%logit_1.0  with_%logit_2.0  hypertension_%logit_2.0 ,_%logit_0.0  but_%logit_2.0  its_%logit_0.0  use_%logit_1.0  is_%logit_0.0  associated_%logit_0.0  with_%logit_0.0  a_%logit_0.0  reduction_%logit_2.0  in_%logit_1.0  the_%logit_1.0  number_%logit_2.0  of_%logit_0.0  deaths_%logit_2.0  and_%logit_2.0  the_%logit_2.0  rate_%logit_0.0  of_%logit_1.0  hyp_%logit_1.0 ogly_%logit_1.0 ca_%logit_2.0 emia_%logit_0.0 ._%logit_0.0  Its_%logit_0.0  use_%logit_0.0  is_%logit_1.0  also_%logit_2.0  associated_%logit_2.0  with_%logit_0.0  an_%logit_0.0  increased_%logit_1.0  risk_%logit_1.0  of_%logit_1.0  maternal_%logit_0.0  death_%logit_1.0 ,_%logit_1.0  a_%logit_2.0  decreased_%logit_2.0  risk_%logit_0.0  of_%logit_0.0  neon_%logit_0.0 atal_%logit_0.0  death_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  a_%logit_1.0  decrease_%logit_1.0  in_%logit_1.0  the_%logit_0.0  incidence_%logit_1.0  of_%logit_0.0  maternal_%logit_1.0  hyper_%logit_1.0 gly_%logit_1.0 ca_%logit_1.0 emia_%logit_2.0 ,_%logit_0.0  an_%logit_0.0  increase_%logit_1.0  in_%logit_1.0  neon_%logit_0.0 atal_%logit_0.0  mortality_%logit_0.0  and_%logit_1.0  a_%logit_1.0  decreased_%logit_2.0  rate_%logit_0.0  of_%logit_1.0  maternal_%logit_1.0  mortality_%logit_0.0 ._%logit_0.0  Its_%logit_0.0  effect_%logit_0.0  on_%logit_2.0  maternal_%logit_2.0  mortality_%logit_2.0  is_%logit_1.0  not_%logit_2.0  clear_%logit_2.0  from_%logit_2.0  this_%logit_1.0  review_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  is_%logit_1.0  likely_%logit_1.0  to_%logit_2.0  be_%logit_1.0  underestimated_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  existence_%logit_1.0  of_%logit_1.0  a_%logit_1.0  mechanism_%logit_0.0  of_%logit_1.0  blood_%logit_0.0  pressure_%logit_2.0  lowering_%logit_0.0  in_%logit_0.0  cold_%logit_0.0 -_%logit_1.0 blooded_%logit_0.0  people_%logit_1.0  with_%logit_2.0  Ray_%logit_2.0 na_%logit_0.0 ud_%logit_2.0 's_%logit_1.0  phenomenon_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_0.0  mechanism_%logit_2.0  by_%logit_0.0  which_%logit_1.0  blood_%logit_2.0  pressure_%logit_1.0  lowers_%logit_1.0  in_%logit_1.0  this_%logit_1.0  population_%logit_0.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  this_%logit_1.0  intervention_%logit_1.0  with_%logit_1.0  other_%logit_0.0  treatments_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_2.0  a_%logit_2.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_2.0  other_%logit_1.0  types_%logit_2.0  of_%logit_2.0  blood_%logit_0.0 pressure_%logit_0.0  lowering_%logit_2.0  techniques_%logit_0.0 ,_%logit_0.0  such_%logit_2.0  as_%logit_1.0  hyd_%logit_2.0 roc_%logit_0.0 oll_%logit_0.0 oid_%logit_2.0  gel_%logit_1.0  gel_%logit_2.0  gel_%logit_0.0  and_%logit_2.0  gel_%logit_2.0 -_%logit_0.0 based_%logit_1.0  gel_%logit_1.0 -_%logit_1.0 containing_%logit_0.0  gel_%logit_0.0  gel_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  existence_%logit_0.0  of_%logit_1.0  a_%logit_0.0  protective_%logit_0.0  effect_%logit_1.0  of_%logit_0.0  omega_%logit_1.0 -_%logit_2.0 3_%logit_0.0  fatty_%logit_0.0  acids_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  arter_%logit_2.0 ial_%logit_2.0  blood_%logit_2.0  pressure_%logit_1.0  in_%logit_2.0  people_%logit_2.0  with_%logit_2.0  peripheral_%logit_2.0  arter_%logit_2.0 ial_%logit_2.0  hypertension_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_2.0  omega_%logit_2.0  3_%logit_2.0  fatty_%logit_2.0  acids_%logit_2.0  on_%logit_1.0  blood_%logit_2.0  pressure_%logit_0.0 ,_%logit_1.0  plate_%logit_1.0 let_%logit_1.0  count_%logit_0.0 ,_%logit_1.0  blood_%logit_0.0  pressure_%logit_2.0  and_%logit_0.0  plate_%logit_1.0 let_%logit_2.0  sensitivity_%logit_2.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_1.0  peripheral_%logit_1.0  artery_%logit_1.0  hypertension_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  long_%logit_1.0 -_%logit_2.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  required_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_0.0  plate_%logit_1.0 let_%logit_2.0  counts_%logit_2.0  and_%logit_0.0  blood_%logit_0.0  sugar_%logit_1.0  levels_%logit_2.0  in_%logit_1.0  patients_%logit_1.0  who_%logit_0.0  are_%logit_1.0  at_%logit_1.0  high_%logit_2.0  risk_%logit_2.0  of_%logit_0.0  cardiovascular_%logit_0.0  disease_%logit_0.0 ._%logit_1.0
 Ant_%logit_0.0 ib_%logit_0.0 iotic_%logit_0.0  pro_%logit_0.0 ph_%logit_0.0 yl_%logit_0.0 axis_%logit_0.0  is_%logit_0.0  effective_%logit_2.0  in_%logit_0.0  reducing_%logit_0.0  the_%logit_0.0  incidence_%logit_0.0  and_%logit_0.0  severity_%logit_2.0  of_%logit_1.0  bacterial_%logit_2.0  infections_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  acute_%logit_2.0  and_%logit_0.0  chronic_%logit_0.0  kidney_%logit_1.0  disease_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_1.0  further_%logit_0.0  research_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  pro_%logit_2.0 -_%logit_2.0 ph_%logit_1.0 yl_%logit_0.0 actic_%logit_0.0  antibiotics_%logit_0.0  in_%logit_0.0  this_%logit_2.0  population_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_0.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_2.0  with_%logit_2.0  each_%logit_2.0  other_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_1.0  mortality_%logit_1.0 ,_%logit_1.0  morbid_%logit_0.0 ity_%logit_1.0  and_%logit_1.0  mortality_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_1.0  and_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotics_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  acute_%logit_1.0  kidney_%logit_2.0  disease_%logit_0.0 ,_%logit_1.0  a_%logit_0.0  randomized_%logit_2.0  controlled_%logit_2.0  trial_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  these_%logit_1.0  drugs_%logit_1.0  to_%logit_1.0  each_%logit_2.0  other_%logit_1.0 ._%logit_2.0
 Ox_%logit_0.0 carb_%logit_2.0 az_%logit_2.0 ep_%logit_0.0 am_%logit_0.0  appears_%logit_0.0  to_%logit_0.0  have_%logit_1.0  a_%logit_1.0  beneficial_%logit_0.0  effect_%logit_1.0  on_%logit_2.0  sleep_%logit_0.0 iness_%logit_1.0  and_%logit_1.0  toler_%logit_2.0 ability_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  alcohol_%logit_0.0  withdrawal_%logit_2.0  syndrome_%logit_1.0 ._%logit_1.0  However_%logit_2.0 ,_%logit_0.0  its_%logit_2.0  use_%logit_0.0  is_%logit_1.0  associated_%logit_2.0  with_%logit_1.0  a_%logit_1.0  significant_%logit_0.0  increase_%logit_2.0  in_%logit_0.0  adverse_%logit_0.0  events_%logit_0.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_1.0  sleep_%logit_0.0 iness_%logit_0.0 ,_%logit_0.0  fatigue_%logit_0.0 ,_%logit_0.0  insomnia_%logit_1.0  and_%logit_1.0  sleep_%logit_1.0 iness_%logit_0.0 ._%logit_0.0  Its_%logit_0.0  use_%logit_0.0  is_%logit_2.0  not_%logit_2.0  associated_%logit_1.0  with_%logit_2.0  an_%logit_1.0  increase_%logit_2.0  in_%logit_2.0  sleep_%logit_2.0 iness_%logit_2.0  or_%logit_1.0  fatigue_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  its_%logit_2.0  use_%logit_1.0  may_%logit_2.0  be_%logit_2.0  associated_%logit_0.0  with_%logit_0.0  increased_%logit_0.0  risk_%logit_0.0  of_%logit_0.0  sleep_%logit_0.0 iness_%logit_2.0  in_%logit_2.0  some_%logit_1.0  patients_%logit_2.0 ._%logit_1.0  Its_%logit_0.0  efficacy_%logit_0.0  is_%logit_2.0  not_%logit_0.0  clear_%logit_1.0  from_%logit_1.0  this_%logit_1.0  review_%logit_0.0 ,_%logit_2.0  as_%logit_0.0  the_%logit_2.0  majority_%logit_1.0  of_%logit_0.0  the_%logit_1.0  articles_%logit_0.0  in_%logit_1.0  this_%logit_2.0  review_%logit_2.0  were_%logit_0.0  published_%logit_0.0  in_%logit_0.0  the_%logit_2.0  United_%logit_0.0  Kingdom_%logit_1.0  and_%logit_0.0  elsewhere_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  difference_%logit_1.0  in_%logit_1.0  blood_%logit_0.0  pressure_%logit_0.0  in_%logit_2.0  my_%logit_0.0 ocard_%logit_1.0 ial_%logit_2.0  is_%logit_0.0 chem_%logit_1.0 ia_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_1.0  to_%logit_2.0  suggest_%logit_2.0  that_%logit_2.0  blood_%logit_0.0  pressure_%logit_0.0  lowering_%logit_0.0  is_%logit_1.0  associated_%logit_2.0  with_%logit_0.0  a_%logit_0.0  reduction_%logit_2.0  in_%logit_0.0  mortality_%logit_0.0  or_%logit_0.0  cardiovascular_%logit_1.0  morbid_%logit_2.0 ity_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  this_%logit_2.0  is_%logit_2.0  based_%logit_2.0  on_%logit_2.0  a_%logit_0.0  small_%logit_1.0  number_%logit_0.0  of_%logit_0.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_2.0  a_%logit_0.0  high_%logit_1.0  risk_%logit_2.0  of_%logit_0.0  bias_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  best_%logit_0.0  way_%logit_1.0  to_%logit_0.0  quantify_%logit_2.0  blood_%logit_2.0  pressure_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  blood_%logit_1.0  pressure_%logit_2.0  reduction_%logit_0.0  with_%logit_2.0  other_%logit_1.0  measures_%logit_2.0  of_%logit_2.0  mortality_%logit_1.0  and_%logit_2.0  cardiovascular_%logit_2.0  morbid_%logit_1.0 ities_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_2.0  recommend_%logit_0.0  the_%logit_2.0  use_%logit_2.0  of_%logit_0.0  prog_%logit_0.0 est_%logit_1.0 ogens_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  REM_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_1.0  timing_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_2.0  best_%logit_2.0  prog_%logit_1.0 est_%logit_0.0 ogen_%logit_2.0  formulation_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_0.0  a_%logit_2.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  prog_%logit_1.0 ester_%logit_0.0 one_%logit_0.0  in_%logit_2.0  REM_%logit_0.0 ._%logit_1.0  This_%logit_2.0  should_%logit_2.0  be_%logit_1.0  done_%logit_0.0  in_%logit_0.0  accordance_%logit_0.0  with_%logit_0.0  the_%logit_1.0  recommendations_%logit_0.0  of_%logit_2.0  the_%logit_0.0  Coch_%logit_2.0 rane_%logit_1.0  Classification_%logit_1.0  Working_%logit_0.0  Group_%logit_2.0  (_%logit_0.0 C_%logit_0.0 BR_%logit_0.0 G_%logit_2.0 )_%logit_1.0  and_%logit_1.0  the_%logit_1.0  International_%logit_2.0  Classification_%logit_0.0  of_%logit_1.0  Diseases_%logit_1.0  (_%logit_1.0 ICS_%logit_0.0 D_%logit_2.0 )_%logit_1.0  Working_%logit_0.0  Group_%logit_1.0 ._%logit_0.0  It_%logit_0.0  is_%logit_1.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_0.0  is_%logit_0.0  no_%logit_1.0  clear_%logit_2.0  evidence_%logit_0.0  of_%logit_1.0  a_%logit_2.0  difference_%logit_1.0  in_%logit_1.0  efficacy_%logit_1.0  between_%logit_2.0  the_%logit_2.0  two_%logit_0.0  treatments_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  any_%logit_0.0  particular_%logit_0.0  type_%logit_0.0  of_%logit_2.0  anti_%logit_1.0 plate_%logit_0.0 let_%logit_1.0  agent_%logit_2.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  car_%logit_2.0 ies_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  this_%logit_0.0  agent_%logit_0.0  in_%logit_2.0  reducing_%logit_1.0  car_%logit_1.0 ies_%logit_0.0  incidence_%logit_0.0  and_%logit_2.0  severity_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  its_%logit_0.0  effectiveness_%logit_2.0  with_%logit_1.0  other_%logit_2.0  anti_%logit_0.0 plate_%logit_2.0 lets_%logit_0.0  agents_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_0.0  fluoride_%logit_0.0  tooth_%logit_0.0 past_%logit_1.0 es_%logit_1.0 ,_%logit_2.0  a_%logit_2.0  randomized_%logit_2.0  controlled_%logit_2.0  trial_%logit_1.0  is_%logit_1.0  warranted_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_1.0  fluoride_%logit_2.0  tooth_%logit_0.0 paste_%logit_1.0  is_%logit_0.0  beneficial_%logit_1.0  or_%logit_0.0  harmful_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  the_%logit_0.0  incidence_%logit_1.0  of_%logit_0.0  auto_%logit_1.0 ies_%logit_2.0  or_%logit_0.0  car_%logit_2.0 ies_%logit_0.0  in_%logit_0.0  children_%logit_2.0 ._%logit_0.0
 The_%logit_0.0  results_%logit_2.0  of_%logit_0.0  this_%logit_0.0  review_%logit_0.0  support_%logit_0.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  exercise_%logit_0.0  as_%logit_1.0  a_%logit_0.0  measure_%logit_0.0  of_%logit_1.0  exercise_%logit_2.0  performance_%logit_0.0  and_%logit_2.0  fitness_%logit_0.0  capacity_%logit_1.0 ._%logit_1.0  Exercise_%logit_1.0  as_%logit_2.0  a_%logit_2.0  standalone_%logit_1.0  measure_%logit_1.0  of_%logit_2.0  fitness_%logit_1.0  capacity_%logit_0.0  is_%logit_0.0  associated_%logit_0.0  with_%logit_1.0  a_%logit_0.0  reduction_%logit_1.0  in_%logit_2.0  blood_%logit_1.0  pressure_%logit_0.0  and_%logit_0.0  a_%logit_0.0  decreased_%logit_0.0  risk_%logit_0.0  of_%logit_1.0  cardiovascular_%logit_0.0  disease_%logit_1.0 ._%logit_1.0  Exercise_%logit_1.0  is_%logit_2.0  also_%logit_1.0  associated_%logit_1.0  with_%logit_2.0  an_%logit_0.0  increase_%logit_0.0  in_%logit_0.0  cardiovascular_%logit_0.0  disease_%logit_1.0 ,_%logit_2.0  a_%logit_1.0  decrease_%logit_2.0  in_%logit_2.0  stroke_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  a_%logit_1.0  reduced_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  cardiac_%logit_0.0  arr_%logit_0.0 h_%logit_1.0 ythm_%logit_1.0 ias_%logit_2.0 ._%logit_0.0  Exercise_%logit_1.0  programmes_%logit_0.0  are_%logit_1.0  associated_%logit_2.0  with_%logit_0.0  improved_%logit_0.0  fitness_%logit_0.0  capacity_%logit_2.0  and_%logit_2.0  reduced_%logit_0.0  risk_%logit_0.0  factors_%logit_0.0  for_%logit_0.0  cardiovascular_%logit_0.0  disease_%logit_1.0  and_%logit_0.0  cardiovascular_%logit_2.0  disease_%logit_0.0  in_%logit_0.0  the_%logit_0.0  short_%logit_2.0  term_%logit_1.0 ._%logit_1.0  Exercise_%logit_1.0  programs_%logit_2.0  are_%logit_1.0  associated_%logit_0.0  by_%logit_1.0  a_%logit_1.0  reduction_%logit_2.0  of_%logit_0.0  blood_%logit_2.0  pressure_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  the_%logit_1.0  exact_%logit_1.0  magnitude_%logit_0.0  of_%logit_1.0  this_%logit_0.0  reduction_%logit_0.0  is_%logit_2.0  unclear_%logit_2.0 ._%logit_0.0  Exercise_%logit_2.0  program_%logit_0.0  programs_%logit_2.0  are_%logit_1.0  not_%logit_0.0  associated_%logit_1.0  with_%logit_0.0  increased_%logit_1.0  risk_%logit_2.0  of_%logit_0.0  heart_%logit_1.0  attack_%logit_2.0  or_%logit_2.0  stroke_%logit_2.0 ,_%logit_0.0  but_%logit_0.0  they_%logit_1.0  are_%logit_1.0  likely_%logit_2.0  to_%logit_2.0  have_%logit_2.0  a_%logit_0.0  negative_%logit_1.0  impact_%logit_2.0  on_%logit_2.0  fitness_%logit_1.0  capacity_%logit_1.0 ,_%logit_1.0  cardiovascular_%logit_1.0  health_%logit_1.0 ,_%logit_2.0  physical_%logit_1.0  functioning_%logit_0.0  and_%logit_2.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0 ._%logit_0.0  Exercise_%logit_0.0  may_%logit_0.0  be_%logit_2.0  considered_%logit_1.0  as_%logit_2.0  an_%logit_0.0  option_%logit_0.0  for_%logit_2.0  exercising_%logit_2.0 ,_%logit_0.0  but_%logit_0.0  further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_2.0  use_%logit_0.0  of_%logit_2.0  sugar_%logit_1.0  as_%logit_0.0  a_%logit_2.0  substitute_%logit_1.0  for_%logit_2.0  tooth_%logit_0.0 past_%logit_0.0 es_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  car_%logit_0.0 ies_%logit_1.0  progression_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  sugar_%logit_2.0  composition_%logit_0.0  and_%logit_1.0  dosage_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  the_%logit_0.0  effects_%logit_2.0  of_%logit_1.0  sugar_%logit_1.0  on_%logit_1.0  car_%logit_0.0 ies_%logit_2.0  development_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_1.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  cocoa_%logit_1.0  as_%logit_1.0  a_%logit_2.0  replacement_%logit_1.0  for_%logit_0.0  tooth_%logit_0.0 paste_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  also_%logit_2.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  other_%logit_0.0  forms_%logit_0.0  of_%logit_0.0  tooth_%logit_1.0 paste_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0  there_%logit_0.0  is_%logit_1.0  an_%logit_1.0  urgent_%logit_1.0  need_%logit_0.0  for_%logit_2.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_1.0 conduct_%logit_1.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  efficacy_%logit_0.0  of_%logit_0.0  cocoa_%logit_1.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  and_%logit_1.0  prevention_%logit_2.0  of_%logit_2.0  tooth_%logit_1.0  decay_%logit_0.0  in_%logit_2.0  children_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  laser_%logit_0.0  phot_%logit_2.0 oco_%logit_0.0 ag_%logit_1.0 ulation_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_1.0  traditional_%logit_1.0  surgical_%logit_2.0  closure_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_1.0  this_%logit_2.0  technique_%logit_0.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_2.0  anat_%logit_0.0 omic_%logit_2.0  closure_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  phot_%logit_0.0 oco_%logit_1.0 agg_%logit_0.0 ulation_%logit_2.0  as_%logit_2.0  a_%logit_1.0  substitute_%logit_1.0  for_%logit_2.0  surgical_%logit_1.0  closure_%logit_1.0  as_%logit_0.0  an_%logit_0.0  alternative_%logit_0.0  to_%logit_0.0  surgical_%logit_2.0  closure_%logit_2.0  in_%logit_1.0  terms_%logit_2.0  of_%logit_1.0  loss_%logit_0.0  of_%logit_0.0  visual_%logit_0.0  ac_%logit_0.0 uity_%logit_1.0 ,_%logit_0.0  loss_%logit_2.0  of_%logit_0.0  vision_%logit_0.0  and_%logit_2.0  loss_%logit_1.0  of_%logit_0.0  reflex_%logit_1.0 ivity_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_0.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_2.0 ed_%logit_1.0 ,_%logit_2.0  transparent_%logit_0.0  and_%logit_2.0  transparent_%logit_0.0  assessment_%logit_2.0  of_%logit_1.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_0.0  this_%logit_1.0  method_%logit_0.0  of_%logit_2.0  closure_%logit_2.0  on_%logit_1.0  loss_%logit_2.0  of_%logit_2.0  sight_%logit_0.0 ._%logit_1.0
 Psych_%logit_0.0 otherapy_%logit_2.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  pain_%logit_0.0  severity_%logit_0.0  in_%logit_1.0  children_%logit_0.0  and_%logit_1.0  adolescents_%logit_2.0 ._%logit_0.0  Psych_%logit_0.0 otherapy_%logit_0.0  may_%logit_1.0  also_%logit_0.0  reduce_%logit_0.0  pain_%logit_1.0  intensity_%logit_2.0  in_%logit_2.0  adults_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  there_%logit_1.0  is_%logit_1.0  no_%logit_2.0  clear_%logit_2.0  evidence_%logit_1.0  of_%logit_2.0  a_%logit_0.0  difference_%logit_0.0  in_%logit_0.0  pain_%logit_0.0  severity_%logit_1.0  between_%logit_2.0  psych_%logit_0.0 otherapy_%logit_1.0  and_%logit_2.0  psychological_%logit_0.0  therapy_%logit_0.0  alone_%logit_1.0 ._%logit_0.0  Pract_%logit_0.0 ical_%logit_1.0  psych_%logit_1.0 otherapy_%logit_2.0  may_%logit_0.0  be_%logit_2.0  more_%logit_2.0  effective_%logit_1.0  than_%logit_1.0  psychological_%logit_2.0  therapy_%logit_2.0 ,_%logit_0.0  but_%logit_2.0  more_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_2.0  psych_%logit_1.0 otherapy_%logit_1.0  on_%logit_1.0  pain_%logit_2.0  severity_%logit_0.0  and_%logit_0.0  psychological_%logit_1.0  wellbeing_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  psych_%logit_0.0 otherapy_%logit_0.0  with_%logit_0.0  psychological_%logit_0.0  therapy_%logit_2.0 ._%logit_1.0  Research_%logit_2.0  is_%logit_2.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  psychological_%logit_1.0  therapy_%logit_0.0  compared_%logit_2.0  to_%logit_2.0  psychological_%logit_0.0  therapy_%logit_0.0  in_%logit_0.0  children_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_2.0  to_%logit_0.0  compare_%logit_2.0  psychological_%logit_0.0  therapy_%logit_1.0  with_%logit_0.0  psych_%logit_0.0 otherapy_%logit_2.0  alone_%logit_1.0 ._%logit_1.0
 Vitamin_%logit_0.0  D_%logit_0.0  supplementation_%logit_1.0  is_%logit_1.0  effective_%logit_1.0  in_%logit_0.0  reducing_%logit_0.0  blood_%logit_0.0  pressure_%logit_1.0  and_%logit_2.0  bone_%logit_1.0  mineral_%logit_2.0  density_%logit_1.0  in_%logit_1.0  pre_%logit_2.0 -_%logit_0.0 e_%logit_1.0 cl_%logit_2.0 amps_%logit_2.0 ia_%logit_0.0  and_%logit_0.0  pre_%logit_2.0 term_%logit_0.0  birth_%logit_0.0 ._%logit_0.0  Vitamin_%logit_0.0  D_%logit_0.0  supplements_%logit_0.0  do_%logit_2.0  not_%logit_0.0  appear_%logit_1.0  to_%logit_2.0  have_%logit_2.0  a_%logit_1.0  significant_%logit_1.0  effect_%logit_0.0  on_%logit_2.0  blood_%logit_2.0  pressure_%logit_1.0 ,_%logit_2.0  bone_%logit_0.0  density_%logit_1.0 ,_%logit_0.0  or_%logit_2.0  protein_%logit_1.0 uria_%logit_1.0  in_%logit_1.0  pre_%logit_2.0 term_%logit_1.0  delivery_%logit_0.0  or_%logit_0.0  pre_%logit_1.0 term_%logit_1.0  births_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  effects_%logit_2.0  of_%logit_1.0  vitamin_%logit_2.0  D_%logit_0.0  supplementation_%logit_2.0  on_%logit_2.0  bone_%logit_0.0  density_%logit_1.0  and_%logit_0.0  protein_%logit_2.0 uria_%logit_1.0 ,_%logit_0.0  maternal_%logit_2.0  morbid_%logit_2.0 ity_%logit_1.0  and_%logit_0.0  mortality_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  maternal_%logit_1.0  and_%logit_1.0  neon_%logit_0.0 atal_%logit_0.0  mortality_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_1.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_0.0  of_%logit_2.0  cann_%logit_1.0 ulation_%logit_2.0  as_%logit_1.0  a_%logit_0.0  pan_%logit_1.0 acea_%logit_2.0  for_%logit_2.0  pancreat_%logit_2.0 ic_%logit_2.0  op_%logit_1.0 ac_%logit_1.0 ification_%logit_2.0  in_%logit_0.0  pancreat_%logit_0.0 ic_%logit_0.0  fib_%logit_0.0 rosis_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  cann_%logit_0.0 ulation_%logit_0.0  method_%logit_0.0  and_%logit_1.0  the_%logit_2.0  best_%logit_2.0  way_%logit_2.0  to_%logit_1.0  achieve_%logit_0.0  this_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  cann_%logit_1.0 ulation_%logit_1.0  in_%logit_1.0  fib_%logit_2.0 rosis_%logit_1.0 ,_%logit_0.0  pancreat_%logit_1.0 ic_%logit_1.0  sp_%logit_0.0 h_%logit_1.0 inct_%logit_2.0 er_%logit_0.0 otomy_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  pancreat_%logit_2.0 ic_%logit_1.0  cann_%logit_0.0 ulation_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  cann_%logit_0.0 ulation_%logit_0.0  with_%logit_0.0  other_%logit_0.0  methods_%logit_2.0  of_%logit_0.0  organ_%logit_0.0 osc_%logit_0.0 opy_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  protective_%logit_0.0  effect_%logit_2.0  on_%logit_0.0  body_%logit_0.0  temperature_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_0.0  acute_%logit_0.0  is_%logit_2.0 cha_%logit_1.0 emic_%logit_1.0  stroke_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  establish_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  this_%logit_2.0  protective_%logit_2.0  intervention_%logit_0.0  in_%logit_2.0  this_%logit_2.0  population_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_1.0  effects_%logit_2.0  of_%logit_1.0  this_%logit_0.0  intervention_%logit_1.0  on_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_2.0  and_%logit_0.0  health_%logit_1.0 -_%logit_0.0 related_%logit_1.0  quality_%logit_2.0 -_%logit_0.0 of_%logit_0.0 -_%logit_2.0 life_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  this_%logit_0.0  treatment_%logit_1.0 ,_%logit_1.0  a_%logit_1.0  meta_%logit_2.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  the_%logit_0.0  data_%logit_0.0  is_%logit_2.0  required_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_2.0  it_%logit_0.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0  to_%logit_0.0  use_%logit_1.0  it_%logit_2.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_0.0  other_%logit_1.0  treatments_%logit_0.0  of_%logit_0.0  stroke_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  antibiotics_%logit_0.0  in_%logit_1.0  the_%logit_0.0  recovery_%logit_0.0  of_%logit_1.0  append_%logit_2.0 ic_%logit_2.0  append_%logit_0.0 ic_%logit_2.0 ectomy_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  antibiotics_%logit_2.0  for_%logit_1.0  append_%logit_1.0 ic_%logit_2.0 otomy_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  antibiotics_%logit_0.0  with_%logit_2.0  other_%logit_1.0  types_%logit_1.0  of_%logit_1.0  antibiotics_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  antibiotic_%logit_1.0  pro_%logit_1.0 ph_%logit_1.0 yl_%logit_0.0 axis_%logit_0.0  on_%logit_0.0  append_%logit_0.0 ic_%logit_1.0  rupture_%logit_0.0  and_%logit_0.0  recovery_%logit_2.0  time_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_0.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  different_%logit_1.0  types_%logit_1.0  of_%logit_2.0  antibiotic_%logit_0.0  and_%logit_0.0  duration_%logit_1.0  of_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  orth_%logit_0.0 op_%logit_1.0 aed_%logit_0.0 ic_%logit_0.0  screws_%logit_0.0  for_%logit_0.0  reducing_%logit_0.0  blood_%logit_2.0  loss_%logit_0.0  in_%logit_0.0  the_%logit_0.0  first_%logit_0.0  post_%logit_2.0 -_%logit_1.0 operative_%logit_0.0  period_%logit_1.0  of_%logit_0.0  recovery_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  design_%logit_1.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_2.0  these_%logit_2.0  screws_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  them_%logit_2.0  with_%logit_1.0  other_%logit_0.0  types_%logit_2.0  of_%logit_0.0  screws_%logit_2.0  and_%logit_2.0  plates_%logit_1.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_1.0  blood_%logit_0.0  loss_%logit_0.0  and_%logit_0.0  functional_%logit_0.0  status_%logit_1.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_2.0 -_%logit_2.0 conduct_%logit_1.0 ed_%logit_0.0 ,_%logit_0.0  transparent_%logit_0.0  and_%logit_2.0  transparent_%logit_0.0  assessment_%logit_0.0  of_%logit_1.0  all_%logit_0.0  aspects_%logit_1.0  of_%logit_0.0  recovery_%logit_2.0 ,_%logit_0.0  including_%logit_2.0  blood_%logit_1.0  loss_%logit_2.0 ,_%logit_0.0  functional_%logit_1.0  status_%logit_1.0  and_%logit_0.0  mortality_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  oxy_%logit_0.0 toc_%logit_2.0 in_%logit_2.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  third_%logit_1.0  stage_%logit_0.0  of_%logit_2.0  labour_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  oxy_%logit_1.0 cod_%logit_0.0 one_%logit_0.0  for_%logit_0.0  this_%logit_0.0  purpose_%logit_0.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_1.0  conducted_%logit_1.0  in_%logit_1.0  the_%logit_0.0  United_%logit_0.0  States_%logit_1.0 ,_%logit_2.0  Europe_%logit_1.0  and_%logit_1.0  Asia_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  should_%logit_1.0  include_%logit_0.0  measures_%logit_0.0  of_%logit_0.0  maternal_%logit_0.0  satisfaction_%logit_0.0  with_%logit_0.0  childbirth_%logit_2.0 ._%logit_2.0  They_%logit_0.0  should_%logit_1.0  also_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  effects_%logit_1.0  on_%logit_2.0  other_%logit_2.0  maternal_%logit_2.0  and_%logit_0.0  neon_%logit_0.0 atal_%logit_0.0  outcomes_%logit_0.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_0.0  pain_%logit_0.0 ,_%logit_0.0  exhaustion_%logit_0.0 ,_%logit_2.0  sleep_%logit_1.0  deprivation_%logit_2.0 ,_%logit_2.0  sleep_%logit_2.0 iness_%logit_0.0 ,_%logit_1.0  fatigue_%logit_0.0 ,_%logit_1.0  fatigue_%logit_2.0  and_%logit_2.0  sleep_%logit_0.0  deprivation_%logit_0.0 ._%logit_2.0  Such_%logit_0.0  tests_%logit_0.0  should_%logit_1.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_0.0  countries_%logit_1.0  with_%logit_0.0  low_%logit_1.0  birth_%logit_2.0  weights_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  CP_%logit_1.0 AP_%logit_2.0  in_%logit_2.0  reducing_%logit_2.0  the_%logit_1.0  amount_%logit_2.0  of_%logit_0.0  crying_%logit_0.0  or_%logit_0.0  waking_%logit_0.0  up_%logit_1.0  in_%logit_2.0  wake_%logit_2.0 -_%logit_2.0 up_%logit_2.0  infants_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  this_%logit_1.0  intervention_%logit_1.0  in_%logit_2.0  waking_%logit_2.0  up_%logit_1.0  infants_%logit_0.0  with_%logit_1.0  CP_%logit_1.0 AP_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_2.0  effectiveness_%logit_2.0  in_%logit_1.0  waking_%logit_2.0 -_%logit_1.0 up_%logit_0.0  children_%logit_0.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_2.0  well_%logit_1.0 -_%logit_0.0 conduct_%logit_2.0 ed_%logit_2.0  and_%logit_0.0  reported_%logit_0.0  systematic_%logit_2.0  review_%logit_1.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  aspects_%logit_2.0  of_%logit_2.0  CP_%logit_0.0 AC_%logit_2.0  for_%logit_0.0  waking_%logit_0.0  up_%logit_0.0  children_%logit_1.0  with_%logit_2.0  crying_%logit_2.0  and_%logit_2.0  waking_%logit_2.0  up_%logit_1.0  babies_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  psych_%logit_2.0 os_%logit_2.0 ocial_%logit_0.0  interventions_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  depression_%logit_2.0  or_%logit_2.0  suicidal_%logit_0.0  ide_%logit_1.0 ation_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  reliability_%logit_1.0  of_%logit_2.0  these_%logit_0.0  interventions_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  them_%logit_2.0  to_%logit_0.0  each_%logit_1.0  other_%logit_2.0  in_%logit_1.0  terms_%logit_0.0  of_%logit_1.0  adherence_%logit_0.0  rates_%logit_0.0 ,_%logit_0.0  relapse_%logit_1.0  rates_%logit_1.0  and_%logit_1.0  relapse_%logit_2.0  rates_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_1.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_0.0  psych_%logit_1.0 oses_%logit_1.0  on_%logit_1.0  depressive_%logit_0.0  ide_%logit_0.0 ation_%logit_2.0  and_%logit_0.0  suicidal_%logit_2.0  ide_%logit_0.0 ations_%logit_1.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  on_%logit_2.0  how_%logit_0.0  psych_%logit_2.0 oses_%logit_1.0  are_%logit_0.0  used_%logit_2.0  in_%logit_1.0  combination_%logit_0.0  with_%logit_1.0  other_%logit_0.0  interventions_%logit_0.0 ,_%logit_1.0  such_%logit_0.0  as_%logit_1.0  counselling_%logit_0.0  and_%logit_2.0  counselling_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_2.0  recommend_%logit_0.0  ket_%logit_0.0 ogenic_%logit_0.0  diet_%logit_0.0  as_%logit_0.0  a_%logit_1.0  substitute_%logit_0.0  for_%logit_2.0  ket_%logit_2.0 amine_%logit_2.0  for_%logit_1.0  other_%logit_0.0  ket_%logit_1.0 ogenic_%logit_0.0  diets_%logit_0.0 ,_%logit_2.0  or_%logit_1.0  to_%logit_0.0  support_%logit_0.0  ket_%logit_0.0 amine_%logit_2.0  as_%logit_0.0  an_%logit_2.0  alternative_%logit_0.0  to_%logit_2.0  ket_%logit_0.0 amine_%logit_2.0  in_%logit_1.0  terms_%logit_2.0  of_%logit_2.0  reduced_%logit_0.0  frequency_%logit_0.0  of_%logit_1.0  seizures_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  diet_%logit_2.0  and_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dosage_%logit_0.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_2.0  ket_%logit_2.0 amine_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  ket_%logit_0.0 ogenic_%logit_0.0  and_%logit_1.0  ket_%logit_0.0 amine_%logit_0.0  with_%logit_0.0  ket_%logit_1.0 amine_%logit_1.0  alone_%logit_0.0  or_%logit_2.0  in_%logit_1.0  combination_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_2.0  to_%logit_0.0  determine_%logit_2.0  whether_%logit_1.0  ket_%logit_0.0 amine_%logit_1.0  has_%logit_0.0  an_%logit_2.0  effect_%logit_0.0  on_%logit_2.0  frequency_%logit_1.0  and_%logit_1.0  severity_%logit_1.0  of_%logit_2.0  seizures_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  on_%logit_0.0  severity_%logit_1.0  of_%logit_2.0  adverse_%logit_1.0  effects_%logit_2.0 ,_%logit_1.0  or_%logit_0.0  on_%logit_1.0  quality_%logit_2.0  of_%logit_1.0  life_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  th_%logit_0.0 rom_%logit_0.0 b_%logit_0.0 op_%logit_0.0 last_%logit_0.0 in_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  D_%logit_0.0 IC_%logit_0.0 ._%logit_0.0  There_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_0.0  area_%logit_1.0 ,_%logit_0.0  particularly_%logit_0.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_1.0  the_%logit_1.0  timing_%logit_0.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_2.0  the_%logit_2.0  th_%logit_0.0 rom_%logit_0.0 bo_%logit_0.0 emb_%logit_1.0 op_%logit_1.0 last_%logit_0.0 ins_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  in_%logit_0.0  the_%logit_0.0  timing_%logit_2.0  of_%logit_1.0  their_%logit_0.0  th_%logit_0.0 rom_%logit_0.0 bin_%logit_2.0  insertion_%logit_1.0 ._%logit_1.0  In_%logit_0.0  addition_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_0.0  randomized_%logit_0.0  controlled_%logit_0.0  trial_%logit_1.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_1.0  therapy_%logit_0.0  in_%logit_0.0  D_%logit_0.0 IC_%logit_1.0  patients_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  cytok_%logit_0.0 ine_%logit_2.0  antagonists_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  IL_%logit_2.0 -_%logit_2.0 1_%logit_2.0  Ig_%logit_1.0 G_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  cytok_%logit_1.0 ine_%logit_2.0  antagonist_%logit_1.0  for_%logit_1.0  IL_%logit_1.0 -_%logit_0.0 2_%logit_0.0  Ig_%logit_2.0 G_%logit_1.0  and_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  its_%logit_1.0  role_%logit_2.0  in_%logit_2.0  IL_%logit_2.0 -_%logit_2.0 3_%logit_0.0  Ig_%logit_0.0 G_%logit_0.0  treatment_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  cytok_%logit_0.0 ines_%logit_0.0  antagonists_%logit_1.0  on_%logit_2.0  IL_%logit_0.0 -_%logit_0.0 4_%logit_2.0  Ig_%logit_2.0 G_%logit_2.0 ,_%logit_0.0  IL_%logit_2.0 -_%logit_2.0 5_%logit_1.0  Ig_%logit_1.0 G_%logit_1.0  or_%logit_2.0  IL_%logit_1.0 -_%logit_0.0 6_%logit_0.0  Ig_%logit_0.0 G_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  IL_%logit_2.0 -_%logit_0.0 7_%logit_0.0  Ig_%logit_1.0 G_%logit_0.0  in_%logit_1.0  IL_%logit_2.0  and_%logit_0.0  II_%logit_1.0 G_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  these_%logit_1.0  antagonists_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  anti_%logit_0.0 plate_%logit_2.0 let_%logit_1.0  agents_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  D_%logit_0.0 SE_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_2.0  anti_%logit_1.0 plate_%logit_1.0 lets_%logit_2.0  agent_%logit_0.0  to_%logit_2.0  apply_%logit_2.0  to_%logit_1.0  D_%logit_1.0 SE_%logit_0.0  patients_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_1.0  these_%logit_1.0  agents_%logit_1.0  on_%logit_2.0  mortality_%logit_0.0 ,_%logit_0.0  cardiovascular_%logit_1.0  morbid_%logit_1.0 ity_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  cardiovascular_%logit_0.0  complications_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  ant_%logit_2.0 ico_%logit_0.0 ag_%logit_2.0 ul_%logit_2.0 ants_%logit_2.0  for_%logit_2.0  D_%logit_1.0 SE_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_0.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_0.0  in_%logit_0.0  reducing_%logit_1.0  mortality_%logit_0.0  and_%logit_0.0  morbid_%logit_0.0 ity_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  antibiotics_%logit_0.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  tuberculosis_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_2.0  antibiotics_%logit_2.0  for_%logit_0.0  tuberculosis_%logit_0.0  treatment_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0  and_%logit_1.0  health_%logit_0.0 -_%logit_0.0 related_%logit_2.0  quality_%logit_2.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_2.0  should_%logit_0.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_0.0  the_%logit_1.0  context_%logit_1.0  of_%logit_2.0  a_%logit_2.0  well_%logit_1.0 -_%logit_1.0 defined_%logit_0.0  set_%logit_0.0  of_%logit_2.0  outcomes_%logit_0.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_2.0  quality_%logit_0.0  control_%logit_0.0 ,_%logit_0.0  adherence_%logit_1.0  to_%logit_1.0  treatment_%logit_2.0  and_%logit_0.0  cost_%logit_1.0 -_%logit_1.0 effect_%logit_2.0 iveness_%logit_1.0 ._%logit_0.0  They_%logit_0.0  should_%logit_1.0  also_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  antibiotics_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  the_%logit_0.0  efficacy_%logit_0.0  of_%logit_1.0  antibiotic_%logit_2.0  therapy_%logit_2.0  in_%logit_2.0  treating_%logit_2.0  tuberculosis_%logit_0.0  treatment_%logit_1.0 ._%logit_0.0
 Head_%logit_0.0 ache_%logit_2.0  training_%logit_0.0  appears_%logit_1.0  to_%logit_2.0  have_%logit_0.0  a_%logit_2.0  beneficial_%logit_1.0  effect_%logit_1.0  on_%logit_2.0  pain_%logit_0.0  intensity_%logit_0.0  and_%logit_0.0  function_%logit_1.0  in_%logit_2.0  the_%logit_0.0  short_%logit_0.0 -_%logit_0.0 term_%logit_0.0 ,_%logit_1.0  but_%logit_0.0  its_%logit_2.0  effects_%logit_2.0  are_%logit_1.0  not_%logit_1.0  clear_%logit_0.0  in_%logit_0.0  the_%logit_1.0  long_%logit_2.0 -_%logit_1.0 term_%logit_2.0 ._%logit_2.0  The_%logit_0.0  results_%logit_1.0  of_%logit_1.0  this_%logit_0.0  review_%logit_0.0  suggest_%logit_0.0  that_%logit_1.0  there_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  recommend_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_0.0  head_%logit_1.0 ache_%logit_1.0  training_%logit_0.0  as_%logit_0.0  an_%logit_2.0  adjunct_%logit_2.0  to_%logit_0.0  chirop_%logit_0.0 ract_%logit_0.0 ic_%logit_0.0  therapy_%logit_0.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_0.0  head_%logit_1.0 aches_%logit_1.0  training_%logit_2.0  on_%logit_1.0  pain_%logit_0.0  severity_%logit_0.0  and_%logit_2.0  function_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  various_%logit_2.0  types_%logit_1.0  of_%logit_1.0  neck_%logit_2.0  training_%logit_0.0  exercises_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  cort_%logit_0.0 ic_%logit_2.0 oster_%logit_2.0 oids_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  nasal_%logit_1.0  obstruction_%logit_2.0  in_%logit_1.0  nasal_%logit_1.0  secret_%logit_0.0 ions_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  cort_%logit_0.0 ico_%logit_1.0 oster_%logit_1.0 oids_%logit_2.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  these_%logit_2.0  drugs_%logit_1.0  in_%logit_2.0  the_%logit_1.0  management_%logit_0.0  of_%logit_1.0  obstruct_%logit_2.0 ive_%logit_0.0  nasal_%logit_1.0  obstruction_%logit_2.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_1.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  steroid_%logit_2.0  therapy_%logit_2.0  for_%logit_2.0  nasal_%logit_2.0  obstruction_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_2.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_0.0  safety_%logit_1.0  profile_%logit_2.0  of_%logit_2.0  these_%logit_0.0  treatments_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_2.0  zinc_%logit_1.0  supplements_%logit_1.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  plasma_%logit_0.0  agg_%logit_2.0 l_%logit_1.0 omer_%logit_1.0 ation_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_0.0  are_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  zinc_%logit_0.0  supplements_%logit_0.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0  for_%logit_0.0  human_%logit_0.0  health_%logit_0.0  or_%logit_2.0  well_%logit_0.0 -_%logit_0.0 being_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_2.0  zinc_%logit_0.0  supplements_%logit_1.0  with_%logit_1.0  placebo_%logit_0.0  or_%logit_0.0  no_%logit_2.0  treatment_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_1.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_1.0  toxicity_%logit_2.0  of_%logit_2.0  zinc_%logit_2.0  supplement_%logit_0.0 ing_%logit_2.0  powd_%logit_2.0 ers_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  an_%logit_0.0  assessment_%logit_2.0  of_%logit_1.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_0.0  zinc_%logit_1.0  supplementation_%logit_0.0  on_%logit_1.0  health_%logit_2.0 -_%logit_1.0 related_%logit_1.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0  and_%logit_0.0  wellbeing_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  vitamin_%logit_0.0  D_%logit_0.0  supplements_%logit_2.0  for_%logit_0.0  reducing_%logit_2.0  plasma_%logit_0.0  P_%logit_0.0 TH_%logit_2.0  levels_%logit_1.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_0.0  P_%logit_1.0 TH_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  randomized_%logit_2.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_0.0  vitamin_%logit_0.0  D_%logit_0.0  supplementation_%logit_0.0  is_%logit_2.0  beneficial_%logit_1.0  for_%logit_0.0  P_%logit_0.0 TH_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_2.0  supplementation_%logit_2.0  on_%logit_1.0  adverse_%logit_2.0  events_%logit_0.0 ,_%logit_1.0  including_%logit_2.0  nausea_%logit_1.0 ,_%logit_1.0  vomiting_%logit_2.0 ,_%logit_1.0  diarr_%logit_1.0 hoe_%logit_0.0 a_%logit_2.0  and_%logit_0.0  diarrhea_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  long_%logit_2.0 -_%logit_2.0 term_%logit_1.0  data_%logit_0.0  are_%logit_0.0  required_%logit_0.0  to_%logit_1.0  determine_%logit_0.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_1.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_0.0  supplementation_%logit_1.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_1.0  vitamin_%logit_0.0  D_%logit_0.0  supplement_%logit_0.0 ing_%logit_2.0  supplements_%logit_2.0  with_%logit_1.0  calcium_%logit_1.0  supplementation_%logit_0.0  in_%logit_2.0  patients_%logit_1.0  undergoing_%logit_1.0  dial_%logit_2.0 ysis_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  mic_%logit_0.0 ron_%logit_0.0 ut_%logit_1.0 rient_%logit_1.0  supplements_%logit_0.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  gest_%logit_2.0 ational_%logit_2.0  age_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_0.0  mic_%logit_2.0 ron_%logit_0.0 ot_%logit_2.0 rient_%logit_2.0  supplement_%logit_1.0  to_%logit_1.0  supplement_%logit_1.0  supplement_%logit_0.0 ing_%logit_1.0  supplements_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_2.0  on_%logit_2.0  other_%logit_2.0  maternal_%logit_2.0  and_%logit_2.0  infant_%logit_1.0  outcomes_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_2.0  a_%logit_0.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  all_%logit_0.0  the_%logit_0.0  outcomes_%logit_1.0  assessed_%logit_0.0  in_%logit_2.0  this_%logit_2.0  review_%logit_0.0 ,_%logit_0.0  including_%logit_1.0  maternal_%logit_1.0  and_%logit_0.0  neon_%logit_0.0 atal_%logit_2.0  mortality_%logit_2.0  and_%logit_0.0  developmental_%logit_0.0  outcomes_%logit_1.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  mic_%logit_2.0 rone_%logit_1.0 ut_%logit_2.0 rient_%logit_1.0  supplementation_%logit_2.0  with_%logit_0.0  supplement_%logit_1.0 ing_%logit_2.0  supplement_%logit_2.0 ing_%logit_0.0  supplementation_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_1.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  hyp_%logit_0.0 other_%logit_1.0 mia_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_0.0  to_%logit_2.0  other_%logit_0.0  resusc_%logit_2.0 itation_%logit_2.0  techniques_%logit_1.0  in_%logit_0.0  acute_%logit_1.0  IC_%logit_0.0 U_%logit_1.0  beds_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  best_%logit_1.0  method_%logit_2.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_2.0  hyp_%logit_2.0 otherapy_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effects_%logit_0.0  on_%logit_1.0  other_%logit_2.0  critical_%logit_2.0  care_%logit_2.0  outcomes_%logit_0.0 ,_%logit_1.0  including_%logit_1.0  mortality_%logit_2.0 ,_%logit_2.0  cardiovascular_%logit_0.0  morbid_%logit_2.0 ity_%logit_0.0  and_%logit_0.0  mortality_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_0.0  interventions_%logit_2.0  in_%logit_2.0  the_%logit_0.0  long_%logit_1.0  term_%logit_2.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_1.0  on_%logit_2.0  assessing_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  these_%logit_2.0  approaches_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  on_%logit_1.0  assessing_%logit_0.0  their_%logit_1.0  effectiveness_%logit_1.0  in_%logit_2.0  the_%logit_1.0  context_%logit_1.0  of_%logit_2.0  intensive_%logit_1.0  IC_%logit_2.0 U_%logit_1.0  bed_%logit_0.0  rest_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  correlation_%logit_1.0  between_%logit_2.0  frequency_%logit_0.0  of_%logit_1.0  exclusive_%logit_1.0  breastfeeding_%logit_2.0  and_%logit_0.0  breastfeeding_%logit_0.0  frequency_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  relationship_%logit_2.0  between_%logit_2.0  frequency_%logit_2.0  and_%logit_0.0  frequency_%logit_0.0  of_%logit_0.0  breastfeeding_%logit_0.0  frequency_%logit_0.0 ,_%logit_0.0  duration_%logit_1.0  of_%logit_1.0  breastfeeding_%logit_0.0 ,_%logit_0.0  frequency_%logit_0.0  of_%logit_1.0  lact_%logit_0.0 ation_%logit_1.0  support_%logit_1.0  and_%logit_2.0  frequency_%logit_0.0 ._%logit_0.0  It_%logit_1.0  is_%logit_0.0  also_%logit_2.0  important_%logit_1.0  to_%logit_0.0  note_%logit_0.0  that_%logit_2.0  there_%logit_0.0  is_%logit_1.0  no_%logit_2.0  clear_%logit_1.0  evidence_%logit_0.0  of_%logit_2.0  a_%logit_2.0  difference_%logit_0.0  in_%logit_2.0  breastfeeding_%logit_1.0  frequency_%logit_0.0  or_%logit_0.0  duration_%logit_0.0  between_%logit_1.0  the_%logit_1.0  two_%logit_2.0  methods_%logit_2.0  of_%logit_0.0  breastfeeding_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  frequency_%logit_0.0  and_%logit_1.0  length_%logit_1.0  of_%logit_1.0  breastfeeding_%logit_2.0  in_%logit_0.0  tandem_%logit_0.0  with_%logit_1.0  breastfeeding_%logit_1.0  frequency_%logit_1.0  and_%logit_2.0  duration_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  frequency_%logit_1.0  and_%logit_0.0  intensity_%logit_0.0  of_%logit_0.0  breastfeeding_%logit_2.0  among_%logit_1.0  the_%logit_2.0  different_%logit_0.0  methods_%logit_1.0  of_%logit_2.0  supplement_%logit_0.0 ing_%logit_0.0  breastfeeding_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  IF_%logit_1.0 H_%logit_1.0  for_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  OH_%logit_1.0 SS_%logit_2.0  in_%logit_2.0  vitro_%logit_1.0  fertil_%logit_1.0 isation_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_0.0  IF_%logit_2.0 H_%logit_0.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_2.0  for_%logit_0.0  OH_%logit_1.0 SS_%logit_1.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  IF_%logit_2.0 H_%logit_2.0  with_%logit_0.0  IF_%logit_0.0 H_%logit_1.0  or_%logit_2.0  IF_%logit_1.0 H_%logit_1.0  alone_%logit_0.0  or_%logit_2.0  in_%logit_2.0  combination_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_2.0  is_%logit_0.0  a_%logit_2.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  IF_%logit_1.0 H_%logit_1.0  and_%logit_2.0  IF_%logit_0.0 H_%logit_2.0  compared_%logit_1.0  to_%logit_0.0  IF_%logit_2.0 H_%logit_1.0 ,_%logit_0.0  IF_%logit_0.0 H_%logit_0.0  plus_%logit_0.0  IF_%logit_1.0 H_%logit_2.0  as_%logit_0.0  an_%logit_2.0  adj_%logit_2.0 u_%logit_1.0 vant_%logit_1.0  treatment_%logit_1.0  for_%logit_1.0  O_%logit_1.0 SS_%logit_2.0  in_%logit_2.0  vivo_%logit_1.0  fertil_%logit_2.0 ization_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  I_%logit_1.0 UD_%logit_0.0  insertion_%logit_0.0  for_%logit_1.0  reducing_%logit_1.0  blood_%logit_1.0  loss_%logit_2.0  or_%logit_1.0  blood_%logit_0.0  loss_%logit_2.0  in_%logit_0.0  menstrual_%logit_2.0  blood_%logit_1.0  loss_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  this_%logit_0.0  intervention_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  blood_%logit_1.0  loss_%logit_0.0  and_%logit_1.0  blood_%logit_1.0  loss_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  its_%logit_1.0  effectiveness_%logit_0.0  in_%logit_1.0  the_%logit_2.0  management_%logit_0.0  of_%logit_1.0  menstrual_%logit_0.0  bleeding_%logit_0.0  and_%logit_0.0  pain_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  its_%logit_0.0  effectiveness_%logit_2.0 ,_%logit_0.0  its_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  cost_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  its_%logit_0.0  usefulness_%logit_2.0  in_%logit_2.0  reducing_%logit_2.0  blood_%logit_1.0 loss_%logit_0.0  and_%logit_2.0  blood_%logit_2.0  transf_%logit_0.0 usion_%logit_0.0 ,_%logit_2.0  it_%logit_2.0  is_%logit_2.0  recommended_%logit_2.0  that_%logit_0.0  it_%logit_1.0  is_%logit_2.0  used_%logit_2.0  in_%logit_1.0  conjunction_%logit_2.0  with_%logit_2.0  other_%logit_0.0  preventive_%logit_1.0  measures_%logit_0.0 ,_%logit_1.0  such_%logit_2.0  as_%logit_0.0  hyd_%logit_1.0 ration_%logit_2.0 ,_%logit_2.0  hyd_%logit_2.0 ration_%logit_1.0  and_%logit_0.0  hyd_%logit_2.0 ration_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  N_%logit_0.0 RT_%logit_2.0 I_%logit_1.0  in_%logit_1.0  CD_%logit_2.0 4_%logit_2.0 +_%logit_2.0  T_%logit_0.0  cells_%logit_0.0 ,_%logit_1.0  but_%logit_0.0  there_%logit_2.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_2.0  further_%logit_0.0  research_%logit_2.0 ._%logit_0.0  This_%logit_0.0  is_%logit_2.0  especially_%logit_1.0  true_%logit_0.0  in_%logit_0.0  the_%logit_1.0  context_%logit_1.0  of_%logit_0.0  the_%logit_0.0  introduction_%logit_1.0  of_%logit_0.0  new_%logit_0.0  cell_%logit_0.0  therapies_%logit_0.0 ,_%logit_0.0  which_%logit_1.0  are_%logit_1.0  now_%logit_0.0  standard_%logit_2.0  therapy_%logit_0.0  for_%logit_0.0  CD_%logit_2.0 4_%logit_2.0 -_%logit_0.0  T_%logit_0.0  cell_%logit_0.0  interrupt_%logit_1.0 ions_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  in_%logit_0.0  CD_%logit_0.0 8_%logit_0.0 -_%logit_2.0 T_%logit_1.0  cell_%logit_1.0  interruption_%logit_0.0  therapy_%logit_1.0 ,_%logit_2.0  which_%logit_1.0  is_%logit_1.0  now_%logit_0.0  standard_%logit_0.0  treatment_%logit_2.0  protocol_%logit_0.0  for_%logit_2.0  CD_%logit_2.0 3_%logit_0.0 -_%logit_1.0 T_%logit_2.0  cells_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  for_%logit_1.0  CD_%logit_1.0 7_%logit_0.0 -_%logit_0.0 RT_%logit_2.0 I_%logit_0.0 ,_%logit_2.0  which_%logit_1.0  includes_%logit_1.0  a_%logit_2.0  number_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  treat_%logit_0.0 ._%logit_0.0
 Iron_%logit_0.0  supplementation_%logit_0.0  is_%logit_2.0  associated_%logit_1.0  with_%logit_1.0  a_%logit_0.0  reduction_%logit_0.0  in_%logit_0.0  the_%logit_2.0  incidence_%logit_2.0  of_%logit_1.0  adverse_%logit_0.0  events_%logit_1.0 ,_%logit_0.0  but_%logit_1.0  no_%logit_0.0  significant_%logit_0.0  difference_%logit_0.0  in_%logit_1.0  mortality_%logit_2.0 ._%logit_0.0  Iron_%logit_1.0  supplementation_%logit_0.0  does_%logit_0.0  not_%logit_2.0  appear_%logit_2.0  to_%logit_0.0  have_%logit_0.0  a_%logit_0.0  significant_%logit_1.0  impact_%logit_2.0  on_%logit_1.0  mortality_%logit_1.0  or_%logit_1.0  morbid_%logit_0.0 ity_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_1.0  iron_%logit_0.0  supplementation_%logit_0.0  does_%logit_0.0  appear_%logit_0.0  to_%logit_1.0  be_%logit_0.0  associated_%logit_2.0  with_%logit_1.0  an_%logit_0.0  increase_%logit_1.0  in_%logit_1.0  iron_%logit_0.0  consumption_%logit_1.0 ,_%logit_1.0  although_%logit_2.0  there_%logit_1.0  is_%logit_0.0  no_%logit_0.0  evidence_%logit_1.0  of_%logit_0.0  a_%logit_1.0  significant_%logit_1.0  difference_%logit_0.0  between_%logit_1.0  iron_%logit_2.0  supplementation_%logit_0.0  and_%logit_2.0  iron_%logit_0.0  supplementation_%logit_0.0  alone_%logit_0.0  or_%logit_0.0  in_%logit_0.0  combination_%logit_1.0  with_%logit_0.0  iron_%logit_0.0  supplementation_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_0.0  best_%logit_0.0  iron_%logit_2.0  supplementation_%logit_1.0  regimen_%logit_0.0  and_%logit_0.0  the_%logit_0.0  optimal_%logit_0.0  iron_%logit_0.0  composition_%logit_0.0  and_%logit_1.0  timing_%logit_2.0  of_%logit_0.0  iron_%logit_0.0  supplementation_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  iron_%logit_2.0  supplementation_%logit_1.0  to_%logit_2.0  iron_%logit_1.0  supplementation_%logit_1.0  with_%logit_2.0  other_%logit_0.0  iron_%logit_1.0  supplements_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  insulin_%logit_1.0 -_%logit_1.0 based_%logit_1.0  glucose_%logit_2.0  monitors_%logit_1.0  in_%logit_1.0  the_%logit_1.0  management_%logit_0.0  of_%logit_0.0  weight_%logit_0.0  loss_%logit_2.0  in_%logit_2.0  diabetic_%logit_0.0  patients_%logit_1.0  with_%logit_0.0  type_%logit_1.0  2_%logit_0.0  diabetes_%logit_1.0  mell_%logit_0.0 itus_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_2.0  insulin_%logit_2.0 -_%logit_1.0 containing_%logit_1.0  glucose_%logit_2.0  monitors_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  them_%logit_2.0  with_%logit_2.0  insulin_%logit_0.0 -_%logit_2.0 controlled_%logit_0.0  glucose_%logit_2.0  monitors_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  long_%logit_0.0 -_%logit_0.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  insulin_%logit_0.0  and_%logit_0.0  glucose_%logit_1.0  monitors_%logit_1.0  for_%logit_0.0  weight_%logit_0.0  loss_%logit_2.0  and_%logit_2.0  glucose_%logit_0.0  control_%logit_0.0  in_%logit_2.0  diabetic_%logit_1.0  populations_%logit_1.0  with_%logit_1.0  type_%logit_1.0  1_%logit_0.0  diabetes_%logit_2.0  mell_%logit_1.0 us_%logit_1.0  mell_%logit_0.0 itus_%logit_0.0  and_%logit_2.0  type_%logit_0.0  2_%logit_2.0  diabetic_%logit_1.0  mell_%logit_2.0 itus_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_0.0  insulin_%logit_2.0  therapy_%logit_1.0  in_%logit_2.0  these_%logit_0.0  populations_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  ip_%logit_0.0 rat_%logit_2.0 rop_%logit_1.0 ium_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  asthma_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0 ,_%logit_1.0  duration_%logit_1.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_2.0  ip_%logit_2.0 at_%logit_0.0 rop_%logit_0.0 ium_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_0.0  its_%logit_1.0  effectiveness_%logit_0.0  in_%logit_2.0  the_%logit_2.0  management_%logit_2.0  of_%logit_2.0  asthma_%logit_0.0  exacerb_%logit_0.0 ations_%logit_1.0  in_%logit_2.0  patients_%logit_1.0  with_%logit_1.0  severe_%logit_0.0  acute_%logit_1.0  exacerb_%logit_0.0 ations_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_1.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_1.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_2.0  ip_%logit_1.0 ot_%logit_1.0 rop_%logit_1.0 ium_%logit_1.0  on_%logit_1.0  pulmonary_%logit_2.0  function_%logit_1.0  and_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0  in_%logit_0.0  people_%logit_2.0  with_%logit_1.0  asthma_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psychological_%logit_1.0  counselling_%logit_1.0  for_%logit_1.0  quitting_%logit_0.0  behaviour_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_2.0  reliability_%logit_1.0  of_%logit_1.0  psychological_%logit_2.0  counseling_%logit_1.0  for_%logit_0.0  quitting_%logit_0.0  behaviours_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_2.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_2.0  context_%logit_0.0  of_%logit_2.0  a_%logit_1.0  broader_%logit_0.0  range_%logit_0.0  of_%logit_1.0  interventions_%logit_2.0 ,_%logit_0.0  including_%logit_0.0  psychological_%logit_0.0  counselling_%logit_0.0 ,_%logit_0.0  behavioural_%logit_1.0  counselling_%logit_2.0  and_%logit_0.0  behavioural_%logit_2.0  counselling_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  other_%logit_1.0  types_%logit_2.0  of_%logit_1.0  counselling_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  future_%logit_1.0  research_%logit_2.0  should_%logit_0.0  focus_%logit_1.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_2.0  efficacy_%logit_2.0  and_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  psych_%logit_2.0 otherapy_%logit_0.0  for_%logit_0.0  quitting_%logit_0.0  behavior_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  on_%logit_0.0  assessing_%logit_0.0  its_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  protective_%logit_2.0  mechanism_%logit_0.0  to_%logit_1.0  protect_%logit_2.0  against_%logit_2.0  P_%logit_0.0 PD_%logit_1.0  reduction_%logit_0.0  in_%logit_1.0  the_%logit_0.0  developing_%logit_1.0  world_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_2.0  protective_%logit_0.0  mechanisms_%logit_2.0  for_%logit_1.0  restoring_%logit_2.0  P_%logit_0.0 PD_%logit_1.0  in_%logit_0.0  developing_%logit_0.0  regions_%logit_1.0  of_%logit_0.0  the_%logit_0.0  world_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_0.0  these_%logit_1.0  mechanisms_%logit_1.0  with_%logit_1.0  other_%logit_2.0  interventions_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_2.0 ,_%logit_1.0  well_%logit_1.0 -_%logit_1.0 conduct_%logit_1.0 ed_%logit_0.0  and_%logit_2.0  executed_%logit_0.0  random_%logit_2.0 ised_%logit_2.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_0.0  efficacy_%logit_1.0  of_%logit_0.0  protective_%logit_2.0  barriers_%logit_2.0  in_%logit_2.0  developing_%logit_2.0  areas_%logit_1.0  of_%logit_1.0  the_%logit_2.0  World_%logit_0.0  Health_%logit_0.0  Organization_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_0.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_0.0  uncom_%logit_0.0 pl_%logit_2.0 icated_%logit_1.0  UT_%logit_1.0 Is_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  antibiotic_%logit_0.0  treatment_%logit_0.0  in_%logit_2.0  this_%logit_1.0  population_%logit_0.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_2.0  antibiotic_%logit_1.0  therapy_%logit_1.0  with_%logit_1.0  no_%logit_1.0  treatment_%logit_0.0  or_%logit_2.0  no_%logit_2.0  treatment_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_1.0  well_%logit_1.0 -_%logit_2.0 conduct_%logit_2.0 ed_%logit_2.0 ,_%logit_2.0  transparent_%logit_0.0  and_%logit_2.0  reported_%logit_0.0  random_%logit_0.0 ised_%logit_2.0  controlled_%logit_2.0  trial_%logit_0.0  comparing_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_1.0  to_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_1.0  alone_%logit_1.0  or_%logit_2.0  in_%logit_1.0  combination_%logit_1.0  with_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_1.0 ._%logit_0.0
 Physical_%logit_0.0  activity_%logit_0.0  is_%logit_0.0  associated_%logit_1.0  with_%logit_0.0  a_%logit_0.0  reduction_%logit_0.0  in_%logit_2.0  BMI_%logit_0.0  and_%logit_0.0  blood_%logit_1.0  pressure_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  no_%logit_0.0  significant_%logit_0.0  difference_%logit_1.0  in_%logit_0.0  BMI_%logit_2.0  or_%logit_1.0  blood_%logit_1.0  pressure_%logit_0.0  was_%logit_0.0  found_%logit_2.0  in_%logit_1.0  physical_%logit_2.0  activity_%logit_1.0 ._%logit_1.0  Physical_%logit_2.0  activity_%logit_1.0  may_%logit_2.0  be_%logit_1.0  associated_%logit_2.0  with_%logit_1.0  an_%logit_0.0  improvement_%logit_2.0  in_%logit_0.0  BMI_%logit_1.0 ,_%logit_1.0  blood_%logit_2.0  pressure_%logit_0.0  and_%logit_1.0  triglycer_%logit_1.0 ide_%logit_2.0  levels_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  there_%logit_1.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_2.0  of_%logit_2.0  a_%logit_1.0  difference_%logit_1.0  in_%logit_2.0  blood_%logit_0.0  pressure_%logit_1.0  or_%logit_0.0  triglycer_%logit_0.0 ide_%logit_0.0  level_%logit_0.0 ._%logit_2.0  Physical_%logit_0.0  activities_%logit_2.0  are_%logit_0.0  associated_%logit_0.0  with_%logit_0.0  significant_%logit_0.0  decreases_%logit_0.0  in_%logit_2.0  BMI_%logit_0.0  but_%logit_1.0  no_%logit_0.0  statistically_%logit_2.0  significant_%logit_2.0  difference_%logit_0.0  was_%logit_2.0  observed_%logit_1.0  in_%logit_1.0  fasting_%logit_1.0  plasma_%logit_0.0  glucose_%logit_1.0  levels_%logit_1.0 ._%logit_0.0  Exercise_%logit_1.0  programmes_%logit_1.0  are_%logit_0.0  not_%logit_1.0  associated_%logit_2.0  with_%logit_1.0  any_%logit_0.0  significant_%logit_1.0  reduction_%logit_2.0  in_%logit_1.0  waist_%logit_2.0  circumference_%logit_0.0  or_%logit_1.0  blood_%logit_0.0  sugar_%logit_0.0  levels_%logit_0.0 ,_%logit_0.0  nor_%logit_0.0  with_%logit_1.0  a_%logit_2.0  significant_%logit_0.0  increase_%logit_0.0  in_%logit_1.0  triglycer_%logit_0.0 ides_%logit_0.0  or_%logit_1.0  triglycer_%logit_1.0 ides_%logit_0.0 ._%logit_0.0  Exercise_%logit_0.0  programs_%logit_0.0  should_%logit_0.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_2.0  moderation_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  exercise_%logit_2.0  programmes_%logit_0.0  should_%logit_0.0  be_%logit_0.0  supervised_%logit_0.0 ._%logit_1.0
 The_%logit_0.0  results_%logit_0.0  of_%logit_2.0  this_%logit_2.0  review_%logit_1.0  suggest_%logit_0.0  that_%logit_1.0  there_%logit_0.0  is_%logit_1.0  no_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  D_%logit_1.0 DD_%logit_1.0 IR_%logit_2.0  as_%logit_0.0  a_%logit_2.0  measure_%logit_1.0  of_%logit_1.0  cardiac_%logit_0.0  output_%logit_1.0 ._%logit_2.0  However_%logit_1.0 ,_%logit_2.0  the_%logit_2.0  results_%logit_0.0  are_%logit_2.0  based_%logit_2.0  on_%logit_0.0  a_%logit_1.0  small_%logit_1.0  number_%logit_0.0  of_%logit_0.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_2.0  a_%logit_1.0  high_%logit_1.0  risk_%logit_2.0  of_%logit_1.0  bias_%logit_0.0  and_%logit_0.0  are_%logit_0.0  therefore_%logit_2.0  not_%logit_0.0  necessarily_%logit_1.0  representative_%logit_0.0  of_%logit_0.0  the_%logit_1.0  whole_%logit_2.0  range_%logit_0.0  of_%logit_0.0  outcomes_%logit_0.0  measured_%logit_0.0  in_%logit_1.0  this_%logit_1.0  review_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  best_%logit_0.0  mode_%logit_2.0  of_%logit_0.0  action_%logit_0.0  and_%logit_0.0  the_%logit_1.0  best_%logit_2.0  way_%logit_2.0  of_%logit_2.0  delivering_%logit_1.0  D_%logit_0.0 DD_%logit_0.0  IR_%logit_1.0  to_%logit_2.0  patients_%logit_2.0  with_%logit_1.0  a_%logit_1.0  history_%logit_0.0  of_%logit_1.0  cardiac_%logit_0.0  arr_%logit_0.0 h_%logit_1.0 ythm_%logit_2.0 ias_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  ant_%logit_0.0 ich_%logit_0.0 olin_%logit_1.0 erg_%logit_1.0 ics_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  PD_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  these_%logit_2.0  agents_%logit_1.0  in_%logit_2.0  the_%logit_0.0  management_%logit_2.0  of_%logit_2.0  PD_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_1.0  on_%logit_1.0  quality_%logit_1.0  of_%logit_2.0  life_%logit_1.0  and_%logit_0.0  disability_%logit_0.0 ._%logit_0.0  It_%logit_2.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_2.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_1.0  these_%logit_0.0  drugs_%logit_1.0  are_%logit_1.0  used_%logit_1.0  to_%logit_0.0  treat_%logit_2.0  PD_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  mechanism_%logit_2.0  by_%logit_0.0  which_%logit_1.0  they_%logit_0.0  are_%logit_0.0  used_%logit_0.0  in_%logit_0.0  the_%logit_1.0  control_%logit_1.0  of_%logit_1.0  PD_%logit_1.0  and_%logit_0.0  its_%logit_1.0  complications_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  mechanical_%logit_0.0  ventilation_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  non_%logit_0.0 -_%logit_1.0 ob_%logit_1.0 structed_%logit_0.0  duct_%logit_2.0 us_%logit_1.0  shun_%logit_1.0 ts_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  whether_%logit_2.0  mechanical_%logit_0.0  ventilation_%logit_1.0  is_%logit_0.0  more_%logit_0.0  effective_%logit_0.0  than_%logit_1.0  mechanical_%logit_1.0  ventilation_%logit_1.0 ,_%logit_2.0  or_%logit_1.0  whether_%logit_2.0  it_%logit_0.0  is_%logit_0.0  more_%logit_1.0  efficient_%logit_0.0  than_%logit_1.0  surgical_%logit_1.0  ventilation_%logit_2.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_1.0  reducing_%logit_0.0  the_%logit_0.0  risk_%logit_0.0  of_%logit_0.0  death_%logit_0.0 ,_%logit_0.0  respiratory_%logit_1.0  distress_%logit_1.0  syndrome_%logit_1.0 ,_%logit_0.0  or_%logit_0.0  other_%logit_0.0  adverse_%logit_2.0  outcomes_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_0.0  area_%logit_1.0 ,_%logit_1.0  particularly_%logit_0.0  in_%logit_0.0  the_%logit_0.0  context_%logit_0.0  of_%logit_1.0  the_%logit_0.0  development_%logit_1.0  of_%logit_2.0  new_%logit_0.0  mechanical_%logit_1.0  ventilation_%logit_0.0  systems_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_2.0  trig_%logit_0.0 em_%logit_1.0 inal_%logit_1.0  neural_%logit_2.0 g_%logit_1.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  acupuncture_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  with_%logit_1.0  other_%logit_2.0  treatments_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  also_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  acupuncture_%logit_0.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_2.0  of_%logit_1.0  acupuncture_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_2.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_1.0 -_%logit_0.0 conduct_%logit_2.0 ed_%logit_2.0 ,_%logit_1.0  transparent_%logit_2.0  and_%logit_2.0  reported_%logit_0.0  random_%logit_0.0 ised_%logit_2.0  controlled_%logit_1.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  efficacy_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  in_%logit_2.0  trig_%logit_2.0 em_%logit_2.0 eral_%logit_0.0  neural_%logit_2.0 g_%logit_1.0 ias_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  any_%logit_0.0  difference_%logit_0.0  in_%logit_2.0  pain_%logit_0.0  relief_%logit_0.0  between_%logit_1.0  the_%logit_1.0  two_%logit_1.0  types_%logit_2.0  of_%logit_2.0  hyd_%logit_1.0 ration_%logit_2.0  systems_%logit_2.0  for_%logit_2.0  post_%logit_0.0 operative_%logit_2.0  pain_%logit_1.0  relief_%logit_0.0 ._%logit_0.0  There_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0 ,_%logit_0.0  conducted_%logit_0.0  and_%logit_2.0  reported_%logit_0.0  random_%logit_2.0 ised_%logit_2.0  controlled_%logit_1.0  trials_%logit_2.0  in_%logit_0.0  this_%logit_1.0  area_%logit_0.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_2.0  are_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_0.0  hyd_%logit_1.0 ration_%logit_1.0  is_%logit_0.0  beneficial_%logit_2.0  or_%logit_2.0  harmful_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_1.0  pain_%logit_2.0  relief_%logit_0.0 ,_%logit_0.0  function_%logit_1.0 ,_%logit_2.0  quality_%logit_2.0  of_%logit_2.0  life_%logit_0.0 ,_%logit_0.0  satisfaction_%logit_0.0  with_%logit_0.0  pain_%logit_2.0  relief_%logit_1.0  and_%logit_2.0  satisfaction_%logit_2.0  with_%logit_0.0  the_%logit_0.0  hyd_%logit_2.0 ration_%logit_0.0  system_%logit_0.0 ._%logit_1.0  They_%logit_0.0  also_%logit_0.0  need_%logit_2.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  various_%logit_0.0  hyd_%logit_0.0 ration_%logit_2.0  techniques_%logit_0.0 ,_%logit_2.0  such_%logit_1.0  as_%logit_2.0  oxy_%logit_1.0 toc_%logit_1.0 in_%logit_2.0 ,_%logit_2.0  oxy_%logit_0.0 cod_%logit_2.0 one_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  hyd_%logit_1.0 ration_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  ib_%logit_0.0 up_%logit_0.0 ro_%logit_0.0 fen_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_0.0  standard_%logit_0.0  ana_%logit_2.0 esthetic_%logit_1.0  therapy_%logit_2.0  for_%logit_0.0  pain_%logit_0.0  relief_%logit_2.0  in_%logit_0.0  ul_%logit_2.0 cer_%logit_0.0  healing_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  establish_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  ib_%logit_1.0 ip_%logit_0.0 ro_%logit_1.0 fen_%logit_2.0  in_%logit_1.0  ul_%logit_0.0 cers_%logit_0.0  healing_%logit_0.0  with_%logit_0.0  or_%logit_0.0  without_%logit_1.0  ant_%logit_1.0 icon_%logit_1.0 v_%logit_1.0 uls_%logit_2.0 ant_%logit_1.0  therapy_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  ib_%logit_0.0 ap_%logit_2.0 ro_%logit_1.0 fen_%logit_2.0  on_%logit_2.0  pain_%logit_2.0  relief_%logit_1.0  and_%logit_1.0  pain_%logit_1.0  relief_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_2.0  its_%logit_1.0  effectiveness_%logit_0.0  in_%logit_0.0  healing_%logit_2.0  ul_%logit_0.0 cer_%logit_2.0  ul_%logit_2.0 cers_%logit_2.0  with_%logit_0.0  ant_%logit_0.0 ico_%logit_1.0 ag_%logit_0.0 ulation_%logit_2.0  therapy_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  CB_%logit_2.0 T_%logit_1.0  for_%logit_1.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  depression_%logit_0.0  or_%logit_0.0  alcohol_%logit_2.0  dependence_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_1.0  best_%logit_2.0  approach_%logit_1.0  to_%logit_0.0  CB_%logit_2.0 T_%logit_2.0 ,_%logit_1.0  the_%logit_1.0  best_%logit_2.0  way_%logit_1.0  to_%logit_2.0  integrate_%logit_0.0  CB_%logit_1.0 T_%logit_0.0  and_%logit_0.0  other_%logit_0.0  psych_%logit_0.0 os_%logit_1.0 ocial_%logit_1.0  interventions_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_0.0  most_%logit_2.0  effective_%logit_1.0  way_%logit_1.0  to_%logit_2.0  deliver_%logit_1.0  CB_%logit_2.0 T_%logit_0.0  to_%logit_0.0  people_%logit_2.0  with_%logit_1.0  depression_%logit_1.0  and_%logit_0.0  alcohol_%logit_0.0  dependence_%logit_2.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  CB_%logit_0.0 T_%logit_0.0  with_%logit_1.0  other_%logit_0.0  types_%logit_0.0  of_%logit_2.0  psycho_%logit_2.0 active_%logit_0.0  interventions_%logit_2.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_2.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  standard_%logit_0.0 ised_%logit_1.0  assessment_%logit_1.0  of_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  effectiveness_%logit_0.0  of_%logit_2.0  the_%logit_1.0  CB_%logit_1.0 T_%logit_2.0  approach_%logit_1.0  to_%logit_1.0  mental_%logit_1.0  health_%logit_0.0  services_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  evaluate_%logit_0.0  the_%logit_2.0  efficacy_%logit_0.0  of_%logit_0.0  the_%logit_2.0  various_%logit_0.0  types_%logit_2.0  of_%logit_2.0  psych_%logit_0.0 otherapy_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_1.0  use_%logit_0.0  of_%logit_1.0  th_%logit_0.0 ym_%logit_2.0 os_%logit_1.0 upp_%logit_1.0 ression_%logit_1.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  T_%logit_1.0  cell_%logit_0.0  carcin_%logit_1.0 oma_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_2.0 ,_%logit_1.0  duration_%logit_2.0  and_%logit_0.0  timing_%logit_2.0  of_%logit_2.0  treatment_%logit_1.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  these_%logit_0.0  agents_%logit_0.0  in_%logit_1.0  terms_%logit_0.0  of_%logit_0.0  survival_%logit_1.0  and_%logit_1.0  progression_%logit_2.0 -_%logit_2.0 free_%logit_2.0  survival_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  metast_%logit_0.0 atic_%logit_0.0  tum_%logit_1.0 ours_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  future_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  these_%logit_0.0  treatments_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  who_%logit_1.0  are_%logit_1.0  undergoing_%logit_1.0  chemotherapy_%logit_1.0  for_%logit_1.0  this_%logit_1.0  condition_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  these_%logit_0.0  treatments_%logit_2.0  with_%logit_2.0  each_%logit_2.0  other_%logit_2.0 ._%logit_1.0  Finally_%logit_0.0  they_%logit_0.0  should_%logit_1.0  assess_%logit_2.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  toxicity_%logit_0.0  of_%logit_1.0  these_%logit_1.0  therapies_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  undergoing_%logit_0.0  chemotherapy_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_1.0  draw_%logit_0.0  conclusions_%logit_2.0  about_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  visual_%logit_1.0  ac_%logit_1.0 uity_%logit_0.0  testing_%logit_2.0  in_%logit_1.0  reducing_%logit_2.0  the_%logit_0.0  incidence_%logit_2.0  of_%logit_1.0  falls_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_0.0  this_%logit_2.0  intervention_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  falls_%logit_2.0  and_%logit_0.0  improving_%logit_0.0  sight_%logit_2.0  ac_%logit_1.0 uity_%logit_2.0  in_%logit_0.0  people_%logit_2.0  with_%logit_2.0  a_%logit_0.0  history_%logit_2.0  of_%logit_2.0  falls_%logit_2.0  and_%logit_1.0  impair_%logit_1.0 ments_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  with_%logit_0.0  other_%logit_1.0  types_%logit_1.0  of_%logit_0.0  assessment_%logit_2.0  and_%logit_2.0  assessment_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_1.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_2.0  assessing_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_0.0  the_%logit_1.0  intervention_%logit_1.0  on_%logit_2.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  on_%logit_1.0  improving_%logit_0.0  the_%logit_1.0  quality_%logit_1.0  and_%logit_2.0  quantity_%logit_2.0  of_%logit_1.0  information_%logit_0.0  provided_%logit_0.0  to_%logit_2.0  people_%logit_1.0  with_%logit_0.0  an_%logit_0.0  impairment_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  computer_%logit_2.0 -_%logit_1.0 generated_%logit_2.0  weight_%logit_0.0  loss_%logit_1.0  calcul_%logit_0.0 ators_%logit_0.0  in_%logit_0.0  the_%logit_1.0  management_%logit_0.0  of_%logit_1.0  weight_%logit_0.0  loss_%logit_0.0  in_%logit_0.0  overweight_%logit_2.0  or_%logit_2.0  obese_%logit_0.0  individuals_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  best_%logit_2.0  way_%logit_1.0  to_%logit_1.0  implement_%logit_0.0  such_%logit_1.0  calcul_%logit_1.0 ators_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_2.0  computer_%logit_1.0  gaming_%logit_0.0  consoles_%logit_1.0  on_%logit_1.0  body_%logit_2.0  weight_%logit_1.0  loss_%logit_1.0  and_%logit_0.0  waist_%logit_1.0  circumference_%logit_1.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_2.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_2.0  measuring_%logit_2.0  body_%logit_2.0  weight_%logit_1.0 ,_%logit_1.0  waist_%logit_2.0  circumference_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  metabolic_%logit_1.0  control_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  on_%logit_1.0  measuring_%logit_0.0  metabolic_%logit_2.0  control_%logit_0.0  and_%logit_0.0  metabolism_%logit_2.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  on_%logit_0.0  the_%logit_0.0  impact_%logit_0.0  on_%logit_2.0  waist_%logit_1.0  circumference_%logit_2.0  and_%logit_2.0  body_%logit_0.0  weight_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  antibiotics_%logit_0.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  f_%logit_2.0 eb_%logit_1.0 ri_%logit_0.0 le_%logit_1.0  neut_%logit_0.0 rop_%logit_0.0 en_%logit_0.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_0.0  antibiotics_%logit_0.0  are_%logit_1.0  beneficial_%logit_0.0  or_%logit_1.0  harmful_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_1.0  reducing_%logit_0.0  mortality_%logit_0.0  and_%logit_0.0  morbid_%logit_2.0 ity_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  antibiotic_%logit_1.0  therapy_%logit_1.0  in_%logit_2.0  this_%logit_1.0  population_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_1.0  should_%logit_0.0  be_%logit_2.0  of_%logit_1.0  high_%logit_1.0  methodological_%logit_2.0  quality_%logit_0.0 ,_%logit_0.0  with_%logit_0.0  a_%logit_1.0  focus_%logit_1.0  on_%logit_2.0  identifying_%logit_0.0  patients_%logit_1.0  who_%logit_2.0  are_%logit_1.0  most_%logit_2.0  likely_%logit_1.0  to_%logit_1.0  benefit_%logit_0.0  from_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_0.0  as_%logit_2.0  identifying_%logit_0.0  those_%logit_0.0  patients_%logit_0.0  who_%logit_1.0  will_%logit_0.0  benefit_%logit_0.0  most_%logit_0.0  from_%logit_1.0  antibiotic_%logit_2.0  treatment_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  az_%logit_0.0 ith_%logit_1.0 romy_%logit_1.0 cin_%logit_2.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  B_%logit_0.0 ._%logit_1.0  conj_%logit_2.0 unct_%logit_2.0 iv_%logit_0.0 itis_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_0.0  timing_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_0.0  most_%logit_1.0  effective_%logit_1.0  antibiotic_%logit_1.0  for_%logit_0.0  the_%logit_1.0  management_%logit_0.0  of_%logit_1.0  this_%logit_0.0  condition_%logit_0.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_0.0  in_%logit_0.0  the_%logit_1.0  management_%logit_1.0  and_%logit_0.0  management_%logit_2.0  of_%logit_0.0  these_%logit_0.0  conditions_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  these_%logit_2.0  drugs_%logit_2.0  with_%logit_0.0  each_%logit_1.0  other_%logit_2.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_0.0  efficacy_%logit_0.0 ,_%logit_0.0  toler_%logit_0.0 ability_%logit_2.0  and_%logit_2.0  safety_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_0.0  of_%logit_2.0  OR_%logit_0.0 S_%logit_2.0  as_%logit_1.0  an_%logit_0.0  adjunct_%logit_2.0  to_%logit_0.0  OR_%logit_2.0 S_%logit_1.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  acute_%logit_2.0  diarr_%logit_2.0 hoe_%logit_2.0 a_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_0.0  OR_%logit_2.0 S_%logit_2.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_2.0  in_%logit_1.0  terms_%logit_0.0  of_%logit_1.0  stool_%logit_0.0  integrity_%logit_1.0  and_%logit_1.0  stool_%logit_2.0  integrity_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_2.0  OR_%logit_2.0 S_%logit_0.0  with_%logit_0.0  OR_%logit_0.0 S_%logit_2.0 ,_%logit_0.0  OR_%logit_0.0 S_%logit_2.0  and_%logit_1.0  OR_%logit_0.0 S_%logit_0.0  alone_%logit_0.0  or_%logit_0.0  in_%logit_2.0  combination_%logit_0.0 ,_%logit_2.0  or_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  OR_%logit_0.0 S_%logit_0.0  regimen_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  also_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  AR_%logit_2.0 S_%logit_0.0  in_%logit_2.0  this_%logit_0.0  population_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_0.0  and_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  IV_%logit_0.0 S_%logit_2.0  with_%logit_1.0  or_%logit_0.0  without_%logit_2.0  OR_%logit_2.0 S_%logit_2.0  or_%logit_0.0  OR_%logit_1.0 S_%logit_2.0  for_%logit_0.0  this_%logit_0.0  population_%logit_2.0 ,_%logit_2.0  a_%logit_2.0  meta_%logit_1.0 -_%logit_0.0 analysis_%logit_0.0  is_%logit_0.0  needed_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_0.0  of_%logit_0.0  supplemental_%logit_0.0  oxygen_%logit_2.0  as_%logit_0.0  a_%logit_1.0  supplemental_%logit_2.0  oxygen_%logit_2.0  for_%logit_2.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  t_%logit_2.0 ach_%logit_1.0 yp_%logit_2.0 n_%logit_0.0 oe_%logit_1.0 a_%logit_0.0  in_%logit_0.0  TT_%logit_0.0 N_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0 ,_%logit_1.0  duration_%logit_2.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_0.0  oxygen_%logit_1.0  supplementation_%logit_0.0  and_%logit_2.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  supplemental_%logit_2.0  Oxy_%logit_1.0 gen_%logit_1.0  as_%logit_0.0  a_%logit_1.0  supplementary_%logit_0.0  oxygen_%logit_0.0  for_%logit_0.0  TT_%logit_0.0 N_%logit_1.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_0.0  weight_%logit_1.0  loss_%logit_0.0 ,_%logit_2.0  oxygen_%logit_0.0  saturation_%logit_1.0  and_%logit_1.0  oxygen_%logit_1.0  saturation_%logit_2.0  in_%logit_2.0  the_%logit_0.0  first_%logit_0.0  24_%logit_1.0  hours_%logit_0.0  after_%logit_0.0  discharge_%logit_0.0  from_%logit_1.0  hospital_%logit_1.0 ._%logit_1.0  It_%logit_0.0  is_%logit_1.0  also_%logit_0.0  important_%logit_0.0  to_%logit_0.0  note_%logit_0.0  that_%logit_2.0  supplemental_%logit_2.0  oxygen_%logit_0.0  is_%logit_2.0  not_%logit_0.0  recommended_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_2.0  supplemental_%logit_1.0  oxygen_%logit_1.0  in_%logit_0.0  patients_%logit_2.0  who_%logit_0.0  are_%logit_2.0  unable_%logit_1.0  to_%logit_2.0  tolerate_%logit_2.0  supplemental_%logit_2.0  oxygen_%logit_0.0  or_%logit_2.0  oxygen_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_1.0  of_%logit_2.0  prog_%logit_1.0 est_%logit_2.0 ogens_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_0.0  S_%logit_0.0 EM_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_1.0  drugs_%logit_0.0  in_%logit_2.0  S_%logit_2.0 EM_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_2.0  prog_%logit_0.0 est_%logit_1.0 ogen_%logit_2.0  with_%logit_1.0  placebo_%logit_2.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_2.0  should_%logit_1.0  be_%logit_0.0  of_%logit_2.0  high_%logit_0.0  quality_%logit_2.0 ,_%logit_1.0  preferably_%logit_2.0  with_%logit_1.0  a_%logit_0.0  high_%logit_0.0  risk_%logit_1.0  of_%logit_0.0  bias_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  should_%logit_1.0  be_%logit_0.0  conducted_%logit_2.0  with_%logit_1.0  a_%logit_2.0  low_%logit_2.0  risk_%logit_2.0  of_%logit_2.0  random_%logit_0.0  errors_%logit_0.0  and_%logit_0.0  unreliable_%logit_2.0  outcome_%logit_1.0  measures_%logit_2.0 ._%logit_0.0  They_%logit_2.0  should_%logit_2.0  also_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  prog_%logit_2.0 ester_%logit_1.0 one_%logit_0.0  in_%logit_0.0  the_%logit_1.0  management_%logit_0.0  of_%logit_2.0  S_%logit_0.0 EMS_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  the_%logit_2.0  impact_%logit_0.0  on_%logit_1.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  on_%logit_1.0  the_%logit_1.0  quality_%logit_0.0  of_%logit_1.0  the_%logit_0.0  life_%logit_0.0  of_%logit_1.0  patients_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  no_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  creatine_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_2.0  rel_%logit_1.0 apses_%logit_0.0  in_%logit_2.0  adults_%logit_2.0  with_%logit_0.0  MS_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_2.0  creatine_%logit_0.0  therapy_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  creatine_%logit_0.0  with_%logit_1.0  placebo_%logit_2.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  long_%logit_1.0 -_%logit_2.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  creatine_%logit_0.0  in_%logit_0.0  preventing_%logit_2.0  rel_%logit_1.0 apses_%logit_0.0  and_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  its_%logit_0.0  effectiveness_%logit_1.0  in_%logit_1.0  the_%logit_1.0  management_%logit_0.0  of_%logit_0.0  MS_%logit_0.0 ._%logit_0.0  Long_%logit_0.0 -_%logit_1.0 term_%logit_0.0  studies_%logit_2.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_1.0  creatine_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  its_%logit_1.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  ip_%logit_0.0 rat_%logit_0.0 rop_%logit_1.0 ium_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_1.0  acute_%logit_1.0  bron_%logit_2.0 ch_%logit_1.0 ocon_%logit_0.0 st_%logit_0.0 riction_%logit_0.0  in_%logit_0.0  RS_%logit_2.0 Is_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  ip_%logit_0.0 at_%logit_0.0 rop_%logit_1.0 ium_%logit_2.0  in_%logit_2.0  this_%logit_0.0  population_%logit_0.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_1.0  conducted_%logit_1.0  in_%logit_1.0  the_%logit_2.0  United_%logit_1.0  States_%logit_2.0 ,_%logit_2.0  Europe_%logit_2.0 ,_%logit_2.0  Asia_%logit_0.0  and_%logit_1.0  Australia_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  should_%logit_1.0  be_%logit_0.0  of_%logit_1.0  high_%logit_1.0  methodological_%logit_2.0  quality_%logit_1.0 ,_%logit_0.0  with_%logit_1.0  a_%logit_0.0  focus_%logit_1.0  on_%logit_0.0  assessing_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0 ,_%logit_2.0  safety_%logit_0.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_0.0  the_%logit_0.0  various_%logit_1.0  treatments_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  any_%logit_1.0  of_%logit_0.0  the_%logit_0.0  interventions_%logit_1.0  reviewed_%logit_0.0  in_%logit_0.0  this_%logit_0.0  review_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  any_%logit_2.0  interventions_%logit_0.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  T_%logit_1.0 MS_%logit_2.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_2.0  should_%logit_0.0  be_%logit_0.0  undertaken_%logit_1.0  in_%logit_0.0  the_%logit_2.0  context_%logit_1.0  of_%logit_0.0  a_%logit_1.0  well_%logit_0.0 -_%logit_1.0 defined_%logit_1.0  set_%logit_0.0  of_%logit_2.0  outcome_%logit_1.0  measures_%logit_1.0 ,_%logit_0.0  such_%logit_0.0  as_%logit_1.0  fatigue_%logit_0.0  and_%logit_0.0  fatigue_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_2.0  an_%logit_0.0  assessment_%logit_0.0  of_%logit_2.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_1.0 ._%logit_0.0  They_%logit_0.0  should_%logit_1.0  also_%logit_2.0  assess_%logit_2.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_1.0  various_%logit_2.0  interventions_%logit_2.0  on_%logit_0.0  T_%logit_2.0 MS_%logit_2.0 ,_%logit_2.0  including_%logit_0.0  walking_%logit_2.0 ,_%logit_2.0  cycling_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  social_%logit_2.0  interaction_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  any_%logit_1.0  of_%logit_1.0  the_%logit_0.0  interventions_%logit_0.0  included_%logit_0.0  in_%logit_2.0  this_%logit_0.0  review_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_1.0  various_%logit_0.0  types_%logit_2.0  of_%logit_2.0  tobacco_%logit_0.0  cessation_%logit_1.0  interventions_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  these_%logit_2.0  interventions_%logit_1.0  in_%logit_0.0  the_%logit_0.0  context_%logit_0.0  of_%logit_0.0  a_%logit_0.0  variety_%logit_1.0  of_%logit_1.0  contexts_%logit_2.0  and_%logit_0.0  settings_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_0.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  of_%logit_1.0  nicotine_%logit_1.0  replacement_%logit_1.0  therapy_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  its_%logit_1.0  effectiveness_%logit_2.0  in_%logit_2.0  specific_%logit_0.0  contexts_%logit_1.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_1.0  smoking_%logit_1.0  cessation_%logit_2.0  programmes_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  impact_%logit_0.0  on_%logit_2.0  health_%logit_0.0 -_%logit_1.0 related_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_0.0  and_%logit_0.0  wellbeing_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  its_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  cost_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_0.0  of_%logit_1.0  insulin_%logit_1.0  analog_%logit_1.0 ues_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  patients_%logit_1.0  with_%logit_1.0  diabetes_%logit_1.0  mell_%logit_2.0 itus_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  insulin_%logit_2.0 -_%logit_1.0  analog_%logit_2.0 ues_%logit_2.0  for_%logit_0.0  these_%logit_0.0  patients_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_2.0  mortality_%logit_0.0 ,_%logit_0.0  cardiovascular_%logit_0.0  morbid_%logit_1.0 ity_%logit_1.0  and_%logit_2.0  morbid_%logit_2.0 ity_%logit_2.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  long_%logit_0.0 -_%logit_2.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_1.0  effects_%logit_2.0  of_%logit_1.0  gluc_%logit_1.0 oc_%logit_1.0 ort_%logit_0.0 ic_%logit_0.0 oid_%logit_0.0  therapy_%logit_0.0  on_%logit_2.0  gly_%logit_1.0 ca_%logit_1.0 emic_%logit_0.0  control_%logit_1.0  in_%logit_0.0  diabetic_%logit_2.0  mell_%logit_0.0 itus_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  on_%logit_1.0  metabolic_%logit_0.0  control_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  type_%logit_1.0  1_%logit_0.0  and_%logit_0.0  type_%logit_0.0  2_%logit_2.0  diabetes_%logit_2.0 ._%logit_0.0
 Functional_%logit_0.0  training_%logit_0.0  may_%logit_2.0  be_%logit_2.0  a_%logit_1.0  useful_%logit_2.0  tool_%logit_1.0  in_%logit_2.0  the_%logit_1.0  management_%logit_1.0  of_%logit_0.0  depression_%logit_0.0  and_%logit_0.0  anxiety_%logit_2.0 ,_%logit_0.0  but_%logit_1.0  its_%logit_2.0  usefulness_%logit_0.0  is_%logit_1.0  limited_%logit_2.0  by_%logit_0.0  the_%logit_0.0  small_%logit_0.0  number_%logit_2.0  of_%logit_0.0  participants_%logit_1.0  and_%logit_0.0  the_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_1.0  in_%logit_0.0  most_%logit_0.0  of_%logit_0.0  the_%logit_0.0  studies_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  functional_%logit_1.0  training_%logit_1.0  in_%logit_2.0  depression_%logit_1.0 ,_%logit_0.0  anxiety_%logit_0.0 ,_%logit_2.0  sleep_%logit_2.0  deprivation_%logit_2.0  and_%logit_0.0  sleep_%logit_0.0  deprivation_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_1.0  functional_%logit_2.0  training_%logit_1.0  with_%logit_0.0  functional_%logit_0.0  training_%logit_2.0  alone_%logit_1.0  or_%logit_1.0  in_%logit_0.0  combination_%logit_2.0  with_%logit_1.0  other_%logit_0.0  forms_%logit_1.0  of_%logit_2.0  mental_%logit_0.0  health_%logit_1.0  services_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_2.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  durability_%logit_1.0  of_%logit_0.0  exercises_%logit_1.0  for_%logit_0.0  depression_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_1.0  impact_%logit_2.0  of_%logit_2.0  exercise_%logit_2.0  training_%logit_2.0  on_%logit_0.0  quality_%logit_2.0  of_%logit_2.0  life_%logit_1.0  and_%logit_1.0  wellbeing_%logit_2.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  impact_%logit_0.0  on_%logit_0.0  depression_%logit_0.0  severity_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  epid_%logit_0.0 ural_%logit_2.0  analges_%logit_0.0 ia_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  acute_%logit_1.0  pain_%logit_1.0  during_%logit_1.0  anesthesia_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  epid_%logit_2.0 ur_%logit_1.0 als_%logit_2.0  for_%logit_2.0  pain_%logit_2.0  relief_%logit_0.0  during_%logit_0.0  anesthesia_%logit_0.0  during_%logit_1.0  anesthesia_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  intra_%logit_1.0 operative_%logit_1.0  analges_%logit_0.0 ia_%logit_0.0  during_%logit_0.0  ana_%logit_0.0 esthesia_%logit_2.0  for_%logit_1.0  acute_%logit_2.0  pain_%logit_2.0  relief_%logit_0.0  in_%logit_2.0  women_%logit_0.0  with_%logit_1.0  acute_%logit_1.0  pain_%logit_1.0  following_%logit_0.0  anesthesia_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_2.0 ,_%logit_2.0  well_%logit_1.0 -_%logit_2.0 conduct_%logit_2.0 ed_%logit_0.0 ,_%logit_1.0  transparent_%logit_1.0  and_%logit_2.0  transparent_%logit_0.0  audit_%logit_0.0  of_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0 ,_%logit_0.0  safety_%logit_0.0  and_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  various_%logit_0.0  analges_%logit_0.0 ia_%logit_0.0  for_%logit_0.0  this_%logit_1.0  purpose_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  psych_%logit_2.0 os_%logit_2.0 ocial_%logit_0.0  interventions_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  anxiety_%logit_1.0  disorders_%logit_1.0  in_%logit_1.0  adults_%logit_0.0  with_%logit_1.0  epilepsy_%logit_1.0 ._%logit_1.0  There_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_2.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  these_%logit_2.0  interventions_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_1.0  should_%logit_1.0  be_%logit_0.0  of_%logit_2.0  high_%logit_0.0  methodological_%logit_2.0  quality_%logit_1.0 ,_%logit_0.0  with_%logit_1.0  appropriate_%logit_1.0  attention_%logit_2.0  paid_%logit_0.0  to_%logit_2.0  outcome_%logit_0.0  measures_%logit_2.0 ._%logit_0.0  They_%logit_0.0  should_%logit_2.0  also_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  efficacy_%logit_1.0  of_%logit_1.0  psychological_%logit_2.0  interventions_%logit_2.0  for_%logit_1.0  anxiety_%logit_1.0  disorders_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  measures_%logit_0.0  of_%logit_0.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_0.0  and_%logit_0.0  wellbeing_%logit_0.0 ._%logit_2.0  They_%logit_0.0  also_%logit_0.0  should_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_1.0  psychological_%logit_2.0  therapies_%logit_2.0  for_%logit_1.0  anxiety_%logit_1.0  disorder_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_1.0 os_%logit_0.0 ocial_%logit_1.0  interventions_%logit_2.0  for_%logit_2.0  depression_%logit_1.0  or_%logit_0.0  anxiety_%logit_1.0  disorders_%logit_1.0  in_%logit_0.0  adults_%logit_2.0  with_%logit_1.0  MS_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  psych_%logit_1.0 otherapy_%logit_1.0  for_%logit_2.0  depression_%logit_1.0  and_%logit_1.0  anxiety_%logit_1.0  disorders_%logit_1.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_2.0  as_%logit_2.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_2.0  effectiveness_%logit_1.0  in_%logit_1.0  children_%logit_1.0  with_%logit_0.0  MS_%logit_2.0  and_%logit_0.0  adults_%logit_0.0  with_%logit_1.0  depression_%logit_1.0  and_%logit_1.0  its_%logit_1.0  severity_%logit_0.0 ._%logit_0.0  It_%logit_1.0  is_%logit_2.0  also_%logit_2.0  important_%logit_2.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  well_%logit_1.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_1.0 -_%logit_1.0 conduct_%logit_2.0 ed_%logit_1.0  and_%logit_2.0  reported_%logit_0.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0 ,_%logit_2.0  safety_%logit_2.0  and_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psychological_%logit_2.0  therapies_%logit_1.0  for_%logit_0.0  depression_%logit_2.0  in_%logit_0.0  adults_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  V_%logit_1.0 AP_%logit_2.0  in_%logit_0.0  reducing_%logit_1.0  mortality_%logit_1.0  or_%logit_0.0  morbid_%logit_2.0 ity_%logit_2.0  in_%logit_1.0  patients_%logit_1.0  admitted_%logit_1.0  to_%logit_2.0  IC_%logit_0.0 U_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  this_%logit_2.0  intervention_%logit_2.0  in_%logit_2.0  improving_%logit_1.0  the_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_2.0  of_%logit_1.0  these_%logit_2.0  patients_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_2.0  impact_%logit_2.0  on_%logit_2.0  mortality_%logit_1.0  and_%logit_1.0  morbid_%logit_2.0 ity_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  future_%logit_2.0  research_%logit_1.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_1.0  impact_%logit_0.0  of_%logit_0.0  the_%logit_0.0  intervention_%logit_0.0  on_%logit_2.0  mortality_%logit_0.0 ,_%logit_2.0  morbid_%logit_0.0 ity_%logit_2.0  and_%logit_0.0  mortality_%logit_2.0  in_%logit_0.0  these_%logit_2.0  patients_%logit_1.0  and_%logit_1.0  on_%logit_1.0  cost_%logit_0.0 -_%logit_0.0 effect_%logit_1.0 iveness_%logit_0.0  of_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  any_%logit_2.0  difference_%logit_1.0  in_%logit_2.0  survival_%logit_2.0  between_%logit_0.0  chem_%logit_2.0 op_%logit_1.0 roph_%logit_2.0 yl_%logit_0.0 axis_%logit_0.0  and_%logit_0.0  chemotherapy_%logit_1.0  alone_%logit_1.0  or_%logit_1.0  in_%logit_0.0  combination_%logit_1.0  with_%logit_0.0  chemotherapy_%logit_0.0  alone_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_0.0  chemotherapy_%logit_1.0  versus_%logit_2.0  chemotherapy_%logit_1.0  alone_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  chemotherapy_%logit_1.0  and_%logit_2.0  radiation_%logit_1.0  therapy_%logit_1.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_0.0  survival_%logit_1.0  and_%logit_0.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  a_%logit_0.0  meta_%logit_2.0 -_%logit_0.0 analysis_%logit_2.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  radiation_%logit_0.0  therapy_%logit_0.0  versus_%logit_0.0  chemotherapy_%logit_1.0  is_%logit_0.0  warranted_%logit_1.0 ._%logit_2.0  The_%logit_1.0  results_%logit_2.0  of_%logit_0.0  this_%logit_0.0  review_%logit_1.0  are_%logit_0.0  based_%logit_2.0  on_%logit_1.0  a_%logit_0.0  small_%logit_2.0  number_%logit_2.0  of_%logit_1.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_2.0  a_%logit_2.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  are_%logit_1.0  subject_%logit_2.0  to_%logit_1.0  a_%logit_0.0  number_%logit_0.0  of_%logit_0.0  uncertainties_%logit_1.0 ._%logit_1.0
 The_%logit_0.0  evidence_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_2.0  psychological_%logit_0.0  interventions_%logit_2.0  for_%logit_0.0  domestic_%logit_2.0  violence_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  these_%logit_0.0  interventions_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_1.0  them_%logit_2.0  to_%logit_2.0  each_%logit_0.0  other_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  their_%logit_0.0  effectiveness_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_2.0  domestic_%logit_1.0  violence_%logit_0.0  and_%logit_0.0  its_%logit_1.0  aftermath_%logit_0.0 ._%logit_0.0  Recommend_%logit_1.0 ations_%logit_1.0  for_%logit_1.0  future_%logit_0.0  research_%logit_0.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_1.0 ,_%logit_1.0  as_%logit_0.0  are_%logit_2.0  recommendations_%logit_0.0  on_%logit_0.0  how_%logit_0.0  best_%logit_0.0  to_%logit_2.0  implement_%logit_0.0  these_%logit_0.0  interventions_%logit_0.0  in_%logit_0.0  the_%logit_1.0  context_%logit_0.0  of_%logit_2.0  a_%logit_0.0  multi_%logit_0.0 -_%logit_1.0 disciplinary_%logit_1.0  approach_%logit_2.0  to_%logit_0.0  addressing_%logit_0.0  domestic_%logit_0.0  violence_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  how_%logit_1.0  to_%logit_2.0  tailor_%logit_0.0  them_%logit_1.0  to_%logit_0.0  the_%logit_0.0  needs_%logit_1.0  of_%logit_0.0  the_%logit_0.0  community_%logit_0.0 ._%logit_0.0
 Immun_%logit_0.0 ogl_%logit_2.0 ob_%logit_1.0 ulin_%logit_2.0  is_%logit_0.0  effective_%logit_2.0  in_%logit_0.0  reducing_%logit_0.0  mortality_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_2.0  pre_%logit_2.0 -_%logit_1.0 existing_%logit_0.0  se_%logit_1.0 ps_%logit_1.0 is_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  there_%logit_1.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  recommend_%logit_0.0  its_%logit_0.0  use_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_0.0  for_%logit_1.0  IV_%logit_2.0 IG_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  pre_%logit_2.0 -_%logit_0.0 term_%logit_2.0  infants_%logit_0.0  with_%logit_0.0  pre_%logit_0.0 term_%logit_1.0  infants_%logit_1.0  who_%logit_1.0  are_%logit_1.0  at_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_1.0  se_%logit_2.0 ps_%logit_1.0 IS_%logit_2.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_0.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_1.0  IV_%logit_2.0 IG_%logit_0.0  therapy_%logit_1.0  in_%logit_1.0  these_%logit_1.0  infants_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  optimal_%logit_0.0  timing_%logit_1.0  and_%logit_1.0  timing_%logit_2.0  of_%logit_2.0  administration_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  immun_%logit_1.0 ogl_%logit_1.0 ob_%logit_1.0 ul_%logit_1.0 ins_%logit_1.0  with_%logit_1.0  IV_%logit_1.0 IG_%logit_2.0 ,_%logit_0.0  IV_%logit_0.0 IG_%logit_2.0  and_%logit_1.0  IV_%logit_1.0 IG_%logit_1.0  alone_%logit_0.0 ._%logit_1.0
 Cognitive_%logit_0.0  performance_%logit_2.0  tests_%logit_0.0  are_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  careg_%logit_1.0 iver_%logit_2.0  stress_%logit_0.0  and_%logit_0.0  improving_%logit_0.0  careg_%logit_0.0 iver_%logit_1.0  competence_%logit_0.0  in_%logit_2.0  the_%logit_1.0  short_%logit_2.0 -_%logit_2.0 term_%logit_2.0 ._%logit_1.0  Cognitive_%logit_0.0  performance_%logit_1.0  test_%logit_1.0  results_%logit_2.0  are_%logit_0.0  similar_%logit_0.0  to_%logit_2.0  those_%logit_1.0  of_%logit_1.0  other_%logit_1.0  cognitive_%logit_2.0  performance_%logit_1.0  tests_%logit_1.0 ._%logit_1.0  However_%logit_2.0 ,_%logit_0.0  the_%logit_1.0  results_%logit_0.0  are_%logit_1.0  based_%logit_2.0  on_%logit_2.0  a_%logit_0.0  small_%logit_0.0  number_%logit_0.0  of_%logit_0.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_2.0  a_%logit_1.0  high_%logit_2.0  risk_%logit_0.0  of_%logit_2.0  bias_%logit_0.0  and_%logit_0.0  a_%logit_0.0  low_%logit_1.0  risk_%logit_1.0  of_%logit_1.0  random_%logit_0.0  errors_%logit_0.0 ._%logit_1.0  The_%logit_1.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_0.0  evidence_%logit_0.0  is_%logit_0.0  low_%logit_0.0  and_%logit_0.0  the_%logit_1.0  results_%logit_0.0  do_%logit_0.0  not_%logit_0.0  indicate_%logit_0.0  a_%logit_2.0  significant_%logit_2.0  difference_%logit_0.0  in_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_1.0  or_%logit_0.0  careg_%logit_0.0 iver_%logit_2.0  satisfaction_%logit_0.0  with_%logit_1.0  cognitive_%logit_1.0  performance_%logit_1.0  test_%logit_1.0 ._%logit_2.0  Cognitive_%logit_2.0  tests_%logit_1.0  are_%logit_2.0  also_%logit_0.0  not_%logit_0.0  significantly_%logit_1.0  different_%logit_1.0  from_%logit_1.0  those_%logit_1.0  of_%logit_1.0  the_%logit_1.0  control_%logit_0.0  group_%logit_0.0 ._%logit_0.0  Positive_%logit_0.0  findings_%logit_0.0  of_%logit_2.0  Cognitive_%logit_2.0  Performance_%logit_2.0  tests_%logit_2.0  are_%logit_1.0  similar_%logit_1.0  in_%logit_1.0  severity_%logit_2.0  and_%logit_1.0  severity_%logit_1.0  of_%logit_1.0  dementia_%logit_0.0 ,_%logit_1.0  but_%logit_1.0  cognitive_%logit_2.0  tests_%logit_0.0  are_%logit_0.0  significantly_%logit_2.0  more_%logit_2.0  likely_%logit_1.0  to_%logit_1.0  be_%logit_1.0  accurate_%logit_0.0  than_%logit_1.0  negative_%logit_2.0  findings_%logit_1.0 ._%logit_0.0  Positive_%logit_1.0  results_%logit_0.0  of_%logit_2.0  cognitive_%logit_2.0  Performance_%logit_0.0  tests_%logit_0.0  should_%logit_2.0  be_%logit_1.0  interpreted_%logit_2.0  with_%logit_1.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  the_%logit_2.0  results_%logit_0.0  of_%logit_2.0  these_%logit_2.0  studies_%logit_2.0  were_%logit_0.0  based_%logit_1.0  on_%logit_1.0  only_%logit_1.0  one_%logit_2.0  study_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  therefore_%logit_2.0  the_%logit_2.0  results_%logit_0.0  cannot_%logit_0.0  be_%logit_0.0  extrap_%logit_0.0 olated_%logit_1.0  to_%logit_1.0  all_%logit_0.0  other_%logit_0.0  cognitive_%logit_2.0  tests_%logit_0.0 ._%logit_1.0  Cognitive_%logit_0.0  Performance_%logit_0.0  test_%logit_0.0  results_%logit_0.0  should_%logit_0.0  be_%logit_2.0  viewed_%logit_0.0  with_%logit_1.0  caution_%logit_2.0  as_%logit_0.0  the_%logit_0.0  majority_%logit_1.0  of_%logit_0.0  the_%logit_1.0  studies_%logit_2.0  were_%logit_0.0  conducted_%logit_0.0  in_%logit_0.0  Japan_%logit_0.0 ,_%logit_0.0  where_%logit_0.0  cognitive_%logit_1.0  performance_%logit_1.0  scores_%logit_0.0  were_%logit_0.0  similar_%logit_0.0  to_%logit_1.0  that_%logit_2.0  of_%logit_0.0  most_%logit_0.0  of_%logit_1.0  the_%logit_2.0  other_%logit_1.0  tests_%logit_0.0  included_%logit_0.0  in_%logit_0.0  this_%logit_1.0  review_%logit_2.0 ._%logit_0.0  The_%logit_1.0  results_%logit_2.0  of_%logit_1.0  this_%logit_0.0  review_%logit_0.0  suggest_%logit_0.0  that_%logit_2.0  Cognitive_%logit_1.0  Performance_%logit_0.0  Tests_%logit_1.0  may_%logit_1.0  be_%logit_0.0  useful_%logit_2.0  in_%logit_0.0  determining_%logit_0.0  the_%logit_2.0  level_%logit_2.0  of_%logit_2.0  cognitive_%logit_0.0  performance_%logit_1.0  testing_%logit_2.0  in_%logit_0.0  Alzheimer_%logit_2.0 's_%logit_2.0  Disease_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  there_%logit_2.0  is_%logit_2.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_0.0  of_%logit_2.0  beta_%logit_1.0  car_%logit_0.0 ot_%logit_0.0 ene_%logit_1.0  supplements_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  cat_%logit_0.0 ar_%logit_2.0 act_%logit_1.0 ._%logit_2.0  There_%logit_0.0  is_%logit_2.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_0.0  area_%logit_1.0 ,_%logit_0.0  particularly_%logit_0.0  in_%logit_0.0  regards_%logit_1.0  to_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  alpha_%logit_0.0  to_%logit_2.0 cop_%logit_2.0 he_%logit_1.0 rol_%logit_2.0  supplements_%logit_0.0  on_%logit_1.0  the_%logit_0.0  severity_%logit_1.0  of_%logit_2.0  the_%logit_2.0  cat_%logit_2.0 ar_%logit_1.0 acts_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  on_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  beta_%logit_1.0 -_%logit_2.0 car_%logit_0.0 ot_%logit_2.0 ene_%logit_0.0  supplementation_%logit_0.0  in_%logit_0.0  reducing_%logit_1.0  the_%logit_0.0  incidence_%logit_0.0  and_%logit_0.0  progression_%logit_2.0  of_%logit_2.0  these_%logit_0.0  conditions_%logit_0.0 ._%logit_2.0  The_%logit_1.0  results_%logit_2.0  of_%logit_1.0  this_%logit_2.0  review_%logit_1.0  are_%logit_0.0  based_%logit_0.0  on_%logit_2.0  a_%logit_0.0  small_%logit_2.0  number_%logit_2.0  of_%logit_2.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_2.0  a_%logit_0.0  high_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  bias_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  are_%logit_1.0  subject_%logit_2.0  to_%logit_2.0  change_%logit_0.0  in_%logit_1.0  interpretation_%logit_2.0  and_%logit_1.0  interpretation_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  existence_%logit_1.0  of_%logit_2.0  an_%logit_2.0  association_%logit_2.0  between_%logit_1.0  cost_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_1.0  in_%logit_0.0  psych_%logit_0.0 opath_%logit_2.0 ology_%logit_0.0  or_%logit_0.0  social_%logit_0.0  functioning_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  most_%logit_0.0  effective_%logit_0.0  way_%logit_0.0  to_%logit_1.0  integrate_%logit_1.0  cost_%logit_2.0  effectiveness_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  cost_%logit_2.0  effectiveness_%logit_0.0  with_%logit_1.0  other_%logit_2.0  forms_%logit_2.0  of_%logit_1.0  psychological_%logit_0.0  therapies_%logit_1.0 ._%logit_0.0  It_%logit_0.0  is_%logit_0.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_2.0  by_%logit_1.0  which_%logit_1.0  cost_%logit_0.0  effectiveness_%logit_0.0  works_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  how_%logit_1.0  cost_%logit_2.0  effectiveness_%logit_2.0  relates_%logit_1.0  to_%logit_0.0  quality_%logit_1.0  and_%logit_1.0  quantity_%logit_0.0  of_%logit_2.0  life_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  the_%logit_0.0  cost_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  the_%logit_1.0  various_%logit_2.0  approaches_%logit_0.0  to_%logit_2.0  cost_%logit_2.0  effectiveness_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  electronic_%logit_1.0  detectors_%logit_1.0  in_%logit_1.0  preventing_%logit_2.0  injury_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_0.0  electronic_%logit_0.0  alarms_%logit_0.0  in_%logit_1.0  detecting_%logit_1.0  injury_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_0.0  as_%logit_1.0  their_%logit_0.0  effectiveness_%logit_0.0  in_%logit_1.0  reducing_%logit_2.0  injury_%logit_0.0  rates_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  their_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  cost_%logit_1.0 -_%logit_0.0 effect_%logit_1.0 iveness_%logit_0.0  in_%logit_0.0  the_%logit_1.0  prevention_%logit_1.0  of_%logit_1.0  injury_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  their_%logit_0.0  effectiveness_%logit_1.0  as_%logit_2.0  a_%logit_2.0  deterrent_%logit_1.0  to_%logit_2.0  injury_%logit_2.0 ._%logit_2.0  It_%logit_1.0  is_%logit_1.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_2.0  electronic_%logit_0.0  detectors_%logit_0.0  are_%logit_1.0  used_%logit_1.0  to_%logit_0.0  detect_%logit_0.0  injury_%logit_1.0 ,_%logit_1.0  the_%logit_2.0  types_%logit_2.0  of_%logit_1.0  detectors_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  how_%logit_1.0  they_%logit_0.0  are_%logit_2.0  used_%logit_0.0  in_%logit_1.0  addition_%logit_1.0  to_%logit_0.0  electronic_%logit_0.0  detectors_%logit_0.0 ._%logit_0.0
 Ant_%logit_0.0 ib_%logit_2.0 iotic_%logit_2.0  pro_%logit_1.0 ph_%logit_1.0 yl_%logit_0.0 axis_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_1.0  improving_%logit_0.0  lung_%logit_0.0  function_%logit_1.0  in_%logit_1.0  patients_%logit_2.0  with_%logit_1.0  a_%logit_2.0  P_%logit_2.0 ._%logit_0.0  aer_%logit_1.0 ug_%logit_1.0 in_%logit_1.0 osa_%logit_1.0  infection_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_2.0  a_%logit_2.0  need_%logit_0.0  for_%logit_2.0  further_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_2.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_2.0  pro_%logit_1.0 ph_%logit_2.0 yle_%logit_0.0 phrine_%logit_2.0  injection_%logit_0.0  on_%logit_0.0  lung_%logit_2.0  function_%logit_0.0  and_%logit_0.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_0.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_2.0 ,_%logit_1.0  duration_%logit_1.0  and_%logit_1.0  duration_%logit_1.0  of_%logit_0.0  therapy_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_0.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  the_%logit_2.0  combination_%logit_0.0  therapy_%logit_2.0  in_%logit_2.0  reducing_%logit_1.0  the_%logit_1.0  risk_%logit_0.0  of_%logit_2.0  pneum_%logit_1.0 oth_%logit_1.0 or_%logit_1.0 ax_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_2.0  gluc_%logit_0.0 oc_%logit_0.0 ort_%logit_1.0 ic_%logit_1.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  agitation_%logit_0.0 ,_%logit_2.0  agitation_%logit_0.0  or_%logit_1.0  psychosis_%logit_0.0  in_%logit_2.0  people_%logit_1.0  with_%logit_1.0  Alzheimer_%logit_0.0 's_%logit_0.0  disease_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_1.0  drugs_%logit_1.0  in_%logit_2.0  treating_%logit_2.0  agitation_%logit_1.0  and_%logit_2.0  agitation_%logit_1.0  in_%logit_0.0  these_%logit_0.0  patients_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_2.0  effects_%logit_1.0  on_%logit_2.0  other_%logit_1.0  outcomes_%logit_2.0 ,_%logit_1.0  such_%logit_1.0  as_%logit_0.0  psychological_%logit_0.0  wellbeing_%logit_2.0  and_%logit_2.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  long_%logit_0.0 -_%logit_2.0 term_%logit_2.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_1.0  gluc_%logit_1.0 os_%logit_0.0 ort_%logit_2.0 ic_%logit_1.0 oid_%logit_1.0  therapy_%logit_0.0  in_%logit_1.0  these_%logit_1.0  conditions_%logit_2.0 ._%logit_0.0
 Sexual_%logit_0.0  risk_%logit_0.0  behaviours_%logit_0.0  are_%logit_0.0  significantly_%logit_0.0  reduced_%logit_0.0  with_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_0.0  social_%logit_2.0  support_%logit_0.0  and_%logit_0.0  psychological_%logit_2.0  support_%logit_0.0 ._%logit_2.0  Sexual_%logit_1.0  support_%logit_0.0  appears_%logit_0.0  to_%logit_1.0  be_%logit_0.0  effective_%logit_0.0  in_%logit_2.0  reducing_%logit_0.0  sexual_%logit_1.0  risk_%logit_1.0  behaviours_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  its_%logit_0.0  effectiveness_%logit_2.0  is_%logit_0.0  not_%logit_0.0  clear_%logit_0.0  from_%logit_0.0  this_%logit_2.0  review_%logit_2.0 ._%logit_2.0  Positive_%logit_0.0  effects_%logit_1.0  on_%logit_2.0  sexual_%logit_2.0  risk_%logit_1.0  behaviors_%logit_0.0  are_%logit_0.0  likely_%logit_1.0  to_%logit_2.0  be_%logit_0.0  sustained_%logit_0.0  over_%logit_0.0  time_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  this_%logit_0.0  is_%logit_2.0  unlikely_%logit_0.0  to_%logit_0.0  translate_%logit_0.0  into_%logit_0.0  a_%logit_2.0  reduction_%logit_0.0  in_%logit_1.0  sexual_%logit_1.0  risk_%logit_0.0  behaviour_%logit_0.0 ._%logit_0.0  Positive_%logit_1.0  results_%logit_1.0  from_%logit_2.0  social_%logit_2.0  support_%logit_1.0  are_%logit_2.0  unlikely_%logit_2.0  to_%logit_0.0  have_%logit_2.0  an_%logit_0.0  immediate_%logit_2.0  impact_%logit_0.0  on_%logit_2.0  sexual_%logit_1.0  risks_%logit_2.0  behaviours_%logit_0.0 ._%logit_2.0  Positive_%logit_2.0  findings_%logit_0.0  from_%logit_2.0  the_%logit_0.0  review_%logit_0.0  suggest_%logit_2.0  that_%logit_1.0  social_%logit_0.0  support_%logit_1.0  may_%logit_2.0  be_%logit_1.0  beneficial_%logit_1.0  for_%logit_2.0  reducing_%logit_2.0  sexual_%logit_0.0  risks_%logit_1.0  behaviors_%logit_1.0 ,_%logit_2.0  but_%logit_0.0  further_%logit_2.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_1.0  this_%logit_1.0  intervention_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  beneficial_%logit_1.0  effect_%logit_1.0  of_%logit_1.0  hyd_%logit_1.0 roc_%logit_1.0 ort_%logit_0.0 is_%logit_1.0 one_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  abdominal_%logit_0.0  tender_%logit_1.0 ness_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  this_%logit_0.0  treatment_%logit_0.0  for_%logit_1.0  tender_%logit_1.0 ness_%logit_2.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  abs_%logit_2.0 cess_%logit_2.0 ed_%logit_1.0  abs_%logit_1.0 cess_%logit_2.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_1.0  should_%logit_0.0  be_%logit_1.0  of_%logit_1.0  sufficient_%logit_1.0  size_%logit_2.0  and_%logit_1.0  duration_%logit_1.0  to_%logit_0.0  provide_%logit_0.0  a_%logit_1.0  better_%logit_2.0  understanding_%logit_2.0  of_%logit_1.0  the_%logit_2.0  mechanisms_%logit_0.0  by_%logit_2.0  which_%logit_1.0  this_%logit_2.0  treatment_%logit_0.0  works_%logit_0.0 ._%logit_1.0  They_%logit_2.0  should_%logit_0.0  also_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  hyd_%logit_2.0 oc_%logit_2.0 ort_%logit_0.0 is_%logit_2.0 ones_%logit_2.0  in_%logit_1.0  the_%logit_0.0  management_%logit_1.0  of_%logit_2.0  tender_%logit_0.0 ness_%logit_2.0 ,_%logit_0.0  pain_%logit_2.0 ,_%logit_1.0  fatigue_%logit_2.0 ,_%logit_2.0  thirst_%logit_1.0 ,_%logit_2.0  fatigue_%logit_2.0  and_%logit_2.0  fatigue_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  acupuncture_%logit_0.0  for_%logit_0.0  pain_%logit_1.0  relief_%logit_1.0  in_%logit_1.0  women_%logit_0.0  with_%logit_0.0  pelvic_%logit_0.0  pain_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  acupuncture_%logit_1.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_1.0  pelvic_%logit_0.0  pain_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  acupuncture_%logit_0.0  with_%logit_1.0  other_%logit_1.0  treatments_%logit_2.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  pain_%logit_0.0  relief_%logit_0.0  for_%logit_0.0  women_%logit_1.0  with_%logit_1.0  chronic_%logit_2.0  pain_%logit_1.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  a_%logit_0.0  comparison_%logit_0.0  of_%logit_0.0  acupuncture_%logit_0.0  to_%logit_0.0  other_%logit_0.0  treatments_%logit_0.0  for_%logit_0.0  pelvic_%logit_1.0  pain_%logit_2.0  relief_%logit_0.0 ._%logit_1.0  Finally_%logit_2.0  there_%logit_0.0  is_%logit_2.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_0.0  for_%logit_1.0  an_%logit_1.0  assessment_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  on_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_0.0  satisfaction_%logit_2.0  with_%logit_0.0  pain_%logit_1.0  relief_%logit_1.0  and_%logit_1.0  satisfaction_%logit_1.0  with_%logit_0.0  satisfaction_%logit_0.0  with_%logit_1.0  analges_%logit_0.0 ia_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_2.0  antioxidant_%logit_1.0  supplements_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_2.0  ALS_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_1.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_2.0  antioxidant_%logit_1.0  supplements_%logit_0.0  are_%logit_2.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0  for_%logit_0.0  ALS_%logit_2.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_1.0  should_%logit_2.0  be_%logit_0.0  undertaken_%logit_0.0  in_%logit_0.0  the_%logit_2.0  context_%logit_0.0  of_%logit_0.0  a_%logit_2.0  well_%logit_0.0 -_%logit_1.0 defined_%logit_1.0  group_%logit_0.0  of_%logit_1.0  patients_%logit_0.0  who_%logit_1.0  are_%logit_2.0  at_%logit_0.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_0.0  relapse_%logit_0.0  or_%logit_0.0  death_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  those_%logit_1.0  who_%logit_2.0  are_%logit_2.0  unable_%logit_0.0  to_%logit_0.0  tolerate_%logit_0.0  or_%logit_0.0  tolerate_%logit_2.0  antioxidant_%logit_1.0  supplements_%logit_2.0 ._%logit_0.0  They_%logit_0.0  should_%logit_0.0  also_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_0.0  antioxidant_%logit_0.0  supplementation_%logit_0.0  on_%logit_0.0  survival_%logit_2.0  and_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  the_%logit_1.0  impact_%logit_0.0  of_%logit_1.0  antioxidant_%logit_1.0  supplement_%logit_1.0 ing_%logit_2.0  supplements_%logit_2.0  on_%logit_1.0  quality_%logit_2.0  and_%logit_2.0  quantity_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  k_%logit_0.0 ang_%logit_2.0 aroo_%logit_0.0  mother_%logit_2.0  care_%logit_2.0  for_%logit_2.0  reducing_%logit_0.0  mortality_%logit_2.0  or_%logit_2.0  morbid_%logit_1.0 ity_%logit_1.0  in_%logit_0.0  infants_%logit_0.0  admitted_%logit_2.0  to_%logit_2.0  NIC_%logit_2.0 U_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  establish_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  this_%logit_0.0  intervention_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  mortality_%logit_1.0 ,_%logit_0.0  morbid_%logit_2.0 ity_%logit_0.0  and_%logit_1.0  morbid_%logit_2.0 ity_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  this_%logit_2.0  approach_%logit_1.0  in_%logit_0.0  improving_%logit_2.0  quality_%logit_0.0  of_%logit_2.0  life_%logit_0.0  and_%logit_2.0  reducing_%logit_2.0  morbid_%logit_0.0 ity_%logit_0.0  or_%logit_0.0  mortality_%logit_1.0  in_%logit_1.0  neon_%logit_2.0 ates_%logit_1.0  admitted_%logit_0.0  to_%logit_0.0  IC_%logit_0.0 U_%logit_0.0 ._%logit_1.0  Recommend_%logit_2.0 ations_%logit_2.0  for_%logit_0.0  future_%logit_0.0  research_%logit_2.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  are_%logit_2.0  recommendations_%logit_0.0  to_%logit_0.0  improve_%logit_0.0  the_%logit_2.0  quality_%logit_0.0  and_%logit_0.0  quantity_%logit_0.0  of_%logit_1.0  research_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  testosterone_%logit_0.0  supplementation_%logit_0.0  for_%logit_2.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  hair_%logit_0.0  loss_%logit_0.0  or_%logit_1.0  hair_%logit_1.0  loss_%logit_2.0  in_%logit_0.0  men_%logit_0.0 opausal_%logit_0.0  women_%logit_1.0  with_%logit_1.0  HD_%logit_0.0 H_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  dosage_%logit_1.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  testosterone_%logit_2.0  therapy_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  testosterone_%logit_1.0  supplementation_%logit_1.0  with_%logit_0.0  other_%logit_0.0  hormonal_%logit_0.0  therapies_%logit_2.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_1.0  prog_%logit_0.0 est_%logit_2.0 ogens_%logit_0.0 ,_%logit_0.0  prog_%logit_0.0 est_%logit_1.0 ogen_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  est_%logit_1.0 rogens_%logit_2.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_1.0  estrogen_%logit_1.0  supplementation_%logit_1.0  on_%logit_2.0  hair_%logit_1.0  loss_%logit_1.0  and_%logit_2.0  hair_%logit_0.0  loss_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_0.0 ,_%logit_0.0  duration_%logit_2.0  and_%logit_2.0  frequency_%logit_1.0  of_%logit_2.0  testosterone_%logit_0.0  treatment_%logit_0.0 ,_%logit_2.0  a_%logit_1.0  meta_%logit_1.0 -_%logit_1.0 analysis_%logit_0.0  is_%logit_0.0  required_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_2.0  testosterone_%logit_0.0  supplementation_%logit_0.0  is_%logit_1.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  lev_%logit_1.0 od_%logit_1.0 opa_%logit_2.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_1.0  Parkinson_%logit_0.0 's_%logit_1.0  disease_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_2.0  and_%logit_1.0  timing_%logit_0.0  of_%logit_2.0  treatment_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  optimal_%logit_1.0  dosage_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  treatment_%logit_2.0 ._%logit_2.0  In_%logit_2.0  addition_%logit_2.0 ,_%logit_2.0  future_%logit_1.0  trials_%logit_0.0  should_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  this_%logit_2.0  therapy_%logit_2.0  in_%logit_2.0  particular_%logit_2.0  for_%logit_1.0  motor_%logit_2.0  impair_%logit_1.0 ments_%logit_2.0  and_%logit_2.0  impaired_%logit_1.0  function_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  other_%logit_0.0  treatments_%logit_0.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_1.0  prost_%logit_0.0 ag_%logit_1.0 land_%logit_2.0 ins_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  for_%logit_0.0  improving_%logit_1.0  motor_%logit_1.0  function_%logit_1.0  in_%logit_0.0  people_%logit_1.0  with_%logit_1.0  early_%logit_1.0  PD_%logit_1.0 ._%logit_0.0
 Ant_%logit_0.0 ip_%logit_1.0 y_%logit_1.0 ret_%logit_0.0 ic_%logit_0.0  drugs_%logit_0.0  are_%logit_0.0  effective_%logit_2.0  in_%logit_2.0  reducing_%logit_1.0  fever_%logit_0.0  severity_%logit_0.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_2.0  treatment_%logit_1.0 ,_%logit_0.0  but_%logit_2.0  there_%logit_1.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_0.0  recommend_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  these_%logit_1.0  drugs_%logit_2.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  fever_%logit_0.0 ish_%logit_0.0  children_%logit_0.0  with_%logit_0.0  malaria_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_1.0  these_%logit_1.0  medications_%logit_0.0  on_%logit_0.0  fever_%logit_2.0  severity_%logit_2.0 ,_%logit_0.0  duration_%logit_2.0  and_%logit_0.0  severity_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  these_%logit_0.0  treatments_%logit_1.0  in_%logit_2.0  reducing_%logit_0.0  temperature_%logit_1.0  severity_%logit_1.0  and_%logit_2.0  severity_%logit_2.0  of_%logit_0.0  fever_%logit_1.0  severity_%logit_1.0  in_%logit_2.0  children_%logit_1.0  with_%logit_2.0  acute_%logit_1.0  malaria_%logit_1.0  and_%logit_2.0  in_%logit_2.0  children_%logit_0.0  younger_%logit_2.0  than_%logit_2.0  two_%logit_2.0  years_%logit_0.0  of_%logit_0.0  age_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  antibiotics_%logit_0.0  in_%logit_0.0  the_%logit_1.0  erad_%logit_1.0 ication_%logit_0.0  of_%logit_0.0  H_%logit_0.0 ._%logit_0.0  p_%logit_0.0 yl_%logit_0.0 ori_%logit_0.0  infection_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_0.0  antibiotics_%logit_0.0  are_%logit_1.0  beneficial_%logit_0.0  or_%logit_1.0  harmful_%logit_2.0  for_%logit_2.0  H_%logit_2.0 ._%logit_2.0 p_%logit_1.0 yl_%logit_1.0 ori_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  whether_%logit_2.0  they_%logit_2.0  should_%logit_2.0  be_%logit_1.0  used_%logit_1.0  in_%logit_0.0  combination_%logit_2.0  with_%logit_0.0  other_%logit_0.0  antim_%logit_1.0 icro_%logit_0.0 b_%logit_1.0 ials_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_1.0  with_%logit_0.0  other_%logit_1.0  antibiotics_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  antibiotics_%logit_1.0  for_%logit_2.0  this_%logit_2.0  condition_%logit_1.0 ._%logit_0.0  These_%logit_0.0  trials_%logit_0.0  should_%logit_2.0  be_%logit_0.0  of_%logit_2.0  sufficient_%logit_1.0  size_%logit_1.0  and_%logit_1.0  duration_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  antibiotic_%logit_1.0  treatment_%logit_1.0  to_%logit_0.0  other_%logit_2.0  antibiotics_%logit_0.0  in_%logit_1.0  this_%logit_0.0  condition_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  also_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  antibiotics_%logit_0.0  with_%logit_0.0  each_%logit_0.0  other_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  silicone_%logit_2.0  plugs_%logit_2.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  pain_%logit_0.0  relief_%logit_0.0  in_%logit_1.0  people_%logit_1.0  with_%logit_2.0  T_%logit_2.0 MC_%logit_2.0  O_%logit_0.0 A_%logit_1.0 ._%logit_1.0  There_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_2.0  for_%logit_1.0  further_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_0.0 ,_%logit_1.0  well_%logit_0.0 -_%logit_0.0 conduct_%logit_0.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_0.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  silicone_%logit_0.0  plug_%logit_2.0  plugs_%logit_0.0  in_%logit_2.0  pain_%logit_0.0  relief_%logit_0.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_2.0  of_%logit_1.0  sufficient_%logit_0.0  size_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  silicone_%logit_2.0  plugs_%logit_0.0  with_%logit_0.0  silicone_%logit_0.0  plugs_%logit_1.0 ._%logit_1.0  They_%logit_0.0  should_%logit_1.0  also_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_1.0  silicone_%logit_2.0  pads_%logit_0.0  on_%logit_0.0  pain_%logit_0.0  relief_%logit_0.0  and_%logit_0.0  function_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  on_%logit_0.0  function_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_1.0  of_%logit_1.0  a_%logit_0.0  protective_%logit_1.0  mechanism_%logit_1.0  for_%logit_2.0  reducing_%logit_0.0  mortality_%logit_0.0  and_%logit_2.0  morbid_%logit_1.0 ity_%logit_1.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  advanced_%logit_2.0  disease_%logit_0.0  who_%logit_0.0  have_%logit_2.0  been_%logit_2.0  treated_%logit_1.0  with_%logit_0.0  cis_%logit_1.0 pl_%logit_0.0 atin_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  this_%logit_1.0  strategy_%logit_1.0  in_%logit_2.0  this_%logit_2.0  population_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  it_%logit_0.0  with_%logit_1.0  other_%logit_1.0  methods_%logit_1.0  of_%logit_1.0  treating_%logit_1.0  advanced_%logit_1.0  disease_%logit_0.0  and_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_0.0  it_%logit_1.0  has_%logit_1.0  a_%logit_1.0  protective_%logit_0.0  effect_%logit_1.0  on_%logit_0.0  survival_%logit_0.0  or_%logit_0.0  morbid_%logit_2.0 ity_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_1.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_2.0  assessing_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  these_%logit_1.0  methods_%logit_0.0  of_%logit_2.0  treatment_%logit_1.0  in_%logit_2.0  advanced_%logit_0.0  disease_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_1.0  orth_%logit_0.0 op_%logit_1.0 aed_%logit_0.0 ic_%logit_2.0  footwear_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  foot_%logit_2.0  pain_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_2.0  footwear_%logit_2.0  for_%logit_2.0  this_%logit_1.0  condition_%logit_2.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  various_%logit_1.0  types_%logit_2.0  of_%logit_1.0  footwear_%logit_1.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_1.0  comfort_%logit_0.0 ,_%logit_2.0  comfort_%logit_1.0  and_%logit_1.0  comfort_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  studies_%logit_0.0  are_%logit_1.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  durability_%logit_2.0  of_%logit_0.0  orth_%logit_0.0 oped_%logit_0.0 ic_%logit_2.0  footwear_%logit_1.0  for_%logit_0.0  pain_%logit_0.0  relief_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_1.0  a_%logit_0.0  chronic_%logit_1.0  condition_%logit_2.0  such_%logit_0.0  as_%logit_0.0  Achilles_%logit_2.0  tendon_%logit_0.0 itis_%logit_2.0  and_%logit_0.0  fib_%logit_2.0 romy_%logit_0.0 algia_%logit_2.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  footwear_%logit_0.0  with_%logit_1.0  other_%logit_2.0  types_%logit_1.0  of_%logit_0.0  shoes_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  prog_%logit_1.0 est_%logit_1.0 ogen_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  premature_%logit_0.0  l_%logit_0.0 ute_%logit_0.0 al_%logit_0.0  eff_%logit_0.0 usion_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_0.0  prog_%logit_0.0 est_%logit_0.0 ogens_%logit_0.0  are_%logit_1.0  beneficial_%logit_2.0  or_%logit_0.0  harmful_%logit_0.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_2.0  should_%logit_1.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_0.0  the_%logit_1.0  absence_%logit_1.0  of_%logit_2.0  a_%logit_1.0  clear_%logit_1.0  indication_%logit_2.0  of_%logit_1.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  prog_%logit_1.0 ester_%logit_0.0 one_%logit_2.0  in_%logit_0.0  this_%logit_1.0  population_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  also_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  hyd_%logit_2.0 est_%logit_1.0 ogen_%logit_2.0  for_%logit_0.0  premature_%logit_1.0  L_%logit_0.0 ute_%logit_0.0 al_%logit_2.0  F_%logit_0.0 usion_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  its_%logit_1.0  safety_%logit_2.0  and_%logit_2.0  effectiveness_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  infrared_%logit_2.0  phot_%logit_2.0 oco_%logit_0.0 ag_%logit_0.0 ulation_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  chronic_%logit_1.0  pain_%logit_2.0  syndrome_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_2.0  method_%logit_0.0  of_%logit_2.0  treatment_%logit_2.0  for_%logit_0.0  pain_%logit_0.0  relief_%logit_1.0  in_%logit_1.0  people_%logit_2.0  with_%logit_1.0  C_%logit_1.0 TS_%logit_1.0 ._%logit_0.0  It_%logit_0.0  is_%logit_0.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_1.0  these_%logit_2.0  results_%logit_0.0  are_%logit_1.0  translated_%logit_2.0  to_%logit_0.0  other_%logit_1.0  chronic_%logit_0.0  pain_%logit_1.0  disorders_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  infrared_%logit_2.0  Phot_%logit_0.0 oco_%logit_0.0 ag_%logit_0.0 ulating_%logit_1.0  for_%logit_2.0  chronic_%logit_2.0  pain_%logit_2.0  relief_%logit_0.0  of_%logit_0.0  C_%logit_1.0 TS_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_1.0  and_%logit_0.0  efficacy_%logit_2.0  of_%logit_1.0  infrared_%logit_2.0  optics_%logit_1.0  for_%logit_1.0  other_%logit_1.0  types_%logit_1.0  of_%logit_0.0  pain_%logit_0.0  relief_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_1.0  ib_%logit_0.0 up_%logit_1.0 ro_%logit_0.0 fen_%logit_0.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  active_%logit_2.0  Cro_%logit_1.0 hn_%logit_0.0 's_%logit_1.0  disease_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_1.0  controlled_%logit_2.0  trials_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  confirm_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  ib_%logit_1.0 ip_%logit_1.0 ro_%logit_0.0 fen_%logit_1.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_1.0  other_%logit_2.0  treatments_%logit_0.0  in_%logit_2.0  the_%logit_2.0  management_%logit_0.0  of_%logit_1.0  these_%logit_1.0  patients_%logit_0.0 ._%logit_2.0  Such_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_2.0  undertaken_%logit_0.0  in_%logit_0.0  the_%logit_2.0  context_%logit_1.0  of_%logit_0.0  a_%logit_1.0  well_%logit_0.0 -_%logit_0.0 defined_%logit_0.0  set_%logit_0.0  of_%logit_1.0  patients_%logit_0.0  who_%logit_0.0  are_%logit_0.0  in_%logit_0.0  need_%logit_2.0  of_%logit_1.0  treatment_%logit_1.0 ._%logit_1.0  They_%logit_1.0  should_%logit_0.0  also_%logit_1.0  include_%logit_1.0  patients_%logit_1.0  with_%logit_1.0  severe_%logit_0.0  disease_%logit_1.0  who_%logit_2.0  are_%logit_2.0  at_%logit_1.0  high_%logit_2.0  risk_%logit_0.0  of_%logit_0.0  relapse_%logit_0.0  and_%logit_1.0  those_%logit_1.0  who_%logit_0.0  are_%logit_1.0  unable_%logit_0.0  to_%logit_0.0  tolerate_%logit_0.0  the_%logit_0.0  drug_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  electro_%logit_0.0 stim_%logit_1.0 ulation_%logit_1.0  as_%logit_0.0  a_%logit_2.0  method_%logit_0.0  of_%logit_2.0  resusc_%logit_1.0 itation_%logit_0.0  in_%logit_0.0  the_%logit_0.0  resusc_%logit_0.0 itation_%logit_2.0  of_%logit_2.0  patients_%logit_0.0  with_%logit_0.0  R_%logit_0.0 OS_%logit_2.0 C_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  best_%logit_0.0  electro_%logit_0.0 stim_%logit_0.0 ulating_%logit_2.0  agent_%logit_2.0  for_%logit_0.0  resusc_%logit_1.0 itation_%logit_1.0  and_%logit_0.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_0.0  effectiveness_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  cardiac_%logit_2.0  arrest_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  its_%logit_0.0  role_%logit_0.0  in_%logit_0.0  other_%logit_0.0  resusc_%logit_0.0 itation_%logit_0.0  procedures_%logit_2.0 ._%logit_0.0  It_%logit_2.0  is_%logit_2.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_1.0  in_%logit_0.0  this_%logit_0.0  area_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_1.0  electro_%logit_1.0 im_%logit_0.0 aging_%logit_1.0  on_%logit_2.0  survival_%logit_1.0  and_%logit_0.0  neurological_%logit_0.0  function_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  who_%logit_2.0  have_%logit_1.0  been_%logit_0.0  discharged_%logit_1.0  from_%logit_2.0  hospital_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  correlation_%logit_1.0  between_%logit_1.0  ov_%logit_1.0 ulation_%logit_1.0  and_%logit_2.0  pregnancy_%logit_0.0  rates_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_1.0  effect_%logit_1.0  of_%logit_2.0  ov_%logit_2.0 ulation_%logit_0.0  on_%logit_0.0  pregnancy_%logit_0.0  rates_%logit_0.0  and_%logit_2.0  fertility_%logit_2.0  rates_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  ov_%logit_1.0 ulation_%logit_1.0  with_%logit_1.0  other_%logit_0.0  methods_%logit_0.0  of_%logit_0.0  fertility_%logit_0.0  management_%logit_0.0 ,_%logit_1.0  such_%logit_1.0  as_%logit_1.0  oxy_%logit_1.0 toc_%logit_2.0 in_%logit_0.0 ,_%logit_0.0  prog_%logit_0.0 est_%logit_1.0 ogen_%logit_2.0 ,_%logit_2.0  prog_%logit_2.0 ester_%logit_2.0 one_%logit_1.0  or_%logit_1.0  prog_%logit_2.0 est_%logit_0.0 ogens_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  other_%logit_2.0  fertility_%logit_2.0  management_%logit_2.0  strategies_%logit_2.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_2.0  ov_%logit_2.0 ulation_%logit_2.0  rates_%logit_1.0  are_%logit_2.0  related_%logit_1.0  to_%logit_0.0  fertility_%logit_1.0  management_%logit_1.0  and_%logit_2.0  fertility_%logit_1.0  outcomes_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  how_%logit_2.0  to_%logit_0.0  tailor_%logit_1.0  ov_%logit_2.0 ulation_%logit_1.0  to_%logit_2.0  the_%logit_0.0  needs_%logit_1.0  of_%logit_2.0  the_%logit_0.0  population_%logit_0.0 ._%logit_1.0
 Functional_%logit_0.0  status_%logit_2.0  and_%logit_0.0  functional_%logit_0.0  status_%logit_1.0  of_%logit_0.0  the_%logit_2.0  foot_%logit_1.0  are_%logit_0.0  the_%logit_2.0  most_%logit_0.0  important_%logit_1.0  determin_%logit_1.0 ants_%logit_0.0  of_%logit_2.0  pain_%logit_1.0  relief_%logit_1.0  for_%logit_2.0  people_%logit_0.0  with_%logit_1.0  functional_%logit_1.0  impair_%logit_1.0 ments_%logit_2.0  in_%logit_1.0  footwear_%logit_0.0 ._%logit_1.0  Functional_%logit_2.0  status_%logit_0.0 ,_%logit_0.0  functional_%logit_0.0  status_%logit_1.0 ,_%logit_0.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_1.0  and_%logit_0.0  satisfaction_%logit_0.0  with_%logit_1.0  pain_%logit_2.0  relief_%logit_0.0  are_%logit_0.0  also_%logit_0.0  important_%logit_0.0  indicators_%logit_0.0  of_%logit_0.0  improvement_%logit_0.0  in_%logit_0.0  functional_%logit_1.0  status_%logit_2.0 ._%logit_1.0  Pain_%logit_0.0  relief_%logit_1.0  is_%logit_0.0  also_%logit_0.0  associated_%logit_0.0  with_%logit_0.0  improvement_%logit_0.0  in_%logit_0.0  function_%logit_1.0 ,_%logit_2.0  pain_%logit_1.0  intensity_%logit_1.0  and_%logit_2.0  function_%logit_1.0  in_%logit_0.0  the_%logit_0.0  upper_%logit_2.0  limb_%logit_2.0 ._%logit_0.0  Pain_%logit_2.0  intensity_%logit_2.0  is_%logit_2.0  also_%logit_1.0  significantly_%logit_2.0  reduced_%logit_2.0  in_%logit_0.0  the_%logit_0.0  lower_%logit_1.0  limb_%logit_1.0 ,_%logit_2.0  but_%logit_2.0  there_%logit_1.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_1.0  recommend_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  functional_%logit_0.0  status_%logit_2.0  or_%logit_0.0  functional_%logit_1.0  status_%logit_0.0  in_%logit_0.0  footwear_%logit_0.0  or_%logit_2.0  footwear_%logit_1.0 ._%logit_0.0  Pain_%logit_1.0  severity_%logit_0.0  and_%logit_0.0  function_%logit_1.0  are_%logit_1.0  also_%logit_0.0  significantly_%logit_0.0  improved_%logit_1.0  in_%logit_0.0  footwear_%logit_0.0  and_%logit_0.0  footwear_%logit_1.0  compared_%logit_0.0  to_%logit_1.0  no_%logit_1.0  treatment_%logit_1.0 ._%logit_1.0  Pain_%logit_2.0  duration_%logit_2.0  and_%logit_0.0  severity_%logit_2.0  are_%logit_0.0  also_%logit_0.0  improved_%logit_1.0  in_%logit_0.0  shoes_%logit_2.0  and_%logit_1.0  shoes_%logit_0.0  compared_%logit_0.0  with_%logit_1.0  no_%logit_1.0  treatment_%logit_0.0  or_%logit_2.0  no_%logit_1.0  treatment_%logit_1.0  compared_%logit_2.0  to_%logit_0.0  other_%logit_0.0  types_%logit_0.0  of_%logit_0.0  footwear_%logit_0.0  or_%logit_1.0  shoes_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  this_%logit_2.0  is_%logit_2.0  based_%logit_2.0  on_%logit_0.0  a_%logit_0.0  very_%logit_0.0  small_%logit_0.0  number_%logit_2.0  of_%logit_1.0  studies_%logit_0.0  with_%logit_1.0  short_%logit_2.0  term_%logit_2.0  follow_%logit_1.0 -_%logit_2.0 up_%logit_2.0  and_%logit_2.0  a_%logit_0.0  very_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_1.0  in_%logit_0.0  many_%logit_1.0  of_%logit_1.0  the_%logit_2.0  studies_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_2.0  of_%logit_2.0  epid_%logit_0.0 ural_%logit_2.0  analges_%logit_2.0 ia_%logit_0.0  for_%logit_0.0  ca_%logit_0.0 es_%logit_1.0 are_%logit_0.0 an_%logit_0.0  section_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  epid_%logit_0.0 ur_%logit_0.0 als_%logit_0.0  in_%logit_0.0  this_%logit_2.0  population_%logit_1.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  maternal_%logit_0.0  satisfaction_%logit_2.0  with_%logit_0.0  labour_%logit_1.0  management_%logit_1.0 ,_%logit_0.0  maternal_%logit_2.0  satisfaction_%logit_1.0  and_%logit_1.0  satisfaction_%logit_2.0  with_%logit_2.0  childbirth_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_2.0 analysis_%logit_1.0  of_%logit_0.0  maternal_%logit_0.0  satisfaction_%logit_0.0 ,_%logit_0.0  satisfaction_%logit_2.0  with_%logit_1.0  labor_%logit_2.0  management_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  maternal_%logit_1.0  and_%logit_1.0  neon_%logit_0.0 atal_%logit_2.0  outcomes_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  epid_%logit_0.0 ural_%logit_0.0  pain_%logit_2.0  management_%logit_0.0  with_%logit_2.0  other_%logit_1.0  methods_%logit_1.0  of_%logit_0.0  labour_%logit_1.0  management_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  ep_%logit_0.0 ine_%logit_2.0 phrine_%logit_2.0  injection_%logit_1.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_0.0  end_%logit_1.0 omet_%logit_2.0 ritis_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_2.0  way_%logit_1.0  to_%logit_2.0  administer_%logit_1.0  ep_%logit_0.0 oxy_%logit_2.0 cl_%logit_0.0 av_%logit_2.0 ul_%logit_2.0 opl_%logit_1.0 asty_%logit_0.0 ,_%logit_1.0  the_%logit_0.0  best_%logit_1.0  route_%logit_0.0  of_%logit_1.0  administration_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_0.0  most_%logit_0.0  effective_%logit_0.0  way_%logit_2.0  to_%logit_0.0  treat_%logit_0.0  end_%logit_2.0 omet_%logit_0.0 ri_%logit_0.0 osis_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  trials_%logit_2.0  are_%logit_0.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  intra_%logit_1.0 uter_%logit_1.0 ine_%logit_1.0  injection_%logit_2.0  for_%logit_2.0  end_%logit_0.0 omet_%logit_0.0 rial_%logit_0.0  carcin_%logit_0.0 oma_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  ep_%logit_2.0 ip_%logit_0.0 hy_%logit_0.0 tic_%logit_1.0  injection_%logit_0.0  with_%logit_2.0  other_%logit_1.0  forms_%logit_2.0  of_%logit_0.0  ep_%logit_2.0 icy_%logit_2.0 cl_%logit_0.0 ic_%logit_0.0  therapy_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  relaxation_%logit_1.0  exercises_%logit_1.0  for_%logit_2.0  relaxation_%logit_1.0  exercises_%logit_2.0  in_%logit_2.0  pain_%logit_0.0  relief_%logit_0.0  or_%logit_2.0  relaxation_%logit_0.0  during_%logit_2.0  relaxation_%logit_0.0  exercises_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  relaxation_%logit_2.0  exercises_%logit_1.0  and_%logit_0.0  relaxation_%logit_2.0  exercises_%logit_0.0  during_%logit_0.0  relaxation_%logit_2.0  exercise_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  relaxation_%logit_1.0  exercises_%logit_1.0  with_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_2.0 ,_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_1.0  or_%logit_1.0  relaxation_%logit_1.0  exercises_%logit_0.0  alone_%logit_0.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_1.0  should_%logit_1.0  evaluate_%logit_0.0  relaxation_%logit_2.0  exercises_%logit_1.0  as_%logit_1.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_2.0  after_%logit_0.0  relaxation_%logit_0.0  exercises_%logit_0.0  have_%logit_2.0  been_%logit_2.0  completed_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  should_%logit_0.0  include_%logit_0.0  measures_%logit_1.0  of_%logit_1.0  relaxation_%logit_1.0  relaxation_%logit_0.0  and_%logit_0.0  relaxation_%logit_0.0  in_%logit_1.0  relaxation_%logit_1.0  exercises_%logit_0.0  (_%logit_1.0 including_%logit_1.0  relaxation_%logit_1.0  exercises_%logit_2.0 )._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  prog_%logit_0.0 ester_%logit_2.0 one_%logit_0.0  for_%logit_2.0  o_%logit_2.0 ocyte_%logit_2.0  retrieval_%logit_0.0  in_%logit_0.0  vitro_%logit_0.0  fertil_%logit_0.0 isation_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_0.0  and_%logit_1.0  duration_%logit_1.0  of_%logit_2.0  prog_%logit_1.0 est_%logit_1.0 ogen_%logit_1.0  therapy_%logit_1.0 ,_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  dosage_%logit_0.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_2.0  hyd_%logit_1.0 raz_%logit_0.0 ole_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  the_%logit_1.0  optimal_%logit_2.0  timing_%logit_0.0  of_%logit_2.0  administration_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_2.0  a_%logit_2.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  investigation_%logit_0.0  of_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  prog_%logit_0.0 oster_%logit_1.0 oids_%logit_2.0  for_%logit_0.0  o_%logit_2.0 ocytes_%logit_2.0  retrieved_%logit_2.0  from_%logit_2.0  vitro_%logit_0.0  fertil_%logit_1.0 ization_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_0.0  of_%logit_2.0  these_%logit_0.0  drugs_%logit_0.0  in_%logit_1.0  the_%logit_2.0  management_%logit_1.0  of_%logit_2.0  o_%logit_0.0 ocytes_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  intra_%logit_0.0 uter_%logit_2.0 ine_%logit_0.0  exc_%logit_0.0 ision_%logit_1.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_0.0  S_%logit_0.0 PC_%logit_1.0 TB_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  exc_%logit_2.0 ision_%logit_0.0  for_%logit_0.0  S_%logit_1.0 PC_%logit_1.0 B_%logit_0.0  in_%logit_2.0  women_%logit_2.0  with_%logit_1.0  P_%logit_2.0 TL_%logit_0.0 ._%logit_1.0  It_%logit_1.0  is_%logit_0.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_2.0  mechanisms_%logit_1.0  by_%logit_0.0  which_%logit_0.0  exc_%logit_0.0 ision_%logit_0.0  may_%logit_0.0  be_%logit_1.0  performed_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  how_%logit_1.0  the_%logit_2.0  exc_%logit_1.0 ision_%logit_2.0  process_%logit_1.0  works_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  mechanism_%logit_0.0  by_%logit_0.0  which_%logit_1.0  it_%logit_0.0  may_%logit_1.0  be_%logit_1.0  done_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_0.0  timing_%logit_0.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_2.0  rec_%logit_1.0 urrence_%logit_1.0  and_%logit_1.0  duration_%logit_0.0  of_%logit_2.0  the_%logit_2.0  rec_%logit_0.0 urrence_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  phot_%logit_1.0 oco_%logit_2.0 ag_%logit_1.0 ulation_%logit_2.0  in_%logit_0.0  my_%logit_0.0 opia_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  phot_%logit_0.0 oco_%logit_0.0 agg_%logit_2.0 ulation_%logit_2.0  technique_%logit_1.0 ,_%logit_1.0  the_%logit_2.0  best_%logit_2.0  way_%logit_1.0  to_%logit_0.0  achieve_%logit_1.0  this_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_1.0  most_%logit_1.0  effective_%logit_1.0  way_%logit_0.0  to_%logit_0.0  minim_%logit_1.0 ise_%logit_2.0  the_%logit_2.0  risk_%logit_0.0  of_%logit_0.0  bias_%logit_0.0  in_%logit_0.0  this_%logit_1.0  review_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  phot_%logit_2.0 oc_%logit_0.0 ag_%logit_2.0 ulation_%logit_2.0  for_%logit_1.0  my_%logit_1.0 opia_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_2.0  approaches_%logit_0.0  to_%logit_2.0  other_%logit_0.0  methods_%logit_2.0  of_%logit_1.0  optical_%logit_2.0  manipulation_%logit_0.0 ,_%logit_0.0  such_%logit_2.0  as_%logit_0.0  bin_%logit_1.0 ocular_%logit_1.0  tom_%logit_2.0 ography_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  az_%logit_0.0 ath_%logit_1.0 iop_%logit_0.0 rine_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_1.0  am_%logit_1.0 pic_%logit_1.0 illin_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_1.0  people_%logit_2.0  with_%logit_0.0  malaria_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_0.0  am_%logit_1.0 ic_%logit_1.0 illin_%logit_0.0 ,_%logit_0.0  the_%logit_1.0  optimal_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  antibiotic_%logit_1.0  therapy_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  dosage_%logit_1.0  and_%logit_0.0  timing_%logit_0.0  of_%logit_2.0  therapy_%logit_2.0 ._%logit_2.0  In_%logit_2.0  addition_%logit_2.0 ,_%logit_2.0  future_%logit_1.0  trials_%logit_0.0  should_%logit_2.0  evaluate_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_0.0  these_%logit_0.0  drugs_%logit_1.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  duration_%logit_1.0  of_%logit_0.0  treatment_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  these_%logit_1.0  drugs_%logit_1.0  with_%logit_2.0  each_%logit_2.0  other_%logit_2.0  in_%logit_2.0  terms_%logit_0.0  of_%logit_1.0  efficacy_%logit_0.0 ,_%logit_0.0  safety_%logit_0.0  and_%logit_2.0  efficacy_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_1.0  mechanism_%logit_1.0  by_%logit_1.0  which_%logit_0.0  healthcare_%logit_1.0  professionals_%logit_0.0  can_%logit_1.0  improve_%logit_2.0  the_%logit_0.0  quality_%logit_1.0  of_%logit_1.0  healthcare_%logit_2.0  services_%logit_0.0  provided_%logit_1.0  to_%logit_0.0  patients_%logit_2.0  in_%logit_2.0  hospital_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  this_%logit_1.0  mechanism_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  its_%logit_0.0  effectiveness_%logit_0.0  in_%logit_1.0  terms_%logit_2.0  of_%logit_1.0  reducing_%logit_1.0  mortality_%logit_1.0  and_%logit_0.0  health_%logit_0.0  service_%logit_0.0  utilization_%logit_0.0 ,_%logit_1.0  improving_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0  and_%logit_0.0  reducing_%logit_1.0  costs_%logit_1.0  of_%logit_2.0  care_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  improving_%logit_2.0  access_%logit_2.0  to_%logit_0.0  care_%logit_1.0 ._%logit_0.0  It_%logit_0.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_2.0  mechanisms_%logit_2.0  by_%logit_0.0  which_%logit_0.0  this_%logit_0.0  can_%logit_0.0  be_%logit_1.0  achieved_%logit_2.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  how_%logit_2.0  it_%logit_0.0  relates_%logit_1.0  to_%logit_1.0  costs_%logit_2.0  and_%logit_0.0  availability_%logit_0.0  of_%logit_0.0  services_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  b_%logit_0.0 ic_%logit_0.0 arbon_%logit_1.0 ate_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_0.0  local_%logit_2.0  ana_%logit_1.0 esthetic_%logit_0.0  therapy_%logit_0.0  for_%logit_1.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  pain_%logit_1.0  relief_%logit_2.0  in_%logit_0.0  patients_%logit_1.0  undergoing_%logit_2.0  surgery_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  b_%logit_0.0 ac_%logit_2.0 arbon_%logit_2.0 ate_%logit_0.0  for_%logit_1.0  pain_%logit_1.0  relief_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  other_%logit_1.0  types_%logit_0.0  of_%logit_2.0  ana_%logit_1.0 esthesia_%logit_0.0  in_%logit_1.0  pain_%logit_1.0  relief_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_1.0 exec_%logit_1.0 uted_%logit_1.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_1.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_0.0  B_%logit_0.0 OC_%logit_0.0 s_%logit_0.0  in_%logit_2.0  this_%logit_2.0  population_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  pro_%logit_0.0 ph_%logit_2.0 yl_%logit_0.0 actic_%logit_0.0  antibiotics_%logit_0.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  CON_%logit_0.0 S_%logit_0.0  bacter_%logit_0.0 a_%logit_0.0 emia_%logit_2.0 ._%logit_1.0  However_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_2.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  antibiotic_%logit_1.0  therapy_%logit_1.0  in_%logit_2.0  the_%logit_2.0  management_%logit_1.0  of_%logit_2.0  these_%logit_1.0  infections_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  optimal_%logit_1.0  antibiotic_%logit_2.0  regimen_%logit_0.0  and_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  timing_%logit_1.0  and_%logit_2.0  duration_%logit_1.0  of_%logit_1.0  antibiotic_%logit_2.0  administration_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  it_%logit_0.0  is_%logit_0.0  important_%logit_2.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_1.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_1.0  works_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  antibiotic_%logit_2.0  therapy_%logit_1.0  with_%logit_1.0  other_%logit_0.0  methods_%logit_0.0  of_%logit_2.0  pur_%logit_1.0 ifying_%logit_2.0  bacteria_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  mechanical_%logit_2.0  ventilation_%logit_2.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  pneumonia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_0.0  best_%logit_0.0  method_%logit_1.0  of_%logit_1.0  ventilation_%logit_0.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_2.0  pneumonia_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_1.0  mechanical_%logit_2.0  ventilation_%logit_1.0  with_%logit_0.0  other_%logit_0.0  methods_%logit_0.0  of_%logit_2.0  ventilation_%logit_2.0 ,_%logit_2.0  such_%logit_1.0  as_%logit_1.0  mechanical_%logit_1.0  ventilation_%logit_1.0 ,_%logit_0.0  or_%logit_1.0  mechanical_%logit_1.0  ventilation_%logit_2.0  alone_%logit_0.0  or_%logit_1.0  in_%logit_2.0  combination_%logit_2.0  with_%logit_0.0  mechanical_%logit_1.0  ventilation_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_1.0  electro_%logit_0.0 stim_%logit_1.0 ulation_%logit_2.0  therapy_%logit_0.0  in_%logit_1.0  this_%logit_0.0  population_%logit_0.0  of_%logit_2.0  patients_%logit_0.0  who_%logit_1.0  are_%logit_0.0  at_%logit_2.0  high_%logit_1.0  risk_%logit_2.0  of_%logit_1.0  pneumonia_%logit_0.0 ,_%logit_1.0  or_%logit_2.0  who_%logit_1.0  are_%logit_2.0  in_%logit_1.0  need_%logit_0.0  of_%logit_1.0  intensive_%logit_2.0  care_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  antidepressants_%logit_1.0  for_%logit_1.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  depression_%logit_0.0  in_%logit_2.0  people_%logit_2.0  with_%logit_2.0  dy_%logit_0.0 sth_%logit_0.0 ym_%logit_1.0 ia_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_1.0  antidepressant_%logit_2.0  for_%logit_1.0  this_%logit_1.0  condition_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  of_%logit_2.0  antidepressants_%logit_2.0  with_%logit_1.0  other_%logit_1.0  antidepressants_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  antidepressants_%logit_1.0  in_%logit_0.0  the_%logit_0.0  management_%logit_0.0  of_%logit_0.0  depressive_%logit_0.0  disorders_%logit_0.0  in_%logit_2.0  these_%logit_1.0  patients_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  antidepressant_%logit_0.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  antidepressant_%logit_2.0  therapy_%logit_2.0 ,_%logit_1.0  a_%logit_1.0  meta_%logit_2.0 -_%logit_2.0 analysis_%logit_1.0  of_%logit_2.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_0.0  antidepressants_%logit_1.0  is_%logit_2.0  warranted_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  iodine_%logit_1.0  supplementation_%logit_2.0  for_%logit_0.0  iodine_%logit_0.0  deficiency_%logit_2.0  in_%logit_0.0  thyroid_%logit_0.0  gland_%logit_0.0  size_%logit_0.0 ,_%logit_1.0  thyroid_%logit_1.0  volume_%logit_1.0 ,_%logit_1.0  thyroid_%logit_2.0  size_%logit_1.0  or_%logit_0.0  thyroid_%logit_2.0  hormone_%logit_0.0  sensitivity_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  iodine_%logit_1.0  supplementation_%logit_1.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_1.0  for_%logit_2.0  thyroid_%logit_2.0  gland_%logit_2.0  function_%logit_0.0 ,_%logit_0.0  thyroid_%logit_2.0  hormones_%logit_0.0 ,_%logit_1.0  thyroid_%logit_1.0  hormone_%logit_1.0  levels_%logit_0.0  and_%logit_1.0  thyroid_%logit_2.0  hormones_%logit_1.0  in_%logit_0.0  thyroid_%logit_1.0  glands_%logit_1.0 ,_%logit_0.0  thyroid_%logit_0.0  tone_%logit_1.0  and_%logit_1.0  thyroid_%logit_1.0  volume_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  iodine_%logit_0.0  supplements_%logit_1.0  for_%logit_2.0  thyroid_%logit_2.0  hormone_%logit_2.0  deficiency_%logit_0.0 ,_%logit_1.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_2.0  of_%logit_0.0  thyroid_%logit_0.0  hormone_%logit_0.0  concentrations_%logit_2.0  is_%logit_1.0  warranted_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  antibiotics_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  EB_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_0.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_1.0  in_%logit_2.0  EB_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  antibiotic_%logit_0.0  treatment_%logit_1.0  in_%logit_2.0  EB_%logit_2.0 ._%logit_2.0  Such_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_0.0  the_%logit_1.0  context_%logit_1.0  of_%logit_0.0  a_%logit_0.0  well_%logit_1.0 -_%logit_1.0 defined_%logit_1.0  group_%logit_1.0  of_%logit_1.0  patients_%logit_0.0  who_%logit_0.0  are_%logit_1.0  at_%logit_2.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_1.0  EB_%logit_0.0  and_%logit_0.0  those_%logit_0.0  who_%logit_0.0  are_%logit_0.0  unable_%logit_2.0  to_%logit_2.0  tolerate_%logit_0.0  antibiotic_%logit_0.0  treatment_%logit_0.0  or_%logit_1.0  who_%logit_1.0  do_%logit_1.0  not_%logit_0.0  wish_%logit_0.0  to_%logit_0.0  use_%logit_0.0  it_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  acupuncture_%logit_0.0  for_%logit_2.0  EM_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  establish_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  acupuncture_%logit_0.0  in_%logit_1.0  EM_%logit_1.0 ._%logit_1.0  It_%logit_1.0  is_%logit_1.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_2.0  acupuncture_%logit_0.0  works_%logit_0.0  for_%logit_2.0  EM_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  types_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  used_%logit_1.0  and_%logit_1.0  how_%logit_1.0  they_%logit_2.0  are_%logit_0.0  used_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  EM_%logit_2.0 ._%logit_1.0  In_%logit_0.0  addition_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  efficacy_%logit_1.0  of_%logit_0.0  acupuncture_%logit_1.0  on_%logit_0.0  EM_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  gluc_%logit_0.0 oc_%logit_0.0 ort_%logit_1.0 ic_%logit_1.0 oids_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  mild_%logit_0.0  le_%logit_1.0 uk_%logit_2.0 open_%logit_2.0 ia_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_1.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_2.0  and_%logit_0.0  timing_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  gluc_%logit_0.0 ocon_%logit_0.0 ort_%logit_0.0 ic_%logit_0.0 oid_%logit_0.0  therapy_%logit_1.0  in_%logit_0.0  this_%logit_1.0  condition_%logit_0.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  gluc_%logit_0.0 os_%logit_0.0 ort_%logit_2.0 ic_%logit_2.0 oster_%logit_2.0 oids_%logit_0.0  in_%logit_0.0  reducing_%logit_1.0  the_%logit_1.0  risk_%logit_2.0  of_%logit_1.0  adverse_%logit_1.0  events_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_1.0  gluc_%logit_2.0 oco_%logit_0.0 ort_%logit_2.0 ic_%logit_0.0 oidal_%logit_0.0  anti_%logit_1.0 -_%logit_0.0 inflammatory_%logit_0.0  drugs_%logit_0.0  (_%logit_0.0 NSA_%logit_1.0 IDs_%logit_0.0 )_%logit_0.0  in_%logit_0.0  this_%logit_1.0  population_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  selective_%logit_2.0  clamp_%logit_1.0 ing_%logit_1.0  as_%logit_0.0  a_%logit_0.0  means_%logit_2.0  of_%logit_0.0  reducing_%logit_2.0  blood_%logit_2.0  loss_%logit_0.0  during_%logit_0.0  liver_%logit_0.0  tr_%logit_0.0 an_%logit_0.0 section_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  best_%logit_0.0  method_%logit_2.0  of_%logit_0.0  clamp_%logit_2.0 ing_%logit_1.0 ,_%logit_0.0  the_%logit_0.0  best_%logit_1.0  way_%logit_0.0  to_%logit_1.0  minim_%logit_1.0 ise_%logit_0.0  blood_%logit_0.0  loss_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_0.0  best_%logit_0.0  technique_%logit_2.0  for_%logit_1.0  clamp_%logit_1.0 ing_%logit_0.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  an_%logit_0.0  assessment_%logit_0.0  of_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  selective_%logit_1.0  graft_%logit_1.0 ing_%logit_1.0  as_%logit_1.0  an_%logit_1.0  alternative_%logit_1.0  to_%logit_0.0  open_%logit_0.0  clamp_%logit_0.0 ing_%logit_0.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_1.0  reduced_%logit_1.0  blood_%logit_1.0  loss_%logit_1.0  and_%logit_2.0  mortality_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_1.0  this_%logit_2.0  approach_%logit_0.0  to_%logit_0.0  open_%logit_1.0  graft_%logit_1.0 ing_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  antibiotic_%logit_0.0  pro_%logit_2.0 ph_%logit_0.0 yl_%logit_2.0 axis_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  antibiotic_%logit_1.0 -_%logit_2.0 resistant_%logit_1.0  py_%logit_0.0 el_%logit_1.0 one_%logit_2.0 ph_%logit_1.0 ritis_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_2.0  controlled_%logit_1.0  trials_%logit_0.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  confirm_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_1.0  pro_%logit_1.0 ph_%logit_2.0 yle_%logit_1.0 phrine_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  antibiotic_%logit_1.0  usage_%logit_0.0  in_%logit_2.0  this_%logit_2.0  condition_%logit_1.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_1.0  should_%logit_1.0  be_%logit_1.0  undertaken_%logit_1.0  in_%logit_1.0  the_%logit_1.0  context_%logit_1.0  of_%logit_0.0  a_%logit_1.0  large_%logit_0.0  number_%logit_1.0  of_%logit_1.0  cases_%logit_2.0  of_%logit_0.0  antibiotic_%logit_0.0  resistance_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  should_%logit_2.0  be_%logit_0.0  of_%logit_0.0  high_%logit_0.0  methodological_%logit_2.0  quality_%logit_2.0 ._%logit_0.0  They_%logit_1.0  should_%logit_0.0  also_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_0.0  antibiotics_%logit_0.0  on_%logit_2.0  the_%logit_2.0  incidence_%logit_1.0  of_%logit_0.0  adverse_%logit_0.0  events_%logit_0.0 ,_%logit_0.0  such_%logit_2.0  as_%logit_1.0  diarr_%logit_1.0 hoe_%logit_1.0 a_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_0.0  duration_%logit_0.0  of_%logit_1.0  antibiotic_%logit_0.0  treatment_%logit_2.0 ._%logit_1.0
 Sal_%logit_0.0 but_%logit_2.0 am_%logit_1.0 ol_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_1.0  pulmonary_%logit_2.0  emb_%logit_1.0 ol_%logit_2.0 isms_%logit_1.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  acute_%logit_0.0  asthma_%logit_0.0 ._%logit_0.0  It_%logit_1.0  is_%logit_0.0  also_%logit_1.0  associated_%logit_0.0  with_%logit_2.0  a_%logit_2.0  reduction_%logit_0.0  in_%logit_0.0  the_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  pneum_%logit_1.0 oth_%logit_1.0 or_%logit_1.0 ax_%logit_0.0 ,_%logit_0.0  a_%logit_0.0  decreased_%logit_2.0  risk_%logit_1.0  of_%logit_0.0  respiratory_%logit_0.0  distress_%logit_2.0  syndrome_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  an_%logit_0.0  increased_%logit_0.0  risk_%logit_2.0  of_%logit_1.0  hyp_%logit_0.0 ox_%logit_1.0 a_%logit_2.0 emia_%logit_0.0 ._%logit_1.0  However_%logit_2.0 ,_%logit_0.0  these_%logit_1.0  results_%logit_2.0  are_%logit_1.0  based_%logit_1.0  on_%logit_0.0  only_%logit_0.0  a_%logit_0.0  small_%logit_2.0  number_%logit_0.0  of_%logit_2.0  patients_%logit_0.0  and_%logit_2.0  are_%logit_0.0  not_%logit_1.0  representative_%logit_1.0  of_%logit_1.0  the_%logit_0.0  whole_%logit_0.0  range_%logit_1.0  of_%logit_1.0  treatments_%logit_0.0  available_%logit_0.0  in_%logit_0.0  this_%logit_1.0  review_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  dose_%logit_0.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  sal_%logit_0.0 but_%logit_2.0 amn_%logit_1.0 ol_%logit_2.0  and_%logit_0.0  the_%logit_2.0  optimal_%logit_0.0  dosage_%logit_0.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_1.0  sal_%logit_2.0 meter_%logit_0.0 ol_%logit_1.0  and_%logit_0.0  its_%logit_1.0  use_%logit_0.0  in_%logit_1.0  these_%logit_2.0  patients_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  human_%logit_1.0  insulin_%logit_1.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  hyp_%logit_1.0 ogly_%logit_0.0 ca_%logit_0.0 emia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_0.0  optimal_%logit_1.0  insulin_%logit_2.0  dose_%logit_0.0  and_%logit_1.0  duration_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  human_%logit_0.0  ins_%logit_2.0 ul_%logit_0.0 ins_%logit_1.0  in_%logit_0.0  this_%logit_0.0  population_%logit_2.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  animal_%logit_2.0  insulin_%logit_0.0  in_%logit_2.0  reducing_%logit_0.0  blood_%logit_0.0  glucose_%logit_1.0  levels_%logit_2.0  in_%logit_1.0  humans_%logit_2.0  and_%logit_1.0  in_%logit_1.0  developing_%logit_2.0  countries_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  also_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  human_%logit_0.0  insulin_%logit_1.0  with_%logit_0.0  animal_%logit_0.0  insulin_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0  there_%logit_0.0  is_%logit_0.0  an_%logit_0.0  urgent_%logit_1.0  need_%logit_1.0  for_%logit_1.0  research_%logit_1.0  into_%logit_0.0  how_%logit_0.0  human_%logit_2.0  insulin_%logit_0.0  should_%logit_0.0  be_%logit_2.0  used_%logit_0.0  in_%logit_0.0  developing_%logit_0.0  nations_%logit_0.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  in_%logit_0.0  developing_%logit_0.0  regions_%logit_0.0  of_%logit_0.0  Europe_%logit_0.0  and_%logit_0.0  Asia_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  an_%logit_0.0  antip_%logit_2.0 sych_%logit_1.0 otic_%logit_2.0  drug_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_1.0  autism_%logit_0.0  spectrum_%logit_0.0  disorders_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_0.0  drug_%logit_0.0  for_%logit_0.0  autism_%logit_0.0  spectrum_%logit_1.0  disorder_%logit_0.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_1.0  are_%logit_2.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  other_%logit_1.0  antidepressant_%logit_1.0  drugs_%logit_1.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_1.0  ib_%logit_2.0 up_%logit_0.0 ro_%logit_2.0 fen_%logit_0.0 ,_%logit_0.0  nap_%logit_0.0 rox_%logit_1.0 en_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  serotonin_%logit_1.0  re_%logit_0.0 upt_%logit_2.0 ake_%logit_0.0  inhibitors_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  these_%logit_2.0  drugs_%logit_0.0  with_%logit_2.0  each_%logit_1.0  other_%logit_1.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  them_%logit_0.0  to_%logit_1.0  each_%logit_2.0  other_%logit_1.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_1.0  efficacy_%logit_0.0  and_%logit_0.0  effectiveness_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  any_%logit_2.0  particular_%logit_1.0  type_%logit_2.0  of_%logit_1.0  optical_%logit_0.0  device_%logit_1.0  for_%logit_1.0  reading_%logit_2.0  speed_%logit_2.0  or_%logit_1.0  accuracy_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_1.0  most_%logit_2.0  effective_%logit_0.0  type_%logit_1.0  and_%logit_1.0  wavelength_%logit_0.0  of_%logit_2.0  optical_%logit_0.0  devices_%logit_0.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_2.0  them_%logit_2.0  to_%logit_0.0  other_%logit_1.0  types_%logit_1.0  of_%logit_2.0  visual_%logit_2.0  aids_%logit_1.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  various_%logit_1.0  types_%logit_1.0  and_%logit_2.0  wavelengths_%logit_2.0  of_%logit_2.0  optical_%logit_2.0  technology_%logit_0.0  for_%logit_2.0  reading_%logit_2.0  accuracy_%logit_0.0  and_%logit_2.0  accuracy_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_1.0  reliability_%logit_1.0  of_%logit_1.0  these_%logit_2.0  technologies_%logit_1.0  to_%logit_2.0  other_%logit_0.0  forms_%logit_2.0  of_%logit_2.0  optical_%logit_1.0  therapy_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_0.0  of_%logit_2.0  any_%logit_2.0  particular_%logit_2.0  type_%logit_0.0  of_%logit_1.0  intervention_%logit_1.0  for_%logit_0.0  the_%logit_1.0  prevention_%logit_0.0  of_%logit_0.0  E_%logit_0.0 TS_%logit_0.0  in_%logit_0.0  mothers_%logit_0.0  or_%logit_2.0  children_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  most_%logit_1.0  effective_%logit_0.0  intervention_%logit_2.0  and_%logit_2.0  the_%logit_1.0  best_%logit_0.0  way_%logit_0.0  to_%logit_1.0  tailor_%logit_2.0  it_%logit_0.0  to_%logit_1.0  the_%logit_1.0  needs_%logit_2.0  of_%logit_2.0  the_%logit_1.0  mother_%logit_1.0  or_%logit_2.0  child_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  different_%logit_0.0  types_%logit_2.0  of_%logit_2.0  intervention_%logit_0.0  in_%logit_0.0  different_%logit_2.0  populations_%logit_1.0  and_%logit_1.0  settings_%logit_2.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_1.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  interventions_%logit_1.0  to_%logit_0.0  reduce_%logit_0.0  E_%logit_2.0 TS_%logit_0.0  exposure_%logit_2.0  in_%logit_0.0  mothers_%logit_0.0  and_%logit_0.0  children_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_0.0  as_%logit_2.0  identify_%logit_0.0  the_%logit_2.0  types_%logit_1.0  of_%logit_0.0  interventions_%logit_2.0  that_%logit_0.0  are_%logit_1.0  most_%logit_1.0  effective_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  nutritional_%logit_2.0  supplements_%logit_2.0  in_%logit_0.0  the_%logit_2.0  management_%logit_1.0  of_%logit_0.0  overweight_%logit_0.0  or_%logit_0.0  obesity_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  nutritional_%logit_0.0  supplement_%logit_1.0  supplementation_%logit_0.0  on_%logit_0.0  body_%logit_1.0  mass_%logit_0.0  index_%logit_0.0  cent_%logit_0.0 ile_%logit_1.0  strength_%logit_0.0  and_%logit_1.0  metabolic_%logit_0.0  fitness_%logit_2.0  in_%logit_2.0  overweight_%logit_2.0  or_%logit_0.0  obese_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  moderate_%logit_1.0  to_%logit_0.0  severe_%logit_1.0  obesity_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  nutritional_%logit_2.0  supplements_%logit_0.0  with_%logit_1.0  placebo_%logit_0.0  or_%logit_1.0  no_%logit_0.0  supplementation_%logit_2.0  in_%logit_0.0  obese_%logit_2.0  patients_%logit_1.0 ._%logit_2.0  Such_%logit_1.0  trials_%logit_2.0  are_%logit_2.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  on_%logit_0.0  metabolic_%logit_2.0  fitness_%logit_0.0 ,_%logit_1.0  metabolic_%logit_2.0  fitness_%logit_0.0  and_%logit_1.0  physical_%logit_0.0  fitness_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  metabolic_%logit_0.0  fitness_%logit_0.0 ._%logit_1.0
 Sal_%logit_0.0 meter_%logit_0.0 ol_%logit_2.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  the_%logit_0.0  number_%logit_0.0  of_%logit_1.0  patients_%logit_0.0  admitted_%logit_0.0  to_%logit_2.0  hospital_%logit_0.0  and_%logit_0.0  improving_%logit_0.0  lung_%logit_0.0  function_%logit_2.0  in_%logit_1.0  the_%logit_1.0  short_%logit_0.0 -_%logit_1.0 term_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  its_%logit_2.0  use_%logit_2.0  is_%logit_1.0  associated_%logit_2.0  with_%logit_1.0  a_%logit_0.0  higher_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  death_%logit_2.0  and_%logit_1.0  a_%logit_0.0  decreased_%logit_1.0  risk_%logit_2.0  of_%logit_2.0  respiratory_%logit_0.0  distress_%logit_1.0  syndrome_%logit_1.0 ._%logit_1.0  Its_%logit_0.0  efficacy_%logit_0.0  is_%logit_1.0  similar_%logit_2.0  to_%logit_2.0  that_%logit_2.0  of_%logit_0.0  sal_%logit_2.0 meter_%logit_0.0 ol_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  with_%logit_1.0  a_%logit_2.0  lower_%logit_2.0  risk_%logit_0.0  of_%logit_0.0  pneumonia_%logit_2.0  and_%logit_1.0  an_%logit_2.0  increased_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  bron_%logit_1.0 ch_%logit_1.0 od_%logit_2.0 il_%logit_0.0 ator_%logit_0.0  toxicity_%logit_0.0 ._%logit_1.0  Its_%logit_0.0  use_%logit_0.0  is_%logit_2.0  not_%logit_2.0  associated_%logit_2.0  with_%logit_2.0  an_%logit_0.0  increase_%logit_0.0  in_%logit_0.0  the_%logit_0.0  risk_%logit_0.0  of_%logit_2.0  pulmonary_%logit_2.0  emb_%logit_1.0 ol_%logit_1.0 isms_%logit_0.0  or_%logit_0.0  death_%logit_2.0 ,_%logit_0.0  or_%logit_0.0  a_%logit_0.0  decreased_%logit_0.0  rate_%logit_1.0  of_%logit_1.0  respiratory_%logit_1.0  failure_%logit_0.0 ._%logit_0.0  Its_%logit_1.0  safety_%logit_1.0  profile_%logit_1.0  is_%logit_2.0  comparable_%logit_2.0  to_%logit_1.0  that_%logit_0.0  that_%logit_0.0  of_%logit_2.0  other_%logit_1.0  inh_%logit_0.0 aled_%logit_0.0  cort_%logit_0.0 ic_%logit_0.0 oster_%logit_0.0 oids_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  it_%logit_1.0  is_%logit_1.0  not_%logit_2.0  clear_%logit_0.0  whether_%logit_0.0  its_%logit_0.0  efficacy_%logit_2.0  is_%logit_1.0  related_%logit_1.0  to_%logit_0.0  its_%logit_0.0  long_%logit_0.0 -_%logit_1.0 term_%logit_0.0  safety_%logit_0.0  profile_%logit_2.0 ._%logit_1.0
 Ant_%logit_0.0 ib_%logit_0.0 iotic_%logit_0.0  pro_%logit_0.0 ph_%logit_1.0 yl_%logit_0.0 axis_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_0.0  bacterial_%logit_0.0  contamination_%logit_1.0  in_%logit_0.0  the_%logit_0.0  first_%logit_2.0  two_%logit_0.0  weeks_%logit_1.0  after_%logit_2.0  surgery_%logit_2.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_1.0  a_%logit_1.0  need_%logit_2.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotic_%logit_0.0  pro_%logit_1.0 th_%logit_1.0 yl_%logit_0.0 axis_%logit_2.0  in_%logit_0.0  this_%logit_1.0  population_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  different_%logit_0.0  antibiotic_%logit_0.0  reg_%logit_2.0 imens_%logit_1.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_1.0  optimal_%logit_0.0  antibiotic_%logit_0.0  regimen_%logit_2.0 ,_%logit_2.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  antibiotic_%logit_1.0  treatment_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_0.0  optimal_%logit_0.0  dosage_%logit_0.0  and_%logit_0.0  timing_%logit_2.0  of_%logit_2.0  antibiotic_%logit_2.0  therapy_%logit_0.0 ,_%logit_0.0  we_%logit_0.0  recommend_%logit_2.0  that_%logit_1.0  all_%logit_0.0  patients_%logit_0.0  receive_%logit_1.0  an_%logit_1.0  appropriate_%logit_2.0  amount_%logit_0.0  of_%logit_1.0  antibiotics_%logit_1.0  to_%logit_1.0  avoid_%logit_2.0  bacterial_%logit_2.0  contamination_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  pro_%logit_2.0 ph_%logit_2.0 yl_%logit_2.0 actic_%logit_0.0  antibiotics_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  CM_%logit_2.0 V_%logit_2.0  infections_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotics_%logit_1.0  in_%logit_2.0  treating_%logit_2.0  CM_%logit_0.0 V_%logit_2.0  infection_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  antibiotics_%logit_2.0  with_%logit_0.0  no_%logit_2.0  treatment_%logit_2.0  or_%logit_0.0  no_%logit_1.0  treatment_%logit_1.0 ._%logit_0.0  Such_%logit_2.0  trials_%logit_0.0  are_%logit_2.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0 ,_%logit_2.0  safety_%logit_0.0  and_%logit_0.0  efficacy_%logit_2.0  of_%logit_2.0  antibiotics_%logit_1.0 ._%logit_0.0  Such_%logit_2.0  studies_%logit_2.0  should_%logit_0.0  also_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  antibiotic_%logit_2.0  therapy_%logit_1.0  in_%logit_1.0  the_%logit_1.0  management_%logit_2.0  of_%logit_1.0  MR_%logit_0.0 V_%logit_0.0  infections_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_0.0  as_%logit_2.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_1.0  evidence_%logit_0.0 ._%logit_0.0
 The_%logit_0.0  results_%logit_2.0  of_%logit_2.0  this_%logit_2.0  review_%logit_0.0  support_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  male_%logit_2.0  condoms_%logit_1.0  in_%logit_2.0  reducing_%logit_2.0  ST_%logit_1.0 I_%logit_0.0  prevalence_%logit_1.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_2.0  recommend_%logit_1.0  male_%logit_0.0  condoms_%logit_1.0  as_%logit_0.0  a_%logit_1.0  substitute_%logit_0.0  for_%logit_2.0  female_%logit_0.0  condoms_%logit_1.0  in_%logit_0.0  the_%logit_1.0  prevention_%logit_1.0  of_%logit_1.0  ST_%logit_2.0 I_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  male_%logit_0.0  condom_%logit_0.0  use_%logit_0.0  in_%logit_1.0  preventing_%logit_1.0  ST_%logit_0.0 I_%logit_0.0  incidence_%logit_0.0  and_%logit_2.0  prevalence_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_1.0  male_%logit_1.0  condoms_%logit_1.0  with_%logit_0.0  female_%logit_0.0  condoms_%logit_2.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  of_%logit_1.0  male_%logit_1.0  and_%logit_1.0  female_%logit_1.0  condoms_%logit_1.0  compared_%logit_0.0  to_%logit_2.0  female_%logit_2.0  condoms_%logit_1.0 ._%logit_0.0  Recommend_%logit_1.0 ations_%logit_2.0  for_%logit_0.0  male_%logit_0.0  condoms_%logit_0.0  should_%logit_0.0  also_%logit_1.0  be_%logit_1.0  made_%logit_2.0  for_%logit_1.0  women_%logit_1.0  and_%logit_1.0  their_%logit_1.0  partners_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  for_%logit_2.0  women_%logit_2.0  with_%logit_1.0  ST_%logit_1.0 I_%logit_2.0  risk_%logit_0.0  factors_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  self_%logit_1.0 -_%logit_2.0 management_%logit_0.0  tools_%logit_0.0  in_%logit_0.0  the_%logit_0.0  management_%logit_2.0  of_%logit_0.0  O_%logit_0.0 AT_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  most_%logit_2.0  effective_%logit_0.0  tools_%logit_1.0  to_%logit_0.0  improve_%logit_1.0  self_%logit_1.0  management_%logit_1.0  tools_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  them_%logit_0.0  with_%logit_2.0  other_%logit_1.0  types_%logit_0.0  of_%logit_2.0  management_%logit_2.0  tools_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  self_%logit_0.0  management_%logit_2.0  technologies_%logit_0.0  in_%logit_2.0  reducing_%logit_2.0  O_%logit_2.0 AT_%logit_0.0  and_%logit_2.0  improving_%logit_2.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_2.0  and_%logit_0.0  cost_%logit_0.0 -_%logit_2.0 effect_%logit_2.0 iveness_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  a_%logit_0.0  history_%logit_0.0  of_%logit_0.0  major_%logit_0.0  bleeding_%logit_1.0  and_%logit_0.0  a_%logit_2.0  focus_%logit_2.0  on_%logit_2.0  improving_%logit_2.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_0.0  evidence_%logit_0.0  base_%logit_0.0 ._%logit_1.0
 Physical_%logit_0.0  activity_%logit_2.0  programmes_%logit_0.0  are_%logit_0.0  effective_%logit_2.0  in_%logit_2.0  lowering_%logit_2.0  blood_%logit_1.0  pressure_%logit_1.0  and_%logit_0.0  reducing_%logit_0.0  triglycer_%logit_0.0 ides_%logit_2.0  in_%logit_0.0  physical_%logit_0.0  activity_%logit_1.0  programmes_%logit_0.0 ._%logit_1.0  Physical_%logit_2.0  activity_%logit_1.0  programs_%logit_0.0  are_%logit_2.0  associated_%logit_2.0  with_%logit_2.0  a_%logit_1.0  reduction_%logit_2.0  in_%logit_1.0  triglycer_%logit_0.0 ides_%logit_1.0  and_%logit_0.0  LDL_%logit_0.0 -_%logit_0.0 ch_%logit_2.0 olesterol_%logit_1.0  levels_%logit_0.0 ._%logit_0.0  Physical_%logit_1.0  activities_%logit_0.0  programmes_%logit_1.0  are_%logit_1.0  also_%logit_2.0  associated_%logit_2.0  with_%logit_2.0  an_%logit_0.0  increase_%logit_1.0  in_%logit_1.0  triglycer_%logit_1.0 ide_%logit_0.0  levels_%logit_1.0  and_%logit_2.0  triglycer_%logit_0.0 ides_%logit_2.0  levels_%logit_0.0 ._%logit_1.0  Exercise_%logit_0.0  programmes_%logit_0.0  may_%logit_2.0  be_%logit_1.0  associated_%logit_2.0  with_%logit_2.0  reduced_%logit_0.0  triglycer_%logit_2.0 ides_%logit_2.0 ,_%logit_2.0  but_%logit_0.0  there_%logit_0.0  is_%logit_0.0  no_%logit_2.0  evidence_%logit_2.0  of_%logit_1.0  an_%logit_1.0  effect_%logit_0.0  on_%logit_0.0  triglycer_%logit_0.0 ides_%logit_1.0  or_%logit_1.0  cholesterol_%logit_0.0  levels_%logit_1.0  in_%logit_1.0  physical_%logit_1.0  activities_%logit_1.0  programmes_%logit_2.0 ._%logit_0.0  Exercise_%logit_0.0  programs_%logit_0.0  may_%logit_0.0  reduce_%logit_2.0  triglycer_%logit_2.0 ides_%logit_0.0  but_%logit_0.0  there_%logit_1.0  are_%logit_0.0  insufficient_%logit_1.0  data_%logit_2.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_0.0  exercise_%logit_0.0  programmes_%logit_1.0  on_%logit_1.0  blood_%logit_1.0  pressure_%logit_2.0 ,_%logit_1.0  cholesterol_%logit_0.0  levels_%logit_0.0  or_%logit_1.0  triglycer_%logit_1.0 ides_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_0.0  type_%logit_2.0  of_%logit_2.0  exercise_%logit_1.0  programme_%logit_2.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  exercise_%logit_0.0  programs_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  existence_%logit_2.0  of_%logit_1.0  a_%logit_0.0  protective_%logit_1.0  effect_%logit_1.0  of_%logit_2.0  immun_%logit_0.0 os_%logit_1.0 upp_%logit_2.0 ressive_%logit_0.0  agents_%logit_0.0  on_%logit_0.0  mortality_%logit_2.0  from_%logit_1.0  CRC_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  these_%logit_1.0  agents_%logit_2.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_2.0  CRC_%logit_2.0 ._%logit_0.0  It_%logit_0.0  is_%logit_2.0  also_%logit_0.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_2.0  these_%logit_0.0  agents_%logit_0.0  are_%logit_1.0  used_%logit_2.0  in_%logit_0.0  the_%logit_2.0  management_%logit_1.0  of_%logit_2.0  CRC_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  how_%logit_2.0  they_%logit_0.0  are_%logit_1.0  applied_%logit_0.0  to_%logit_0.0  individuals_%logit_1.0  with_%logit_0.0  a_%logit_0.0  high_%logit_0.0  risk_%logit_0.0  of_%logit_1.0  death_%logit_2.0  from_%logit_0.0  CRC_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_1.0  these_%logit_2.0  treatments_%logit_1.0  on_%logit_1.0  quality_%logit_2.0  of_%logit_1.0  life_%logit_1.0  and_%logit_0.0  mortality_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_1.0  use_%logit_2.0  of_%logit_2.0  ip_%logit_0.0 rat_%logit_0.0 rop_%logit_0.0 ium_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  premature_%logit_1.0  discontin_%logit_2.0 uation_%logit_1.0  due_%logit_0.0  to_%logit_2.0  adverse_%logit_1.0  events_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  confirm_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  ip_%logit_2.0 at_%logit_1.0 rop_%logit_1.0 ium_%logit_0.0  in_%logit_2.0  treating_%logit_1.0  premature_%logit_0.0  discontin_%logit_1.0 uations_%logit_0.0  of_%logit_1.0  ep_%logit_0.0 ine_%logit_1.0 phrine_%logit_1.0  and_%logit_0.0  phen_%logit_0.0 y_%logit_0.0 to_%logit_1.0 in_%logit_0.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  its_%logit_0.0  efficacy_%logit_0.0  in_%logit_0.0  the_%logit_1.0  management_%logit_1.0  of_%logit_1.0  these_%logit_1.0  adverse_%logit_0.0  events_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_2.0  its_%logit_1.0  efficacy_%logit_0.0  with_%logit_1.0  other_%logit_1.0  treatments_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  a_%logit_0.0  randomized_%logit_1.0  controlled_%logit_2.0  trial_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  efficacy_%logit_2.0  of_%logit_2.0  ip_%logit_0.0 ot_%logit_1.0 rop_%logit_2.0 ium_%logit_2.0  as_%logit_2.0  an_%logit_1.0  adj_%logit_1.0 u_%logit_0.0 vant_%logit_1.0  therapy_%logit_0.0  for_%logit_0.0  premature_%logit_2.0  discontin_%logit_0.0 ation_%logit_0.0  due_%logit_1.0  to_%logit_2.0  poor_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_2.0  evidence_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  bu_%logit_0.0 p_%logit_2.0 iv_%logit_1.0 ac_%logit_0.0 aine_%logit_0.0  as_%logit_0.0  a_%logit_1.0  substitute_%logit_2.0  for_%logit_1.0  oxy_%logit_1.0 toc_%logit_0.0 in_%logit_0.0  for_%logit_0.0  epid_%logit_0.0 ural_%logit_1.0  analges_%logit_0.0 ia_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  to_%logit_2.0  support_%logit_2.0  its_%logit_1.0  use_%logit_1.0  as_%logit_0.0  an_%logit_2.0  alternative_%logit_2.0  to_%logit_1.0  epid_%logit_0.0 ural_%logit_0.0  ana_%logit_1.0 esthesia_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_0.0  duration_%logit_1.0  of_%logit_0.0  bu_%logit_1.0 pp_%logit_1.0 iv_%logit_2.0 ac_%logit_2.0 ain_%logit_2.0 ,_%logit_2.0  the_%logit_0.0  optimal_%logit_1.0  dosage_%logit_0.0  and_%logit_0.0  timing_%logit_2.0  of_%logit_2.0  epid_%logit_0.0 ural_%logit_0.0  administration_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_0.0  most_%logit_0.0  effective_%logit_0.0  analges_%logit_1.0 ia_%logit_2.0  for_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  pain_%logit_1.0  relief_%logit_0.0  in_%logit_0.0  women_%logit_1.0  in_%logit_0.0  labor_%logit_1.0  and_%logit_1.0  childbirth_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  other_%logit_2.0  analges_%logit_1.0 ia_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  cervical_%logit_0.0  dil_%logit_0.0 at_%logit_0.0 ation_%logit_2.0  as_%logit_0.0  a_%logit_1.0  treatment_%logit_1.0  for_%logit_2.0  cervical_%logit_2.0  rip_%logit_0.0 ening_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_0.0  cervical_%logit_1.0  d_%logit_0.0 ilation_%logit_0.0  as_%logit_1.0  an_%logit_2.0  alternative_%logit_1.0  to_%logit_1.0  cervical_%logit_0.0  dil_%logit_1.0 ation_%logit_1.0  as_%logit_0.0  an_%logit_2.0  adj_%logit_1.0 u_%logit_1.0 vant_%logit_2.0  treatment_%logit_1.0  to_%logit_1.0  cervical_%logit_0.0  exc_%logit_2.0 ision_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_1.0  cervical_%logit_1.0  dil_%logit_1.0 atal_%logit_1.0  exc_%logit_0.0 ision_%logit_2.0  with_%logit_2.0  cervical_%logit_2.0  dil_%logit_2.0 ating_%logit_2.0  as_%logit_0.0  a_%logit_0.0  non_%logit_0.0 -_%logit_1.0 ide_%logit_0.0 al_%logit_2.0  treatment_%logit_0.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_2.0 ,_%logit_2.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_1.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_0.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  comparing_%logit_0.0  cervical_%logit_2.0  dil_%logit_2.0 ate_%logit_0.0  with_%logit_0.0  cervical_%logit_0.0  rip_%logit_0.0 ener_%logit_1.0  as_%logit_1.0  a_%logit_1.0  standard_%logit_0.0  treatment_%logit_1.0 ._%logit_1.0  Such_%logit_2.0  a_%logit_2.0  trial_%logit_0.0  is_%logit_0.0  warranted_%logit_0.0  in_%logit_0.0  order_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  best_%logit_2.0  method_%logit_0.0  of_%logit_0.0  dil_%logit_0.0 ating_%logit_0.0  cervical_%logit_2.0  dil_%logit_0.0 ates_%logit_0.0 ._%logit_0.0
 The_%logit_0.0  results_%logit_2.0  of_%logit_0.0  this_%logit_0.0  review_%logit_0.0  suggest_%logit_0.0  that_%logit_2.0  there_%logit_0.0  is_%logit_1.0  no_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  manual_%logit_0.0  walking_%logit_0.0  aids_%logit_1.0  for_%logit_0.0  enhancing_%logit_1.0  walking_%logit_1.0  speed_%logit_0.0  or_%logit_0.0  endurance_%logit_0.0  in_%logit_1.0  disabled_%logit_2.0  persons_%logit_1.0 ._%logit_2.0  However_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_1.0  into_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  manual_%logit_2.0  walk_%logit_1.0  aids_%logit_2.0  for_%logit_2.0  disabled_%logit_1.0  persons_%logit_2.0  with_%logit_0.0  impaired_%logit_2.0  limb_%logit_2.0  function_%logit_2.0  and_%logit_2.0  functional_%logit_2.0  independence_%logit_1.0  after_%logit_0.0  discharge_%logit_2.0  from_%logit_1.0  hospital_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_1.0  manual_%logit_0.0 -_%logit_1.0 assisted_%logit_0.0  walking_%logit_1.0  aids_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  manual_%logit_0.0  walking_%logit_0.0  aid_%logit_0.0  with_%logit_0.0  manual_%logit_2.0 -_%logit_2.0 based_%logit_0.0  walking_%logit_0.0  aids_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  for_%logit_1.0  pain_%logit_2.0  relief_%logit_0.0  in_%logit_0.0  adults_%logit_2.0  with_%logit_0.0  T_%logit_0.0 MD_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  acupuncture_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  acupuncture_%logit_1.0  with_%logit_1.0  other_%logit_2.0  treatments_%logit_2.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  of_%logit_2.0  acupuncture_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_0.0  T_%logit_1.0 MD_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  a_%logit_1.0  comparison_%logit_1.0  of_%logit_1.0  acupuncture_%logit_2.0  to_%logit_0.0  other_%logit_0.0  treatments_%logit_2.0  in_%logit_0.0  adults_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0  there_%logit_0.0  is_%logit_2.0  an_%logit_0.0  issue_%logit_1.0  of_%logit_1.0  the_%logit_1.0  quality_%logit_0.0  of_%logit_1.0  the_%logit_0.0  evidence_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_1.0  the_%logit_0.0  reliability_%logit_1.0  of_%logit_0.0  the_%logit_0.0  results_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_1.0  usefulness_%logit_1.0  of_%logit_1.0  these_%logit_0.0  findings_%logit_0.0 ._%logit_1.0
 Technical_%logit_0.0  skill_%logit_0.0  training_%logit_1.0  is_%logit_2.0  a_%logit_2.0  useful_%logit_2.0  tool_%logit_2.0  in_%logit_0.0  the_%logit_0.0  management_%logit_1.0  of_%logit_2.0  pain_%logit_0.0  and_%logit_2.0  discomfort_%logit_2.0  associated_%logit_0.0  with_%logit_0.0  end_%logit_2.0 oscopic_%logit_0.0  insertion_%logit_0.0  and_%logit_2.0  negotiation_%logit_0.0  of_%logit_1.0  rect_%logit_0.0 os_%logit_0.0 igm_%logit_0.0 oid_%logit_0.0  junction_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_2.0  it_%logit_0.0  is_%logit_0.0  not_%logit_2.0  clear_%logit_0.0  whether_%logit_0.0  technical_%logit_0.0  skill_%logit_0.0  training_%logit_0.0  has_%logit_0.0  a_%logit_2.0  beneficial_%logit_2.0  effect_%logit_2.0  on_%logit_2.0  pain_%logit_0.0  or_%logit_1.0  discomfort_%logit_0.0 ._%logit_0.0  Pract_%logit_1.0 ition_%logit_0.0 ers_%logit_2.0  should_%logit_0.0  be_%logit_2.0  aware_%logit_0.0  that_%logit_0.0  there_%logit_1.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_2.0  further_%logit_0.0  research_%logit_2.0  into_%logit_0.0  technical_%logit_1.0  skills_%logit_2.0  training_%logit_1.0  in_%logit_0.0  this_%logit_1.0  area_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_0.0  the_%logit_0.0  most_%logit_1.0  effective_%logit_2.0  technical_%logit_1.0  training_%logit_2.0  and_%logit_0.0  the_%logit_0.0  most_%logit_2.0  appropriate_%logit_0.0  tool_%logit_0.0  to_%logit_1.0  employ_%logit_2.0  in_%logit_0.0  this_%logit_2.0  role_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  recommend_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  n_%logit_0.0 alt_%logit_2.0 rex_%logit_0.0 one_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  relapse_%logit_0.0  or_%logit_0.0  relapse_%logit_1.0  of_%logit_1.0  heroin_%logit_2.0  dependence_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  N_%logit_2.0 alt_%logit_0.0 rex_%logit_1.0 ones_%logit_0.0  for_%logit_2.0  relapse_%logit_1.0  and_%logit_0.0  relapse_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  N_%logit_1.0 ALT_%logit_1.0 rex_%logit_2.0 one_%logit_2.0  with_%logit_1.0  other_%logit_0.0  antidepressants_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  also_%logit_2.0  to_%logit_0.0  assess_%logit_2.0  its_%logit_0.0  efficacy_%logit_0.0  in_%logit_2.0  relapse_%logit_2.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_1.0  should_%logit_1.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_1.0  impact_%logit_0.0  on_%logit_2.0  relapse_%logit_2.0  severity_%logit_0.0  and_%logit_0.0  relapse_%logit_2.0  severity_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  its_%logit_0.0  effectiveness_%logit_1.0  in_%logit_1.0  reducing_%logit_0.0  relapse_%logit_0.0  severity_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  pressure_%logit_0.0  cat_%logit_0.0 he_%logit_2.0 ters_%logit_0.0  for_%logit_2.0  per_%logit_2.0 ip_%logit_1.0 art_%logit_2.0 al_%logit_2.0  infection_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_0.0  best_%logit_0.0  pressure_%logit_2.0  cat_%logit_0.0 heter_%logit_0.0  for_%logit_0.0  this_%logit_2.0  purpose_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  different_%logit_1.0  methods_%logit_0.0  of_%logit_2.0  pressure_%logit_1.0 -_%logit_0.0 cat_%logit_2.0 heter_%logit_2.0  administration_%logit_2.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0  randomized_%logit_0.0  controlled_%logit_1.0  trial_%logit_1.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  various_%logit_1.0  methods_%logit_2.0  of_%logit_2.0  cat_%logit_1.0 heter_%logit_1.0  drainage_%logit_1.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  this_%logit_2.0  condition_%logit_1.0 ._%logit_2.0  It_%logit_2.0  is_%logit_0.0  also_%logit_1.0  important_%logit_2.0  to_%logit_1.0  note_%logit_0.0  that_%logit_2.0  the_%logit_0.0  data_%logit_0.0  are_%logit_1.0  based_%logit_2.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_2.0  of_%logit_0.0  cases_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  therefore_%logit_1.0  the_%logit_0.0  conclusions_%logit_1.0  of_%logit_0.0  this_%logit_0.0  review_%logit_2.0  are_%logit_2.0  not_%logit_0.0  necessarily_%logit_0.0  definitive_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  recommend_%logit_1.0  pro_%logit_2.0 ph_%logit_2.0 yl_%logit_2.0 actic_%logit_0.0  immun_%logit_0.0 ogl_%logit_1.0 ob_%logit_1.0 ulin_%logit_0.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  G_%logit_0.0 V_%logit_1.0 HD_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_2.0  immun_%logit_2.0 ogl_%logit_2.0 ub_%logit_2.0 ulin_%logit_1.0  regimen_%logit_2.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  its_%logit_2.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  and_%logit_2.0  prevention_%logit_2.0  of_%logit_0.0  G_%logit_2.0 GV_%logit_2.0 HD_%logit_0.0 ._%logit_1.0  It_%logit_0.0  is_%logit_0.0  also_%logit_2.0  important_%logit_1.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_2.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  immun_%logit_1.0 ogl_%logit_2.0 ab_%logit_2.0 ulin_%logit_0.0  in_%logit_0.0  the_%logit_0.0  management_%logit_1.0  of_%logit_2.0  these_%logit_1.0  diseases_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_1.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_0.0  for_%logit_2.0  a_%logit_1.0  large_%logit_0.0  scale_%logit_2.0 ,_%logit_2.0  multi_%logit_2.0 -_%logit_2.0 cent_%logit_1.0 re_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trial_%logit_0.0  comparing_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_0.0  immun_%logit_0.0 os_%logit_0.0 upp_%logit_1.0 ressive_%logit_2.0  therapy_%logit_1.0  to_%logit_0.0  standard_%logit_2.0  therapy_%logit_2.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_0.0  should_%logit_1.0  include_%logit_0.0  a_%logit_1.0  large_%logit_1.0  number_%logit_1.0  of_%logit_1.0  patients_%logit_0.0  and_%logit_0.0  involve_%logit_2.0  a_%logit_0.0  number_%logit_1.0  of_%logit_1.0  participants_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  N_%logit_0.0 alt_%logit_2.0 rex_%logit_1.0 one_%logit_0.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  opioid_%logit_0.0  addicts_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  establish_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  this_%logit_2.0  drug_%logit_0.0 ._%logit_2.0  It_%logit_2.0  is_%logit_2.0  also_%logit_0.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_2.0  by_%logit_1.0  which_%logit_0.0  this_%logit_0.0  drug_%logit_0.0  works_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  how_%logit_0.0  it_%logit_1.0  relates_%logit_2.0  to_%logit_2.0  other_%logit_2.0  psych_%logit_0.0 os_%logit_2.0 ocial_%logit_0.0  interventions_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  other_%logit_0.0  interventions_%logit_0.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_2.0  nicotine_%logit_1.0  replacement_%logit_1.0  therapy_%logit_2.0 ,_%logit_0.0  antidepressants_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  other_%logit_1.0  psychological_%logit_1.0  therapies_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  of_%logit_2.0  these_%logit_1.0  interventions_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  opioid_%logit_1.0  consumption_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  z_%logit_0.0 id_%logit_2.0 ov_%logit_2.0 ud_%logit_0.0 ine_%logit_0.0  as_%logit_0.0  a_%logit_0.0  mon_%logit_1.0 otherapy_%logit_2.0  for_%logit_1.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  d_%logit_0.0 ise_%logit_0.0 ase_%logit_0.0  progression_%logit_0.0  or_%logit_0.0  death_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_0.0  advanced_%logit_0.0  HIV_%logit_1.0  disease_%logit_0.0 ._%logit_1.0  However_%logit_0.0 ,_%logit_1.0  z_%logit_0.0 id_%logit_2.0 iv_%logit_0.0 ud_%logit_2.0 ine_%logit_1.0  appears_%logit_1.0  to_%logit_0.0  be_%logit_1.0  a_%logit_2.0  viable_%logit_0.0  option_%logit_0.0  for_%logit_1.0  those_%logit_0.0  patients_%logit_0.0  who_%logit_1.0  are_%logit_2.0  at_%logit_2.0  high_%logit_1.0  risk_%logit_2.0  of_%logit_2.0  death_%logit_0.0  from_%logit_0.0  this_%logit_2.0  treatment_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_0.0  z_%logit_1.0 ir_%logit_2.0 av_%logit_1.0 ud_%logit_2.0 ine_%logit_0.0 ,_%logit_1.0  the_%logit_1.0  optimal_%logit_1.0  dosage_%logit_0.0  and_%logit_1.0  timing_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  the_%logit_2.0  best_%logit_1.0  way_%logit_0.0  to_%logit_1.0  administer_%logit_2.0  it_%logit_0.0 ._%logit_1.0  It_%logit_2.0  is_%logit_2.0  also_%logit_0.0  important_%logit_1.0  to_%logit_2.0  note_%logit_0.0  that_%logit_0.0  the_%logit_2.0  data_%logit_2.0  in_%logit_0.0  this_%logit_2.0  review_%logit_2.0  are_%logit_1.0  based_%logit_2.0  on_%logit_0.0  a_%logit_0.0  small_%logit_1.0  number_%logit_2.0  of_%logit_0.0  patients_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  therefore_%logit_1.0  the_%logit_1.0  conclusions_%logit_2.0  of_%logit_0.0  this_%logit_1.0  review_%logit_1.0  may_%logit_0.0  not_%logit_0.0  necessarily_%logit_1.0  apply_%logit_2.0  to_%logit_0.0  all_%logit_0.0  patients_%logit_0.0 ,_%logit_0.0  or_%logit_0.0  to_%logit_0.0  those_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  severe_%logit_1.0  disease_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_1.0  of_%logit_2.0  isot_%logit_1.0 ret_%logit_1.0 ino_%logit_1.0 in_%logit_0.0  for_%logit_1.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  cervical_%logit_1.0  carcin_%logit_1.0 oma_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  isot_%logit_1.0 ret_%logit_0.0 o_%logit_1.0 in_%logit_1.0  concentration_%logit_1.0 ,_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  therapy_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  long_%logit_0.0 -_%logit_0.0 term_%logit_0.0  outcomes_%logit_0.0 ,_%logit_1.0  including_%logit_2.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  on_%logit_1.0  other_%logit_0.0  aspects_%logit_2.0  of_%logit_2.0  life_%logit_1.0  and_%logit_0.0  health_%logit_2.0 -_%logit_0.0 related_%logit_1.0  quality_%logit_1.0 -_%logit_1.0 of_%logit_0.0 -_%logit_2.0 life_%logit_0.0 ,_%logit_0.0  including_%logit_1.0  the_%logit_0.0  occurrence_%logit_0.0  of_%logit_2.0  adverse_%logit_1.0  events_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  magnesium_%logit_0.0  supplementation_%logit_2.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  e_%logit_0.0 cl_%logit_1.0 amps_%logit_0.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_0.0  timing_%logit_2.0  of_%logit_2.0  supplementation_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_2.0  magnesium_%logit_2.0  supplementation_%logit_1.0  with_%logit_0.0  other_%logit_0.0  supplements_%logit_2.0 ,_%logit_2.0  especially_%logit_1.0  magnesium_%logit_1.0  supplements_%logit_1.0 ,_%logit_0.0  in_%logit_0.0  the_%logit_2.0  management_%logit_1.0  of_%logit_1.0  E_%logit_1.0 CL_%logit_2.0 amps_%logit_1.0 ia_%logit_0.0  in_%logit_2.0  women_%logit_1.0  with_%logit_2.0  pre_%logit_2.0 -_%logit_1.0 existing_%logit_2.0  hypertension_%logit_0.0  or_%logit_1.0  pre_%logit_1.0 -_%logit_0.0 men_%logit_0.0 opausal_%logit_1.0  conditions_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  long_%logit_0.0 -_%logit_1.0 term_%logit_1.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  dosage_%logit_1.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  magnesium_%logit_0.0  supplements_%logit_0.0  and_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  whether_%logit_2.0  magnesium_%logit_2.0  supplementation_%logit_1.0  is_%logit_0.0  beneficial_%logit_1.0  or_%logit_2.0  harmful_%logit_2.0  for_%logit_0.0  the_%logit_2.0  prevention_%logit_2.0  and_%logit_1.0  management_%logit_1.0  of_%logit_0.0  recurrent_%logit_0.0  E_%logit_1.0 CL_%logit_2.0 AMP_%logit_0.0 IA_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  gluc_%logit_1.0 oc_%logit_0.0 ort_%logit_2.0 ic_%logit_2.0 oids_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  acute_%logit_1.0  bron_%logit_0.0 ch_%logit_1.0 ocon_%logit_2.0 st_%logit_1.0 riction_%logit_1.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  asthma_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  randomized_%logit_1.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_2.0  confirm_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_2.0  in_%logit_2.0  reducing_%logit_1.0  the_%logit_2.0  incidence_%logit_2.0  of_%logit_2.0  asthma_%logit_0.0 -_%logit_0.0 related_%logit_1.0  adverse_%logit_1.0  events_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_0.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_1.0  of_%logit_1.0  gluc_%logit_0.0 oco_%logit_1.0 ort_%logit_2.0 ic_%logit_1.0 oid_%logit_0.0  therapy_%logit_0.0  in_%logit_1.0  these_%logit_1.0  patients_%logit_0.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_2.0  long_%logit_0.0 -_%logit_1.0 term_%logit_2.0  data_%logit_0.0  are_%logit_0.0  required_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  gluc_%logit_1.0 os_%logit_1.0 ort_%logit_2.0 ic_%logit_2.0 oster_%logit_1.0 oids_%logit_0.0  in_%logit_0.0  this_%logit_0.0  patient_%logit_0.0  population_%logit_1.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  their_%logit_0.0  effectiveness_%logit_2.0  in_%logit_1.0  the_%logit_2.0  management_%logit_2.0  of_%logit_1.0  asthma_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_1.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  pro_%logit_0.0 ph_%logit_2.0 yl_%logit_0.0 actic_%logit_0.0  chem_%logit_0.0 op_%logit_2.0 roph_%logit_0.0 yl_%logit_2.0 actic_%logit_2.0  chemotherapy_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  cancer_%logit_0.0 -_%logit_0.0 specific_%logit_2.0  survival_%logit_1.0 ._%logit_2.0  However_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_1.0  for_%logit_1.0  further_%logit_1.0  research_%logit_2.0  in_%logit_0.0  this_%logit_0.0  area_%logit_2.0 ._%logit_0.0  The_%logit_0.0  results_%logit_1.0  of_%logit_0.0  this_%logit_2.0  review_%logit_2.0  are_%logit_0.0  based_%logit_0.0  on_%logit_1.0  a_%logit_1.0  small_%logit_0.0  number_%logit_1.0  of_%logit_0.0  patients_%logit_0.0 ,_%logit_0.0  all_%logit_2.0  of_%logit_2.0  whom_%logit_0.0  are_%logit_1.0  undergoing_%logit_1.0  chemotherapy_%logit_0.0  for_%logit_0.0  cancer_%logit_0.0 -_%logit_2.0 related_%logit_0.0  survival_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_0.0  chemotherapy_%logit_0.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_2.0  optimal_%logit_0.0  dosage_%logit_1.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_2.0  chemotherapy_%logit_0.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_2.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  pro_%logit_2.0 -_%logit_1.0 ph_%logit_1.0 yl_%logit_1.0 axis_%logit_1.0  in_%logit_1.0  cancer_%logit_0.0 -_%logit_2.0 associated_%logit_0.0  survival_%logit_2.0 ,_%logit_1.0  a_%logit_1.0  meta_%logit_2.0 -_%logit_2.0 analysis_%logit_2.0  is_%logit_0.0  needed_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_1.0  use_%logit_0.0  of_%logit_2.0  o_%logit_0.0 lan_%logit_1.0 z_%logit_0.0 ap_%logit_0.0 ine_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_2.0  P_%logit_0.0 AN_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  its_%logit_2.0  role_%logit_2.0  in_%logit_0.0  the_%logit_0.0  management_%logit_0.0  of_%logit_0.0  weight_%logit_1.0  gain_%logit_0.0  in_%logit_1.0  people_%logit_2.0  with_%logit_2.0  schizophrenia_%logit_0.0 ._%logit_0.0  It_%logit_1.0  is_%logit_1.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  number_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  treat_%logit_2.0  patients_%logit_0.0  with_%logit_1.0  schizophrenia_%logit_1.0  to_%logit_1.0  prevent_%logit_2.0  them_%logit_2.0  from_%logit_0.0  relapse_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_1.0  evaluate_%logit_0.0  its_%logit_1.0  efficacy_%logit_2.0  in_%logit_1.0  the_%logit_1.0  long_%logit_0.0  term_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_2.0  an_%logit_0.0  urgent_%logit_1.0  need_%logit_0.0  for_%logit_1.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  this_%logit_2.0  drug_%logit_0.0  in_%logit_2.0  patients_%logit_1.0  with_%logit_0.0  severe_%logit_2.0  schizophrenia_%logit_1.0 ._%logit_2.0
 Tele_%logit_0.0 phone_%logit_0.0  bill_%logit_0.0 ings_%logit_0.0  are_%logit_0.0  effective_%logit_0.0  in_%logit_1.0  reducing_%logit_2.0  telephone_%logit_1.0  bill_%logit_0.0 ings_%logit_1.0  and_%logit_1.0  reducing_%logit_1.0  the_%logit_0.0  number_%logit_1.0  of_%logit_0.0  calls_%logit_0.0  made_%logit_0.0  by_%logit_0.0  telephone_%logit_2.0  call_%logit_0.0 ers_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_0.0  recommend_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  bill_%logit_0.0 ings_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_1.0  phone_%logit_0.0  calls_%logit_2.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_0.0  reducing_%logit_0.0  phone_%logit_0.0  bill_%logit_0.0 ings_%logit_0.0  or_%logit_0.0  reducing_%logit_0.0  calls_%logit_2.0  missed_%logit_0.0  by_%logit_0.0  call_%logit_2.0 ers_%logit_0.0  or_%logit_0.0  others_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  bill_%logit_2.0 ing_%logit_2.0  and_%logit_2.0  phone_%logit_0.0  calls_%logit_2.0  as_%logit_2.0  alternatives_%logit_1.0  to_%logit_0.0  phone_%logit_0.0  calls_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  bill_%logit_0.0 ings_%logit_2.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_2.0  of_%logit_2.0  telephone_%logit_1.0  bills_%logit_1.0  and_%logit_0.0  telephone_%logit_2.0  calls_%logit_2.0 ._%logit_2.0
 Pro_%logit_0.0 ph_%logit_0.0 yl_%logit_2.0 actic_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_0.0  with_%logit_0.0  c_%logit_1.0 ip_%logit_2.0 ro_%logit_1.0 fl_%logit_0.0 ox_%logit_1.0 ac_%logit_1.0 in_%logit_1.0  is_%logit_2.0  associated_%logit_1.0  with_%logit_0.0  a_%logit_0.0  significant_%logit_2.0  reduction_%logit_2.0  in_%logit_1.0  mortality_%logit_1.0 ,_%logit_0.0  but_%logit_1.0  a_%logit_1.0  significant_%logit_2.0  increase_%logit_1.0  in_%logit_0.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_0.0  adverse_%logit_0.0  events_%logit_1.0 ,_%logit_2.0  including_%logit_0.0  diarr_%logit_0.0 hoe_%logit_1.0 a_%logit_0.0 ,_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_1.0  uncom_%logit_0.0 pl_%logit_1.0 icated_%logit_2.0  bacterial_%logit_1.0  per_%logit_0.0 iton_%logit_0.0 itis_%logit_0.0  who_%logit_0.0  are_%logit_0.0  receiving_%logit_2.0  antibiotic_%logit_0.0  therapy_%logit_2.0 ._%logit_1.0  The_%logit_1.0  risk_%logit_2.0 -_%logit_1.0 benefit_%logit_0.0  ratio_%logit_1.0  of_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_0.0  is_%logit_1.0  low_%logit_1.0 ,_%logit_1.0  but_%logit_1.0  the_%logit_1.0  number_%logit_2.0  of_%logit_2.0  cases_%logit_0.0  of_%logit_2.0  adverse_%logit_0.0  effects_%logit_0.0  is_%logit_2.0  very_%logit_1.0  low_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  there_%logit_0.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0 ._%logit_0.0  It_%logit_0.0  is_%logit_0.0  unlikely_%logit_2.0  that_%logit_2.0  antibiotic_%logit_0.0  therapy_%logit_0.0  will_%logit_0.0  result_%logit_0.0  in_%logit_0.0  any_%logit_2.0  significant_%logit_2.0  difference_%logit_2.0  in_%logit_2.0  mortality_%logit_1.0  or_%logit_0.0  morbid_%logit_0.0 ity_%logit_1.0  in_%logit_0.0  patients_%logit_2.0  receiving_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  phen_%logit_0.0 y_%logit_2.0 to_%logit_0.0 in_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  g_%logit_2.0 ing_%logit_2.0 ival_%logit_0.0  over_%logit_0.0 -_%logit_2.0 growth_%logit_1.0 ._%logit_0.0  There_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_0.0 conduct_%logit_0.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_1.0 ised_%logit_2.0  controlled_%logit_0.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  this_%logit_0.0  treatment_%logit_0.0 ._%logit_1.0  Such_%logit_1.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_2.0  of_%logit_1.0  sufficient_%logit_1.0  size_%logit_2.0  to_%logit_0.0  detect_%logit_2.0  clinically_%logit_0.0  important_%logit_2.0  differences_%logit_1.0  in_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  between_%logit_1.0  the_%logit_1.0  two_%logit_1.0  treatments_%logit_1.0 ._%logit_1.0  They_%logit_0.0  should_%logit_0.0  also_%logit_1.0  assess_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_0.0  other_%logit_1.0  treatments_%logit_1.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_0.0  calcium_%logit_0.0  channel_%logit_0.0  blockers_%logit_2.0 ,_%logit_2.0  magnesium_%logit_0.0  sulph_%logit_1.0 ate_%logit_2.0  and_%logit_1.0  calcium_%logit_1.0  channel_%logit_0.0  blocker_%logit_1.0  blockers_%logit_2.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  these_%logit_0.0  treatments_%logit_1.0  on_%logit_2.0  bone_%logit_1.0  mineral_%logit_0.0  content_%logit_1.0  and_%logit_1.0  bone_%logit_2.0  mineral_%logit_2.0  density_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  intraven_%logit_0.0 ous_%logit_0.0  immun_%logit_0.0 ogl_%logit_0.0 ob_%logit_0.0 ul_%logit_0.0 ins_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_0.0  malaria_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  establish_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  this_%logit_2.0  therapy_%logit_2.0  in_%logit_2.0  reducing_%logit_1.0  mortality_%logit_1.0  and_%logit_2.0  morbid_%logit_1.0 ity_%logit_1.0  in_%logit_2.0  patients_%logit_0.0  with_%logit_1.0  severe_%logit_0.0  malaria_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_0.0  this_%logit_0.0  treatment_%logit_0.0  with_%logit_1.0  other_%logit_1.0  treatments_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_1.0  optimal_%logit_1.0  dose_%logit_0.0  and_%logit_2.0  duration_%logit_1.0  of_%logit_2.0  administration_%logit_0.0 ,_%logit_0.0  the_%logit_2.0  optimal_%logit_1.0  dosage_%logit_0.0  and_%logit_0.0  timing_%logit_0.0  of_%logit_0.0  administration_%logit_2.0  and_%logit_0.0  the_%logit_1.0  best_%logit_2.0  way_%logit_0.0  to_%logit_2.0  administer_%logit_1.0  it_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  the_%logit_2.0  most_%logit_0.0  effective_%logit_2.0  way_%logit_2.0  to_%logit_2.0  deliver_%logit_1.0  it_%logit_1.0  to_%logit_1.0  patients_%logit_0.0  in_%logit_1.0  severe_%logit_0.0  malaria_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  workplace_%logit_1.0  erg_%logit_1.0 onomic_%logit_1.0  interventions_%logit_0.0  for_%logit_0.0  improving_%logit_2.0  worker_%logit_2.0  satisfaction_%logit_0.0  and_%logit_0.0  productivity_%logit_2.0 ._%logit_0.0  Work_%logit_0.0 place_%logit_1.0  erg_%logit_2.0 onomic_%logit_1.0  training_%logit_0.0  may_%logit_0.0  improve_%logit_1.0  worker_%logit_0.0  satisfaction_%logit_1.0 ,_%logit_1.0  productivity_%logit_1.0  and_%logit_2.0  satisfaction_%logit_1.0  with_%logit_2.0  work_%logit_0.0 ,_%logit_2.0  but_%logit_0.0  there_%logit_2.0  is_%logit_2.0  a_%logit_2.0  need_%logit_0.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0 ._%logit_0.0  The_%logit_0.0  findings_%logit_2.0  of_%logit_0.0  this_%logit_0.0  review_%logit_1.0  should_%logit_0.0  be_%logit_0.0  interpreted_%logit_0.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  the_%logit_0.0  conclusions_%logit_0.0  are_%logit_0.0  based_%logit_0.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_2.0  of_%logit_1.0  studies_%logit_2.0 ,_%logit_0.0  with_%logit_0.0  a_%logit_2.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_0.0  bias_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  are_%logit_2.0  subject_%logit_2.0  to_%logit_0.0  interpretation_%logit_2.0  and_%logit_0.0  interpretation_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  these_%logit_0.0  interventions_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  them_%logit_1.0  to_%logit_1.0  other_%logit_1.0  types_%logit_0.0  of_%logit_0.0  erg_%logit_1.0 onomic_%logit_1.0  exercises_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  epid_%logit_0.0 ural_%logit_2.0  analges_%logit_1.0 ia_%logit_2.0  for_%logit_0.0  post_%logit_1.0 -_%logit_2.0 operative_%logit_0.0  complications_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_0.0  epid_%logit_0.0 ur_%logit_0.0 als_%logit_1.0  for_%logit_0.0  post_%logit_0.0 operative_%logit_0.0  complications_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  the_%logit_1.0  various_%logit_2.0  analges_%logit_1.0 ia_%logit_2.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_1.0  pain_%logit_0.0  relief_%logit_0.0 ,_%logit_0.0  function_%logit_1.0 ,_%logit_1.0  fatigue_%logit_0.0 ,_%logit_1.0  sleep_%logit_2.0 iness_%logit_1.0 ,_%logit_2.0  fatigue_%logit_2.0  and_%logit_0.0  sleep_%logit_2.0 iness_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  efficacy_%logit_1.0  of_%logit_0.0  intra_%logit_0.0 operative_%logit_2.0  analges_%logit_2.0 ia_%logit_0.0  compared_%logit_0.0  to_%logit_2.0  epid_%logit_0.0 ural_%logit_1.0  ana_%logit_1.0 esthesia_%logit_1.0  alone_%logit_0.0  or_%logit_0.0  in_%logit_2.0  combination_%logit_2.0  with_%logit_0.0  other_%logit_0.0  analges_%logit_2.0 ia_%logit_1.0 ,_%logit_1.0  to_%logit_2.0  compare_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  epid_%logit_0.0 uran_%logit_0.0  analges_%logit_0.0 ia_%logit_2.0  versus_%logit_1.0  epid_%logit_0.0 ural_%logit_1.0  opioid_%logit_1.0  analges_%logit_0.0 ia_%logit_0.0  alone_%logit_0.0 ._%logit_0.0
 Red_%logit_0.0  blood_%logit_0.0  cell_%logit_1.0  transf_%logit_0.0 usion_%logit_0.0  does_%logit_0.0  not_%logit_0.0  appear_%logit_1.0  to_%logit_2.0  have_%logit_0.0  a_%logit_1.0  significant_%logit_2.0  effect_%logit_0.0  on_%logit_0.0  survival_%logit_0.0  or_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0  in_%logit_1.0  patients_%logit_1.0  with_%logit_1.0  advanced_%logit_0.0  cancer_%logit_0.0  receiving_%logit_0.0  chemotherapy_%logit_2.0 ._%logit_1.0  However_%logit_1.0 ,_%logit_1.0  it_%logit_0.0  does_%logit_1.0  appear_%logit_1.0  to_%logit_1.0  reduce_%logit_1.0  the_%logit_0.0  risk_%logit_2.0  of_%logit_2.0  death_%logit_1.0  and_%logit_1.0  the_%logit_2.0  need_%logit_2.0  for_%logit_0.0  transf_%logit_1.0 usion_%logit_2.0  in_%logit_0.0  these_%logit_0.0  patients_%logit_0.0 ._%logit_0.0  Red_%logit_1.0  blood_%logit_0.0  cells_%logit_0.0  transf_%logit_2.0 usion_%logit_1.0  is_%logit_1.0  associated_%logit_1.0  with_%logit_1.0  a_%logit_1.0  reduction_%logit_0.0  in_%logit_0.0  the_%logit_0.0  incidence_%logit_1.0  of_%logit_2.0  adverse_%logit_0.0  events_%logit_1.0 ,_%logit_0.0  including_%logit_1.0  blood_%logit_1.0  transf_%logit_1.0 usion_%logit_0.0 -_%logit_0.0 related_%logit_0.0  deaths_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  a_%logit_1.0  decrease_%logit_0.0  in_%logit_1.0  blood_%logit_2.0  transf_%logit_0.0 usions_%logit_1.0 -_%logit_0.0 related_%logit_1.0  mortality_%logit_2.0 ._%logit_0.0  Red_%logit_2.0 -_%logit_1.0 blood_%logit_1.0  transf_%logit_1.0 usion_%logit_2.0  therapy_%logit_2.0  appears_%logit_1.0  to_%logit_2.0  be_%logit_2.0  associated_%logit_0.0  with_%logit_0.0  an_%logit_0.0  increased_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  infection_%logit_1.0  and_%logit_1.0  a_%logit_2.0  decreased_%logit_1.0  risk_%logit_2.0  of_%logit_0.0  transf_%logit_0.0 usion_%logit_0.0  failure_%logit_2.0 ,_%logit_2.0  but_%logit_1.0  the_%logit_0.0  exact_%logit_0.0  extent_%logit_1.0  of_%logit_1.0  this_%logit_1.0  risk_%logit_1.0  is_%logit_0.0  unclear_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  I_%logit_0.0 UD_%logit_2.0  removal_%logit_2.0  for_%logit_1.0  PID_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_0.0  this_%logit_0.0  treatment_%logit_0.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_2.0  should_%logit_0.0  be_%logit_2.0  undertaken_%logit_2.0  in_%logit_0.0  the_%logit_1.0  context_%logit_0.0  of_%logit_1.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 defined_%logit_2.0  group_%logit_0.0  of_%logit_0.0  patients_%logit_1.0  who_%logit_2.0  are_%logit_2.0  at_%logit_1.0  high_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  PID_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  those_%logit_0.0  who_%logit_0.0  are_%logit_0.0  unable_%logit_0.0  to_%logit_1.0  tolerate_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0 ._%logit_0.0  They_%logit_1.0  should_%logit_0.0  also_%logit_0.0  include_%logit_0.0  those_%logit_1.0  patients_%logit_1.0  who_%logit_1.0  do_%logit_0.0  not_%logit_2.0  have_%logit_0.0  a_%logit_0.0  history_%logit_1.0  of_%logit_1.0  PID_%logit_0.0  and_%logit_1.0  those_%logit_1.0  patients_%logit_2.0  with_%logit_0.0  an_%logit_0.0  elevated_%logit_1.0  incidence_%logit_2.0  of_%logit_1.0  PID_%logit_1.0 ._%logit_0.0  Such_%logit_2.0  tests_%logit_1.0  should_%logit_0.0  be_%logit_2.0  carried_%logit_0.0  out_%logit_2.0  in_%logit_1.0  a_%logit_0.0  separate_%logit_0.0  setting_%logit_1.0 ,_%logit_1.0  with_%logit_0.0  appropriate_%logit_2.0  attention_%logit_1.0  to_%logit_0.0  detail_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  cort_%logit_0.0 ic_%logit_0.0 oster_%logit_0.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  chronic_%logit_2.0  asthma_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_1.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  steroids_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_1.0  in_%logit_2.0  the_%logit_2.0  management_%logit_1.0  of_%logit_0.0  these_%logit_0.0  patients_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  a_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trial_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_1.0  these_%logit_1.0  medications_%logit_1.0  in_%logit_2.0  treating_%logit_0.0  patients_%logit_1.0  with_%logit_1.0  severe_%logit_2.0  asthma_%logit_2.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_0.0  are_%logit_2.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_0.0  the_%logit_2.0  dose_%logit_1.0  is_%logit_2.0  appropriate_%logit_2.0  for_%logit_2.0  each_%logit_2.0  patient_%logit_1.0  and_%logit_0.0  their_%logit_1.0  circumstances_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  benz_%logit_0.0 od_%logit_1.0 iazep_%logit_2.0 ines_%logit_2.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  negative_%logit_0.0  symptoms_%logit_0.0  of_%logit_1.0  depression_%logit_1.0  or_%logit_0.0  dys_%logit_2.0 k_%logit_1.0 ines_%logit_0.0 ia_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_1.0  and_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  benz_%logit_0.0 ad_%logit_2.0 iazep_%logit_2.0 ines_%logit_2.0 ,_%logit_2.0  the_%logit_0.0  optimal_%logit_2.0  dosage_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  optimal_%logit_1.0  duration_%logit_2.0  of_%logit_1.0  treatment_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_1.0  should_%logit_2.0  focus_%logit_2.0  on_%logit_0.0  improving_%logit_0.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_2.0  life_%logit_0.0  of_%logit_2.0  people_%logit_0.0  with_%logit_0.0  depression_%logit_0.0  and_%logit_2.0  Dys_%logit_0.0 k_%logit_1.0 ines_%logit_0.0 ias_%logit_2.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  assessing_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  other_%logit_1.0  drugs_%logit_1.0 ,_%logit_1.0  such_%logit_2.0  as_%logit_2.0  antidepressants_%logit_0.0  and_%logit_1.0  antidepressants_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  any_%logit_1.0  of_%logit_2.0  the_%logit_0.0  interventions_%logit_0.0  included_%logit_0.0  in_%logit_0.0  this_%logit_1.0  review_%logit_1.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_0.0  reducing_%logit_0.0  mortality_%logit_0.0  and_%logit_2.0  disability_%logit_1.0  in_%logit_0.0  hospital_%logit_0.0  wards_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_1.0  effectiveness_%logit_2.0  of_%logit_0.0  these_%logit_2.0  interventions_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  mortality_%logit_0.0 ,_%logit_1.0  disability_%logit_2.0  and_%logit_1.0  morbid_%logit_2.0 ity_%logit_1.0  in_%logit_1.0  hospitals_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  them_%logit_1.0  to_%logit_1.0  each_%logit_2.0  other_%logit_2.0 ._%logit_0.0  It_%logit_0.0  is_%logit_1.0  also_%logit_2.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_2.0  by_%logit_1.0  which_%logit_2.0  these_%logit_0.0  interventions_%logit_0.0  are_%logit_0.0  implemented_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  how_%logit_1.0  they_%logit_0.0  are_%logit_1.0  implemented_%logit_0.0  in_%logit_0.0  different_%logit_2.0  settings_%logit_1.0 ,_%logit_1.0  settings_%logit_1.0  and_%logit_2.0  settings_%logit_1.0 ._%logit_1.0
 Water_%logit_0.0  disinfect_%logit_0.0 ion_%logit_2.0  is_%logit_2.0  effective_%logit_1.0  in_%logit_2.0  reducing_%logit_0.0  diarr_%logit_2.0 hoe_%logit_0.0 a_%logit_0.0  incidence_%logit_0.0  and_%logit_2.0  reducing_%logit_2.0  water_%logit_0.0  contamination_%logit_1.0  in_%logit_1.0  households_%logit_1.0 ._%logit_1.0  It_%logit_0.0  is_%logit_0.0  not_%logit_1.0  clear_%logit_1.0  whether_%logit_0.0  water_%logit_1.0  disinfect_%logit_1.0 ion_%logit_0.0  has_%logit_0.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_2.0  on_%logit_2.0  the_%logit_1.0  incidence_%logit_0.0  or_%logit_2.0  severity_%logit_2.0  of_%logit_1.0  diarrhea_%logit_2.0  or_%logit_1.0  on_%logit_2.0  water_%logit_2.0  contamination_%logit_0.0 ._%logit_2.0  Water_%logit_1.0  disinfect_%logit_2.0 ions_%logit_2.0  are_%logit_0.0  effective_%logit_0.0  in_%logit_2.0  decreasing_%logit_2.0  diarr_%logit_1.0 hoe_%logit_1.0 al_%logit_0.0  morbid_%logit_0.0 ity_%logit_1.0  in_%logit_2.0  households_%logit_0.0 ,_%logit_1.0  but_%logit_1.0  there_%logit_1.0  is_%logit_1.0  a_%logit_2.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  disinfect_%logit_2.0 ion_%logit_1.0  and_%logit_0.0  disinfect_%logit_0.0 ion_%logit_2.0  in_%logit_0.0  households_%logit_2.0  with_%logit_1.0  water_%logit_1.0  contamination_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  in_%logit_1.0  households_%logit_2.0  without_%logit_1.0  water_%logit_2.0  pur_%logit_2.0 ification_%logit_2.0  or_%logit_2.0  disinfect_%logit_2.0 ion_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  for_%logit_1.0  pain_%logit_0.0  relief_%logit_0.0  in_%logit_0.0  adults_%logit_0.0  with_%logit_0.0  oste_%logit_0.0 op_%logit_2.0 or_%logit_2.0 osis_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  acupuncture_%logit_1.0  in_%logit_0.0  adults_%logit_1.0 ._%logit_1.0  It_%logit_0.0  is_%logit_0.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_1.0  by_%logit_1.0  which_%logit_1.0  acupuncture_%logit_0.0  works_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  how_%logit_2.0  it_%logit_1.0  relates_%logit_1.0  to_%logit_0.0  pain_%logit_0.0  relief_%logit_0.0  and_%logit_0.0  function_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  acupuncture_%logit_0.0  with_%logit_1.0  other_%logit_2.0  types_%logit_2.0  of_%logit_0.0  pain_%logit_0.0  relief_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  acupuncture_%logit_1.0  on_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_1.0  and_%logit_2.0  satisfaction_%logit_2.0  with_%logit_0.0  pain_%logit_0.0  relief_%logit_2.0 ,_%logit_0.0  pain_%logit_2.0  management_%logit_0.0  and_%logit_2.0  function_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  I_%logit_1.0 UD_%logit_0.0  insertion_%logit_1.0  as_%logit_2.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_2.0  pelvic_%logit_0.0  floor_%logit_2.0  cleaning_%logit_2.0  in_%logit_0.0  preventing_%logit_2.0  accidental_%logit_1.0  vaginal_%logit_2.0  bleeding_%logit_2.0  or_%logit_1.0  accidental_%logit_0.0  vaginal_%logit_1.0  discharge_%logit_0.0  from_%logit_0.0  the_%logit_1.0  I_%logit_0.0 UD_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_1.0  this_%logit_1.0  intervention_%logit_1.0  as_%logit_1.0  an_%logit_0.0  adj_%logit_1.0 u_%logit_0.0 vant_%logit_0.0  treatment_%logit_0.0  for_%logit_0.0  unintentional_%logit_1.0  vaginal_%logit_1.0  discharge_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_1.0  its_%logit_1.0  effectiveness_%logit_2.0  as_%logit_2.0  a_%logit_0.0  complement_%logit_1.0  to_%logit_0.0  pelvic_%logit_0.0  floors_%logit_0.0  cleaning_%logit_2.0  in_%logit_1.0  the_%logit_1.0  management_%logit_2.0  of_%logit_0.0  accidental_%logit_0.0  vaginal_%logit_0.0  leakage_%logit_0.0  from_%logit_0.0  a_%logit_2.0  tub_%logit_1.0 al_%logit_2.0  tub_%logit_1.0 al_%logit_2.0  basin_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_0.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_1.0  assessing_%logit_1.0  its_%logit_2.0  effectiveness_%logit_1.0  in_%logit_0.0  reducing_%logit_2.0  the_%logit_2.0  incidence_%logit_1.0  of_%logit_1.0  unintended_%logit_1.0  vaginal_%logit_2.0  discharge_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  on_%logit_1.0  determining_%logit_0.0  its_%logit_2.0  safety_%logit_1.0  and_%logit_0.0  effectiveness_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_0.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  omega_%logit_0.0 -_%logit_0.0 3_%logit_0.0  fatty_%logit_0.0  acids_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  people_%logit_2.0  with_%logit_2.0  at_%logit_0.0 opic_%logit_1.0  dermat_%logit_1.0 itis_%logit_2.0 ._%logit_0.0  There_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_2.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_0.0 conduct_%logit_0.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_2.0  omega_%logit_2.0  3_%logit_2.0  fatty_%logit_2.0  acids_%logit_2.0  on_%logit_2.0  skin_%logit_0.0  colour_%logit_0.0 ,_%logit_0.0  texture_%logit_1.0 ,_%logit_1.0  texture_%logit_2.0  and_%logit_1.0  texture_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_0.0  effects_%logit_2.0  on_%logit_1.0  skin_%logit_0.0  color_%logit_1.0  and_%logit_1.0  texture_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  standard_%logit_0.0 ised_%logit_1.0  assessment_%logit_2.0  of_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  omega_%logit_1.0  2_%logit_0.0  fatty_%logit_0.0  acids_%logit_0.0  for_%logit_2.0  dermat_%logit_1.0 itis_%logit_1.0  and_%logit_0.0  ps_%logit_0.0 or_%logit_0.0 iasis_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  a_%logit_0.0  standard_%logit_2.0  assessment_%logit_2.0  of_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_2.0  positive_%logit_1.0  effect_%logit_2.0  of_%logit_0.0  media_%logit_0.0  ads_%logit_2.0  on_%logit_2.0  smoking_%logit_1.0  risk_%logit_2.0  factors_%logit_1.0  in_%logit_2.0  children_%logit_2.0  and_%logit_1.0  adolescents_%logit_2.0 ._%logit_1.0  There_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  media_%logit_2.0  ad_%logit_1.0 verts_%logit_2.0  on_%logit_2.0  risk_%logit_1.0  factors_%logit_2.0 ,_%logit_1.0  such_%logit_1.0  as_%logit_1.0  smoking_%logit_1.0  prevalence_%logit_2.0  and_%logit_0.0  relapse_%logit_0.0  rates_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_0.0  media_%logit_2.0  advertisements_%logit_0.0  in_%logit_0.0  the_%logit_0.0  prevention_%logit_2.0  of_%logit_2.0  relapse_%logit_1.0  and_%logit_0.0  relapse_%logit_1.0 ._%logit_2.0  Such_%logit_2.0  studies_%logit_2.0  should_%logit_0.0  focus_%logit_2.0  on_%logit_2.0  identifying_%logit_0.0  the_%logit_0.0  most_%logit_2.0  effective_%logit_2.0  media_%logit_2.0  ads_%logit_0.0  and_%logit_0.0  the_%logit_2.0  most_%logit_2.0  appropriate_%logit_2.0  media_%logit_2.0  ads_%logit_1.0  for_%logit_1.0  each_%logit_2.0  type_%logit_2.0  of_%logit_2.0  media_%logit_1.0  advertisement_%logit_1.0 ._%logit_1.0  They_%logit_2.0  should_%logit_0.0  also_%logit_0.0  include_%logit_0.0  measures_%logit_0.0  of_%logit_1.0  relapse_%logit_2.0 ,_%logit_2.0  relapse_%logit_1.0 ,_%logit_2.0  quality_%logit_2.0  of_%logit_2.0  life_%logit_1.0  and_%logit_1.0  relapse_%logit_1.0  rate_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_1.0  psych_%logit_0.0 os_%logit_1.0 ocial_%logit_1.0  interventions_%logit_1.0  for_%logit_1.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  alcohol_%logit_0.0  dependence_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  psych_%logit_1.0 otherapy_%logit_1.0  for_%logit_0.0  alcohol_%logit_0.0  dependence_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_2.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  efficacy_%logit_2.0  of_%logit_2.0  psych_%logit_0.0 other_%logit_1.0 ape_%logit_0.0 utic_%logit_2.0  interventions_%logit_2.0  for_%logit_0.0  other_%logit_0.0  types_%logit_1.0  of_%logit_2.0  alcoholic_%logit_1.0  dependence_%logit_1.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_2.0  cocaine_%logit_0.0  or_%logit_0.0  cocaine_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_1.0  whether_%logit_0.0  psych_%logit_2.0 otherapy_%logit_0.0  is_%logit_1.0  more_%logit_0.0  effective_%logit_0.0  than_%logit_1.0  no_%logit_0.0  treatment_%logit_0.0  or_%logit_0.0  no_%logit_0.0  treatment_%logit_2.0  at_%logit_0.0  all_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_2.0  should_%logit_2.0  focus_%logit_2.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0 ,_%logit_0.0  safety_%logit_1.0  and_%logit_1.0  efficacy_%logit_2.0  of_%logit_2.0  psychological_%logit_1.0  therapies_%logit_2.0  for_%logit_2.0  alcoholism_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  on_%logit_2.0  assessing_%logit_0.0  their_%logit_0.0  effectiveness_%logit_1.0  in_%logit_1.0  reducing_%logit_1.0  alcohol_%logit_2.0  dependence_%logit_1.0  and_%logit_1.0  relapse_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  any_%logit_0.0  of_%logit_2.0  the_%logit_2.0  recommended_%logit_0.0  analges_%logit_0.0 ic_%logit_1.0  agents_%logit_2.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_1.0  post_%logit_1.0 operative_%logit_1.0  pain_%logit_1.0  relief_%logit_0.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_2.0  reduction_%logit_0.0  in_%logit_0.0  blood_%logit_1.0  loss_%logit_1.0 ,_%logit_0.0  reduction_%logit_0.0  in_%logit_1.0  prol_%logit_0.0 apse_%logit_2.0  rec_%logit_2.0 urrence_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  improvement_%logit_2.0  in_%logit_0.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_2.0  compared_%logit_0.0  to_%logit_0.0  standard_%logit_0.0  ana_%logit_1.0 esthesia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_1.0  analges_%logit_1.0 ic_%logit_2.0  regime_%logit_2.0  and_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dosage_%logit_1.0  and_%logit_2.0  duration_%logit_1.0  of_%logit_0.0  analges_%logit_1.0 ia_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  different_%logit_1.0  analges_%logit_2.0 ic_%logit_2.0  reg_%logit_1.0 imens_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_2.0  should_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  various_%logit_0.0  analges_%logit_1.0 ics_%logit_2.0  in_%logit_1.0  the_%logit_2.0  management_%logit_0.0  of_%logit_2.0  post_%logit_0.0 op_%logit_1.0  pain_%logit_0.0  relief_%logit_2.0  and_%logit_2.0  recovery_%logit_1.0  from_%logit_0.0  post_%logit_1.0 operative_%logit_2.0  complications_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  T_%logit_1.0 ENS_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  neck_%logit_0.0  pain_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  T_%logit_0.0 ENS_%logit_1.0  regime_%logit_2.0 ,_%logit_0.0  the_%logit_2.0  optimal_%logit_0.0  intensity_%logit_0.0  and_%logit_0.0  duration_%logit_2.0  of_%logit_0.0  T_%logit_0.0 ES_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  the_%logit_1.0  best_%logit_2.0  way_%logit_0.0  to_%logit_2.0  deliver_%logit_2.0  T_%logit_2.0 ENS_%logit_0.0  to_%logit_0.0  people_%logit_1.0  with_%logit_0.0  chronic_%logit_1.0  pain_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  evaluation_%logit_0.0  of_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  T_%logit_0.0 ens_%logit_1.0  in_%logit_2.0  chronic_%logit_0.0  pain_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_2.0  T_%logit_0.0 ENS_%logit_1.0  with_%logit_1.0  T_%logit_0.0 ENS_%logit_2.0 ,_%logit_2.0  T_%logit_0.0 ENS_%logit_2.0  and_%logit_0.0  T_%logit_0.0 ENS_%logit_1.0  for_%logit_0.0  pain_%logit_0.0  relief_%logit_1.0  and_%logit_1.0  function_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_0.0  of_%logit_0.0  pro_%logit_1.0 ph_%logit_2.0 yl_%logit_2.0 actic_%logit_0.0  antibiotics_%logit_1.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_2.0  candid_%logit_0.0 iasis_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  these_%logit_1.0  agents_%logit_2.0  in_%logit_2.0  terms_%logit_1.0  of_%logit_0.0  efficacy_%logit_2.0 ,_%logit_0.0  toler_%logit_2.0 ability_%logit_1.0  and_%logit_0.0  safety_%logit_0.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  antibiotic_%logit_2.0  therapy_%logit_2.0  in_%logit_2.0  candid_%logit_2.0 iasis_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_1.0  these_%logit_0.0  agents_%logit_1.0  to_%logit_1.0  each_%logit_1.0  other_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_0.0  future_%logit_1.0  trials_%logit_1.0  should_%logit_1.0  evaluate_%logit_1.0  the_%logit_1.0  efficacy_%logit_2.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  antibiotic_%logit_2.0  treatment_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  also_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  antibiotic_%logit_2.0  reg_%logit_0.0 imens_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  the_%logit_0.0  duration_%logit_2.0  of_%logit_1.0  treatment_%logit_0.0 ,_%logit_2.0  respectively_%logit_1.0 ._%logit_1.0
 Walking_%logit_0.0  distance_%logit_2.0  and_%logit_2.0  speed_%logit_0.0  tests_%logit_0.0  are_%logit_2.0  effective_%logit_1.0  in_%logit_0.0  improving_%logit_2.0  walking_%logit_0.0  distance_%logit_1.0  and_%logit_2.0  walking_%logit_0.0  speed_%logit_0.0  in_%logit_2.0  patients_%logit_1.0  with_%logit_1.0  Parkinson_%logit_1.0 's_%logit_1.0  disease_%logit_2.0 ._%logit_1.0  Improvement_%logit_1.0  in_%logit_1.0  walking_%logit_1.0  distance_%logit_2.0 ,_%logit_1.0  speed_%logit_0.0  and_%logit_1.0  stride_%logit_0.0  length_%logit_0.0  were_%logit_2.0  not_%logit_2.0  significantly_%logit_1.0  different_%logit_1.0  from_%logit_0.0  decreases_%logit_0.0  in_%logit_0.0  walking_%logit_2.0  speed_%logit_2.0  or_%logit_0.0  speed_%logit_2.0 ._%logit_1.0  However_%logit_0.0 ,_%logit_1.0  the_%logit_1.0  results_%logit_0.0  are_%logit_1.0  based_%logit_2.0  on_%logit_1.0  a_%logit_1.0  small_%logit_0.0  number_%logit_0.0  of_%logit_0.0  short_%logit_0.0 -_%logit_0.0 term_%logit_0.0  studies_%logit_0.0  with_%logit_0.0  a_%logit_0.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  walking_%logit_1.0  distance_%logit_1.0  tests_%logit_1.0  on_%logit_2.0  walking_%logit_1.0  speed_%logit_0.0  and_%logit_2.0  speed_%logit_2.0  and_%logit_0.0  to_%logit_1.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  treadmill_%logit_0.0  tests_%logit_1.0  in_%logit_1.0  reducing_%logit_2.0  falls_%logit_2.0  and_%logit_1.0  falling_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  CP_%logit_0.0 AP_%logit_2.0  in_%logit_1.0  the_%logit_1.0  management_%logit_2.0  of_%logit_2.0  lung_%logit_0.0  function_%logit_2.0  in_%logit_1.0  people_%logit_2.0  with_%logit_2.0  chronic_%logit_0.0  lung_%logit_2.0  disease_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_1.0 ised_%logit_0.0  controlled_%logit_0.0  trials_%logit_1.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  this_%logit_0.0  therapy_%logit_0.0  in_%logit_0.0  these_%logit_0.0  patients_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_0.0  should_%logit_1.0  be_%logit_1.0  of_%logit_2.0  high_%logit_0.0  methodological_%logit_2.0  quality_%logit_2.0 ,_%logit_2.0  with_%logit_0.0  a_%logit_1.0  focus_%logit_2.0  on_%logit_2.0  assessing_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  the_%logit_1.0  therapy_%logit_2.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  these_%logit_1.0  patients_%logit_0.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  on_%logit_0.0  the_%logit_0.0  long_%logit_2.0 -_%logit_1.0 term_%logit_1.0  effects_%logit_0.0  of_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0 ._%logit_1.0  They_%logit_0.0  should_%logit_1.0  also_%logit_2.0  evaluate_%logit_0.0  the_%logit_2.0  effect_%logit_2.0  of_%logit_0.0  the_%logit_1.0  intervention_%logit_1.0  on_%logit_1.0  lung_%logit_0.0  function_%logit_1.0  and_%logit_1.0  on_%logit_0.0  breathing_%logit_1.0  capacity_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  psych_%logit_1.0 otherapy_%logit_0.0  for_%logit_1.0  rel_%logit_1.0 apses_%logit_0.0  of_%logit_0.0  depression_%logit_2.0  or_%logit_2.0  bipolar_%logit_0.0  disorder_%logit_1.0 ._%logit_2.0  There_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_2.0 ised_%logit_0.0  controlled_%logit_0.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  psych_%logit_0.0 otherapy_%logit_1.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_1.0  other_%logit_1.0  psych_%logit_1.0 otherapy_%logit_2.0  approaches_%logit_0.0  to_%logit_1.0  depression_%logit_1.0  and_%logit_1.0  bipolar_%logit_2.0  disorder_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  psych_%logit_1.0 otherapy_%logit_2.0  with_%logit_1.0  other_%logit_0.0  psychological_%logit_1.0  therapies_%logit_0.0 ._%logit_2.0  Such_%logit_1.0  trials_%logit_1.0  should_%logit_0.0  be_%logit_0.0  conducted_%logit_0.0  in_%logit_2.0  a_%logit_0.0  variety_%logit_1.0  of_%logit_1.0  settings_%logit_2.0 ,_%logit_1.0  with_%logit_0.0  appropriate_%logit_2.0  attention_%logit_2.0  paid_%logit_0.0  to_%logit_1.0  outcome_%logit_0.0  measures_%logit_2.0  and_%logit_0.0  time_%logit_1.0  to_%logit_2.0  relapse_%logit_1.0  and_%logit_0.0  duration_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_2.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  G_%logit_1.0 -_%logit_2.0 CS_%logit_1.0 F_%logit_1.0  as_%logit_0.0  a_%logit_2.0  pro_%logit_0.0 ph_%logit_2.0 yl_%logit_0.0 actic_%logit_1.0  agent_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_2.0  acute_%logit_1.0  neut_%logit_2.0 rop_%logit_2.0 en_%logit_1.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_1.0 ,_%logit_1.0  duration_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  duration_%logit_2.0  of_%logit_2.0  therapy_%logit_2.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  the_%logit_2.0  best_%logit_0.0  dose_%logit_0.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_2.0  therapy_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_0.0  these_%logit_1.0  agents_%logit_1.0  on_%logit_1.0  survival_%logit_2.0  and_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_1.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  this_%logit_0.0  condition_%logit_0.0 ._%logit_0.0  In_%logit_2.0  addition_%logit_0.0 ,_%logit_1.0  future_%logit_1.0  research_%logit_0.0  should_%logit_1.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_1.0  these_%logit_2.0  drugs_%logit_0.0  in_%logit_1.0  the_%logit_2.0  management_%logit_2.0  of_%logit_1.0  this_%logit_2.0  condition_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  also_%logit_1.0  evaluate_%logit_0.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_2.0  toxicity_%logit_0.0  of_%logit_2.0  these_%logit_1.0  treatments_%logit_0.0  in_%logit_2.0  particular_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  testosterone_%logit_1.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_1.0  sexual_%logit_1.0  dysfunction_%logit_1.0  in_%logit_0.0  men_%logit_0.0  with_%logit_0.0  schizophrenia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  testosterone_%logit_2.0  concentration_%logit_1.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_2.0  testosterone_%logit_0.0  therapy_%logit_0.0 ,_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_0.0  optimal_%logit_2.0  frequency_%logit_0.0  of_%logit_0.0  testosterone_%logit_2.0  injections_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_1.0  testosterone_%logit_1.0  supplementation_%logit_0.0  on_%logit_0.0  sexual_%logit_1.0  dysfunction_%logit_0.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_1.0  as_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  testosterone_%logit_0.0  replacement_%logit_1.0  therapy_%logit_2.0  in_%logit_2.0  preventing_%logit_1.0  deterioration_%logit_2.0  of_%logit_0.0  sexual_%logit_0.0  function_%logit_1.0  in_%logit_2.0  men_%logit_1.0  who_%logit_0.0  are_%logit_2.0  suffering_%logit_2.0  from_%logit_2.0  schizophrenia_%logit_2.0  or_%logit_0.0  bipolar_%logit_0.0  disorder_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  condoms_%logit_0.0  in_%logit_2.0  the_%logit_2.0  prevention_%logit_0.0  of_%logit_1.0  ST_%logit_1.0 I_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  condoms_%logit_0.0  for_%logit_0.0  ST_%logit_0.0 I_%logit_0.0  prevention_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  whether_%logit_1.0  condoms_%logit_2.0  are_%logit_1.0  effective_%logit_0.0  in_%logit_0.0  preventing_%logit_0.0  ST_%logit_2.0 I_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  whether_%logit_1.0  they_%logit_2.0  are_%logit_1.0  safe_%logit_1.0  and_%logit_2.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_1.0  ST_%logit_0.0 I_%logit_0.0  incidence_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  studies_%logit_1.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  condoms_%logit_2.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  contraceptive_%logit_2.0  effectiveness_%logit_0.0  and_%logit_2.0  cost_%logit_1.0 -_%logit_0.0 effect_%logit_1.0 iveness_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  how_%logit_1.0  best_%logit_0.0  to_%logit_2.0  tailor_%logit_0.0  condoms_%logit_0.0  to_%logit_1.0  the_%logit_1.0  needs_%logit_0.0  of_%logit_0.0  the_%logit_0.0  population_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  immun_%logit_1.0 os_%logit_0.0 upp_%logit_2.0 ressive_%logit_2.0  agents_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  D_%logit_2.0 MD_%logit_2.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_1.0  immun_%logit_1.0 otherapy_%logit_1.0  in_%logit_2.0  D_%logit_0.0 MD_%logit_2.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0 ,_%logit_2.0  safety_%logit_2.0  and_%logit_2.0  efficacy_%logit_0.0  of_%logit_0.0  these_%logit_2.0  agents_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_1.0  for_%logit_2.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  profiles_%logit_1.0  of_%logit_2.0  these_%logit_2.0  treatments_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0  there_%logit_0.0  is_%logit_0.0  an_%logit_0.0  issue_%logit_0.0  of_%logit_1.0  the_%logit_2.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_1.0  evidence_%logit_0.0  and_%logit_0.0  the_%logit_2.0  reliability_%logit_1.0  of_%logit_1.0  the_%logit_2.0  results_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_2.0  nit_%logit_0.0 ric_%logit_1.0  oxide_%logit_0.0  as_%logit_0.0  an_%logit_2.0  adjunct_%logit_1.0  to_%logit_1.0  standard_%logit_1.0  oxygen_%logit_1.0  therapy_%logit_0.0  in_%logit_1.0  patients_%logit_2.0  with_%logit_1.0  acute_%logit_0.0  respiratory_%logit_0.0  distress_%logit_0.0  syndrome_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_0.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_1.0  Nit_%logit_2.0 ric_%logit_0.0  oxide_%logit_1.0  therapy_%logit_0.0  in_%logit_0.0  these_%logit_0.0  patients_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_1.0  therapy_%logit_0.0  with_%logit_1.0  standard_%logit_2.0  oxygen_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  its_%logit_1.0  effectiveness_%logit_2.0  in_%logit_2.0  the_%logit_2.0  management_%logit_2.0  of_%logit_2.0  patients_%logit_0.0  with_%logit_1.0  severe_%logit_2.0  A_%logit_1.0 HR_%logit_2.0 F_%logit_2.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_2.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_0.0  identifying_%logit_0.0  the_%logit_0.0  most_%logit_2.0  effective_%logit_0.0  dose_%logit_0.0  and_%logit_2.0  timing_%logit_1.0  of_%logit_1.0  administration_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  best_%logit_0.0  dose_%logit_0.0 ,_%logit_1.0  duration_%logit_1.0  and_%logit_0.0  duration_%logit_2.0 ._%logit_1.0
 Screen_%logit_0.0 ing_%logit_0.0  mamm_%logit_0.0 ography_%logit_0.0  for_%logit_0.0  breast_%logit_1.0  cancer_%logit_0.0  is_%logit_2.0  associated_%logit_0.0  with_%logit_2.0  a_%logit_0.0  reduction_%logit_1.0  in_%logit_1.0  the_%logit_2.0  incidence_%logit_1.0  of_%logit_1.0  death_%logit_2.0 ,_%logit_1.0  but_%logit_0.0  a_%logit_1.0  significant_%logit_2.0  increase_%logit_0.0  in_%logit_0.0  the_%logit_0.0  rate_%logit_0.0  of_%logit_0.0  metast_%logit_1.0 atic_%logit_1.0  breast_%logit_0.0  cancer_%logit_2.0 ._%logit_2.0  Screen_%logit_1.0 ing_%logit_0.0  for_%logit_1.0  breast_%logit_0.0  cancers_%logit_2.0  for_%logit_0.0  breast_%logit_2.0  screening_%logit_2.0  for_%logit_2.0  breast_%logit_1.0  reconstruction_%logit_2.0  appears_%logit_2.0  to_%logit_1.0  have_%logit_1.0  a_%logit_1.0  beneficial_%logit_2.0  effect_%logit_2.0  on_%logit_2.0  survival_%logit_1.0  and_%logit_0.0  quality_%logit_2.0  of_%logit_2.0  life_%logit_1.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_2.0  for_%logit_1.0  further_%logit_0.0  research_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  screening_%logit_0.0  on_%logit_1.0  survival_%logit_1.0 ,_%logit_1.0  quality_%logit_2.0  and_%logit_1.0  time_%logit_1.0  to_%logit_1.0  progression_%logit_1.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  screening_%logit_2.0  with_%logit_1.0  other_%logit_0.0  methods_%logit_2.0  of_%logit_1.0  screening_%logit_1.0 ,_%logit_2.0  including_%logit_2.0  mamm_%logit_2.0 ography_%logit_1.0  in_%logit_2.0  terms_%logit_0.0  of_%logit_2.0  time_%logit_1.0  to_%logit_0.0  death_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_1.0  screening_%logit_1.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  breast_%logit_1.0  cancer_%logit_0.0  mortality_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  cognitive_%logit_0.0  enh_%logit_1.0 ancers_%logit_0.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  cognitive_%logit_0.0  impairment_%logit_0.0  in_%logit_1.0  Alzheimer_%logit_1.0 �_%logit_0.0 �_%logit_2.0 s_%logit_0.0  dement_%logit_0.0 ed_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  dementia_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  enh_%logit_1.0 ancers_%logit_0.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_0.0  in_%logit_0.0  this_%logit_0.0  patient_%logit_0.0  population_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  whether_%logit_1.0  they_%logit_1.0  are_%logit_1.0  useful_%logit_0.0  in_%logit_1.0  the_%logit_2.0  management_%logit_0.0  of_%logit_0.0  cognitive_%logit_0.0  impair_%logit_1.0 ments_%logit_2.0  in_%logit_1.0  dementia_%logit_2.0 ,_%logit_0.0  or_%logit_1.0  whether_%logit_2.0  enh_%logit_2.0 ancer_%logit_0.0  therapy_%logit_0.0  is_%logit_0.0  beneficial_%logit_0.0  in_%logit_0.0  reducing_%logit_1.0  cognitive_%logit_0.0  impairment_%logit_0.0  or_%logit_2.0  dementia_%logit_2.0 -_%logit_2.0 like_%logit_0.0  symptoms_%logit_1.0  in_%logit_1.0  these_%logit_2.0  patients_%logit_1.0 ._%logit_0.0  The_%logit_0.0  results_%logit_1.0  of_%logit_0.0  this_%logit_1.0  review_%logit_0.0  should_%logit_0.0  be_%logit_1.0  interpreted_%logit_2.0  with_%logit_1.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  the_%logit_0.0  conclusions_%logit_0.0  of_%logit_2.0  the_%logit_1.0  review_%logit_1.0  are_%logit_1.0  based_%logit_1.0  on_%logit_0.0  only_%logit_0.0  a_%logit_0.0  small_%logit_2.0  number_%logit_2.0  of_%logit_1.0  patients_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_1.0  results_%logit_2.0  of_%logit_1.0  the_%logit_2.0  two_%logit_2.0  included_%logit_2.0  studies_%logit_0.0  were_%logit_1.0  not_%logit_0.0  representative_%logit_2.0  of_%logit_2.0  the_%logit_1.0  whole_%logit_0.0  range_%logit_0.0  of_%logit_0.0  dementia_%logit_0.0  types_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  hyd_%logit_0.0 roc_%logit_1.0 ort_%logit_1.0 is_%logit_0.0 one_%logit_1.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_1.0  hypot_%logit_1.0 ension_%logit_1.0  in_%logit_1.0  patients_%logit_1.0  undergoing_%logit_0.0  elect_%logit_2.0 ive_%logit_1.0  surgery_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  hyd_%logit_2.0 roc_%logit_1.0 ORT_%logit_2.0 is_%logit_0.0 one_%logit_0.0  formulation_%logit_2.0 ,_%logit_0.0  the_%logit_2.0  optimal_%logit_1.0  dose_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  dosage_%logit_2.0  and_%logit_2.0  timing_%logit_1.0  of_%logit_2.0  electroly_%logit_2.0 te_%logit_1.0  administration_%logit_2.0 ._%logit_1.0  In_%logit_2.0  addition_%logit_2.0 ,_%logit_2.0  further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  hyd_%logit_2.0 oc_%logit_0.0 ort_%logit_1.0 is_%logit_0.0 ones_%logit_2.0  in_%logit_2.0  reducing_%logit_2.0  blood_%logit_0.0  loss_%logit_2.0  and_%logit_0.0  blood_%logit_0.0  loss_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  hypot_%logit_2.0 ension_%logit_0.0  during_%logit_0.0  elect_%logit_2.0 ive_%logit_0.0  surgeries_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_1.0  their_%logit_1.0  effects_%logit_1.0  on_%logit_0.0  mortality_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  self_%logit_1.0 -_%logit_1.0 eval_%logit_0.0 uation_%logit_0.0  tools_%logit_1.0  for_%logit_1.0  enhancing_%logit_0.0  partner_%logit_1.0 -_%logit_0.0 selection_%logit_2.0  behaviour_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_0.0  best_%logit_2.0  tools_%logit_0.0  to_%logit_2.0  improve_%logit_2.0  self_%logit_2.0 -_%logit_2.0 effic_%logit_2.0 acy_%logit_0.0  in_%logit_0.0  partner_%logit_0.0  selection_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  various_%logit_1.0  types_%logit_2.0  of_%logit_1.0  self_%logit_2.0  assessment_%logit_0.0  tools_%logit_2.0 ,_%logit_2.0  and_%logit_0.0  also_%logit_2.0  to_%logit_2.0  assess_%logit_1.0  their_%logit_0.0  effectiveness_%logit_0.0  in_%logit_1.0  the_%logit_1.0  context_%logit_0.0  of_%logit_0.0  a_%logit_2.0  variety_%logit_0.0  of_%logit_1.0  contexts_%logit_0.0 ,_%logit_0.0  settings_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  contexts_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_2.0  on_%logit_2.0  assessing_%logit_2.0  the_%logit_2.0  efficacy_%logit_2.0  of_%logit_2.0  self_%logit_2.0  assessments_%logit_0.0  and_%logit_2.0  assessing_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0 ,_%logit_2.0  reliability_%logit_2.0 ,_%logit_1.0  reliability_%logit_2.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_2.0  self_%logit_0.0  appraisal_%logit_1.0  tools_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_2.0  as_%logit_0.0  assessing_%logit_0.0  their_%logit_0.0  effectiveness_%logit_1.0 ._%logit_1.0
 Immun_%logit_0.0 ogen_%logit_0.0 icity_%logit_1.0  and_%logit_0.0  immun_%logit_0.0 ogen_%logit_1.0 icity_%logit_1.0  are_%logit_2.0  similar_%logit_0.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_2.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_1.0 ._%logit_1.0  However_%logit_2.0 ,_%logit_0.0  the_%logit_2.0  risk_%logit_0.0  of_%logit_0.0  toxicity_%logit_1.0  is_%logit_2.0  higher_%logit_1.0  in_%logit_1.0  those_%logit_0.0  receiving_%logit_2.0  an_%logit_2.0  immun_%logit_2.0 ogen_%logit_1.0 etic_%logit_2.0  antibody_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  in_%logit_2.0  those_%logit_2.0  who_%logit_2.0  are_%logit_2.0  receiving_%logit_0.0  an_%logit_1.0  adj_%logit_0.0 u_%logit_1.0 vant_%logit_0.0  vaccine_%logit_0.0 ._%logit_0.0  The_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  adverse_%logit_1.0  events_%logit_0.0  is_%logit_0.0  lower_%logit_1.0  with_%logit_1.0  an_%logit_1.0  EL_%logit_2.0 ISA_%logit_2.0  antibody_%logit_1.0 ,_%logit_1.0  but_%logit_2.0  the_%logit_1.0  number_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  treat_%logit_0.0  is_%logit_0.0  much_%logit_0.0  higher_%logit_1.0  with_%logit_1.0  a_%logit_2.0  EL_%logit_0.0 ISA_%logit_0.0  vaccine_%logit_1.0 ._%logit_0.0  There_%logit_2.0  is_%logit_1.0  a_%logit_2.0  need_%logit_1.0  for_%logit_1.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_1.0  and_%logit_1.0  reported_%logit_1.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_0.0  toxicity_%logit_2.0  of_%logit_2.0  EL_%logit_2.0 ISA_%logit_2.0  vaccines_%logit_1.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  EL_%logit_2.0 ISA_%logit_0.0  with_%logit_0.0  EL_%logit_2.0 ISA_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  p_%logit_0.0 ali_%logit_0.0 per_%logit_1.0 id_%logit_0.0 one_%logit_0.0  pal_%logit_0.0 mit_%logit_2.0 ate_%logit_0.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_2.0  time_%logit_1.0 -_%logit_1.0 to_%logit_2.0 -_%logit_0.0 rel_%logit_0.0 apse_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_2.0  schizophrenia_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_0.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_0.0  p_%logit_1.0 ili_%logit_1.0 per_%logit_0.0 id_%logit_0.0 ones_%logit_0.0 ,_%logit_1.0  the_%logit_2.0  optimal_%logit_1.0  dosage_%logit_0.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_1.0  administration_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  timing_%logit_0.0  of_%logit_2.0  discontin_%logit_2.0 uation_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  future_%logit_2.0  research_%logit_0.0  should_%logit_2.0  focus_%logit_0.0  on_%logit_0.0  the_%logit_1.0  long_%logit_1.0 -_%logit_2.0 term_%logit_2.0  efficacy_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_1.0  as_%logit_2.0  on_%logit_0.0  the_%logit_0.0  mechanisms_%logit_0.0  by_%logit_1.0  which_%logit_2.0  they_%logit_0.0  are_%logit_0.0  used_%logit_0.0  in_%logit_0.0  the_%logit_0.0  management_%logit_0.0  of_%logit_0.0  relapse_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  orth_%logit_0.0 op_%logit_1.0 aed_%logit_1.0 ic_%logit_0.0  braces_%logit_1.0  for_%logit_1.0  skeletal_%logit_1.0  deform_%logit_2.0 ity_%logit_2.0  in_%logit_2.0  adults_%logit_1.0  with_%logit_1.0  mal_%logit_1.0 oc_%logit_0.0 clusion_%logit_0.0  of_%logit_0.0  the_%logit_0.0  upper_%logit_1.0  inc_%logit_1.0 is_%logit_1.0 ors_%logit_2.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_0.0  these_%logit_0.0  braces_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_1.0  devices_%logit_0.0  to_%logit_2.0  other_%logit_1.0  types_%logit_2.0  of_%logit_2.0  braces_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  these_%logit_0.0  to_%logit_0.0  each_%logit_0.0  other_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_0.0  deform_%logit_2.0 ity_%logit_0.0  and_%logit_0.0  bone_%logit_0.0  deform_%logit_0.0 ity_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_1.0  the_%logit_0.0  evaluation_%logit_2.0  of_%logit_0.0  structural_%logit_1.0  deform_%logit_0.0 ity_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  on_%logit_1.0  determining_%logit_2.0  the_%logit_0.0  optimal_%logit_1.0  type_%logit_0.0  and_%logit_2.0  duration_%logit_1.0  of_%logit_0.0  treatment_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  also_%logit_1.0  on_%logit_2.0  the_%logit_0.0  optimal_%logit_1.0  length_%logit_1.0  of_%logit_0.0  treatment_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_1.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_1.0  soft_%logit_0.0  tissue_%logit_0.0  as_%logit_0.0  a_%logit_2.0  substitute_%logit_1.0  for_%logit_0.0  soft_%logit_1.0  tissue_%logit_1.0  for_%logit_2.0  soft_%logit_2.0  tissues_%logit_1.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  Im_%logit_0.0 plant_%logit_1.0  deform_%logit_0.0 ity_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  whether_%logit_0.0  soft_%logit_0.0  tissue_%logit_1.0  is_%logit_0.0  superior_%logit_0.0  to_%logit_0.0  soft_%logit_0.0  tissue_%logit_1.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_0.0  bone_%logit_0.0  loss_%logit_0.0 ,_%logit_1.0  bone_%logit_1.0  regeneration_%logit_1.0  and_%logit_1.0  bone_%logit_1.0  regeneration_%logit_2.0 ,_%logit_2.0  bone_%logit_0.0  thickness_%logit_2.0 ,_%logit_2.0  bone_%logit_2.0  density_%logit_0.0 ,_%logit_1.0  bone_%logit_1.0  integrity_%logit_1.0  and_%logit_1.0  bone_%logit_1.0  density_%logit_0.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  soft_%logit_0.0  tissue_%logit_1.0  soft_%logit_0.0  tissues_%logit_2.0  as_%logit_2.0  a_%logit_0.0  replacement_%logit_1.0  for_%logit_0.0  rigid_%logit_0.0  tissue_%logit_1.0  soft_%logit_1.0  tissue_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_2.0  of_%logit_2.0  dietary_%logit_1.0  fibre_%logit_0.0  supplements_%logit_1.0  in_%logit_2.0  the_%logit_1.0  management_%logit_1.0  of_%logit_1.0  weight_%logit_2.0  loss_%logit_0.0  in_%logit_1.0  overweight_%logit_0.0  or_%logit_1.0  obese_%logit_0.0  individuals_%logit_0.0  with_%logit_0.0  diabetes_%logit_1.0  mell_%logit_0.0 itus_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  fibre_%logit_1.0  supplements_%logit_0.0  for_%logit_0.0  weight_%logit_1.0  loss_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_1.0  effects_%logit_2.0  of_%logit_1.0  fiber_%logit_2.0  supplements_%logit_1.0  on_%logit_0.0  health_%logit_2.0 -_%logit_0.0 related_%logit_2.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_0.0  and_%logit_0.0  physical_%logit_2.0  fitness_%logit_0.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  long_%logit_0.0 -_%logit_2.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_1.0  fibre_%logit_1.0  supplements_%logit_0.0  are_%logit_2.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_1.0  for_%logit_2.0  overweight_%logit_0.0  or_%logit_1.0  obesity_%logit_2.0  in_%logit_1.0  obese_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  a_%logit_1.0  history_%logit_0.0  of_%logit_1.0  cardiovascular_%logit_0.0  disease_%logit_0.0 ._%logit_1.0
 Cognitive_%logit_0.0  training_%logit_2.0  may_%logit_1.0  improve_%logit_0.0  cognitive_%logit_2.0  performance_%logit_0.0  in_%logit_1.0  people_%logit_2.0  with_%logit_0.0  MS_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  its_%logit_0.0  use_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_2.0  other_%logit_0.0  cognitive_%logit_0.0  training_%logit_0.0  programmes_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_0.0  cognitive_%logit_1.0  training_%logit_0.0  on_%logit_1.0  performance_%logit_0.0 ,_%logit_1.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  fatigue_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  cognitive_%logit_0.0  training_%logit_2.0  with_%logit_0.0  other_%logit_0.0  training_%logit_1.0  programmes_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_1.0  to_%logit_2.0  assess_%logit_1.0  fatigue_%logit_2.0 ,_%logit_2.0  fatigue_%logit_1.0 ,_%logit_2.0  mood_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  cognitive_%logit_1.0  functioning_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  future_%logit_0.0  research_%logit_1.0  should_%logit_0.0  focus_%logit_2.0  on_%logit_2.0  assessing_%logit_0.0  the_%logit_1.0  effects_%logit_2.0  on_%logit_0.0  fatigue_%logit_2.0  and_%logit_2.0  cognitive_%logit_2.0  function_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  on_%logit_2.0  assessing_%logit_0.0  fatigue_%logit_0.0  and_%logit_0.0  mood_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_2.0  on_%logit_0.0  fatigue_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  physical_%logit_1.0  fitness_%logit_2.0  training_%logit_1.0  for_%logit_0.0  developing_%logit_1.0  self_%logit_2.0 -_%logit_1.0 esteem_%logit_1.0  or_%logit_1.0  self_%logit_2.0 -_%logit_0.0 confidence_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_2.0  these_%logit_1.0  exercises_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_1.0  effects_%logit_2.0  of_%logit_0.0  training_%logit_2.0  on_%logit_2.0  self_%logit_0.0  esteem_%logit_1.0  and_%logit_1.0  self_%logit_2.0  confidence_%logit_1.0 ._%logit_1.0  Future_%logit_2.0  research_%logit_2.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_1.0  measuring_%logit_1.0  self_%logit_0.0  esteem_%logit_0.0 ,_%logit_0.0  self_%logit_1.0  confidence_%logit_0.0  and_%logit_0.0  self_%logit_2.0  esteem_%logit_0.0  in_%logit_0.0  children_%logit_1.0  and_%logit_1.0  adolescents_%logit_0.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  on_%logit_0.0  assessing_%logit_0.0  psychological_%logit_2.0  fitness_%logit_2.0  and_%logit_2.0  self_%logit_0.0 -_%logit_1.0 effic_%logit_0.0 acy_%logit_1.0  in_%logit_2.0  adults_%logit_2.0  and_%logit_0.0  children_%logit_1.0  with_%logit_0.0  developmental_%logit_1.0  disabilities_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  anti_%logit_0.0 plate_%logit_2.0 let_%logit_2.0  agents_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  end_%logit_2.0 ov_%logit_2.0 ascular_%logit_1.0  f_%logit_1.0 ibr_%logit_2.0 ino_%logit_1.0 ly_%logit_0.0 sis_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_2.0  agents_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_2.0  them_%logit_0.0  with_%logit_1.0  other_%logit_1.0  anti_%logit_2.0 plate_%logit_0.0 lets_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_2.0  a_%logit_2.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_1.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  plate_%logit_1.0 let_%logit_0.0  agents_%logit_2.0  on_%logit_0.0  the_%logit_2.0  development_%logit_0.0  of_%logit_0.0  end_%logit_1.0 oph_%logit_2.0 aryn_%logit_0.0 ge_%logit_0.0 al_%logit_2.0  fib_%logit_0.0 rosis_%logit_1.0 ._%logit_2.0  This_%logit_2.0  should_%logit_2.0  be_%logit_1.0  done_%logit_2.0  in_%logit_1.0  conjunction_%logit_0.0  with_%logit_1.0  an_%logit_1.0  assessment_%logit_0.0  of_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  anti_%logit_2.0 -_%logit_2.0 plate_%logit_0.0 let_%logit_1.0  drugs_%logit_0.0  in_%logit_0.0  the_%logit_2.0  management_%logit_0.0  of_%logit_2.0  this_%logit_0.0  condition_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_0.0  of_%logit_1.0  pro_%logit_2.0 ph_%logit_1.0 yl_%logit_0.0 actic_%logit_1.0  th_%logit_0.0 rom_%logit_2.0 bo_%logit_2.0 emb_%logit_2.0 olic_%logit_0.0  agents_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  pre_%logit_1.0 -_%logit_1.0 e_%logit_1.0 cl_%logit_1.0 amps_%logit_1.0 ia_%logit_2.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  establish_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_0.0  of_%logit_1.0  pro_%logit_2.0 th_%logit_1.0 romy_%logit_2.0 cin_%logit_2.0  and_%logit_2.0  its_%logit_2.0  analog_%logit_2.0 ues_%logit_2.0  in_%logit_2.0  this_%logit_2.0  population_%logit_0.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_0.0  optimal_%logit_2.0  dose_%logit_2.0  and_%logit_1.0  timing_%logit_0.0  of_%logit_0.0  th_%logit_1.0 rom_%logit_0.0 b_%logit_2.0 op_%logit_0.0 roph_%logit_0.0 yl_%logit_0.0 actic_%logit_0.0  agents_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_1.0  agents_%logit_0.0  with_%logit_1.0  placebo_%logit_0.0  or_%logit_1.0  no_%logit_1.0  treatment_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_0.0  safety_%logit_1.0  aspects_%logit_0.0  of_%logit_0.0  these_%logit_1.0  interventions_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  che_%logit_1.0 mor_%logit_2.0 ad_%logit_1.0 ox_%logit_1.0 ine_%logit_2.0  as_%logit_0.0  an_%logit_0.0  adj_%logit_2.0 u_%logit_2.0 vant_%logit_0.0  to_%logit_0.0  radi_%logit_0.0 otherapy_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  metast_%logit_0.0 atic_%logit_2.0  lung_%logit_1.0  cancer_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_1.0  dose_%logit_1.0 ,_%logit_1.0  duration_%logit_2.0  and_%logit_1.0  timing_%logit_0.0  for_%logit_2.0  che_%logit_1.0 mor_%logit_2.0 adi_%logit_2.0 otherapy_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  dosage_%logit_1.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_1.0  chemotherapy_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  timing_%logit_1.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_0.0  chemotherapy_%logit_1.0  in_%logit_1.0  these_%logit_2.0  patients_%logit_1.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  future_%logit_1.0  research_%logit_2.0  should_%logit_2.0  focus_%logit_0.0  on_%logit_1.0  determining_%logit_0.0  the_%logit_0.0  optimal_%logit_1.0  doses_%logit_1.0  and_%logit_1.0  timing_%logit_2.0 ,_%logit_0.0  duration_%logit_0.0 ,_%logit_1.0  duration_%logit_2.0  of_%logit_0.0  chem_%logit_0.0 otherapy_%logit_0.0  and_%logit_2.0  the_%logit_1.0  most_%logit_0.0  effective_%logit_0.0  chemotherapy_%logit_1.0  reg_%logit_0.0 imens_%logit_1.0  for_%logit_2.0  these_%logit_1.0  patients_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_1.0  as_%logit_2.0  the_%logit_0.0  optimal_%logit_2.0  duration_%logit_0.0  of_%logit_0.0  treatment_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_2.0  of_%logit_0.0  benz_%logit_0.0 od_%logit_0.0 iazep_%logit_0.0 ines_%logit_2.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_1.0  aggressive_%logit_1.0  aggression_%logit_0.0  in_%logit_0.0  people_%logit_1.0  with_%logit_1.0  drug_%logit_0.0 -_%logit_1.0 resistant_%logit_2.0  aggression_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  dose_%logit_1.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_1.0  frequency_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_2.0  optimal_%logit_2.0  dosage_%logit_0.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_1.0  benz_%logit_2.0 ad_%logit_1.0 iazep_%logit_2.0 ines_%logit_2.0  in_%logit_1.0  this_%logit_2.0  population_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  psych_%logit_0.0 os_%logit_0.0 ocial_%logit_1.0  interventions_%logit_0.0  for_%logit_0.0  aggressive_%logit_0.0  aggression_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  these_%logit_0.0  interventions_%logit_2.0  in_%logit_1.0  reducing_%logit_1.0  aggression_%logit_0.0  in_%logit_0.0  these_%logit_0.0  populations_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  t_%logit_0.0 inn_%logit_0.0 itus_%logit_2.0  management_%logit_0.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  id_%logit_1.0 iop_%logit_1.0 ath_%logit_1.0 ic_%logit_0.0  t_%logit_0.0 inn_%logit_2.0 us_%logit_0.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  this_%logit_2.0  treatment_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  profiles_%logit_2.0  of_%logit_1.0  t_%logit_1.0 amn_%logit_2.0 os_%logit_2.0 ide_%logit_1.0  therapy_%logit_2.0  in_%logit_2.0  this_%logit_1.0  setting_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0  there_%logit_1.0  is_%logit_2.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_1.0  for_%logit_1.0  an_%logit_2.0  assessment_%logit_0.0  of_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0 ,_%logit_0.0  safety_%logit_2.0  and_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  the_%logit_0.0  t_%logit_0.0 inn_%logit_2.0 os_%logit_0.0 ide_%logit_1.0  treatment_%logit_1.0  in_%logit_0.0  this_%logit_2.0  population_%logit_2.0 ._%logit_1.0  Finally_%logit_2.0  a_%logit_1.0  review_%logit_2.0  of_%logit_2.0  the_%logit_2.0  quality_%logit_0.0  of_%logit_0.0  the_%logit_0.0  current_%logit_1.0  evidence_%logit_0.0  is_%logit_0.0  warranted_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  psych_%logit_0.0 os_%logit_0.0 ocial_%logit_1.0  interventions_%logit_0.0  for_%logit_0.0  reducing_%logit_1.0  smoking_%logit_1.0  behaviour_%logit_1.0  in_%logit_1.0  psychiatric_%logit_1.0  patients_%logit_0.0  with_%logit_1.0  schizophrenia_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_1.0  these_%logit_2.0  interventions_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  them_%logit_0.0  to_%logit_0.0  each_%logit_2.0  other_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_2.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  these_%logit_2.0  approaches_%logit_2.0  to_%logit_1.0  other_%logit_2.0  psychiatric_%logit_0.0  therapies_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  future_%logit_1.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_0.0  assessing_%logit_0.0  the_%logit_2.0  efficacy_%logit_1.0  of_%logit_0.0  psych_%logit_2.0 oses_%logit_0.0  and_%logit_0.0  their_%logit_0.0  effects_%logit_0.0  on_%logit_1.0  relapse_%logit_2.0  rates_%logit_0.0  and_%logit_1.0  relapse_%logit_1.0  rates_%logit_1.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  on_%logit_0.0  the_%logit_0.0  severity_%logit_0.0  of_%logit_0.0  relapse_%logit_1.0  and_%logit_1.0  relapse_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  waterproof_%logit_0.0  waterproof_%logit_2.0 ing_%logit_2.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_0.0  skin_%logit_0.0  imperfect_%logit_2.0 ions_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_0.0  waterproof_%logit_0.0 ing_%logit_0.0  waterproof_%logit_1.0 ing_%logit_1.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_2.0  for_%logit_0.0  the_%logit_0.0  healing_%logit_2.0  of_%logit_2.0  imperfect_%logit_1.0 ions_%logit_2.0  in_%logit_1.0  the_%logit_2.0  skin_%logit_0.0  imperfect_%logit_2.0 ion_%logit_2.0  of_%logit_1.0  the_%logit_1.0  inner_%logit_0.0 most_%logit_0.0  layers_%logit_2.0  of_%logit_0.0  the_%logit_2.0  outer_%logit_0.0 most_%logit_1.0  layer_%logit_2.0  of_%logit_0.0  the_%logit_0.0  skin_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  trials_%logit_2.0  are_%logit_2.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_2.0  waterproof_%logit_2.0 ing_%logit_1.0 ,_%logit_0.0  waterproof_%logit_2.0 ing_%logit_0.0  and_%logit_1.0  waterproof_%logit_1.0 ing_%logit_0.0  on_%logit_0.0  the_%logit_0.0  inner_%logit_0.0  inner_%logit_2.0 most_%logit_1.0  layer_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  waterproof_%logit_1.0 ing_%logit_1.0  with_%logit_0.0  waterproof_%logit_0.0 ing_%logit_2.0  or_%logit_1.0  waterproof_%logit_1.0 ing_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  trials_%logit_0.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  durability_%logit_1.0  of_%logit_1.0  waterproof_%logit_1.0  outer_%logit_0.0 most_%logit_2.0  layers_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_2.0  of_%logit_0.0  cran_%logit_0.0 berry_%logit_2.0  supplements_%logit_1.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  sympt_%logit_0.0 omatic_%logit_0.0  UT_%logit_1.0 I_%logit_1.0 ._%logit_1.0  There_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_1.0  area_%logit_1.0 ,_%logit_1.0  particularly_%logit_2.0  in_%logit_2.0  the_%logit_1.0  context_%logit_1.0  of_%logit_2.0  the_%logit_2.0  development_%logit_0.0  of_%logit_1.0  new_%logit_1.0  antibiotics_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  in_%logit_1.0  combination_%logit_2.0  with_%logit_2.0  the_%logit_0.0  introduction_%logit_2.0  of_%logit_1.0  newer_%logit_0.0  antibiotics_%logit_2.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  it_%logit_2.0  is_%logit_1.0  important_%logit_2.0  to_%logit_1.0  note_%logit_2.0  that_%logit_1.0  cran_%logit_1.0 berry_%logit_0.0  supplement_%logit_0.0 ing_%logit_2.0  is_%logit_0.0  associated_%logit_1.0  with_%logit_1.0  an_%logit_2.0  increased_%logit_0.0  risk_%logit_1.0  of_%logit_2.0  bacterial_%logit_0.0  contamination_%logit_0.0  and_%logit_0.0  bacterial_%logit_1.0  contamination_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  a_%logit_0.0  decreased_%logit_1.0  risk_%logit_1.0  of_%logit_2.0  infection_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  compared_%logit_0.0  to_%logit_0.0  placebo_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  tr_%logit_0.0 an_%logit_2.0 ex_%logit_0.0 amic_%logit_0.0  acid_%logit_1.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  non_%logit_1.0 -_%logit_2.0 f_%logit_2.0 atal_%logit_0.0  acute_%logit_0.0  my_%logit_0.0 ocard_%logit_1.0 ial_%logit_1.0  inf_%logit_1.0 ar_%logit_1.0 ction_%logit_1.0 ,_%logit_0.0  or_%logit_0.0  to_%logit_0.0  support_%logit_1.0  its_%logit_2.0  use_%logit_2.0  as_%logit_2.0  an_%logit_2.0  alternative_%logit_2.0  to_%logit_2.0  aspirin_%logit_1.0  in_%logit_1.0  the_%logit_2.0  management_%logit_1.0  of_%logit_1.0  these_%logit_2.0  patients_%logit_1.0 ._%logit_2.0  There_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_1.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_0.0  area_%logit_0.0 ,_%logit_2.0  especially_%logit_0.0  in_%logit_2.0  the_%logit_1.0  context_%logit_0.0  of_%logit_2.0  the_%logit_1.0  introduction_%logit_0.0  of_%logit_0.0  anti_%logit_1.0 plate_%logit_2.0 let_%logit_0.0  agents_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_2.0  as_%logit_0.0  in_%logit_0.0  the_%logit_1.0  development_%logit_2.0  of_%logit_1.0  new_%logit_2.0  anti_%logit_2.0 plate_%logit_1.0 lets_%logit_2.0 ,_%logit_0.0  such_%logit_0.0  as_%logit_2.0  ib_%logit_0.0 up_%logit_1.0 ro_%logit_2.0 fen_%logit_0.0 ,_%logit_0.0  ib_%logit_0.0 up_%logit_1.0 rop_%logit_0.0 ub_%logit_2.0 ic_%logit_0.0  acid_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  aspirin_%logit_1.0 ,_%logit_1.0  in_%logit_2.0  patients_%logit_2.0  with_%logit_1.0  a_%logit_1.0  history_%logit_2.0  of_%logit_2.0  vascular_%logit_0.0  death_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  ib_%logit_0.0 up_%logit_0.0 ro_%logit_0.0 fen_%logit_0.0  for_%logit_0.0  pain_%logit_1.0  relief_%logit_0.0  in_%logit_0.0  adults_%logit_0.0  with_%logit_1.0  chronic_%logit_2.0  pain_%logit_0.0 ._%logit_2.0  Further_%logit_2.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  confirm_%logit_1.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  ib_%logit_1.0 ip_%logit_0.0 ro_%logit_1.0 fen_%logit_2.0  in_%logit_2.0  children_%logit_0.0  with_%logit_0.0  acute_%logit_2.0  pain_%logit_0.0 ._%logit_1.0  Such_%logit_1.0  trials_%logit_1.0  are_%logit_2.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  ib_%logit_2.0 ap_%logit_2.0 ro_%logit_2.0 fen_%logit_2.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_0.0  for_%logit_2.0  other_%logit_2.0  analges_%logit_1.0 ics_%logit_2.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_1.0  oxy_%logit_1.0 toc_%logit_1.0 in_%logit_1.0 ,_%logit_2.0  ib_%logit_0.0 up_%logit_1.0 rog_%logit_0.0 el_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  aspirin_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  its_%logit_0.0  effectiveness_%logit_2.0  in_%logit_2.0  children_%logit_0.0  and_%logit_0.0  adolescents_%logit_0.0 ._%logit_0.0
 Dietary_%logit_0.0  fruit_%logit_0.0  and_%logit_0.0  vegetables_%logit_1.0  are_%logit_1.0  effective_%logit_0.0  in_%logit_2.0  reducing_%logit_2.0  body_%logit_0.0  weight_%logit_1.0  and_%logit_1.0  improving_%logit_0.0  physical_%logit_0.0  fitness_%logit_0.0  in_%logit_0.0  children_%logit_0.0  and_%logit_0.0  adolescents_%logit_2.0 ._%logit_2.0  They_%logit_0.0  are_%logit_0.0  also_%logit_1.0  associated_%logit_2.0  with_%logit_2.0  a_%logit_0.0  reduction_%logit_2.0  in_%logit_0.0  BMI_%logit_2.0 ,_%logit_1.0  BMI_%logit_0.0  and_%logit_1.0  triglycer_%logit_0.0 ides_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  a_%logit_1.0  decreased_%logit_1.0  risk_%logit_1.0  of_%logit_2.0  cardiovascular_%logit_2.0  disease_%logit_2.0 ._%logit_1.0  They_%logit_1.0  also_%logit_2.0  appear_%logit_1.0  to_%logit_1.0  have_%logit_0.0  a_%logit_0.0  positive_%logit_0.0  effect_%logit_2.0  on_%logit_1.0  BMI_%logit_2.0  and_%logit_1.0  on_%logit_2.0  triglycer_%logit_2.0 ides_%logit_1.0  and_%logit_2.0  on_%logit_1.0  blood_%logit_2.0  pressure_%logit_1.0 ._%logit_1.0  They_%logit_0.0  do_%logit_2.0  not_%logit_2.0  appear_%logit_0.0  to_%logit_0.0  be_%logit_0.0  associated_%logit_1.0  with_%logit_1.0  an_%logit_2.0  increase_%logit_2.0  in_%logit_2.0  BMI_%logit_2.0  or_%logit_1.0  triglycer_%logit_1.0 ides_%logit_2.0 ._%logit_0.0  They_%logit_0.0  may_%logit_0.0  have_%logit_2.0  a_%logit_2.0  negative_%logit_1.0  impact_%logit_1.0  on_%logit_2.0  BMI_%logit_1.0  or_%logit_0.0  on_%logit_0.0  triglycer_%logit_1.0 ide_%logit_2.0  levels_%logit_2.0 ._%logit_0.0  Their_%logit_0.0  effect_%logit_0.0  on_%logit_1.0  body_%logit_1.0  mass_%logit_1.0  is_%logit_0.0  not_%logit_0.0  clear_%logit_1.0 ._%logit_1.0  Their_%logit_0.0  effects_%logit_1.0  on_%logit_2.0  BMI_%logit_2.0  are_%logit_0.0  not_%logit_0.0  clear_%logit_2.0  from_%logit_1.0  this_%logit_2.0  review_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  they_%logit_1.0  should_%logit_1.0  be_%logit_2.0  viewed_%logit_1.0  with_%logit_2.0  caution_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  antidepressants_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  depressive_%logit_0.0  symptoms_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_2.0  antidepressant_%logit_2.0  for_%logit_2.0  depressive_%logit_1.0  symptoms_%logit_0.0  and_%logit_0.0  the_%logit_0.0  best_%logit_0.0  combination_%logit_2.0  of_%logit_2.0  antidepressant_%logit_0.0  and_%logit_0.0  antidepressant_%logit_0.0  therapy_%logit_2.0  for_%logit_1.0  these_%logit_1.0  conditions_%logit_2.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  antidepressant_%logit_0.0  therapy_%logit_0.0  on_%logit_2.0  depressive_%logit_1.0  symptoms_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  a_%logit_1.0  comparison_%logit_0.0  of_%logit_1.0  antidepressant_%logit_1.0  medication_%logit_0.0  with_%logit_1.0  placebo_%logit_2.0  or_%logit_0.0  no_%logit_1.0  treatment_%logit_1.0  or_%logit_0.0  other_%logit_0.0  antidepressant_%logit_1.0  treatments_%logit_1.0  for_%logit_2.0  depressive_%logit_2.0  episodes_%logit_0.0 ._%logit_2.0  Finally_%logit_1.0  there_%logit_0.0  is_%logit_0.0  an_%logit_0.0  issue_%logit_2.0  of_%logit_0.0  the_%logit_2.0  quality_%logit_2.0  of_%logit_2.0  the_%logit_2.0  evidence_%logit_0.0  and_%logit_0.0  the_%logit_2.0  reliability_%logit_1.0  of_%logit_2.0  the_%logit_1.0  results_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  psychological_%logit_2.0  interventions_%logit_1.0  for_%logit_1.0  enhancing_%logit_1.0  adherence_%logit_2.0  to_%logit_1.0  alcohol_%logit_0.0  treatment_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_2.0  psychological_%logit_0.0  therapies_%logit_2.0  for_%logit_0.0  reducing_%logit_0.0  compliance_%logit_0.0  with_%logit_2.0  alcohol_%logit_2.0  treatment_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  psychological_%logit_0.0  interventions_%logit_2.0  with_%logit_0.0  other_%logit_2.0  types_%logit_1.0  of_%logit_1.0  alcohol_%logit_0.0  treatment_%logit_1.0  (_%logit_1.0 e_%logit_2.0 ._%logit_2.0 g_%logit_0.0 ._%logit_1.0  alcohol_%logit_1.0  counselling_%logit_2.0 ,_%logit_2.0  behavioural_%logit_2.0  counselling_%logit_1.0 ,_%logit_2.0  cognitive_%logit_2.0  behavioural_%logit_1.0  therapy_%logit_1.0 ,_%logit_2.0  counselling_%logit_2.0 ,_%logit_1.0  counselling_%logit_1.0 )._%logit_2.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  psychological_%logit_0.0  interventions_%logit_1.0  to_%logit_0.0  improve_%logit_1.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_1.0  of_%logit_0.0  people_%logit_0.0  with_%logit_0.0  alcohol_%logit_2.0  problems_%logit_0.0 ._%logit_1.0
 Functional_%logit_0.0  strength_%logit_2.0  training_%logit_0.0  appears_%logit_0.0  to_%logit_1.0  have_%logit_0.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_1.0  on_%logit_1.0  walking_%logit_2.0  speed_%logit_1.0 ,_%logit_0.0  balance_%logit_2.0  and_%logit_1.0  function_%logit_1.0  in_%logit_2.0  the_%logit_1.0  short_%logit_1.0 -_%logit_1.0 term_%logit_0.0 ,_%logit_1.0  but_%logit_1.0  is_%logit_2.0  associated_%logit_0.0  with_%logit_0.0  a_%logit_0.0  significant_%logit_1.0  increase_%logit_1.0  in_%logit_1.0  falls_%logit_0.0  and_%logit_1.0  disability_%logit_1.0 ._%logit_1.0  Strength_%logit_0.0  training_%logit_0.0  may_%logit_1.0  have_%logit_0.0  a_%logit_2.0  positive_%logit_0.0  effect_%logit_1.0  on_%logit_0.0  fitness_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  its_%logit_1.0  effect_%logit_1.0  on_%logit_1.0  disability_%logit_1.0  is_%logit_1.0  not_%logit_0.0  clear_%logit_2.0  from_%logit_1.0  this_%logit_1.0  review_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_0.0  strength_%logit_0.0  training_%logit_2.0  on_%logit_0.0  fitness_%logit_0.0  and_%logit_0.0  disability_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  strength_%logit_0.0  training_%logit_2.0  with_%logit_0.0  other_%logit_0.0  types_%logit_2.0  of_%logit_0.0  physical_%logit_0.0  rehabilitation_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_2.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  effects_%logit_2.0  on_%logit_0.0  fatigue_%logit_0.0  and_%logit_0.0  disability_%logit_0.0  in_%logit_0.0  the_%logit_1.0  longer_%logit_0.0  term_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_2.0  the_%logit_2.0  use_%logit_2.0  of_%logit_2.0  any_%logit_1.0  particular_%logit_0.0  form_%logit_0.0  of_%logit_2.0  anti_%logit_1.0 hy_%logit_1.0 pert_%logit_2.0 ensive_%logit_2.0  medication_%logit_0.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_2.0  G_%logit_2.0 OR_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  therapy_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  different_%logit_2.0  types_%logit_2.0  of_%logit_1.0  ant_%logit_1.0 ich_%logit_0.0 olin_%logit_2.0 erg_%logit_1.0 ics_%logit_2.0  in_%logit_0.0  G_%logit_2.0 OR_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  different_%logit_1.0  combinations_%logit_1.0  of_%logit_0.0  ant_%logit_1.0 ith_%logit_0.0 olin_%logit_2.0 erg_%logit_1.0 ic_%logit_1.0  drugs_%logit_1.0  on_%logit_0.0  G_%logit_1.0 OR_%logit_1.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_2.0  asthma_%logit_2.0  and_%logit_0.0  in_%logit_1.0  those_%logit_1.0  with_%logit_1.0  G_%logit_1.0 OR_%logit_1.0  who_%logit_2.0  do_%logit_1.0  not_%logit_1.0  have_%logit_2.0  a_%logit_0.0  history_%logit_0.0  of_%logit_0.0  asthma_%logit_0.0  or_%logit_0.0  who_%logit_0.0  do_%logit_2.0  have_%logit_0.0  a_%logit_2.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_0.0  respiratory_%logit_1.0  distress_%logit_1.0  syndrome_%logit_2.0 ._%logit_1.0
 Phys_%logit_0.0 i_%logit_0.0 ore_%logit_1.0 spir_%logit_0.0 atory_%logit_0.0  fitness_%logit_0.0  tests_%logit_0.0  are_%logit_1.0  effective_%logit_0.0  in_%logit_0.0  improving_%logit_2.0  lung_%logit_1.0  function_%logit_2.0  in_%logit_2.0  children_%logit_1.0  and_%logit_0.0  adults_%logit_1.0  with_%logit_0.0  asthma_%logit_1.0 ,_%logit_0.0  but_%logit_0.0  they_%logit_2.0  do_%logit_2.0  not_%logit_2.0  appear_%logit_2.0  to_%logit_1.0  have_%logit_0.0  a_%logit_1.0  clinically_%logit_2.0  meaningful_%logit_2.0  effect_%logit_1.0  on_%logit_2.0  lung_%logit_2.0  function_%logit_1.0  or_%logit_0.0  respiratory_%logit_1.0  rate_%logit_0.0 ._%logit_0.0  They_%logit_2.0  do_%logit_1.0  not_%logit_2.0  seem_%logit_2.0  to_%logit_0.0  have_%logit_0.0  an_%logit_0.0  effect_%logit_1.0  on_%logit_1.0  respiratory_%logit_2.0  rate_%logit_1.0  or_%logit_1.0  lung_%logit_0.0  function_%logit_0.0 ._%logit_1.0  They_%logit_2.0  may_%logit_1.0  have_%logit_2.0  an_%logit_2.0  impact_%logit_1.0  on_%logit_2.0  pulmonary_%logit_0.0  function_%logit_1.0  and_%logit_2.0  respiratory_%logit_1.0  rate_%logit_0.0 ,_%logit_0.0  but_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_2.0  need_%logit_1.0  for_%logit_1.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  studies_%logit_1.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_1.0  exercise_%logit_0.0  training_%logit_0.0  on_%logit_1.0  respiratory_%logit_1.0  rates_%logit_1.0 ,_%logit_2.0  respiratory_%logit_0.0  rate_%logit_1.0  and_%logit_0.0  lung_%logit_1.0  function_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  on_%logit_0.0  pulmonary_%logit_0.0  functions_%logit_0.0  and_%logit_2.0  respiratory_%logit_0.0  rates_%logit_1.0 ._%logit_1.0
 Pro_%logit_0.0 ph_%logit_2.0 yl_%logit_0.0 actic_%logit_0.0  band_%logit_0.0 aging_%logit_0.0  is_%logit_0.0  effective_%logit_1.0  in_%logit_2.0  reducing_%logit_1.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_0.0  var_%logit_2.0 ice_%logit_2.0 al_%logit_0.0  hemorrh_%logit_0.0 age_%logit_0.0  and_%logit_0.0  reducing_%logit_1.0  the_%logit_0.0  risk_%logit_0.0  of_%logit_0.0  death_%logit_2.0 ,_%logit_2.0  but_%logit_0.0  the_%logit_0.0  extent_%logit_1.0  to_%logit_0.0  which_%logit_2.0  this_%logit_1.0  effect_%logit_0.0  is_%logit_0.0  achieved_%logit_0.0  is_%logit_2.0  unclear_%logit_1.0 ._%logit_0.0  The_%logit_1.0  number_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  remove_%logit_0.0  band_%logit_1.0 aging_%logit_2.0  from_%logit_0.0  the_%logit_0.0  band_%logit_2.0 aging_%logit_1.0  does_%logit_1.0  not_%logit_1.0  appear_%logit_2.0  to_%logit_0.0  be_%logit_2.0  affected_%logit_0.0  by_%logit_0.0  the_%logit_1.0  use_%logit_1.0  of_%logit_2.0  band_%logit_0.0 aging_%logit_2.0 ,_%logit_0.0  but_%logit_2.0  it_%logit_2.0  is_%logit_1.0  possible_%logit_0.0  that_%logit_1.0  band_%logit_0.0 aging_%logit_2.0  may_%logit_1.0  have_%logit_0.0  a_%logit_0.0  role_%logit_2.0  in_%logit_1.0  reducing_%logit_2.0  blood_%logit_0.0  loss_%logit_0.0 ,_%logit_0.0  but_%logit_2.0  this_%logit_1.0  conclusion_%logit_2.0  is_%logit_0.0  based_%logit_1.0  on_%logit_1.0  a_%logit_1.0  small_%logit_2.0  number_%logit_1.0  of_%logit_0.0  trials_%logit_2.0  and_%logit_0.0  uncertainties_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  band_%logit_2.0 aging_%logit_1.0  and_%logit_0.0  the_%logit_1.0  best_%logit_1.0  band_%logit_1.0 aging_%logit_0.0  method_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  tro_%logit_0.0 cars_%logit_2.0  in_%logit_2.0  orth_%logit_0.0 oped_%logit_1.0 ic_%logit_0.0  surgery_%logit_1.0 ._%logit_0.0  Further_%logit_1.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_0.0  tro_%logit_0.0 cars_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_2.0  for_%logit_1.0  orth_%logit_1.0 op_%logit_2.0 aed_%logit_2.0 ic_%logit_2.0  surgery_%logit_0.0  in_%logit_0.0  this_%logit_1.0  population_%logit_2.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_1.0  should_%logit_2.0  be_%logit_0.0  undertaken_%logit_2.0  in_%logit_1.0  the_%logit_1.0  context_%logit_2.0  of_%logit_1.0  a_%logit_0.0  well_%logit_2.0 -_%logit_0.0 defined_%logit_0.0  set_%logit_1.0  of_%logit_0.0  outcomes_%logit_0.0 ,_%logit_0.0  such_%logit_1.0  as_%logit_1.0  complication_%logit_0.0  rates_%logit_1.0  and_%logit_1.0  length_%logit_0.0  of_%logit_0.0  hospital_%logit_1.0  stay_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_2.0  the_%logit_0.0  extent_%logit_0.0  to_%logit_0.0  which_%logit_0.0  tro_%logit_1.0 cars_%logit_0.0  may_%logit_0.0  be_%logit_1.0  useful_%logit_2.0  in_%logit_0.0  this_%logit_0.0  patient_%logit_2.0  population_%logit_2.0 ._%logit_2.0  These_%logit_2.0  trials_%logit_0.0  should_%logit_1.0  include_%logit_0.0  a_%logit_1.0  number_%logit_1.0  of_%logit_2.0  parameters_%logit_0.0 ,_%logit_0.0  including_%logit_0.0  length_%logit_0.0  of_%logit_1.0  stay_%logit_0.0 ,_%logit_0.0  severity_%logit_0.0  of_%logit_0.0  infection_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  duration_%logit_0.0  of_%logit_2.0  recovery_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  intraven_%logit_0.0 ous_%logit_2.0  transf_%logit_2.0 usion_%logit_2.0  as_%logit_0.0  a_%logit_2.0  means_%logit_0.0  of_%logit_2.0  reducing_%logit_1.0  blood_%logit_1.0  transf_%logit_1.0 usion_%logit_0.0  rates_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  best_%logit_0.0  method_%logit_2.0  of_%logit_2.0  transf_%logit_1.0 usion_%logit_1.0  and_%logit_2.0  the_%logit_1.0  best_%logit_2.0  way_%logit_0.0  to_%logit_2.0  administer_%logit_2.0  transf_%logit_0.0 usion_%logit_2.0  to_%logit_0.0  patients_%logit_2.0  with_%logit_0.0  pre_%logit_0.0 -_%logit_1.0 existing_%logit_1.0  congen_%logit_1.0 ital_%logit_1.0  heart_%logit_1.0  defects_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  investigation_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  transf_%logit_0.0 usions_%logit_1.0  as_%logit_1.0  an_%logit_1.0  alternative_%logit_0.0  to_%logit_0.0  intraven_%logit_0.0 ous_%logit_1.0  immun_%logit_2.0 ogl_%logit_0.0 ob_%logit_0.0 ul_%logit_0.0 ins_%logit_2.0  in_%logit_0.0  reducing_%logit_1.0  blood_%logit_2.0  loss_%logit_0.0  in_%logit_0.0  the_%logit_1.0  first_%logit_1.0  week_%logit_1.0  of_%logit_1.0  life_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_1.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_1.0  of_%logit_2.0  ip_%logit_1.0 rat_%logit_1.0 rop_%logit_0.0 ium_%logit_0.0  for_%logit_1.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_0.0  stre_%logit_0.0 pt_%logit_2.0 ococ_%logit_0.0 cal_%logit_1.0  infections_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_1.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_2.0  and_%logit_1.0  timing_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  best_%logit_0.0  way_%logit_2.0  to_%logit_2.0  administer_%logit_2.0  ip_%logit_0.0 rat_%logit_1.0 rep_%logit_0.0 ium_%logit_2.0  for_%logit_0.0  these_%logit_0.0  infections_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  these_%logit_1.0  drugs_%logit_2.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_2.0  reducing_%logit_2.0  blood_%logit_1.0  loss_%logit_2.0  and_%logit_0.0  mortality_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_0.0  safety_%logit_2.0 ,_%logit_2.0  a_%logit_1.0  meta_%logit_2.0 -_%logit_0.0 analysis_%logit_2.0  of_%logit_2.0  the_%logit_2.0  data_%logit_0.0  is_%logit_1.0  needed_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  relaxation_%logit_1.0  exercises_%logit_1.0  in_%logit_2.0  sleep_%logit_2.0  disturbance_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  whether_%logit_0.0  relaxation_%logit_2.0  exercises_%logit_1.0  are_%logit_0.0  beneficial_%logit_0.0  for_%logit_0.0  sleep_%logit_0.0  disturbance_%logit_2.0 ,_%logit_0.0  wake_%logit_1.0 fulness_%logit_1.0 ,_%logit_0.0  sleep_%logit_1.0  disturbance_%logit_1.0  or_%logit_0.0  sleep_%logit_1.0  disturbance_%logit_2.0  in_%logit_0.0  people_%logit_1.0  with_%logit_0.0  insomnia_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_0.0  effects_%logit_2.0  on_%logit_1.0  sleep_%logit_1.0  disturbance_%logit_1.0  and_%logit_2.0  sleep_%logit_1.0  disturbance_%logit_1.0  on_%logit_0.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_2.0 ,_%logit_0.0  sleep_%logit_0.0  disturbances_%logit_1.0  and_%logit_2.0  sleep_%logit_2.0  disturbances_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  studies_%logit_2.0  are_%logit_0.0  also_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  evaluate_%logit_2.0  relaxation_%logit_0.0  exercises_%logit_1.0  for_%logit_0.0  sleep_%logit_1.0  disturbances_%logit_0.0 ,_%logit_2.0  sleep_%logit_2.0  deprivation_%logit_2.0 ,_%logit_1.0  sleep_%logit_1.0 lessness_%logit_1.0 ,_%logit_2.0  sleep_%logit_2.0 iness_%logit_1.0  and_%logit_0.0  sleep_%logit_2.0  deprivation_%logit_2.0  in_%logit_1.0  people_%logit_0.0  who_%logit_0.0  are_%logit_1.0  awake_%logit_1.0  or_%logit_1.0  asleep_%logit_1.0  at_%logit_0.0  night_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  mechanism_%logit_2.0  of_%logit_1.0  action_%logit_1.0  to_%logit_0.0  reduce_%logit_1.0  mortality_%logit_0.0  or_%logit_2.0  improve_%logit_1.0  quality_%logit_0.0  of_%logit_2.0  life_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  mechanism_%logit_0.0  by_%logit_2.0  which_%logit_2.0  this_%logit_1.0  mechanism_%logit_0.0  works_%logit_0.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  this_%logit_1.0  intervention_%logit_0.0  with_%logit_1.0  other_%logit_1.0  methods_%logit_1.0  of_%logit_0.0  action_%logit_0.0  in_%logit_0.0  the_%logit_2.0  management_%logit_0.0  of_%logit_0.0  mortality_%logit_1.0  and_%logit_0.0  morbid_%logit_2.0 ity_%logit_0.0  in_%logit_0.0  adults_%logit_1.0  with_%logit_0.0  dementia_%logit_0.0  or_%logit_0.0  in_%logit_0.0  children_%logit_1.0  with_%logit_1.0  dementia_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_1.0  this_%logit_0.0  method_%logit_0.0  of_%logit_1.0  action_%logit_1.0 ,_%logit_0.0  a_%logit_0.0  meta_%logit_2.0 -_%logit_1.0 analysis_%logit_0.0  will_%logit_0.0  be_%logit_2.0  undertaken_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  cort_%logit_1.0 ic_%logit_0.0 oster_%logit_0.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  pr_%logit_0.0 ur_%logit_2.0 itus_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_1.0  and_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  steroids_%logit_0.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_2.0  in_%logit_2.0  the_%logit_1.0  management_%logit_2.0  of_%logit_2.0  pr_%logit_2.0 uria_%logit_0.0 itus_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  long_%logit_2.0 -_%logit_2.0 term_%logit_2.0  data_%logit_2.0  are_%logit_2.0  needed_%logit_1.0  on_%logit_1.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_1.0  steroids_%logit_0.0  on_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  life_%logit_1.0  and_%logit_2.0  productivity_%logit_0.0 ._%logit_0.0  Long_%logit_2.0 -_%logit_2.0 term_%logit_2.0  studies_%logit_0.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  steroids_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_1.0  effectiveness_%logit_2.0  of_%logit_0.0  steroids_%logit_1.0  in_%logit_1.0  the_%logit_2.0  control_%logit_2.0  group_%logit_2.0  of_%logit_2.0  patients_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_2.0  cis_%logit_1.0 pl_%logit_1.0 atin_%logit_0.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_2.0  chemotherapy_%logit_2.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_0.0  survival_%logit_2.0 ,_%logit_2.0  toxicity_%logit_2.0 ,_%logit_1.0  toxicity_%logit_2.0  and_%logit_1.0  survival_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  randomized_%logit_2.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_2.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  toxicity_%logit_1.0  profiles_%logit_0.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_2.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  advanced_%logit_2.0  stages_%logit_0.0  of_%logit_2.0  renal_%logit_1.0  toxicity_%logit_1.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_1.0  should_%logit_2.0  be_%logit_0.0  undertaken_%logit_1.0  in_%logit_0.0  accordance_%logit_1.0  with_%logit_1.0  the_%logit_0.0  recommendations_%logit_0.0  of_%logit_0.0  the_%logit_0.0  Coch_%logit_0.0 rane_%logit_0.0  Guidelines_%logit_2.0  on_%logit_0.0  Immun_%logit_0.0 otherapy_%logit_1.0  for_%logit_1.0  renal_%logit_2.0  toxicity_%logit_1.0  in_%logit_0.0  advanced_%logit_0.0  stages_%logit_1.0  renal_%logit_1.0  toxicity_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_1.0  in_%logit_0.0  patients_%logit_0.0  who_%logit_2.0  are_%logit_0.0  undergoing_%logit_0.0  chemotherapy_%logit_1.0  in_%logit_1.0  advanced_%logit_2.0  stage_%logit_1.0  renal_%logit_1.0  toxicity_%logit_0.0  and_%logit_0.0  those_%logit_2.0  who_%logit_1.0  are_%logit_1.0  unable_%logit_1.0  to_%logit_2.0  tolerate_%logit_1.0  chemotherapy_%logit_2.0  in_%logit_0.0  these_%logit_1.0  patients_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_0.0  of_%logit_0.0  p_%logit_0.0 aren_%logit_1.0 ter_%logit_0.0 al_%logit_2.0  ana_%logit_0.0 esthesia_%logit_1.0  as_%logit_0.0  an_%logit_0.0  adjunct_%logit_1.0  to_%logit_2.0  other_%logit_0.0  surgical_%logit_1.0  procedures_%logit_1.0  in_%logit_0.0  terms_%logit_2.0  of_%logit_1.0  minim_%logit_0.0 ising_%logit_0.0  mortality_%logit_2.0  and_%logit_0.0  morbid_%logit_1.0 ity_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_1.0  duration_%logit_1.0  of_%logit_2.0  p_%logit_1.0 ren_%logit_2.0 ter_%logit_2.0 al_%logit_2.0  an_%logit_1.0 hyd_%logit_1.0 rase_%logit_2.0  inhibitors_%logit_2.0 ,_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  duration_%logit_2.0  of_%logit_1.0  ext_%logit_0.0 rac_%logit_1.0 aps_%logit_2.0 ular_%logit_0.0  exc_%logit_1.0 ision_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  the_%logit_0.0  optimal_%logit_0.0  timing_%logit_0.0  of_%logit_0.0  end_%logit_2.0 oscopic_%logit_0.0  exc_%logit_1.0 ision_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_0.0  should_%logit_1.0  focus_%logit_1.0  on_%logit_0.0  determining_%logit_0.0  the_%logit_0.0  optimal_%logit_1.0  intensity_%logit_0.0  and_%logit_0.0  timing_%logit_2.0  of_%logit_0.0  ana_%logit_1.0 esthesia_%logit_0.0  and_%logit_2.0  the_%logit_0.0  most_%logit_1.0  effective_%logit_1.0  way_%logit_2.0  of_%logit_0.0  delivering_%logit_2.0  ana_%logit_1.0 esthesia_%logit_1.0  to_%logit_2.0  the_%logit_0.0  patient_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_2.0  of_%logit_1.0  anti_%logit_0.0 plate_%logit_0.0 let_%logit_2.0  agents_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  vas_%logit_0.0 osp_%logit_2.0 asm_%logit_1.0 ._%logit_1.0  There_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effects_%logit_1.0  of_%logit_1.0  plate_%logit_1.0 let_%logit_2.0  agents_%logit_2.0  on_%logit_0.0  arter_%logit_2.0 ial_%logit_0.0  blood_%logit_2.0  flow_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  these_%logit_2.0  agents_%logit_1.0  in_%logit_1.0  reducing_%logit_0.0  blood_%logit_0.0  loss_%logit_2.0  and_%logit_2.0  bleeding_%logit_1.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_1.0  a_%logit_1.0  sub_%logit_0.0 -_%logit_1.0 group_%logit_2.0  of_%logit_0.0  patients_%logit_0.0  who_%logit_0.0  are_%logit_0.0  at_%logit_0.0  high_%logit_0.0  risk_%logit_0.0  of_%logit_0.0  infection_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_2.0  and_%logit_0.0  executed_%logit_0.0  random_%logit_0.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  plate_%logit_1.0 lets_%logit_0.0  and_%logit_2.0  other_%logit_0.0  agents_%logit_0.0  for_%logit_2.0  reducing_%logit_2.0  blood_%logit_2.0  flow_%logit_1.0  and_%logit_0.0  blood_%logit_0.0  loss_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_0.0  a_%logit_0.0  peripheral_%logit_0.0  artery_%logit_2.0  les_%logit_0.0 ion_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  visual_%logit_0.0  ac_%logit_1.0 uity_%logit_0.0  training_%logit_0.0  for_%logit_0.0  visual_%logit_2.0  health_%logit_2.0  improvement_%logit_2.0  in_%logit_2.0  people_%logit_2.0  with_%logit_1.0  visual_%logit_1.0  impair_%logit_2.0 ments_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  this_%logit_2.0  training_%logit_2.0  for_%logit_2.0  people_%logit_0.0  with_%logit_0.0  impair_%logit_0.0 ments_%logit_2.0  with_%logit_2.0  visual_%logit_1.0  impairment_%logit_2.0 ._%logit_2.0  It_%logit_1.0  is_%logit_0.0  also_%logit_2.0  important_%logit_1.0  to_%logit_0.0  note_%logit_0.0  that_%logit_0.0  there_%logit_1.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  further_%logit_1.0  research_%logit_2.0  in_%logit_0.0  this_%logit_0.0  area_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  in_%logit_0.0  other_%logit_0.0  areas_%logit_0.0  of_%logit_2.0  visual_%logit_1.0  impairment_%logit_1.0 ,_%logit_2.0  such_%logit_1.0  as_%logit_2.0  in_%logit_0.0  contrast_%logit_1.0  to_%logit_2.0  other_%logit_1.0  types_%logit_2.0  of_%logit_1.0  training_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  in_%logit_1.0  contrast_%logit_2.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_1.0  of_%logit_2.0  training_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_1.0  an_%logit_0.0  urgent_%logit_1.0  need_%logit_1.0  for_%logit_2.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_2.0 ,_%logit_1.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_1.0 ed_%logit_1.0  and_%logit_1.0  reported_%logit_1.0  randomized_%logit_0.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  effectiveness_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0 ,_%logit_1.0  safety_%logit_1.0  and_%logit_1.0  efficacy_%logit_0.0  of_%logit_2.0  various_%logit_0.0  types_%logit_2.0  of_%logit_1.0  cognitive_%logit_0.0  training_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  solitary_%logit_1.0  confinement_%logit_0.0  as_%logit_1.0  a_%logit_0.0  means_%logit_0.0  of_%logit_2.0  reducing_%logit_1.0  the_%logit_1.0  number_%logit_0.0  of_%logit_2.0  days_%logit_0.0  spent_%logit_0.0  as_%logit_0.0  an_%logit_0.0  involuntary_%logit_0.0  ward_%logit_0.0  in_%logit_2.0  mental_%logit_0.0  health_%logit_0.0  facilities_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  solitary_%logit_2.0  solitary_%logit_2.0  confinement_%logit_0.0  in_%logit_0.0  isolation_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  solitary_%logit_0.0  confinement_%logit_0.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_2.0  of_%logit_0.0  isolation_%logit_0.0  in_%logit_0.0  a_%logit_1.0  population_%logit_1.0  with_%logit_1.0  a_%logit_0.0  history_%logit_1.0  of_%logit_1.0  mental_%logit_0.0  health_%logit_0.0  problems_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  also_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  how_%logit_1.0  solitary_%logit_0.0  confinement_%logit_2.0  differs_%logit_0.0  from_%logit_1.0  isolation_%logit_1.0  in_%logit_1.0  terms_%logit_2.0  of_%logit_2.0  length_%logit_0.0  of_%logit_1.0  stay_%logit_0.0  in_%logit_0.0  a_%logit_0.0  mental_%logit_1.0  health_%logit_2.0  facility_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  prost_%logit_1.0 ag_%logit_1.0 land_%logit_1.0 ins_%logit_0.0  for_%logit_0.0  ser_%logit_1.0 ocon_%logit_1.0 version_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_2.0  prost_%logit_2.0 ig_%logit_0.0 land_%logit_0.0 ins_%logit_0.0  in_%logit_0.0  ser_%logit_1.0 ocon_%logit_1.0 versions_%logit_1.0 ._%logit_2.0  It_%logit_2.0  is_%logit_2.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanisms_%logit_2.0  by_%logit_0.0  which_%logit_0.0  prost_%logit_0.0 ag_%logit_0.0 LAND_%logit_0.0 ins_%logit_0.0  are_%logit_0.0  used_%logit_1.0  to_%logit_0.0  achieve_%logit_0.0  their_%logit_2.0  goal_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  how_%logit_1.0  they_%logit_0.0  are_%logit_1.0  used_%logit_0.0  in_%logit_1.0  the_%logit_2.0  context_%logit_1.0  of_%logit_0.0  a_%logit_0.0  reduction_%logit_2.0  in_%logit_2.0  extr_%logit_0.0 aneous_%logit_0.0  extr_%logit_1.0 aneous_%logit_0.0  organ_%logit_2.0  prol_%logit_2.0 apse_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  trials_%logit_0.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_2.0  prost_%logit_0.0 ig_%logit_0.0 LAND_%logit_0.0 ins_%logit_0.0  with_%logit_2.0  other_%logit_0.0  treatments_%logit_1.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_2.0  oxy_%logit_0.0 toc_%logit_1.0 in_%logit_1.0 ,_%logit_2.0  ib_%logit_2.0 up_%logit_2.0 ro_%logit_1.0 fen_%logit_1.0  and_%logit_0.0  ib_%logit_1.0 up_%logit_0.0 rop_%logit_0.0 ub_%logit_2.0 ic_%logit_1.0  acid_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  recommend_%logit_0.0  the_%logit_1.0  use_%logit_2.0  of_%logit_0.0  ib_%logit_2.0 up_%logit_1.0 ro_%logit_1.0 fen_%logit_1.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  nasal_%logit_0.0  congestion_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  a_%logit_0.0  common_%logit_2.0  cold_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  in_%logit_0.0  this_%logit_1.0  area_%logit_1.0 ,_%logit_0.0  particularly_%logit_0.0  in_%logit_2.0  patients_%logit_1.0  who_%logit_1.0  are_%logit_2.0  at_%logit_1.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_0.0  complications_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  in_%logit_2.0  those_%logit_0.0  who_%logit_0.0  are_%logit_0.0  unable_%logit_0.0  to_%logit_0.0  tolerate_%logit_0.0  the_%logit_0.0  drug_%logit_1.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_1.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_2.0  for_%logit_2.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0  and_%logit_1.0  executed_%logit_2.0  randomized_%logit_2.0  controlled_%logit_2.0  trial_%logit_2.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  ib_%logit_2.0 ip_%logit_2.0 ro_%logit_0.0 fen_%logit_2.0  for_%logit_1.0  the_%logit_0.0  treatment_%logit_1.0  and_%logit_2.0  prevention_%logit_1.0  of_%logit_0.0  congestion_%logit_2.0  in_%logit_0.0  the_%logit_2.0  common_%logit_1.0  cold_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_1.0  evaluate_%logit_2.0  its_%logit_0.0  effectiveness_%logit_1.0  in_%logit_2.0  other_%logit_2.0  chronic_%logit_0.0  cold_%logit_0.0  conditions_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  hyd_%logit_0.0 roc_%logit_0.0 oll_%logit_2.0 oid_%logit_0.0  gel_%logit_0.0  as_%logit_2.0  a_%logit_2.0  substitute_%logit_1.0  for_%logit_1.0  other_%logit_0.0  analges_%logit_0.0 ics_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  acute_%logit_0.0  pain_%logit_2.0  fractures_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  Hyd_%logit_1.0 roc_%logit_2.0 oll_%logit_0.0 oids_%logit_0.0  gel_%logit_0.0  as_%logit_2.0  an_%logit_1.0  adjunct_%logit_1.0  to_%logit_0.0  other_%logit_1.0  analges_%logit_1.0 ic_%logit_1.0  treatments_%logit_0.0  for_%logit_2.0  pain_%logit_1.0  relief_%logit_2.0  in_%logit_0.0  adults_%logit_0.0  with_%logit_2.0  fractures_%logit_1.0  of_%logit_0.0  the_%logit_1.0  inner_%logit_2.0 most_%logit_2.0  limb_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_0.0  of_%logit_2.0  hyd_%logit_1.0 oc_%logit_2.0 oll_%logit_2.0 oid_%logit_0.0  therapy_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  future_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  durability_%logit_1.0  of_%logit_0.0  hyd_%logit_2.0 rop_%logit_2.0 oll_%logit_1.0 oid_%logit_1.0  treatment_%logit_0.0  for_%logit_1.0  acute_%logit_0.0  pain_%logit_0.0  relief_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_2.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  durability_%logit_2.0 ,_%logit_2.0  in_%logit_1.0  adults_%logit_0.0  and_%logit_0.0  children_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  cort_%logit_1.0 ic_%logit_1.0 oster_%logit_0.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  ul_%logit_0.0 cer_%logit_1.0 ative_%logit_1.0  col_%logit_0.0 itis_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_0.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_0.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  steroids_%logit_1.0  and_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_1.0  in_%logit_2.0  the_%logit_1.0  management_%logit_1.0  of_%logit_2.0  these_%logit_2.0  patients_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  these_%logit_2.0  medications_%logit_1.0  in_%logit_2.0  treating_%logit_0.0  patients_%logit_0.0  with_%logit_2.0  mild_%logit_0.0  to_%logit_0.0  moderately_%logit_1.0  severe_%logit_2.0  disease_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  also_%logit_1.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  durability_%logit_1.0  of_%logit_2.0  these_%logit_1.0  treatments_%logit_0.0  in_%logit_0.0  terms_%logit_0.0  of_%logit_0.0  their_%logit_1.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  any_%logit_0.0  specific_%logit_2.0  type_%logit_0.0  of_%logit_2.0  orth_%logit_0.0 op_%logit_0.0 aed_%logit_1.0 ic_%logit_0.0  instrument_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  post_%logit_0.0 -_%logit_2.0 operative_%logit_0.0  hem_%logit_0.0 em_%logit_0.0 or_%logit_2.0 rh_%logit_1.0 agic_%logit_2.0  complications_%logit_0.0 ._%logit_0.0  There_%logit_0.0  is_%logit_2.0  a_%logit_0.0  need_%logit_1.0  for_%logit_2.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_1.0 ,_%logit_0.0  conducted_%logit_0.0  and_%logit_1.0  reported_%logit_0.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_1.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  orth_%logit_2.0 oped_%logit_1.0 ic_%logit_2.0  instrument_%logit_0.0 ation_%logit_0.0  in_%logit_1.0  reducing_%logit_0.0  mortality_%logit_2.0  and_%logit_2.0  morbid_%logit_0.0 ity_%logit_1.0  in_%logit_1.0  post_%logit_1.0 operative_%logit_1.0  hem_%logit_1.0 mor_%logit_0.0 rh_%logit_0.0 agic_%logit_2.0  injuries_%logit_2.0 ._%logit_2.0  Such_%logit_1.0  trials_%logit_0.0  should_%logit_0.0  be_%logit_1.0  undertaken_%logit_0.0  in_%logit_0.0  the_%logit_2.0  context_%logit_0.0  of_%logit_0.0  a_%logit_2.0  large_%logit_2.0  number_%logit_1.0  of_%logit_1.0  patients_%logit_2.0 ,_%logit_0.0  with_%logit_2.0  a_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  with_%logit_1.0  a_%logit_1.0  low_%logit_2.0  risk_%logit_2.0  of_%logit_1.0  random_%logit_0.0  errors_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  topical_%logit_0.0  gel_%logit_0.0  gel_%logit_2.0  gel_%logit_1.0  as_%logit_1.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_1.0  topical_%logit_2.0  gel_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_0.0  ven_%logit_1.0 ous_%logit_0.0  punct_%logit_0.0 ure_%logit_1.0  pain_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  whether_%logit_2.0  gel_%logit_0.0  gel_%logit_1.0  is_%logit_0.0  more_%logit_0.0  effective_%logit_1.0  than_%logit_2.0  gel_%logit_0.0  gel_%logit_2.0  in_%logit_0.0  relie_%logit_1.0 ving_%logit_0.0  pain_%logit_0.0  or_%logit_0.0  discomfort_%logit_1.0  in_%logit_1.0  patients_%logit_1.0  with_%logit_1.0  ven_%logit_2.0 ous_%logit_2.0  occ_%logit_0.0 l_%logit_2.0 usion_%logit_0.0  pain_%logit_0.0 ,_%logit_0.0  or_%logit_1.0  if_%logit_1.0  gel_%logit_1.0  gel_%logit_2.0  should_%logit_2.0  be_%logit_0.0  used_%logit_0.0  in_%logit_1.0  conjunction_%logit_1.0  with_%logit_2.0  gel_%logit_1.0  gel_%logit_1.0  or_%logit_0.0  gel_%logit_0.0  gel_%logit_0.0 ,_%logit_0.0  or_%logit_2.0  in_%logit_0.0  combination_%logit_0.0  with_%logit_1.0  other_%logit_0.0  gel_%logit_0.0  preparations_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  trials_%logit_0.0  are_%logit_2.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  gel_%logit_2.0  gel_%logit_1.0  and_%logit_1.0  gel_%logit_1.0  gel_%logit_2.0  for_%logit_2.0  pain_%logit_2.0  relief_%logit_2.0  in_%logit_2.0  patients_%logit_0.0  undergoing_%logit_1.0  ven_%logit_2.0 ous_%logit_2.0  ep_%logit_0.0 ine_%logit_2.0 phrine_%logit_1.0  injections_%logit_2.0 ._%logit_0.0
 Learning_%logit_0.0  aids_%logit_0.0  are_%logit_2.0  effective_%logit_1.0  in_%logit_1.0  reducing_%logit_0.0  the_%logit_0.0  incidence_%logit_0.0  of_%logit_2.0  repeat_%logit_2.0  birth_%logit_1.0 ._%logit_0.0  Learning_%logit_0.0  aids_%logit_2.0  may_%logit_1.0  reduce_%logit_1.0  the_%logit_2.0  frequency_%logit_2.0  of_%logit_0.0  unintended_%logit_1.0  pregnancies_%logit_0.0 ,_%logit_1.0  but_%logit_2.0  they_%logit_1.0  do_%logit_2.0  not_%logit_1.0  appear_%logit_1.0  to_%logit_0.0  have_%logit_0.0  a_%logit_1.0  significant_%logit_1.0  impact_%logit_1.0  on_%logit_2.0  maternal_%logit_0.0  satisfaction_%logit_2.0  with_%logit_2.0  learning_%logit_0.0  aids_%logit_0.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  learning_%logit_2.0  aids_%logit_1.0  in_%logit_1.0  reducing_%logit_1.0  repeat_%logit_1.0  birth_%logit_1.0  rates_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  their_%logit_1.0  effectiveness_%logit_0.0  in_%logit_2.0  reducing_%logit_1.0  unintended_%logit_1.0  pregnancies_%logit_2.0 ._%logit_0.0  Research_%logit_2.0  is_%logit_1.0  also_%logit_0.0  needed_%logit_1.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_0.0  educational_%logit_0.0  aids_%logit_2.0  in_%logit_1.0  enhancing_%logit_1.0  knowledge_%logit_0.0  and_%logit_1.0  informing_%logit_2.0  parents_%logit_0.0  about_%logit_2.0  the_%logit_2.0  risks_%logit_2.0  and_%logit_2.0  benefits_%logit_0.0  of_%logit_0.0  knowledge_%logit_0.0  aids_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  erg_%logit_0.0 ost_%logit_0.0 asis_%logit_0.0  for_%logit_1.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_2.0  my_%logit_1.0 ot_%logit_1.0 onia_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_0.0  erg_%logit_0.0 ost_%logit_1.0 as_%logit_0.0 one_%logit_1.0  is_%logit_2.0  beneficial_%logit_1.0  or_%logit_1.0  harmful_%logit_0.0  for_%logit_2.0  people_%logit_2.0  with_%logit_1.0  this_%logit_0.0  condition_%logit_2.0 ,_%logit_2.0  or_%logit_2.0  whether_%logit_1.0  it_%logit_0.0  is_%logit_1.0  beneficial_%logit_2.0  for_%logit_0.0  them_%logit_0.0  to_%logit_0.0  use_%logit_0.0  it_%logit_2.0  as_%logit_2.0  an_%logit_2.0  adjunct_%logit_1.0  to_%logit_0.0  other_%logit_0.0  forms_%logit_0.0  of_%logit_0.0  physical_%logit_1.0  activity_%logit_0.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_2.0  walking_%logit_0.0 ,_%logit_0.0  cycling_%logit_0.0 ,_%logit_1.0  or_%logit_1.0  other_%logit_1.0  activities_%logit_2.0  of_%logit_2.0  daily_%logit_1.0  life_%logit_2.0 ._%logit_0.0  It_%logit_1.0  is_%logit_1.0  also_%logit_0.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_2.0  mechanisms_%logit_1.0  by_%logit_0.0  which_%logit_0.0  erg_%logit_0.0 ost_%logit_0.0 asm_%logit_1.0  works_%logit_2.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_0.0  as_%logit_1.0  the_%logit_0.0  mechanism_%logit_0.0  by_%logit_2.0  which_%logit_0.0  it_%logit_2.0  works_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_2.0  interventions_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_2.0  use_%logit_0.0  of_%logit_0.0  cervical_%logit_0.0  ultr_%logit_1.0 ason_%logit_0.0 ography_%logit_0.0  as_%logit_2.0  a_%logit_0.0  diagnostic_%logit_1.0  tool_%logit_0.0  for_%logit_0.0  HPV_%logit_0.0  testing_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  best_%logit_1.0  cervical_%logit_2.0  ultr_%logit_2.0 ator_%logit_1.0 ography_%logit_1.0  technique_%logit_0.0  and_%logit_2.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_1.0  best_%logit_2.0  way_%logit_1.0  to_%logit_1.0  achieve_%logit_2.0  this_%logit_2.0  objective_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_2.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  ultr_%logit_0.0 ason_%logit_2.0 ographic_%logit_0.0  techniques_%logit_0.0  in_%logit_0.0  HPV_%logit_1.0  testing_%logit_1.0 ,_%logit_0.0  especially_%logit_2.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_0.0  accuracy_%logit_0.0 ,_%logit_1.0  specificity_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  specificity_%logit_0.0 ._%logit_2.0  The_%logit_1.0  results_%logit_0.0  of_%logit_2.0  this_%logit_0.0  review_%logit_0.0  should_%logit_0.0  be_%logit_0.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  results_%logit_0.0  are_%logit_0.0  based_%logit_1.0  on_%logit_2.0  only_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_1.0  of_%logit_1.0  studies_%logit_2.0  and_%logit_0.0  the_%logit_1.0  results_%logit_1.0  are_%logit_1.0  not_%logit_1.0  representative_%logit_1.0  of_%logit_1.0  the_%logit_2.0  whole_%logit_0.0  range_%logit_0.0  of_%logit_1.0  HPV_%logit_1.0  testing_%logit_2.0  methods_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  hyd_%logit_0.0 roc_%logit_0.0 obal_%logit_0.0 amin_%logit_2.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  c_%logit_0.0 obal_%logit_2.0 amin_%logit_2.0  deficiency_%logit_1.0  in_%logit_1.0  people_%logit_0.0  with_%logit_1.0  C_%logit_0.0 obal_%logit_1.0 amin_%logit_0.0  deficient_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_0.0  optimal_%logit_0.0  hyd_%logit_0.0 roc_%logit_2.0 ouble_%logit_1.0 asin_%logit_0.0  formulation_%logit_0.0 ,_%logit_0.0  the_%logit_0.0  best_%logit_0.0  formulation_%logit_1.0  and_%logit_2.0  timing_%logit_0.0  of_%logit_1.0  hyd_%logit_2.0 oc_%logit_2.0 obal_%logit_2.0 amin_%logit_0.0  supplementation_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  the_%logit_1.0  best_%logit_1.0  way_%logit_1.0  to_%logit_2.0  administer_%logit_1.0  it_%logit_1.0 ._%logit_2.0  In_%logit_2.0  addition_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_1.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_0.0  and_%logit_0.0  executed_%logit_2.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  efficacy_%logit_2.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  hyd_%logit_1.0 rop_%logit_0.0 obal_%logit_1.0 amin_%logit_2.0  in_%logit_2.0  this_%logit_0.0  population_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_1.0  of_%logit_0.0  benz_%logit_2.0 od_%logit_2.0 iazep_%logit_1.0 ine_%logit_2.0  for_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  P_%logit_0.0 N_%logit_0.0 SS_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  confirm_%logit_1.0  the_%logit_2.0  existence_%logit_0.0  and_%logit_1.0  validity_%logit_0.0  of_%logit_1.0  these_%logit_0.0  findings_%logit_1.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_2.0  in_%logit_2.0  the_%logit_1.0  management_%logit_1.0  of_%logit_1.0  P_%logit_0.0 AN_%logit_0.0 SS_%logit_2.0 ._%logit_0.0  Recommend_%logit_0.0 ations_%logit_0.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_2.0  clarify_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  profile_%logit_0.0  of_%logit_1.0  benz_%logit_2.0 ad_%logit_1.0 iazep_%logit_2.0 ine_%logit_1.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  its_%logit_2.0  efficacy_%logit_0.0  and_%logit_1.0  toler_%logit_2.0 ability_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  its_%logit_0.0  effectiveness_%logit_0.0  in_%logit_1.0  other_%logit_1.0  situations_%logit_0.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_1.0  insomnia_%logit_0.0  or_%logit_1.0  depression_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  antidepressants_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  depression_%logit_0.0  in_%logit_1.0  children_%logit_1.0  and_%logit_0.0  adolescents_%logit_0.0  with_%logit_0.0  major_%logit_0.0  depression_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  identify_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  antidepressant_%logit_2.0  dose_%logit_1.0  and_%logit_2.0  duration_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_2.0  efficacy_%logit_1.0  of_%logit_2.0  antidepressants_%logit_2.0  with_%logit_1.0  other_%logit_1.0  antidepressants_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_2.0  as_%logit_2.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  antidepressants_%logit_0.0  for_%logit_0.0  depression_%logit_2.0  in_%logit_2.0  these_%logit_2.0  children_%logit_2.0  or_%logit_2.0  adolescents_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_2.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  antidepressant_%logit_0.0  therapy_%logit_0.0  in_%logit_0.0  reducing_%logit_0.0  depression_%logit_1.0  severity_%logit_0.0  and_%logit_1.0  severity_%logit_0.0  in_%logit_0.0  these_%logit_1.0  patients_%logit_1.0 ,_%logit_0.0  a_%logit_2.0  meta_%logit_1.0 -_%logit_2.0 analysis_%logit_2.0  is_%logit_0.0  required_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_0.0  optimal_%logit_2.0  dosage_%logit_0.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_2.0  antidepressants_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  erg_%logit_1.0 onomic_%logit_1.0  tools_%logit_1.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_1.0  TH_%logit_1.0 Ds_%logit_1.0 ._%logit_1.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  erg_%logit_0.0 onomic_%logit_0.0  techniques_%logit_1.0  are_%logit_2.0  effective_%logit_1.0  in_%logit_0.0  reducing_%logit_2.0  TH_%logit_1.0 Ds_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  TH_%logit_1.0 Ds_%logit_0.0 ,_%logit_0.0  or_%logit_1.0  whether_%logit_1.0  they_%logit_2.0  should_%logit_0.0  be_%logit_2.0  used_%logit_0.0  as_%logit_0.0  a_%logit_2.0  substitute_%logit_1.0  for_%logit_0.0  erg_%logit_0.0 onomic_%logit_0.0  methods_%logit_0.0  in_%logit_1.0  treating_%logit_0.0  TH_%logit_2.0 Ds_%logit_0.0  with_%logit_0.0  erg_%logit_1.0 onomic_%logit_1.0  materials_%logit_0.0 ._%logit_0.0  In_%logit_2.0  addition_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_1.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  erg_%logit_2.0 onomic_%logit_0.0  technologies_%logit_2.0  for_%logit_2.0  TH_%logit_2.0 Ds_%logit_0.0  and_%logit_1.0  other_%logit_0.0  aspects_%logit_2.0  of_%logit_0.0  TH_%logit_1.0 D_%logit_2.0  management_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  F_%logit_0.0 SH_%logit_1.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_0.0  mature_%logit_0.0  o_%logit_0.0 ocytes_%logit_0.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_1.0  F_%logit_1.0 SH_%logit_2.0  should_%logit_0.0  be_%logit_0.0  used_%logit_2.0  for_%logit_1.0  mature_%logit_1.0  o_%logit_0.0 ocyte_%logit_0.0  retrieval_%logit_2.0 ,_%logit_0.0  the_%logit_2.0  timing_%logit_2.0  and_%logit_2.0  duration_%logit_0.0  of_%logit_2.0  foll_%logit_1.0 icle_%logit_2.0  retrieval_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  the_%logit_0.0  optimal_%logit_0.0  timing_%logit_0.0  and_%logit_1.0  timing_%logit_1.0  of_%logit_0.0  administration_%logit_2.0  in_%logit_0.0  these_%logit_0.0  o_%logit_2.0 ocytes_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  well_%logit_2.0  as_%logit_0.0  the_%logit_0.0  optimal_%logit_1.0  dosage_%logit_2.0  and_%logit_1.0  timing_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  long_%logit_0.0 -_%logit_0.0 term_%logit_1.0  follow_%logit_0.0 -_%logit_1.0 up_%logit_2.0  data_%logit_0.0  are_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  the_%logit_0.0  F_%logit_0.0 SH_%logit_2.0  treatment_%logit_0.0  in_%logit_2.0  mature_%logit_2.0  and_%logit_2.0  developing_%logit_0.0  o_%logit_2.0 ocytes_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  the_%logit_0.0  various_%logit_0.0  F_%logit_1.0 SH_%logit_1.0  reg_%logit_0.0 imens_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  prog_%logit_0.0 est_%logit_0.0 ogens_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  uter_%logit_0.0 ine_%logit_0.0  le_%logit_0.0 i_%logit_0.0 omy_%logit_1.0 oma_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  prog_%logit_2.0 est_%logit_2.0 ogen_%logit_1.0  formulation_%logit_0.0  and_%logit_2.0  dosage_%logit_2.0 ,_%logit_0.0  duration_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  duration_%logit_0.0  of_%logit_1.0  treatment_%logit_1.0  in_%logit_1.0  this_%logit_1.0  population_%logit_1.0 ._%logit_2.0  Such_%logit_2.0  trials_%logit_0.0  should_%logit_0.0  include_%logit_0.0  a_%logit_2.0  number_%logit_1.0  of_%logit_2.0  patients_%logit_1.0 ,_%logit_0.0  preferably_%logit_1.0  with_%logit_1.0  a_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  bias_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  follow_%logit_0.0 -_%logit_0.0 up_%logit_0.0  of_%logit_0.0  at_%logit_2.0  least_%logit_0.0  one_%logit_0.0  year_%logit_0.0 ._%logit_0.0  Such_%logit_1.0  studies_%logit_2.0  should_%logit_2.0  also_%logit_1.0  assess_%logit_1.0  the_%logit_1.0  effects_%logit_2.0  on_%logit_1.0  quality_%logit_0.0  of_%logit_2.0  life_%logit_0.0 ,_%logit_0.0  quality_%logit_0.0  and_%logit_1.0  quantity_%logit_1.0  of_%logit_2.0  life_%logit_0.0 ._%logit_0.0  They_%logit_0.0  should_%logit_2.0  also_%logit_1.0  evaluate_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  prog_%logit_1.0 ester_%logit_0.0 one_%logit_1.0  in_%logit_1.0  the_%logit_1.0  management_%logit_2.0  of_%logit_0.0  my_%logit_0.0 ocard_%logit_0.0 ial_%logit_1.0  inf_%logit_0.0 ar_%logit_1.0 ction_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_2.0  of_%logit_0.0  cat_%logit_0.0 he_%logit_2.0 ters_%logit_2.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_0.0  per_%logit_2.0 iton_%logit_1.0 itis_%logit_0.0  or_%logit_0.0  exit_%logit_1.0  site_%logit_0.0  leaks_%logit_2.0 ._%logit_0.0  Cat_%logit_0.0 he_%logit_2.0 ters_%logit_0.0  should_%logit_0.0  not_%logit_0.0  be_%logit_0.0  used_%logit_0.0  as_%logit_0.0  a_%logit_1.0  substitute_%logit_2.0  for_%logit_0.0  closed_%logit_0.0  cat_%logit_2.0 heter_%logit_1.0  systems_%logit_2.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_0.0  cat_%logit_1.0 heter_%logit_0.0  survival_%logit_0.0  and_%logit_0.0  cat_%logit_0.0 heter_%logit_1.0  removal_%logit_1.0 ._%logit_0.0  Cat_%logit_0.0 heter_%logit_0.0  removal_%logit_2.0  should_%logit_0.0  be_%logit_2.0  carried_%logit_2.0  out_%logit_0.0  in_%logit_0.0  accordance_%logit_1.0  with_%logit_0.0  the_%logit_0.0  standard_%logit_0.0  procedure_%logit_0.0 ,_%logit_1.0  which_%logit_1.0  should_%logit_2.0  be_%logit_1.0  followed_%logit_2.0  by_%logit_2.0  a_%logit_2.0  cat_%logit_1.0 heter_%logit_1.0  cleaning_%logit_2.0  cycle_%logit_0.0 ._%logit_1.0  The_%logit_1.0  use_%logit_0.0  of_%logit_2.0  a_%logit_0.0  cat_%logit_2.0 he_%logit_0.0 ter_%logit_1.0  cleaning_%logit_2.0  cycle_%logit_0.0  should_%logit_0.0  be_%logit_0.0  considered_%logit_0.0  when_%logit_0.0  determining_%logit_0.0  the_%logit_1.0  optimal_%logit_2.0  cat_%logit_2.0 heter_%logit_2.0  configuration_%logit_0.0  and_%logit_2.0  timing_%logit_0.0  of_%logit_2.0  removal_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_2.0  existence_%logit_1.0  of_%logit_1.0  a_%logit_1.0  causal_%logit_2.0  relationship_%logit_2.0  between_%logit_2.0  skin_%logit_2.0  colour_%logit_1.0 ing_%logit_2.0  and_%logit_0.0  the_%logit_0.0  frequency_%logit_1.0  and_%logit_0.0  severity_%logit_1.0  of_%logit_1.0  Ray_%logit_0.0 na_%logit_1.0 ud_%logit_2.0 's_%logit_2.0  phenomenon_%logit_2.0 ._%logit_1.0  However_%logit_1.0 ,_%logit_2.0  there_%logit_2.0  is_%logit_1.0  a_%logit_2.0  need_%logit_1.0  for_%logit_1.0  further_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_2.0  and_%logit_0.0  executed_%logit_2.0  random_%logit_2.0 ised_%logit_2.0  controlled_%logit_0.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  skin_%logit_0.0  color_%logit_0.0 ning_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  this_%logit_1.0  common_%logit_0.0  phenomenon_%logit_2.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_1.0  should_%logit_1.0  be_%logit_0.0  of_%logit_1.0  high_%logit_0.0  methodological_%logit_0.0  quality_%logit_2.0 ,_%logit_1.0  with_%logit_1.0  a_%logit_1.0  focus_%logit_0.0  on_%logit_0.0  identifying_%logit_0.0  participants_%logit_0.0  who_%logit_2.0  are_%logit_0.0  most_%logit_1.0  likely_%logit_0.0  to_%logit_0.0  benefit_%logit_0.0  from_%logit_0.0  skin_%logit_0.0  color_%logit_0.0 ing_%logit_0.0 ._%logit_2.0  They_%logit_1.0  should_%logit_0.0  also_%logit_2.0  include_%logit_0.0  participants_%logit_2.0  who_%logit_1.0  have_%logit_1.0  been_%logit_2.0  diagnosed_%logit_2.0  with_%logit_1.0  a_%logit_0.0  similar_%logit_1.0  frequency_%logit_1.0  of_%logit_0.0  symptoms_%logit_1.0  as_%logit_0.0  those_%logit_2.0  who_%logit_1.0  are_%logit_2.0  not_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  aeros_%logit_0.0 ols_%logit_2.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  nasal_%logit_0.0  congestion_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_2.0  aeros_%logit_2.0 ols_%logit_2.0  for_%logit_2.0  nasal_%logit_2.0  congestion_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  aeros_%logit_1.0 ols_%logit_1.0  to_%logit_1.0  aeros_%logit_1.0 ols_%logit_2.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  aeros_%logit_1.0 ol_%logit_2.0  inhal_%logit_1.0 ation_%logit_1.0  therapy_%logit_0.0  in_%logit_2.0  the_%logit_1.0  management_%logit_1.0  of_%logit_1.0  respiratory_%logit_1.0  distress_%logit_1.0  syndrome_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_1.0  should_%logit_1.0  focus_%logit_2.0  on_%logit_1.0  assessing_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  aeros_%logit_1.0 oles_%logit_0.0  in_%logit_1.0  nasal_%logit_2.0  congestion_%logit_1.0  and_%logit_0.0  on_%logit_0.0  identifying_%logit_0.0  the_%logit_0.0  most_%logit_2.0  effective_%logit_0.0  aeros_%logit_0.0 ols_%logit_2.0  and_%logit_0.0  the_%logit_2.0  most_%logit_0.0  efficient_%logit_1.0  aeros_%logit_0.0 ols_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  pro_%logit_1.0 ph_%logit_2.0 yl_%logit_2.0 actic_%logit_0.0  blood_%logit_0.0  transf_%logit_1.0 usion_%logit_2.0  in_%logit_0.0  post_%logit_2.0 -_%logit_1.0 operative_%logit_1.0  liver_%logit_0.0  loss_%logit_0.0 ._%logit_1.0  Further_%logit_1.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_1.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  this_%logit_1.0  intervention_%logit_0.0 ._%logit_1.0  Such_%logit_1.0  trials_%logit_2.0  should_%logit_0.0  be_%logit_2.0  undertaken_%logit_0.0  in_%logit_2.0  the_%logit_1.0  absence_%logit_2.0  of_%logit_2.0  a_%logit_2.0  documented_%logit_0.0  adverse_%logit_0.0  event_%logit_2.0  profile_%logit_2.0 ._%logit_2.0  They_%logit_2.0  should_%logit_0.0  also_%logit_1.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_1.0  of_%logit_0.0  transf_%logit_0.0 usion_%logit_2.0  on_%logit_2.0  liver_%logit_1.0  function_%logit_0.0  and_%logit_1.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  on_%logit_2.0  mortality_%logit_1.0 ,_%logit_2.0  liver_%logit_2.0  function_%logit_1.0 ,_%logit_1.0  liver_%logit_0.0  autonomy_%logit_0.0  and_%logit_1.0  liver_%logit_1.0  autonomy_%logit_2.0 ._%logit_2.0  They_%logit_0.0  also_%logit_0.0  should_%logit_2.0  evaluate_%logit_1.0  the_%logit_0.0  effect_%logit_0.0  of_%logit_1.0  transf_%logit_1.0 usions_%logit_2.0  on_%logit_0.0  liver_%logit_1.0  autonomy_%logit_0.0 ,_%logit_0.0  liver_%logit_2.0  independence_%logit_0.0  and_%logit_0.0  liver_%logit_1.0  function_%logit_2.0 ._%logit_0.0  They_%logit_0.0  are_%logit_0.0  also_%logit_2.0  required_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_1.0  effects_%logit_0.0  on_%logit_0.0  liver_%logit_2.0  integrity_%logit_1.0  and_%logit_1.0  liver_%logit_0.0  integrity_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_2.0  any_%logit_1.0  of_%logit_1.0  the_%logit_2.0  interventions_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_2.0  prostate_%logit_2.0  enlarg_%logit_2.0 ement_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  these_%logit_2.0  interventions_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_0.0  them_%logit_1.0  in_%logit_2.0  particular_%logit_2.0  in_%logit_0.0  the_%logit_2.0  management_%logit_1.0  of_%logit_1.0  enlarged_%logit_1.0  prostate_%logit_0.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  them_%logit_0.0  on_%logit_2.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_2.0  and_%logit_0.0  health_%logit_1.0 -_%logit_0.0 related_%logit_0.0  productivity_%logit_2.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  to_%logit_2.0  determine_%logit_1.0  whether_%logit_1.0  these_%logit_2.0  interventions_%logit_2.0  are_%logit_1.0  beneficial_%logit_1.0  or_%logit_0.0  harmful_%logit_1.0 ,_%logit_0.0  the_%logit_1.0  results_%logit_2.0  should_%logit_2.0  be_%logit_1.0  interpreted_%logit_0.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  they_%logit_1.0  are_%logit_1.0  based_%logit_2.0  on_%logit_0.0  only_%logit_0.0  a_%logit_0.0  small_%logit_1.0  number_%logit_1.0  of_%logit_1.0  patients_%logit_2.0  and_%logit_0.0  are_%logit_0.0  subject_%logit_1.0  to_%logit_1.0  a_%logit_1.0  high_%logit_0.0  risk_%logit_0.0  of_%logit_1.0  bias_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  antidepressants_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  depression_%logit_0.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  establish_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_1.0  antidepressants_%logit_2.0  for_%logit_0.0  depression_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  antidepressants_%logit_1.0  with_%logit_0.0  other_%logit_0.0  antidepressants_%logit_2.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_1.0  improvement_%logit_2.0  in_%logit_1.0  mood_%logit_1.0 ,_%logit_1.0  cognition_%logit_1.0  and_%logit_1.0  function_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_2.0  to_%logit_2.0  determine_%logit_0.0  the_%logit_2.0  efficacy_%logit_2.0  of_%logit_0.0  antidepressants_%logit_0.0  as_%logit_2.0  an_%logit_0.0  adjunct_%logit_0.0  to_%logit_0.0  other_%logit_0.0  antidepressants_%logit_1.0 ,_%logit_1.0  future_%logit_2.0  research_%logit_1.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  aspects_%logit_0.0  of_%logit_2.0  antidepressants_%logit_1.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  on_%logit_0.0  their_%logit_0.0  effectiveness_%logit_0.0  in_%logit_2.0  reducing_%logit_2.0  depressive_%logit_0.0  symptoms_%logit_1.0 ,_%logit_1.0  and_%logit_0.0  on_%logit_1.0  improving_%logit_2.0  mood_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  prog_%logit_0.0 est_%logit_1.0 ogen_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_0.0  for_%logit_1.0  oxy_%logit_1.0 toc_%logit_2.0 in_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_0.0  IGF_%logit_2.0 -_%logit_2.0 I_%logit_1.0  or_%logit_0.0  IGF_%logit_1.0 -_%logit_0.0 II_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_2.0  controlled_%logit_0.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  whether_%logit_0.0  prog_%logit_2.0 est_%logit_1.0 ogens_%logit_0.0  are_%logit_1.0  beneficial_%logit_2.0  or_%logit_0.0  harmful_%logit_0.0  in_%logit_0.0  improving_%logit_0.0  fetal_%logit_2.0  wellbeing_%logit_2.0  and_%logit_2.0  maternal_%logit_2.0  wellbeing_%logit_1.0 ._%logit_1.0  Such_%logit_2.0  trials_%logit_1.0  should_%logit_2.0  be_%logit_1.0  undertaken_%logit_2.0  in_%logit_1.0  the_%logit_2.0  context_%logit_0.0  of_%logit_0.0  a_%logit_1.0  well_%logit_1.0 -_%logit_1.0 defined_%logit_2.0  group_%logit_0.0  of_%logit_1.0  women_%logit_0.0  who_%logit_0.0  are_%logit_0.0  at_%logit_2.0  risk_%logit_1.0  of_%logit_2.0  developing_%logit_2.0  IGF_%logit_1.0 -_%logit_1.0 1_%logit_2.0  deficiency_%logit_0.0  or_%logit_1.0  developing_%logit_2.0  IGF_%logit_1.0 2_%logit_2.0  deficiency_%logit_1.0 ._%logit_0.0  They_%logit_0.0  should_%logit_0.0  also_%logit_2.0  include_%logit_2.0  women_%logit_0.0  who_%logit_1.0  have_%logit_2.0  been_%logit_0.0  diagnosed_%logit_2.0  with_%logit_2.0  IGF_%logit_0.0 -_%logit_0.0 2_%logit_0.0  deficiency_%logit_0.0  and_%logit_0.0  those_%logit_1.0  who_%logit_1.0  do_%logit_1.0  not_%logit_0.0  have_%logit_1.0  an_%logit_0.0  IGF_%logit_1.0 -_%logit_2.0 3_%logit_2.0  deficiency_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  alcohol_%logit_0.0  as_%logit_1.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_1.0  tea_%logit_2.0  or_%logit_1.0  tea_%logit_0.0  as_%logit_1.0  an_%logit_0.0  adjunct_%logit_2.0  to_%logit_2.0  tea_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_2.0  gast_%logit_0.0 ric_%logit_2.0  volume_%logit_1.0  and_%logit_1.0  pH_%logit_2.0  imbalance_%logit_2.0  in_%logit_2.0  patients_%logit_1.0  with_%logit_1.0  ana_%logit_1.0 esthesia_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  ratio_%logit_2.0  of_%logit_1.0  alcohol_%logit_1.0  and_%logit_0.0  tea_%logit_0.0  to_%logit_0.0  tea_%logit_0.0  and_%logit_1.0  tea_%logit_1.0  as_%logit_0.0  a_%logit_0.0  supplement_%logit_0.0  to_%logit_0.0  tea_%logit_2.0  or_%logit_0.0  water_%logit_0.0  as_%logit_1.0  a_%logit_2.0  complement_%logit_0.0  to_%logit_2.0  tea_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_1.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_1.0  alcohol_%logit_1.0  on_%logit_0.0  gast_%logit_0.0 ric_%logit_0.0  volumes_%logit_0.0  and_%logit_0.0  pH_%logit_1.0  in_%logit_0.0  patients_%logit_2.0  undergoing_%logit_0.0  ana_%logit_2.0 esthesia_%logit_1.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_2.0  as_%logit_1.0  the_%logit_0.0  effect_%logit_0.0  of_%logit_0.0  tea_%logit_0.0  and_%logit_2.0  water_%logit_1.0  as_%logit_0.0  an_%logit_2.0  adj_%logit_1.0 u_%logit_0.0 vant_%logit_2.0  to_%logit_1.0  tea_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  on_%logit_2.0  the_%logit_2.0  incidence_%logit_2.0  of_%logit_0.0  adverse_%logit_0.0  effects_%logit_1.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_1.0  nausea_%logit_2.0  and_%logit_0.0  vomiting_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_0.0  of_%logit_2.0  hyd_%logit_1.0 rog_%logit_1.0 el_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_0.0  local_%logit_1.0  tum_%logit_1.0 our_%logit_2.0  rec_%logit_1.0 urrence_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_0.0  optimal_%logit_2.0  hyd_%logit_2.0 rog_%logit_1.0 els_%logit_2.0  and_%logit_0.0  the_%logit_2.0  optimal_%logit_2.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_1.0  and_%logit_2.0  timing_%logit_2.0  of_%logit_2.0  hyd_%logit_0.0 og_%logit_0.0 el_%logit_1.0  in_%logit_0.0  treating_%logit_2.0  local_%logit_1.0  tum_%logit_0.0 ours_%logit_0.0  and_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  formulation_%logit_2.0  and_%logit_0.0  timing_%logit_1.0 ._%logit_1.0  The_%logit_0.0  results_%logit_0.0  of_%logit_0.0  this_%logit_1.0  review_%logit_0.0  should_%logit_1.0  be_%logit_2.0  interpreted_%logit_2.0  with_%logit_2.0  caution_%logit_0.0 ,_%logit_0.0  as_%logit_0.0  the_%logit_0.0  conclusions_%logit_2.0  are_%logit_2.0  based_%logit_1.0  on_%logit_1.0  a_%logit_1.0  small_%logit_0.0  number_%logit_0.0  of_%logit_2.0  small_%logit_0.0  studies_%logit_0.0  with_%logit_1.0  a_%logit_1.0  high_%logit_1.0  risk_%logit_1.0  of_%logit_1.0  bias_%logit_1.0  and_%logit_0.0  are_%logit_1.0  subject_%logit_1.0  to_%logit_0.0  change_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  difference_%logit_2.0  in_%logit_1.0  body_%logit_2.0  mass_%logit_0.0 ,_%logit_2.0  caloric_%logit_2.0  intake_%logit_0.0 ,_%logit_1.0  protein_%logit_1.0  intake_%logit_2.0  or_%logit_1.0  protein_%logit_0.0  intake_%logit_0.0  between_%logit_0.0  the_%logit_0.0  two_%logit_1.0  methods_%logit_0.0  of_%logit_0.0  measuring_%logit_2.0  body_%logit_2.0  mass_%logit_2.0  and_%logit_0.0  protein_%logit_0.0  intake_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  best_%logit_0.0  way_%logit_1.0  to_%logit_2.0  measure_%logit_1.0  body_%logit_2.0  mass_%logit_1.0  in_%logit_0.0  relation_%logit_1.0  to_%logit_0.0  protein_%logit_2.0  intake_%logit_0.0 ,_%logit_1.0  carbohydrate_%logit_0.0  intake_%logit_2.0  and_%logit_1.0  protein_%logit_0.0  intakes_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_0.0  as_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  protein_%logit_0.0  intake_%logit_1.0  on_%logit_2.0  energy_%logit_0.0  intake_%logit_2.0  and_%logit_2.0  caloric_%logit_1.0  intake_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_0.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_2.0  measuring_%logit_0.0  protein_%logit_0.0  intake_%logit_0.0  and_%logit_0.0  carbohydrate_%logit_2.0  intake_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  on_%logit_1.0  measuring_%logit_0.0  energy_%logit_1.0  intake_%logit_0.0 ,_%logit_2.0  nutrient_%logit_1.0  intake_%logit_2.0  and_%logit_1.0  nutrient_%logit_0.0  intake_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_1.0  phot_%logit_0.0 oco_%logit_0.0 ag_%logit_0.0 ulation_%logit_2.0  for_%logit_1.0  spherical_%logit_0.0  equivalent_%logit_2.0  ref_%logit_1.0 ract_%logit_1.0 ory_%logit_0.0  vision_%logit_1.0  correction_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_2.0  optimal_%logit_0.0  phot_%logit_2.0 oco_%logit_0.0 agg_%logit_2.0 ulation_%logit_0.0  technique_%logit_2.0 ,_%logit_1.0  the_%logit_2.0  best_%logit_1.0  way_%logit_0.0  to_%logit_1.0  achieve_%logit_2.0  this_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  the_%logit_2.0  most_%logit_0.0  effective_%logit_0.0  phot_%logit_1.0 o_%logit_0.0 ag_%logit_2.0 ulation_%logit_2.0  technique_%logit_0.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  evaluation_%logit_0.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_1.0  aspects_%logit_1.0  of_%logit_2.0  phot_%logit_2.0 oc_%logit_0.0 ag_%logit_0.0 ulation_%logit_2.0  in_%logit_2.0  spherical_%logit_1.0  equivalent_%logit_1.0  vision_%logit_2.0  correction_%logit_0.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  phot_%logit_2.0 otherapy_%logit_1.0  in_%logit_1.0  spherical_%logit_1.0  or_%logit_0.0  spherical_%logit_2.0  equivalent_%logit_0.0  correction_%logit_0.0 ._%logit_2.0
 In_%logit_0.0 flix_%logit_0.0 im_%logit_2.0 ab_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  maintaining_%logit_2.0  remission_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  with_%logit_2.0  Cro_%logit_0.0 hn_%logit_0.0 's_%logit_0.0  disease_%logit_0.0 ._%logit_0.0  Its_%logit_1.0  efficacy_%logit_2.0  is_%logit_2.0  similar_%logit_0.0  to_%logit_2.0  that_%logit_1.0  of_%logit_0.0  infl_%logit_0.0 ix_%logit_1.0 im_%logit_1.0 ab_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  with_%logit_0.0  a_%logit_1.0  lower_%logit_1.0  incidence_%logit_2.0  of_%logit_2.0  adverse_%logit_1.0  events_%logit_1.0 ._%logit_2.0  It_%logit_0.0  is_%logit_0.0  not_%logit_0.0  clear_%logit_1.0  whether_%logit_1.0  it_%logit_0.0  has_%logit_2.0  an_%logit_1.0  effect_%logit_0.0  on_%logit_1.0  the_%logit_1.0  number_%logit_0.0  of_%logit_0.0  days_%logit_0.0  lost_%logit_2.0  to_%logit_0.0  treatment_%logit_2.0  or_%logit_2.0  on_%logit_0.0  the_%logit_0.0  severity_%logit_0.0  of_%logit_2.0  the_%logit_0.0  disease_%logit_1.0 ,_%logit_1.0  but_%logit_2.0  it_%logit_0.0  is_%logit_1.0  unlikely_%logit_0.0  that_%logit_2.0  it_%logit_1.0  will_%logit_0.0  have_%logit_0.0  an_%logit_0.0  impact_%logit_0.0  on_%logit_0.0  the_%logit_0.0  quality_%logit_0.0  of_%logit_1.0  life_%logit_1.0  of_%logit_1.0  patients_%logit_1.0  who_%logit_0.0  are_%logit_1.0  unable_%logit_1.0  to_%logit_2.0  tolerate_%logit_2.0  it_%logit_0.0 ._%logit_0.0  It_%logit_0.0  may_%logit_1.0  have_%logit_2.0  a_%logit_1.0  beneficial_%logit_0.0  effect_%logit_2.0  on_%logit_2.0  blood_%logit_2.0  pressure_%logit_2.0 ,_%logit_1.0  but_%logit_1.0  its_%logit_2.0  effects_%logit_2.0  are_%logit_2.0  not_%logit_2.0  clear_%logit_2.0  from_%logit_0.0  this_%logit_0.0  review_%logit_0.0 ._%logit_0.0  It_%logit_0.0  should_%logit_0.0  be_%logit_1.0  noted_%logit_1.0  that_%logit_1.0  the_%logit_0.0  data_%logit_0.0  in_%logit_0.0  this_%logit_1.0  review_%logit_1.0  are_%logit_0.0  based_%logit_0.0  on_%logit_0.0  a_%logit_0.0  small_%logit_2.0  number_%logit_1.0  of_%logit_0.0  patients_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  therefore_%logit_2.0  the_%logit_1.0  conclusions_%logit_0.0  of_%logit_1.0  this_%logit_2.0  review_%logit_1.0  should_%logit_1.0  be_%logit_0.0  interpreted_%logit_0.0  cautiously_%logit_0.0 ._%logit_0.0
 The_%logit_0.0  results_%logit_2.0  of_%logit_2.0  this_%logit_2.0  review_%logit_0.0  support_%logit_0.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  automated_%logit_2.0  PCR_%logit_1.0  kits_%logit_2.0  to_%logit_2.0  enhance_%logit_2.0  the_%logit_2.0  uptake_%logit_1.0  of_%logit_0.0  HIV_%logit_0.0  testing_%logit_0.0  in_%logit_0.0  pregnant_%logit_1.0  women_%logit_1.0  and_%logit_0.0  their_%logit_1.0  partners_%logit_0.0 ._%logit_2.0  However_%logit_0.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_2.0  into_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  such_%logit_2.0  kits_%logit_2.0  in_%logit_1.0  improving_%logit_1.0  the_%logit_1.0  quality_%logit_2.0  of_%logit_0.0  testing_%logit_2.0  and_%logit_2.0  reducing_%logit_0.0  attrition_%logit_0.0  in_%logit_1.0  the_%logit_0.0  workforce_%logit_1.0 ._%logit_0.0  This_%logit_1.0  is_%logit_1.0  especially_%logit_0.0  true_%logit_0.0  in_%logit_2.0  the_%logit_0.0  context_%logit_0.0  of_%logit_2.0  the_%logit_1.0  increasing_%logit_1.0  prevalence_%logit_0.0  of_%logit_0.0  HIV_%logit_2.0  infection_%logit_1.0  in_%logit_1.0  the_%logit_2.0  developing_%logit_0.0  world_%logit_2.0 ,_%logit_2.0  where_%logit_0.0  the_%logit_2.0  prevalence_%logit_1.0  of_%logit_2.0  viral_%logit_0.0  loads_%logit_2.0  is_%logit_1.0  high_%logit_0.0 ._%logit_1.0  Future_%logit_2.0  research_%logit_1.0  should_%logit_0.0  focus_%logit_0.0  on_%logit_1.0  assessing_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  these_%logit_0.0  kits_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  assessing_%logit_0.0  the_%logit_0.0  cost_%logit_0.0 -_%logit_1.0 effect_%logit_0.0 iveness_%logit_0.0  of_%logit_0.0  the_%logit_1.0  kits_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  also_%logit_1.0  on_%logit_0.0  the_%logit_2.0  impact_%logit_2.0  on_%logit_2.0  maternal_%logit_2.0  satisfaction_%logit_0.0  with_%logit_1.0  the_%logit_0.0  kits_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_0.0  of_%logit_0.0  benz_%logit_1.0 od_%logit_2.0 iazep_%logit_1.0 ines_%logit_0.0  in_%logit_0.0  the_%logit_0.0  management_%logit_1.0  of_%logit_2.0  autonom_%logit_1.0 ic_%logit_2.0  liability_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_1.0  optimal_%logit_0.0  dose_%logit_1.0 ,_%logit_0.0  duration_%logit_1.0  and_%logit_1.0  timing_%logit_1.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_2.0  best_%logit_2.0  way_%logit_0.0  to_%logit_2.0  deliver_%logit_1.0  benz_%logit_1.0 od_%logit_0.0 ine_%logit_0.0  to_%logit_0.0  people_%logit_2.0  with_%logit_2.0  schizophrenia_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  evaluate_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_1.0  other_%logit_1.0  types_%logit_0.0  of_%logit_0.0 iazep_%logit_1.0 ines_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  also_%logit_2.0  to_%logit_2.0  assess_%logit_1.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_0.0  of_%logit_1.0  other_%logit_2.0  forms_%logit_0.0  of_%logit_0.0 iazep_%logit_0.0 ine_%logit_2.0  therapy_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_1.0  future_%logit_0.0  research_%logit_1.0  should_%logit_2.0  evaluate_%logit_0.0  the_%logit_0.0  efficacy_%logit_1.0  of_%logit_0.0  other_%logit_2.0  kinds_%logit_1.0  of_%logit_1.0 iazep_%logit_2.0 am_%logit_0.0  therapy_%logit_0.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_1.0  as_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_0.0  aspects_%logit_1.0  of_%logit_2.0  these_%logit_0.0  treatments_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_0.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  antibiotics_%logit_0.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  mel_%logit_0.0 io_%logit_2.0 id_%logit_2.0 osis_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_2.0  establish_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_2.0  in_%logit_0.0  this_%logit_1.0  population_%logit_1.0 ._%logit_2.0  It_%logit_2.0  is_%logit_0.0  also_%logit_1.0  important_%logit_0.0  to_%logit_0.0  understand_%logit_0.0  the_%logit_0.0  mechanism_%logit_1.0  by_%logit_2.0  which_%logit_0.0  antibiotic_%logit_1.0  treatment_%logit_0.0  differs_%logit_1.0  from_%logit_1.0  antibiotic_%logit_1.0  treatment_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  mechanisms_%logit_0.0  by_%logit_1.0  which_%logit_0.0  it_%logit_0.0  differs_%logit_0.0  from_%logit_0.0  treatment_%logit_0.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_0.0  duration_%logit_0.0  of_%logit_1.0  treatment_%logit_1.0  and_%logit_0.0  severity_%logit_0.0  of_%logit_2.0  mortality_%logit_2.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_2.0  is_%logit_2.0  a_%logit_2.0  need_%logit_1.0  for_%logit_1.0  further_%logit_1.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  efficacy_%logit_0.0  of_%logit_1.0  antibiotic_%logit_0.0  therapy_%logit_0.0  in_%logit_0.0  this_%logit_1.0  group_%logit_1.0  of_%logit_0.0  patients_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  also_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  antibiotic_%logit_2.0  treatment_%logit_0.0  with_%logit_2.0  treatment_%logit_0.0  with_%logit_2.0  antibiotic_%logit_1.0  treatment_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  no_%logit_2.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_2.0  the_%logit_2.0  use_%logit_2.0  of_%logit_1.0  antibiotics_%logit_0.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  pur_%logit_0.0 ulent_%logit_2.0  rh_%logit_2.0 in_%logit_2.0 or_%logit_0.0 rh_%logit_0.0 oe_%logit_0.0 a_%logit_0.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  antibiotic_%logit_0.0  therapy_%logit_1.0  in_%logit_2.0  this_%logit_0.0  condition_%logit_2.0 ._%logit_1.0  In_%logit_2.0  addition_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  are_%logit_0.0  concerns_%logit_1.0  about_%logit_2.0  potential_%logit_1.0  side_%logit_1.0  effects_%logit_2.0 ,_%logit_1.0  such_%logit_0.0  as_%logit_1.0  nausea_%logit_2.0 ,_%logit_0.0  vomiting_%logit_1.0 ,_%logit_2.0  diarr_%logit_1.0 hoe_%logit_0.0 a_%logit_1.0 ,_%logit_0.0  sleep_%logit_0.0 iness_%logit_0.0 ,_%logit_2.0  sleep_%logit_0.0 lessness_%logit_1.0 ,_%logit_0.0  fatigue_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  sleep_%logit_2.0 lessness_%logit_1.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  antibiotics_%logit_0.0  for_%logit_0.0  this_%logit_2.0  condition_%logit_2.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_0.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  antibiotic_%logit_2.0  therapy_%logit_2.0  with_%logit_2.0  other_%logit_0.0  treatments_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  hyd_%logit_0.0 roc_%logit_0.0 ort_%logit_1.0 is_%logit_0.0 one_%logit_0.0  as_%logit_0.0  an_%logit_2.0  electroly_%logit_2.0 te_%logit_2.0  solution_%logit_2.0  for_%logit_1.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_1.0  hard_%logit_2.0  stool_%logit_2.0  formation_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  hyd_%logit_2.0 roc_%logit_2.0 ORT_%logit_2.0 is_%logit_0.0 one_%logit_2.0  formulation_%logit_2.0 ,_%logit_0.0  the_%logit_2.0  optimal_%logit_1.0  electroly_%logit_2.0 te_%logit_0.0  formulation_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_1.0  best_%logit_2.0  electroly_%logit_0.0 te_%logit_1.0  composition_%logit_0.0  for_%logit_0.0  the_%logit_1.0  management_%logit_1.0  of_%logit_2.0  soft_%logit_1.0  stool_%logit_2.0  formation_%logit_1.0  in_%logit_0.0  people_%logit_0.0  with_%logit_2.0  hard_%logit_1.0  stool_%logit_1.0  drainage_%logit_0.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  efficacy_%logit_2.0  and_%logit_1.0  toxicity_%logit_0.0  profiles_%logit_2.0  of_%logit_2.0  various_%logit_2.0  electroly_%logit_0.0 te_%logit_1.0  solutions_%logit_2.0  for_%logit_0.0  soft_%logit_1.0  stool_%logit_1.0  drainage_%logit_1.0  in_%logit_0.0  people_%logit_1.0  who_%logit_0.0  are_%logit_1.0  suffering_%logit_1.0  hard_%logit_1.0  const_%logit_2.0 ipation_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_1.0  hyd_%logit_1.0 roc_%logit_1.0 oll_%logit_0.0 oid_%logit_1.0  therapy_%logit_1.0  in_%logit_1.0  reducing_%logit_1.0  the_%logit_1.0  frequency_%logit_2.0  of_%logit_2.0  wet_%logit_1.0  nights_%logit_2.0  in_%logit_0.0  humans_%logit_2.0  with_%logit_1.0  no_%logit_1.0  known_%logit_2.0  adverse_%logit_1.0  effects_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_0.0 ,_%logit_2.0  and_%logit_2.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_0.0  effectiveness_%logit_0.0 ,_%logit_0.0  effectiveness_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  these_%logit_2.0  treatments_%logit_1.0  in_%logit_2.0  human_%logit_2.0  beings_%logit_0.0  with_%logit_1.0  no_%logit_1.0  apparent_%logit_0.0  adverse_%logit_0.0  effects_%logit_2.0  on_%logit_2.0  bladder_%logit_1.0  capacity_%logit_1.0  or_%logit_2.0  bladder_%logit_1.0  capacity_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_0.0  long_%logit_0.0 -_%logit_0.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  evaluate_%logit_2.0  the_%logit_0.0  efficacy_%logit_1.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_0.0  hydro_%logit_2.0 xy_%logit_0.0 ethyl_%logit_1.0 pred_%logit_0.0 nis_%logit_0.0 ol_%logit_1.0 one_%logit_1.0  in_%logit_2.0  humans_%logit_0.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_2.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  its_%logit_1.0  effectiveness_%logit_1.0  in_%logit_2.0  humans_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  phot_%logit_0.0 oco_%logit_2.0 ag_%logit_2.0 ulation_%logit_1.0  in_%logit_1.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_2.0  I_%logit_0.0 OP_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  phot_%logit_1.0 o_%logit_2.0 ag_%logit_0.0 ulation_%logit_0.0  for_%logit_1.0  I_%logit_2.0 OP_%logit_2.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_1.0  this_%logit_2.0  technique_%logit_0.0  with_%logit_1.0  other_%logit_0.0  methods_%logit_2.0  of_%logit_1.0  optical_%logit_2.0  infiltration_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_1.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_0.0  efficacy_%logit_0.0  and_%logit_0.0  safety_%logit_2.0  aspects_%logit_2.0  of_%logit_2.0  phot_%logit_0.0 oc_%logit_0.0 ag_%logit_0.0 ulation_%logit_2.0 ,_%logit_0.0  as_%logit_0.0  well_%logit_0.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  these_%logit_2.0  methods_%logit_1.0  with_%logit_1.0  other_%logit_2.0  techniques_%logit_1.0  of_%logit_1.0  optical_%logit_2.0  infiltr_%logit_2.0 ators_%logit_2.0 ._%logit_1.0
 Cognitive_%logit_0.0  enh_%logit_0.0 ancers_%logit_0.0  are_%logit_0.0  effective_%logit_2.0  in_%logit_0.0  reducing_%logit_2.0  pain_%logit_1.0  intensity_%logit_2.0  in_%logit_0.0  people_%logit_1.0  with_%logit_0.0  chronic_%logit_0.0  low_%logit_0.0 -_%logit_2.0 back_%logit_2.0  pain_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  are_%logit_2.0  associated_%logit_2.0  with_%logit_2.0  a_%logit_0.0  higher_%logit_0.0  incidence_%logit_2.0  of_%logit_0.0  adverse_%logit_1.0  effects_%logit_1.0 ,_%logit_0.0  such_%logit_0.0  as_%logit_1.0  nausea_%logit_1.0 ,_%logit_1.0  vomiting_%logit_2.0 ,_%logit_1.0  sleep_%logit_2.0 iness_%logit_1.0  and_%logit_0.0  sleep_%logit_1.0 iness_%logit_0.0 ._%logit_2.0  Positive_%logit_0.0  effects_%logit_1.0  were_%logit_2.0  found_%logit_1.0  in_%logit_2.0  patients_%logit_0.0  with_%logit_2.0  low_%logit_1.0  pain_%logit_0.0  intensity_%logit_1.0 ,_%logit_2.0  but_%logit_2.0  were_%logit_1.0  not_%logit_0.0  statistically_%logit_0.0  significant_%logit_0.0  in_%logit_0.0  those_%logit_2.0  with_%logit_1.0  sub_%logit_1.0 ac_%logit_1.0 ute_%logit_1.0  pain_%logit_0.0  intensity_%logit_0.0 ._%logit_1.0  Negative_%logit_1.0  effects_%logit_0.0  were_%logit_2.0  observed_%logit_1.0  in_%logit_2.0  those_%logit_1.0  receiving_%logit_1.0  enh_%logit_0.0 ancers_%logit_2.0 ._%logit_1.0  Positive_%logit_1.0  results_%logit_0.0  were_%logit_1.0  consistent_%logit_1.0  with_%logit_0.0  those_%logit_1.0  seen_%logit_0.0  in_%logit_2.0  the_%logit_2.0  previous_%logit_0.0  version_%logit_0.0  of_%logit_0.0  this_%logit_1.0  review_%logit_0.0 ,_%logit_0.0  which_%logit_1.0  was_%logit_0.0  published_%logit_2.0  in_%logit_1.0  the_%logit_0.0  same_%logit_0.0  volume_%logit_0.0  as_%logit_0.0  the_%logit_0.0  original_%logit_0.0  edition_%logit_0.0 ._%logit_2.0  Positive_%logit_2.0  findings_%logit_0.0  were_%logit_1.0  consistent_%logit_2.0  in_%logit_1.0  the_%logit_2.0  assessment_%logit_0.0  of_%logit_1.0  pain_%logit_1.0  intensity_%logit_0.0  and_%logit_2.0  function_%logit_2.0 ,_%logit_0.0  and_%logit_2.0  in_%logit_0.0  those_%logit_0.0  patients_%logit_0.0  receiving_%logit_1.0  enh_%logit_1.0 ancer_%logit_0.0  therapy_%logit_0.0 ._%logit_0.0  Negative_%logit_1.0  results_%logit_1.0  were_%logit_1.0  not_%logit_2.0  reported_%logit_0.0  in_%logit_1.0  the_%logit_0.0  original_%logit_0.0  version_%logit_0.0  of_%logit_0.0  the_%logit_0.0  review_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  the_%logit_1.0  new_%logit_1.0  version_%logit_0.0  has_%logit_2.0  now_%logit_0.0  been_%logit_1.0  published_%logit_1.0  in_%logit_0.0  full_%logit_0.0 ._%logit_0.0  Positive_%logit_0.0  conclusions_%logit_1.0  from_%logit_1.0  this_%logit_2.0  review_%logit_0.0  should_%logit_1.0  be_%logit_1.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  however_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  the_%logit_1.0  review_%logit_1.0  was_%logit_2.0  based_%logit_1.0  on_%logit_0.0  a_%logit_0.0  small_%logit_1.0  number_%logit_1.0  of_%logit_2.0  studies_%logit_0.0  and_%logit_0.0  therefore_%logit_0.0  the_%logit_0.0  conclusions_%logit_2.0  of_%logit_2.0  the_%logit_1.0  original_%logit_0.0  article_%logit_2.0  are_%logit_2.0  not_%logit_2.0  necessarily_%logit_0.0  the_%logit_2.0  same_%logit_2.0 ._%logit_2.0
 Mel_%logit_0.0 ars_%logit_0.0 op_%logit_0.0 rol_%logit_0.0  is_%logit_0.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  relapse_%logit_0.0  rates_%logit_0.0  and_%logit_2.0  severity_%logit_1.0  of_%logit_0.0  adverse_%logit_1.0  events_%logit_1.0 ,_%logit_0.0  but_%logit_1.0  its_%logit_0.0  effectiveness_%logit_2.0  is_%logit_2.0  not_%logit_1.0  clear_%logit_1.0 ._%logit_1.0  Its_%logit_2.0  efficacy_%logit_1.0  is_%logit_1.0  similar_%logit_0.0  to_%logit_1.0  that_%logit_0.0  of_%logit_1.0  mel_%logit_1.0 ars_%logit_0.0 op_%logit_0.0 rop_%logit_0.0 rol_%logit_2.0 ,_%logit_0.0  but_%logit_1.0  with_%logit_2.0  a_%logit_2.0  higher_%logit_1.0  incidence_%logit_0.0  of_%logit_2.0  adverse_%logit_2.0  effects_%logit_1.0 ._%logit_0.0  Its_%logit_0.0  effectiveness_%logit_1.0  is_%logit_2.0  comparable_%logit_2.0  to_%logit_1.0  that_%logit_2.0  seen_%logit_0.0  in_%logit_1.0  the_%logit_2.0  earlier_%logit_2.0  version_%logit_2.0  of_%logit_2.0  this_%logit_0.0  review_%logit_0.0 ._%logit_0.0  Its_%logit_2.0  duration_%logit_2.0  is_%logit_0.0  longer_%logit_1.0 ,_%logit_2.0  and_%logit_0.0  its_%logit_1.0  duration_%logit_0.0  is_%logit_2.0  shorter_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  the_%logit_1.0  severity_%logit_2.0  of_%logit_2.0  relapse_%logit_2.0  is_%logit_0.0  less_%logit_0.0  clear_%logit_0.0 ._%logit_0.0  It_%logit_0.0  is_%logit_0.0  unlikely_%logit_2.0  that_%logit_2.0  the_%logit_0.0  new_%logit_0.0  version_%logit_2.0  will_%logit_2.0  have_%logit_2.0  a_%logit_2.0  similar_%logit_1.0  efficacy_%logit_1.0  as_%logit_2.0  the_%logit_1.0  older_%logit_0.0  version_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_2.0  hyd_%logit_0.0 roc_%logit_1.0 ort_%logit_0.0 is_%logit_2.0 one_%logit_0.0  in_%logit_0.0  the_%logit_2.0  management_%logit_2.0  of_%logit_2.0  arter_%logit_1.0 ios_%logit_1.0 us_%logit_2.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  vas_%logit_2.0 op_%logit_0.0 ress_%logit_0.0 in_%logit_1.0 -_%logit_0.0 induced_%logit_0.0  hyp_%logit_1.0 ogly_%logit_1.0 ca_%logit_1.0 emia_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_2.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  optimal_%logit_2.0  hyd_%logit_2.0 roc_%logit_2.0 ORT_%logit_1.0 is_%logit_0.0 one_%logit_0.0  formulation_%logit_0.0  and_%logit_1.0  dosage_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  hyd_%logit_2.0 oc_%logit_2.0 ort_%logit_2.0 is_%logit_2.0 ones_%logit_1.0  in_%logit_2.0  this_%logit_0.0  population_%logit_1.0 ._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_2.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  electroly_%logit_2.0 te_%logit_0.0  supplements_%logit_2.0  in_%logit_0.0  this_%logit_2.0  setting_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0  there_%logit_1.0  is_%logit_1.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_0.0  for_%logit_2.0  a_%logit_0.0  well_%logit_0.0 -_%logit_2.0 designed_%logit_1.0 ,_%logit_0.0  conducted_%logit_0.0  and_%logit_2.0  reported_%logit_2.0  randomized_%logit_1.0  controlled_%logit_1.0  trial_%logit_2.0  to_%logit_1.0  evaluate_%logit_2.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_1.0  and_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  various_%logit_1.0  electroly_%logit_1.0 te_%logit_2.0  formulations_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  antiv_%logit_0.0 iral_%logit_1.0  drugs_%logit_0.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_1.0  candid_%logit_0.0 iasis_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_2.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  confirm_%logit_1.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  antiv_%logit_1.0 ir_%logit_0.0 als_%logit_0.0  in_%logit_1.0  preventing_%logit_1.0  candid_%logit_1.0 iasis_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_0.0  other_%logit_1.0  candid_%logit_2.0 iasis_%logit_2.0  types_%logit_1.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_1.0  oral_%logit_0.0  antiv_%logit_2.0 iral_%logit_0.0  agents_%logit_1.0 ,_%logit_1.0  as_%logit_0.0  well_%logit_1.0  as_%logit_1.0  to_%logit_0.0  assess_%logit_0.0  whether_%logit_2.0  antiv_%logit_1.0 iral_%logit_1.0  medications_%logit_2.0  are_%logit_1.0  more_%logit_2.0  effective_%logit_1.0  than_%logit_1.0  antiv_%logit_1.0 iral_%logit_0.0  treatments_%logit_2.0  in_%logit_0.0  reducing_%logit_0.0  candid_%logit_0.0 iasis_%logit_2.0  severity_%logit_1.0  and_%logit_0.0  duration_%logit_2.0 ._%logit_1.0  Such_%logit_0.0  trials_%logit_2.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  evaluate_%logit_1.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  antiv_%logit_1.0 irus_%logit_1.0  drugs_%logit_0.0  in_%logit_2.0  candid_%logit_0.0 iasis_%logit_1.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_2.0  antiv_%logit_2.0 iral_%logit_0.0  therapies_%logit_0.0  to_%logit_2.0  antiv_%logit_1.0 iral_%logit_2.0  ones_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  erg_%logit_2.0 onomic_%logit_1.0  screws_%logit_2.0  for_%logit_0.0  improving_%logit_2.0  patient_%logit_2.0  satisfaction_%logit_1.0  with_%logit_1.0  pain_%logit_1.0  management_%logit_2.0  and_%logit_2.0  function_%logit_2.0  in_%logit_2.0  low_%logit_1.0 -_%logit_0.0 back_%logit_0.0  pain_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_2.0  erg_%logit_1.0 onomic_%logit_0.0  screw_%logit_1.0  screws_%logit_0.0  improve_%logit_0.0  patient_%logit_1.0  satisfaction_%logit_0.0  or_%logit_0.0  function_%logit_2.0  in_%logit_2.0  the_%logit_1.0  short_%logit_0.0 -_%logit_1.0 term_%logit_1.0  or_%logit_1.0  long_%logit_0.0 -_%logit_2.0 term_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  erg_%logit_2.0 onomic_%logit_0.0  devices_%logit_0.0  with_%logit_0.0  other_%logit_2.0  types_%logit_0.0  of_%logit_0.0  screws_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_2.0  of_%logit_2.0  erg_%logit_2.0 onom_%logit_0.0 ics_%logit_0.0  for_%logit_1.0  reducing_%logit_0.0  patient_%logit_1.0  satisfaction_%logit_2.0  and_%logit_2.0  function_%logit_2.0 ,_%logit_0.0  a_%logit_0.0  meta_%logit_1.0 -_%logit_1.0 analysis_%logit_0.0  of_%logit_0.0  the_%logit_1.0  results_%logit_0.0  of_%logit_1.0  this_%logit_0.0  review_%logit_0.0  is_%logit_1.0  warranted_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  support_%logit_1.0  or_%logit_1.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  che_%logit_0.0 mor_%logit_0.0 ad_%logit_1.0 ox_%logit_0.0 ine_%logit_0.0  as_%logit_0.0  a_%logit_0.0  substitute_%logit_1.0  for_%logit_1.0  cis_%logit_0.0 pl_%logit_1.0 atin_%logit_0.0  for_%logit_0.0  radi_%logit_2.0 otherapy_%logit_1.0  in_%logit_1.0  terms_%logit_1.0  of_%logit_1.0  overall_%logit_0.0  survival_%logit_1.0  and_%logit_1.0  progression_%logit_1.0 -_%logit_0.0 free_%logit_2.0  survival_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_0.0  there_%logit_2.0  is_%logit_1.0  a_%logit_2.0  need_%logit_1.0  for_%logit_0.0  further_%logit_0.0  research_%logit_1.0  into_%logit_1.0  che_%logit_1.0 mor_%logit_1.0 adi_%logit_0.0 otherapy_%logit_1.0  in_%logit_1.0  this_%logit_0.0  population_%logit_0.0 ._%logit_0.0  In_%logit_1.0  particular_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  are_%logit_1.0  concerns_%logit_1.0  about_%logit_1.0  the_%logit_1.0  impact_%logit_2.0  on_%logit_0.0  survival_%logit_0.0  and_%logit_2.0  quality_%logit_0.0  of_%logit_0.0  life_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_2.0  possibility_%logit_1.0  of_%logit_1.0  a_%logit_2.0  relapse_%logit_1.0  in_%logit_1.0  patients_%logit_1.0  with_%logit_2.0  metast_%logit_0.0 atic_%logit_2.0  disease_%logit_1.0 ,_%logit_1.0  which_%logit_1.0  has_%logit_1.0  been_%logit_1.0  reported_%logit_1.0  in_%logit_0.0  the_%logit_0.0  past_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  any_%logit_0.0  specific_%logit_2.0  type_%logit_2.0  of_%logit_2.0  counselling_%logit_1.0  for_%logit_2.0  smoking_%logit_0.0  cessation_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_0.0  most_%logit_2.0  effective_%logit_0.0  type_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  counselling_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_1.0  of_%logit_1.0  counselling_%logit_0.0  with_%logit_0.0  other_%logit_0.0  types_%logit_2.0  of_%logit_1.0  counselling_%logit_2.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_0.0  psychological_%logit_0.0  counselling_%logit_1.0  for_%logit_2.0  nicotine_%logit_2.0  replacement_%logit_0.0  therapy_%logit_2.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_0.0  as_%logit_1.0  to_%logit_0.0  compare_%logit_0.0  psychological_%logit_1.0  counselling_%logit_0.0  with_%logit_2.0  counselling_%logit_0.0  alone_%logit_2.0  or_%logit_1.0  in_%logit_2.0  combination_%logit_2.0  with_%logit_0.0  other_%logit_0.0  forms_%logit_1.0  of_%logit_0.0  counselling_%logit_2.0  and_%logit_1.0  counselling_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_2.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  any_%logit_0.0  of_%logit_0.0  the_%logit_1.0  interventions_%logit_0.0  reviewed_%logit_2.0  in_%logit_1.0  this_%logit_1.0  review_%logit_0.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_1.0  a_%logit_0.0  need_%logit_2.0  for_%logit_1.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  trials_%logit_2.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  these_%logit_1.0  interventions_%logit_2.0  in_%logit_2.0  terms_%logit_0.0  of_%logit_1.0  blood_%logit_0.0  transf_%logit_2.0 usion_%logit_1.0 ,_%logit_2.0  blood_%logit_2.0  loss_%logit_1.0 ,_%logit_2.0  transf_%logit_1.0 usion_%logit_2.0  capacity_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  transf_%logit_0.0 usion_%logit_2.0  efficiency_%logit_1.0 ._%logit_0.0  Import_%logit_1.0 antly_%logit_2.0 ,_%logit_2.0  these_%logit_0.0  trials_%logit_0.0  should_%logit_2.0  be_%logit_1.0  of_%logit_1.0  high_%logit_1.0  quality_%logit_0.0 ,_%logit_0.0  with_%logit_0.0  a_%logit_1.0  focus_%logit_2.0  on_%logit_1.0  reducing_%logit_0.0  blood_%logit_0.0  loss_%logit_1.0  and_%logit_2.0  blood_%logit_0.0  loss_%logit_0.0  in_%logit_0.0  patients_%logit_1.0  undergoing_%logit_1.0  transf_%logit_1.0 usion_%logit_2.0  and_%logit_2.0  blood_%logit_1.0  transf_%logit_0.0 usions_%logit_0.0 ,_%logit_2.0  rather_%logit_1.0  than_%logit_2.0  on_%logit_0.0  transf_%logit_0.0 usion_%logit_0.0  duration_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  alcohol_%logit_0.0  disinfect_%logit_1.0 ion_%logit_2.0  as_%logit_0.0  an_%logit_2.0  alternative_%logit_0.0  to_%logit_0.0  manual_%logit_1.0  cord_%logit_0.0  cleaning_%logit_2.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  umb_%logit_1.0 il_%logit_1.0 ical_%logit_0.0  cord_%logit_0.0  separation_%logit_0.0 ._%logit_2.0  Further_%logit_1.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_0.0  best_%logit_0.0  disinfect_%logit_1.0 ion_%logit_1.0  regimen_%logit_1.0 ,_%logit_1.0  the_%logit_0.0  best_%logit_1.0  method_%logit_1.0  of_%logit_0.0  disinfect_%logit_0.0 ion_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_1.0  most_%logit_0.0  effective_%logit_0.0  disinfect_%logit_2.0 ion_%logit_0.0  method_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  trials_%logit_2.0  are_%logit_1.0  also_%logit_1.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_1.0  water_%logit_1.0  disinfect_%logit_0.0 ion_%logit_1.0  in_%logit_0.0  reducing_%logit_1.0  cord_%logit_0.0  separation_%logit_2.0  time_%logit_0.0  and_%logit_2.0  to_%logit_2.0  compare_%logit_1.0  disinfect_%logit_1.0 ion_%logit_1.0  with_%logit_0.0  manual_%logit_0.0  cord_%logit_2.0  cleansing_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  future_%logit_1.0  trials_%logit_2.0  should_%logit_2.0  evaluate_%logit_0.0  the_%logit_1.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  disinfect_%logit_2.0 ing_%logit_1.0  cord_%logit_1.0  cleaning_%logit_1.0  as_%logit_0.0  a_%logit_1.0  complementary_%logit_1.0  treatment_%logit_1.0  to_%logit_2.0  manual_%logit_1.0  disinfect_%logit_0.0 ion_%logit_1.0 ._%logit_2.0
 Walking_%logit_0.0  speed_%logit_1.0  and_%logit_0.0  g_%logit_0.0 ait_%logit_2.0  speed_%logit_0.0  are_%logit_0.0  similar_%logit_0.0  to_%logit_0.0  those_%logit_1.0  measured_%logit_1.0  in_%logit_1.0  the_%logit_0.0  Functional_%logit_1.0  Balance_%logit_1.0  Scale_%logit_1.0 ,_%logit_1.0  but_%logit_0.0  the_%logit_1.0  difference_%logit_2.0  in_%logit_2.0  fitness_%logit_2.0  is_%logit_0.0  smaller_%logit_1.0 ._%logit_2.0  Walking_%logit_0.0  speed_%logit_1.0  is_%logit_0.0  associated_%logit_0.0  with_%logit_2.0  a_%logit_2.0  decreased_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  falls_%logit_0.0  and_%logit_0.0  falls_%logit_1.0 ,_%logit_2.0  but_%logit_2.0  is_%logit_1.0  not_%logit_1.0  associated_%logit_0.0  with_%logit_2.0  an_%logit_0.0  increase_%logit_2.0  in_%logit_2.0  risk_%logit_1.0  of_%logit_1.0  falling_%logit_1.0 ._%logit_2.0  Running_%logit_2.0  speed_%logit_0.0  appears_%logit_2.0  to_%logit_2.0  have_%logit_0.0  a_%logit_0.0  beneficial_%logit_2.0  effect_%logit_0.0  on_%logit_2.0  fitness_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  there_%logit_0.0  is_%logit_2.0  no_%logit_1.0  evidence_%logit_1.0  of_%logit_0.0  an_%logit_0.0  improvement_%logit_2.0  in_%logit_0.0  fitness_%logit_1.0 ._%logit_0.0  Running_%logit_0.0  Speed_%logit_1.0  appears_%logit_1.0  to_%logit_1.0  be_%logit_0.0  faster_%logit_0.0  than_%logit_0.0  walking_%logit_2.0  speed_%logit_1.0  or_%logit_0.0  g_%logit_1.0 ait_%logit_1.0  velocity_%logit_2.0 ,_%logit_2.0  but_%logit_1.0  this_%logit_0.0  is_%logit_2.0  not_%logit_2.0  clear_%logit_1.0  from_%logit_2.0  this_%logit_0.0  review_%logit_0.0 ._%logit_2.0  Running_%logit_2.0  time_%logit_1.0  is_%logit_0.0  slower_%logit_0.0  than_%logit_2.0  treadmill_%logit_2.0  speed_%logit_1.0 ._%logit_2.0  Running_%logit_0.0  speeds_%logit_2.0  appear_%logit_1.0  to_%logit_0.0  be_%logit_0.0  slower_%logit_0.0  in_%logit_0.0  the_%logit_0.0  short_%logit_2.0 -_%logit_2.0 term_%logit_0.0 ,_%logit_2.0  but_%logit_2.0  not_%logit_2.0  in_%logit_1.0  the_%logit_0.0  long_%logit_0.0 -_%logit_1.0 term_%logit_0.0 ._%logit_2.0  Run_%logit_0.0  time_%logit_1.0  is_%logit_2.0  faster_%logit_2.0  in_%logit_0.0  the_%logit_0.0  intermediate_%logit_1.0 -_%logit_0.0 term_%logit_0.0  and_%logit_1.0  longer_%logit_1.0 -_%logit_1.0 term_%logit_2.0  than_%logit_0.0  in_%logit_1.0  the_%logit_2.0  shorter_%logit_1.0 -_%logit_0.0 term_%logit_1.0  but_%logit_2.0  the_%logit_1.0  longer_%logit_2.0  term_%logit_0.0  results_%logit_2.0  are_%logit_2.0  still_%logit_0.0  not_%logit_2.0  clear_%logit_2.0 ._%logit_0.0  Running_%logit_2.0  times_%logit_2.0  are_%logit_0.0  slower_%logit_0.0  than_%logit_2.0  walking_%logit_1.0  time_%logit_0.0 ,_%logit_0.0  but_%logit_0.0  more_%logit_1.0  accurate_%logit_2.0 ._%logit_1.0  Running_%logit_2.0  distances_%logit_0.0  are_%logit_0.0  slower_%logit_1.0 ,_%logit_2.0  but_%logit_2.0  slower_%logit_2.0 ._%logit_1.0  Running_%logit_0.0  distance_%logit_0.0  is_%logit_2.0  slower_%logit_1.0 ,_%logit_1.0  and_%logit_1.0  slower_%logit_2.0  in_%logit_2.0  shorter_%logit_0.0  intervals_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  faster_%logit_2.0  in_%logit_0.0  longer_%logit_0.0  intervals_%logit_1.0 ._%logit_0.0  Running_%logit_0.0  lengths_%logit_0.0  are_%logit_1.0  slower_%logit_1.0  and_%logit_0.0  faster_%logit_0.0  in_%logit_0.0  shorter_%logit_0.0  periods_%logit_0.0 ,_%logit_0.0  but_%logit_1.0  are_%logit_2.0  not_%logit_2.0  as_%logit_0.0  fast_%logit_2.0  as_%logit_1.0  treadmill_%logit_2.0  speed_%logit_0.0  or_%logit_2.0  treadmill_%logit_1.0  speed_%logit_2.0 ,_%logit_1.0  or_%logit_1.0  faster_%logit_0.0  in_%logit_2.0  slower_%logit_2.0  periods_%logit_0.0 ,_%logit_0.0  or_%logit_2.0  longer_%logit_2.0  periods_%logit_1.0 ._%logit_0.0  Running_%logit_1.0  intervals_%logit_0.0  are_%logit_1.0  slower_%logit_1.0  in_%logit_1.0  slower_%logit_1.0 -_%logit_0.0 term_%logit_2.0  runners_%logit_0.0  than_%logit_0.0  treadmill_%logit_2.0  speeds_%logit_0.0 ,_%logit_0.0  but_%logit_2.0  shorter_%logit_1.0  in_%logit_0.0  shorter_%logit_1.0  term_%logit_1.0  runners_%logit_2.0 ._%logit_2.0  Run_%logit_1.0 -_%logit_2.0 time_%logit_2.0  is_%logit_1.0  slower_%logit_1.0  in_%logit_0.0  older_%logit_2.0  runners_%logit_0.0  than_%logit_2.0  in_%logit_0.0  younger_%logit_1.0  runners_%logit_0.0 ._%logit_0.0  Running_%logit_1.0  tests_%logit_2.0  are_%logit_2.0  faster_%logit_1.0  in_%logit_1.0  older_%logit_2.0  people_%logit_2.0 ,_%logit_1.0  but_%logit_2.0  longer_%logit_2.0  term_%logit_1.0  data_%logit_0.0  are_%logit_1.0  still_%logit_2.0  lacking_%logit_0.0 ._%logit_1.0  Running_%logit_0.0  machines_%logit_0.0  appear_%logit_0.0  to_%logit_2.0  have_%logit_0.0  fewer_%logit_0.0  adverse_%logit_1.0  effects_%logit_1.0  in_%logit_2.0  younger_%logit_2.0  people_%logit_2.0  than_%logit_2.0  treadmill_%logit_1.0  time_%logit_0.0 ._%logit_1.0  Running_%logit_0.0  shoes_%logit_2.0  appear_%logit_1.0  to_%logit_0.0  improve_%logit_0.0  speed_%logit_0.0  and_%logit_1.0  fitness_%logit_1.0  in_%logit_2.0  slower_%logit_2.0  runners_%logit_0.0 ,_%logit_1.0  but_%logit_1.0  further_%logit_2.0  research_%logit_2.0  is_%logit_1.0  needed_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_1.0  this_%logit_2.0  is_%logit_1.0  true_%logit_2.0  for_%logit_2.0  younger_%logit_2.0  people_%logit_0.0  or_%logit_2.0  older_%logit_2.0  people_%logit_1.0 ._%logit_0.0  Run_%logit_2.0  tests_%logit_1.0  are_%logit_2.0  more_%logit_0.0  likely_%logit_1.0  to_%logit_1.0  have_%logit_0.0  an_%logit_0.0  adverse_%logit_2.0  impact_%logit_0.0  on_%logit_0.0  fitness_%logit_0.0  and_%logit_1.0  fitness_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  are_%logit_2.0  less_%logit_1.0  likely_%logit_0.0  to_%logit_2.0  be_%logit_0.0  carried_%logit_0.0  out_%logit_1.0  in_%logit_1.0  older_%logit_1.0  patients_%logit_1.0 ._%logit_1.0  Running_%logit_1.0  test_%logit_0.0  results_%logit_1.0  are_%logit_1.0  less_%logit_2.0  consistent_%logit_1.0  in_%logit_1.0  younger_%logit_2.0  and_%logit_0.0  older_%logit_1.0  people_%logit_1.0  than_%logit_2.0  in_%logit_2.0  older_%logit_0.0  adults_%logit_0.0 ,_%logit_1.0  but_%logit_2.0  results_%logit_0.0  are_%logit_0.0  more_%logit_1.0  consistent_%logit_2.0  in_%logit_0.0  older_%logit_2.0  and_%logit_2.0  younger_%logit_1.0  people_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  in_%logit_2.0  younger_%logit_1.0  adults_%logit_2.0 ._%logit_1.0  Run_%logit_1.0  test_%logit_1.0  results_%logit_2.0  should_%logit_0.0  be_%logit_2.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_2.0  however_%logit_0.0 ,_%logit_2.0  as_%logit_1.0  they_%logit_2.0  are_%logit_2.0  based_%logit_2.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_0.0  of_%logit_0.0  repet_%logit_0.0 itions_%logit_0.0  of_%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_1.0  pro_%logit_0.0 ph_%logit_2.0 yl_%logit_2.0 actic_%logit_0.0  st_%logit_0.0 enting_%logit_1.0  as_%logit_2.0  an_%logit_0.0  alternative_%logit_2.0  to_%logit_0.0  conventional_%logit_0.0  st_%logit_2.0 enting_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_0.0  a_%logit_2.0  prox_%logit_2.0 imal_%logit_2.0  risk_%logit_0.0  of_%logit_2.0  death_%logit_1.0 ,_%logit_0.0  or_%logit_1.0  who_%logit_0.0  are_%logit_0.0  unable_%logit_2.0  to_%logit_0.0  tolerate_%logit_0.0  st_%logit_1.0 enting_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_1.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  optimal_%logit_0.0  st_%logit_2.0 enting_%logit_2.0  technique_%logit_0.0 ,_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  timing_%logit_1.0  and_%logit_1.0  duration_%logit_1.0  of_%logit_1.0  st_%logit_1.0 enting_%logit_2.0 ,_%logit_1.0  and_%logit_2.0  the_%logit_1.0  optimal_%logit_2.0  duration_%logit_1.0  of_%logit_2.0  the_%logit_0.0  st_%logit_2.0 ent_%logit_2.0  procedure_%logit_1.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_1.0  future_%logit_1.0  research_%logit_1.0  should_%logit_1.0  evaluate_%logit_1.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_2.0  cost_%logit_0.0 -_%logit_0.0 effect_%logit_1.0 iveness_%logit_1.0  of_%logit_0.0  anti_%logit_0.0 -_%logit_1.0 ang_%logit_1.0 inal_%logit_1.0  drugs_%logit_0.0  as_%logit_0.0  alternatives_%logit_1.0  to_%logit_1.0  traditional_%logit_0.0  st_%logit_0.0 enting_%logit_0.0  and_%logit_1.0  replace_%logit_1.0  st_%logit_2.0 enting_%logit_0.0  with_%logit_0.0  anti_%logit_1.0 plate_%logit_2.0 let_%logit_1.0  agents_%logit_2.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  these_%logit_2.0  drugs_%logit_0.0  in_%logit_2.0  terms_%logit_2.0  of_%logit_1.0  reduced_%logit_0.0  mortality_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_0.0  use_%logit_0.0  of_%logit_1.0  IL_%logit_1.0 -_%logit_1.0 2_%logit_2.0  inhibitors_%logit_2.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  rel_%logit_0.0 apses_%logit_2.0  in_%logit_1.0  patients_%logit_2.0  with_%logit_0.0  rel_%logit_1.0 apses_%logit_1.0  rem_%logit_2.0 itting_%logit_0.0  or_%logit_0.0  rel_%logit_0.0 apse_%logit_1.0 -_%logit_1.0 rem_%logit_2.0 itting_%logit_1.0  MS_%logit_1.0 ._%logit_0.0  Further_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_1.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  IL_%logit_0.0 2_%logit_0.0  inhibitors_%logit_2.0 ,_%logit_1.0  the_%logit_1.0  optimal_%logit_2.0  dosage_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  duration_%logit_1.0  of_%logit_0.0  therapy_%logit_0.0  in_%logit_2.0  these_%logit_0.0  patients_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  long_%logit_0.0 -_%logit_1.0 term_%logit_1.0  data_%logit_1.0  are_%logit_2.0  required_%logit_1.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_1.0  IL_%logit_1.0 3_%logit_1.0  inhibitors_%logit_2.0  in_%logit_1.0  removing_%logit_2.0  rel_%logit_0.0 apses_%logit_1.0  and_%logit_2.0  rel_%logit_1.0 aps_%logit_2.0 ing_%logit_0.0  rem_%logit_1.0 itting_%logit_1.0  and_%logit_0.0  rel_%logit_0.0 apses_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_1.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_1.0  these_%logit_1.0  drugs_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_1.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_2.0  effectiveness_%logit_0.0  of_%logit_0.0  acupuncture_%logit_2.0  for_%logit_2.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  pain_%logit_0.0  relief_%logit_2.0  in_%logit_0.0  neural_%logit_1.0 g_%logit_0.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_2.0  acupuncture_%logit_0.0 ,_%logit_2.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  acupuncture_%logit_1.0  with_%logit_1.0  other_%logit_2.0  forms_%logit_2.0  of_%logit_1.0  analges_%logit_1.0 ic_%logit_1.0  therapy_%logit_1.0  for_%logit_1.0  pain_%logit_1.0  relief_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_0.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_1.0  acupuncture_%logit_2.0  is_%logit_2.0  more_%logit_2.0  effective_%logit_0.0  than_%logit_0.0  no_%logit_0.0  treatment_%logit_1.0  or_%logit_0.0  no_%logit_2.0  treatment_%logit_2.0  at_%logit_0.0  all_%logit_2.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  future_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  evaluate_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  of_%logit_1.0  acupuncture_%logit_0.0  compared_%logit_0.0  to_%logit_0.0  no_%logit_2.0  treatment_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  should_%logit_1.0  include_%logit_0.0  participants_%logit_2.0  with_%logit_0.0  a_%logit_1.0  history_%logit_1.0  of_%logit_2.0  pain_%logit_0.0  disorders_%logit_2.0 ._%logit_1.0
 Pro_%logit_0.0 l_%logit_0.0 act_%logit_2.0 in_%logit_0.0  is_%logit_0.0  an_%logit_0.0  effective_%logit_0.0  treatment_%logit_2.0  for_%logit_0.0  people_%logit_0.0  with_%logit_0.0  schizophrenia_%logit_0.0  who_%logit_0.0  are_%logit_1.0  struggling_%logit_2.0  with_%logit_0.0  relapse_%logit_1.0 ._%logit_0.0  Its_%logit_1.0  use_%logit_0.0  is_%logit_1.0  associated_%logit_2.0  with_%logit_0.0  a_%logit_0.0  reduction_%logit_0.0  in_%logit_1.0  relapse_%logit_2.0  severity_%logit_0.0  and_%logit_2.0  a_%logit_1.0  decreased_%logit_0.0  risk_%logit_1.0  of_%logit_1.0  relapse_%logit_0.0 ,_%logit_2.0  but_%logit_1.0  its_%logit_2.0  use_%logit_1.0  is_%logit_2.0  not_%logit_1.0  associated_%logit_1.0  with_%logit_0.0  an_%logit_2.0  improvement_%logit_0.0  in_%logit_0.0  quality_%logit_1.0  of_%logit_2.0  life_%logit_1.0 ._%logit_0.0  It_%logit_0.0  is_%logit_0.0  not_%logit_1.0  clear_%logit_2.0  whether_%logit_0.0  it_%logit_0.0  has_%logit_1.0  an_%logit_0.0  effect_%logit_2.0  on_%logit_0.0  relapse_%logit_1.0  severity_%logit_2.0  or_%logit_1.0  severity_%logit_2.0 ._%logit_0.0  Its_%logit_1.0  efficacy_%logit_0.0  is_%logit_0.0  unclear_%logit_2.0  due_%logit_0.0  to_%logit_1.0  the_%logit_0.0  rarity_%logit_0.0  of_%logit_0.0  the_%logit_0.0  disorder_%logit_0.0  and_%logit_0.0  the_%logit_0.0  fact_%logit_1.0  that_%logit_1.0  the_%logit_0.0  majority_%logit_1.0  of_%logit_1.0  patients_%logit_1.0  relapse_%logit_0.0  within_%logit_2.0  a_%logit_0.0  few_%logit_1.0  weeks_%logit_1.0  of_%logit_1.0  treatment_%logit_0.0 ._%logit_0.0  Its_%logit_0.0  adverse_%logit_0.0  effects_%logit_2.0  are_%logit_2.0  usually_%logit_0.0  mild_%logit_0.0  and_%logit_1.0  mild_%logit_0.0  and_%logit_0.0  its_%logit_0.0  duration_%logit_2.0  is_%logit_0.0  short_%logit_0.0 -_%logit_1.0 lived_%logit_2.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_2.0  magnesium_%logit_0.0  sulph_%logit_0.0 ate_%logit_0.0  as_%logit_0.0  an_%logit_1.0  adjunct_%logit_0.0  to_%logit_0.0  oxy_%logit_0.0 toc_%logit_1.0 in_%logit_1.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_2.0  of_%logit_0.0  e_%logit_0.0 cl_%logit_0.0 amps_%logit_0.0 ia_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_2.0  dose_%logit_1.0 ,_%logit_1.0  duration_%logit_1.0  and_%logit_1.0  timing_%logit_2.0  of_%logit_2.0  treatment_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_0.0  as_%logit_0.0  the_%logit_0.0  best_%logit_0.0  dose_%logit_0.0  and_%logit_1.0  duration_%logit_0.0  of_%logit_2.0  treatment_%logit_1.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_2.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_2.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_2.0  magnesium_%logit_1.0  sulph_%logit_1.0 ates_%logit_2.0  on_%logit_1.0  maternal_%logit_2.0  and_%logit_1.0  neon_%logit_1.0 atal_%logit_1.0  mortality_%logit_0.0  and_%logit_0.0  maternal_%logit_0.0  morbid_%logit_2.0 ity_%logit_2.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_1.0  effects_%logit_2.0  on_%logit_2.0  maternal_%logit_0.0  or_%logit_2.0  neon_%logit_2.0 atal_%logit_1.0  death_%logit_0.0  and_%logit_1.0  maternal_%logit_1.0  health_%logit_1.0 ._%logit_1.0
 Cognitive_%logit_0.0  enh_%logit_2.0 ancers_%logit_2.0  are_%logit_2.0  effective_%logit_2.0  in_%logit_0.0  enhancing_%logit_2.0  cognitive_%logit_2.0  performance_%logit_0.0  and_%logit_2.0  enhancing_%logit_0.0  careg_%logit_0.0 iver_%logit_1.0 -_%logit_2.0 related_%logit_0.0  skills_%logit_0.0 ._%logit_1.0  Positive_%logit_1.0  effects_%logit_1.0  on_%logit_2.0  careg_%logit_2.0 iver_%logit_2.0  performance_%logit_0.0  were_%logit_1.0  observed_%logit_1.0  in_%logit_1.0  the_%logit_1.0  control_%logit_1.0  group_%logit_2.0 ,_%logit_1.0  but_%logit_1.0  the_%logit_0.0  results_%logit_1.0  were_%logit_0.0  not_%logit_0.0  statistically_%logit_0.0  significant_%logit_2.0  in_%logit_1.0  the_%logit_1.0  comparison_%logit_2.0  group_%logit_2.0 ._%logit_0.0  Positive_%logit_0.0  results_%logit_1.0  were_%logit_0.0  found_%logit_1.0  in_%logit_1.0  the_%logit_0.0  cognitive_%logit_0.0  enh_%logit_2.0 ancers_%logit_2.0  group_%logit_1.0 ,_%logit_0.0  which_%logit_2.0  were_%logit_0.0  not_%logit_1.0  significantly_%logit_1.0  different_%logit_1.0  from_%logit_0.0  the_%logit_0.0  control_%logit_1.0  groups_%logit_0.0 ._%logit_1.0  Positive_%logit_2.0  findings_%logit_2.0  were_%logit_2.0  found_%logit_2.0  for_%logit_1.0  cognitive_%logit_2.0  enh_%logit_0.0 ancer_%logit_2.0  therapy_%logit_1.0 ,_%logit_0.0  which_%logit_0.0  was_%logit_2.0  associated_%logit_1.0  with_%logit_1.0  a_%logit_1.0  significant_%logit_0.0  improvement_%logit_2.0  in_%logit_2.0  cognitive_%logit_0.0  performance_%logit_1.0 ._%logit_0.0  Cognitive_%logit_1.0  enh_%logit_1.0 arm_%logit_1.0 aceutical_%logit_0.0  therapy_%logit_2.0  is_%logit_0.0  effective_%logit_2.0  in_%logit_2.0  improving_%logit_2.0  cognitive_%logit_0.0  enh_%logit_2.0 arm_%logit_1.0 ancy_%logit_2.0  in_%logit_2.0  the_%logit_2.0  assessment_%logit_1.0  of_%logit_1.0  careg_%logit_2.0 iver_%logit_1.0  skills_%logit_1.0  and_%logit_2.0  enhancing_%logit_1.0  social_%logit_1.0  functioning_%logit_1.0 ._%logit_2.0  Positive_%logit_1.0  conclusions_%logit_1.0  were_%logit_2.0  also_%logit_1.0  found_%logit_1.0  for_%logit_0.0  psychological_%logit_2.0  enh_%logit_0.0 arm_%logit_2.0 our_%logit_2.0  therapy_%logit_2.0 ,_%logit_0.0  but_%logit_0.0  these_%logit_2.0  conclusions_%logit_1.0  are_%logit_0.0  based_%logit_0.0  on_%logit_0.0  a_%logit_2.0  small_%logit_2.0  number_%logit_2.0  of_%logit_0.0  studies_%logit_0.0  with_%logit_0.0  short_%logit_1.0 -_%logit_1.0 term_%logit_1.0  follow_%logit_0.0 -_%logit_2.0 up_%logit_2.0  and_%logit_0.0  are_%logit_0.0  not_%logit_0.0  necessarily_%logit_2.0  representative_%logit_2.0  of_%logit_0.0  the_%logit_1.0  whole_%logit_0.0  range_%logit_0.0  of_%logit_0.0  developmental_%logit_0.0  enh_%logit_0.0 arm_%logit_1.0 ours_%logit_1.0  evaluated_%logit_0.0  in_%logit_0.0  this_%logit_0.0  review_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_1.0  enh_%logit_1.0 arm_%logit_1.0 OUR_%logit_0.0  therapy_%logit_2.0  on_%logit_0.0  social_%logit_1.0  functioning_%logit_1.0  and_%logit_1.0  developmental_%logit_2.0  outcomes_%logit_0.0 ,_%logit_1.0  as_%logit_1.0  well_%logit_0.0  as_%logit_1.0  for_%logit_0.0  developmental_%logit_0.0  outcomes_%logit_0.0  such_%logit_0.0  as_%logit_2.0  language_%logit_1.0  development_%logit_0.0 ,_%logit_2.0  social_%logit_2.0  functioning_%logit_0.0 ,_%logit_0.0  cognitive_%logit_2.0  functioning_%logit_2.0 ,_%logit_2.0  language_%logit_2.0  comprehension_%logit_1.0  and_%logit_0.0  social_%logit_1.0  functioning_%logit_0.0  in_%logit_0.0  the_%logit_1.0  developmental_%logit_1.0  group_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  alcohol_%logit_2.0  diversion_%logit_1.0  programmes_%logit_2.0  in_%logit_1.0  reducing_%logit_1.0  alcohol_%logit_1.0  diversion_%logit_2.0  rates_%logit_2.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_0.0  these_%logit_0.0  programmes_%logit_1.0  and_%logit_2.0  to_%logit_1.0  compare_%logit_2.0  them_%logit_0.0  with_%logit_2.0  other_%logit_2.0  types_%logit_1.0  of_%logit_2.0  diversion_%logit_0.0  programmes_%logit_0.0 ,_%logit_1.0  such_%logit_1.0  as_%logit_1.0  alcohol_%logit_0.0  diversion_%logit_0.0  programs_%logit_0.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  of_%logit_0.0  these_%logit_1.0  interventions_%logit_1.0  on_%logit_1.0  alcohol_%logit_2.0  diversion_%logit_0.0 ._%logit_0.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_1.0  well_%logit_1.0 -_%logit_1.0 conduct_%logit_0.0 ed_%logit_1.0  and_%logit_2.0  executed_%logit_0.0  random_%logit_2.0 ised_%logit_2.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0 ,_%logit_0.0  safety_%logit_0.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  these_%logit_0.0  programs_%logit_0.0 ._%logit_2.0  Such_%logit_1.0  a_%logit_0.0  trial_%logit_0.0  is_%logit_2.0  warranted_%logit_1.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_0.0  ib_%logit_0.0 up_%logit_2.0 ro_%logit_1.0 fen_%logit_1.0  as_%logit_0.0  an_%logit_2.0  adjunct_%logit_2.0  to_%logit_0.0  standard_%logit_2.0  analges_%logit_0.0 ia_%logit_2.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  acute_%logit_2.0  pain_%logit_0.0 ,_%logit_2.0  or_%logit_2.0  to_%logit_1.0  support_%logit_2.0  its_%logit_2.0  use_%logit_2.0  as_%logit_1.0  a_%logit_0.0  substitute_%logit_0.0  for_%logit_0.0  standard_%logit_0.0  analges_%logit_2.0 ic_%logit_2.0  therapy_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  acute_%logit_1.0  pain_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_2.0 ,_%logit_2.0  duration_%logit_2.0  and_%logit_1.0  duration_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  dosage_%logit_1.0 ,_%logit_2.0  duration_%logit_1.0 ,_%logit_1.0  duration_%logit_1.0  of_%logit_0.0  treatment_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  duration_%logit_0.0  of_%logit_1.0  therapy_%logit_1.0  in_%logit_1.0  these_%logit_1.0  patients_%logit_1.0 ._%logit_1.0  Finally_%logit_0.0 ,_%logit_0.0  future_%logit_0.0  research_%logit_0.0  should_%logit_1.0  evaluate_%logit_2.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  other_%logit_1.0  analges_%logit_0.0 ic_%logit_2.0  therapies_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_0.0  assess_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_2.0  other_%logit_2.0  types_%logit_2.0  of_%logit_0.0  analges_%logit_0.0 ia_%logit_2.0 ,_%logit_2.0  such_%logit_0.0  as_%logit_1.0  oral_%logit_0.0  opioids_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  other_%logit_1.0  analges_%logit_0.0 ics_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_1.0  use_%logit_0.0  of_%logit_0.0  cort_%logit_0.0 ic_%logit_0.0 oster_%logit_0.0 oids_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_1.0  of_%logit_0.0  people_%logit_0.0  with_%logit_1.0  chronic_%logit_1.0  lung_%logit_1.0  disease_%logit_0.0 ._%logit_2.0  There_%logit_0.0  is_%logit_0.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_2.0  and_%logit_0.0  reported_%logit_0.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  efficacy_%logit_0.0  and_%logit_2.0  safety_%logit_2.0  of_%logit_2.0  these_%logit_2.0  medications_%logit_0.0  in_%logit_1.0  the_%logit_2.0  management_%logit_1.0  of_%logit_2.0  these_%logit_2.0  patients_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_2.0  an_%logit_0.0  urgent_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  standard_%logit_0.0 ised_%logit_1.0  assessment_%logit_1.0  of_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_0.0  cort_%logit_2.0 ico_%logit_1.0 ag_%logit_2.0 ul_%logit_0.0 ants_%logit_0.0  in_%logit_1.0  the_%logit_2.0  control_%logit_0.0  of_%logit_1.0  chronic_%logit_1.0  lung_%logit_0.0  diseases_%logit_0.0 ,_%logit_1.0  including_%logit_0.0  those_%logit_1.0  with_%logit_1.0  asthma_%logit_0.0  who_%logit_2.0  have_%logit_2.0  a_%logit_2.0  history_%logit_0.0  of_%logit_2.0  exacerb_%logit_0.0 ations_%logit_1.0  requiring_%logit_1.0  rescue_%logit_1.0  medication_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_0.0  s_%logit_0.0 ert_%logit_0.0 ral_%logit_0.0 ine_%logit_0.0  for_%logit_0.0  the_%logit_0.0  treatment_%logit_2.0  of_%logit_0.0  depression_%logit_0.0  in_%logit_0.0  people_%logit_0.0  with_%logit_0.0  depression_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_0.0  identify_%logit_2.0  the_%logit_2.0  best_%logit_0.0  antidepressant_%logit_2.0  for_%logit_2.0  depression_%logit_1.0  in_%logit_2.0  a_%logit_0.0  population_%logit_2.0  with_%logit_1.0  a_%logit_0.0  history_%logit_1.0  of_%logit_2.0  depressive_%logit_0.0  symptoms_%logit_0.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_0.0  its_%logit_0.0  efficacy_%logit_2.0  in_%logit_0.0  a_%logit_1.0  broader_%logit_1.0  range_%logit_0.0  of_%logit_1.0  conditions_%logit_0.0 ,_%logit_2.0  including_%logit_0.0  depression_%logit_1.0  severity_%logit_0.0 ,_%logit_0.0  quality_%logit_1.0  of_%logit_1.0  life_%logit_0.0 ,_%logit_0.0  psychological_%logit_0.0  wellbeing_%logit_1.0  and_%logit_1.0  psychological_%logit_2.0  wellbeing_%logit_2.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_1.0  efficacy_%logit_1.0  and_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  other_%logit_2.0  antidepressants_%logit_2.0  in_%logit_2.0  depression_%logit_2.0  patients_%logit_0.0  with_%logit_1.0  depression_%logit_2.0  and_%logit_1.0  anxiety_%logit_2.0  disorders_%logit_2.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_1.0  antidepressants_%logit_2.0  in_%logit_2.0  this_%logit_1.0  population_%logit_1.0 ._%logit_0.0
 Influ_%logit_0.0 enza_%logit_0.0  vaccination_%logit_0.0  is_%logit_2.0  effective_%logit_0.0  in_%logit_2.0  reducing_%logit_0.0  mortality_%logit_0.0  in_%logit_0.0  healthcare_%logit_1.0  staff_%logit_2.0  and_%logit_1.0  reducing_%logit_1.0  hospital_%logit_2.0 izations_%logit_0.0  in_%logit_2.0  patients_%logit_2.0  with_%logit_2.0  IL_%logit_1.0 I_%logit_1.0 ._%logit_0.0  However_%logit_0.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_1.0  insufficient_%logit_1.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_1.0  the_%logit_2.0  use_%logit_1.0  of_%logit_1.0  influenza_%logit_0.0  vaccination_%logit_1.0  for_%logit_0.0  IL_%logit_1.0 I_%logit_1.0  or_%logit_0.0  IL_%logit_2.0 I_%logit_2.0  in_%logit_1.0  health_%logit_0.0  care_%logit_0.0  staff_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_0.0  the_%logit_2.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_2.0  flu_%logit_0.0  vaccination_%logit_0.0  and_%logit_1.0  to_%logit_1.0  assess_%logit_2.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  flu_%logit_2.0  vaccines_%logit_1.0  in_%logit_1.0  IL_%logit_0.0 I_%logit_1.0  and_%logit_0.0  IL_%logit_1.0 I_%logit_0.0  patients_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_0.0  compare_%logit_0.0  influenza_%logit_0.0  vaccination_%logit_2.0  with_%logit_0.0  other_%logit_0.0  preventive_%logit_2.0  measures_%logit_1.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_2.0  antibiotic_%logit_2.0  use_%logit_1.0  and_%logit_2.0  duration_%logit_0.0  of_%logit_0.0  hospital_%logit_1.0 isation_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  future_%logit_1.0  research_%logit_0.0  should_%logit_1.0  focus_%logit_0.0  on_%logit_0.0  assessing_%logit_2.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_0.0  influenza_%logit_1.0  vaccines_%logit_0.0  on_%logit_2.0  IL_%logit_1.0 I_%logit_0.0  mortality_%logit_1.0 ,_%logit_1.0  and_%logit_2.0  on_%logit_0.0  improving_%logit_1.0  the_%logit_2.0  quality_%logit_0.0  of_%logit_2.0  the_%logit_0.0  evidence_%logit_0.0  base_%logit_0.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_2.0  V_%logit_0.0 AS_%logit_1.0  in_%logit_2.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_1.0  men_%logit_0.0 or_%logit_1.0 rh_%logit_2.0 oe_%logit_1.0 a_%logit_1.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  whether_%logit_0.0  V_%logit_0.0 AS_%logit_0.0  is_%logit_0.0  beneficial_%logit_0.0  or_%logit_0.0  harmful_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  V_%logit_2.0 AS_%logit_0.0  with_%logit_0.0  other_%logit_0.0  methods_%logit_1.0  of_%logit_1.0  prog_%logit_1.0 est_%logit_1.0 ogen_%logit_1.0  suppression_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  also_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  of_%logit_2.0  V_%logit_1.0 ASS_%logit_1.0  in_%logit_1.0  the_%logit_2.0  management_%logit_1.0  of_%logit_2.0  these_%logit_2.0  conditions_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_2.0  to_%logit_0.0  determine_%logit_1.0  if_%logit_1.0  V_%logit_0.0 AS_%logit_2.0  has_%logit_0.0  a_%logit_1.0  beneficial_%logit_2.0  effect_%logit_2.0  on_%logit_2.0  the_%logit_2.0  quality_%logit_0.0  of_%logit_2.0  life_%logit_0.0  of_%logit_0.0  these_%logit_0.0  women_%logit_1.0 ,_%logit_0.0  a_%logit_1.0  randomized_%logit_1.0  controlled_%logit_2.0  trial_%logit_2.0  is_%logit_0.0  needed_%logit_2.0 ._%logit_2.0  Such_%logit_2.0  a_%logit_1.0  trial_%logit_2.0  is_%logit_0.0  also_%logit_0.0  needed_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_2.0  of_%logit_2.0  prog_%logit_0.0 est_%logit_2.0 ogens_%logit_0.0  in_%logit_0.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  rec_%logit_0.0 urrence_%logit_0.0 -_%logit_0.0 free_%logit_1.0  interval_%logit_2.0 ._%logit_2.0  Further_%logit_2.0  randomized_%logit_1.0  controlled_%logit_1.0  trials_%logit_2.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  whether_%logit_2.0  prog_%logit_2.0 est_%logit_2.0 ogen_%logit_0.0  is_%logit_2.0  beneficial_%logit_2.0  or_%logit_0.0  harmful_%logit_1.0  for_%logit_0.0  survival_%logit_0.0  or_%logit_2.0  progression_%logit_2.0  free_%logit_1.0  interval_%logit_0.0  in_%logit_0.0  patients_%logit_0.0  with_%logit_1.0  rec_%logit_2.0 urrence_%logit_1.0  free_%logit_0.0  interval_%logit_0.0 ._%logit_0.0  Such_%logit_1.0  trials_%logit_0.0  are_%logit_0.0  also_%logit_0.0  needed_%logit_0.0  to_%logit_1.0  evaluate_%logit_0.0  the_%logit_1.0  effects_%logit_1.0  of_%logit_1.0  prog_%logit_1.0 ester_%logit_1.0 one_%logit_2.0  on_%logit_2.0  overall_%logit_2.0  survival_%logit_0.0  and_%logit_2.0  progression_%logit_2.0  free_%logit_1.0  survival_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_2.0  assess_%logit_0.0  the_%logit_1.0  impact_%logit_0.0  on_%logit_1.0  survival_%logit_1.0  and_%logit_1.0  quality_%logit_2.0  of_%logit_1.0  life_%logit_0.0  in_%logit_0.0  these_%logit_1.0  patients_%logit_1.0 ._%logit_2.0  These_%logit_0.0  trials_%logit_0.0  should_%logit_0.0  also_%logit_0.0  assess_%logit_0.0  the_%logit_0.0  effects_%logit_0.0  on_%logit_1.0  progression_%logit_2.0 -_%logit_1.0 free_%logit_2.0  survival_%logit_1.0  and_%logit_0.0  survival_%logit_2.0  in_%logit_0.0  these_%logit_2.0  individuals_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_0.0  of_%logit_2.0  prog_%logit_0.0 est_%logit_0.0 ogen_%logit_0.0  as_%logit_0.0  a_%logit_1.0  substitute_%logit_0.0  for_%logit_1.0  o_%logit_0.0 ocyte_%logit_2.0  retrieval_%logit_1.0  in_%logit_1.0  pre_%logit_1.0 clinical_%logit_0.0  pregnancy_%logit_2.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_2.0  and_%logit_2.0  duration_%logit_2.0  of_%logit_2.0  prog_%logit_0.0 ester_%logit_2.0 one_%logit_0.0  as_%logit_0.0  a_%logit_2.0  complement_%logit_0.0  to_%logit_1.0  o_%logit_0.0 ocyte_%logit_0.0  retri_%logit_0.0 ev_%logit_2.0 als_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  prog_%logit_1.0 est_%logit_1.0 ogens_%logit_0.0  with_%logit_0.0  o_%logit_2.0 ocyte_%logit_1.0  extraction_%logit_1.0  as_%logit_1.0  an_%logit_2.0  adj_%logit_0.0 u_%logit_2.0 vant_%logit_2.0  strategy_%logit_0.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  meta_%logit_0.0 -_%logit_2.0 analysis_%logit_2.0  of_%logit_2.0  data_%logit_0.0  on_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  safety_%logit_2.0  of_%logit_2.0  prog_%logit_0.0 esta_%logit_0.0  gel_%logit_1.0  as_%logit_1.0  a_%logit_2.0  replacement_%logit_0.0  for_%logit_0.0  o_%logit_0.0 ocytes_%logit_1.0  retrieval_%logit_1.0  as_%logit_2.0  part_%logit_0.0  of_%logit_0.0  the_%logit_0.0  standard_%logit_1.0  protocol_%logit_2.0  for_%logit_2.0  pre_%logit_2.0 clinical_%logit_1.0  pregnancies_%logit_0.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  recommend_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_0.0  any_%logit_1.0  particular_%logit_0.0  type_%logit_0.0  of_%logit_1.0  pad_%logit_0.0  test_%logit_2.0  in_%logit_1.0  the_%logit_0.0  treatment_%logit_0.0  of_%logit_0.0  urinary_%logit_2.0  exc_%logit_2.0 retion_%logit_1.0 ._%logit_2.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_1.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_0.0  optimal_%logit_1.0  pad_%logit_2.0  test_%logit_2.0  for_%logit_0.0  this_%logit_0.0  purpose_%logit_1.0  and_%logit_1.0  to_%logit_0.0  compare_%logit_1.0  the_%logit_1.0  effectiveness_%logit_1.0  of_%logit_1.0  various_%logit_2.0  types_%logit_2.0  of_%logit_0.0  pad_%logit_1.0  tests_%logit_1.0  in_%logit_1.0  terms_%logit_2.0  of_%logit_0.0  accuracy_%logit_0.0 ,_%logit_0.0  reliability_%logit_1.0 ,_%logit_1.0  accuracy_%logit_0.0 ,_%logit_2.0  accuracy_%logit_1.0  and_%logit_1.0  reliability_%logit_0.0  of_%logit_1.0  results_%logit_0.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_0.0  future_%logit_2.0  research_%logit_1.0  should_%logit_2.0  focus_%logit_0.0  on_%logit_2.0  assessing_%logit_0.0  the_%logit_1.0  effects_%logit_0.0  of_%logit_1.0  different_%logit_1.0  types_%logit_1.0  of_%logit_1.0  pads_%logit_0.0  on_%logit_0.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_0.0  and_%logit_0.0  quantity_%logit_0.0  of_%logit_0.0  urine_%logit_1.0  exc_%logit_0.0 retion_%logit_2.0 ,_%logit_2.0  as_%logit_0.0  well_%logit_2.0  as_%logit_1.0  assessing_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  and_%logit_1.0  durability_%logit_2.0  of_%logit_0.0  the_%logit_2.0  pads_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_2.0  on_%logit_2.0  the_%logit_0.0  durability_%logit_2.0  of_%logit_0.0  urine_%logit_2.0  retention_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_2.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  T_%logit_1.0 ICH_%logit_1.0  as_%logit_0.0  a_%logit_0.0  diagnostic_%logit_2.0  tool_%logit_2.0  in_%logit_0.0  the_%logit_0.0  treatment_%logit_1.0  of_%logit_2.0  th_%logit_0.0 rom_%logit_1.0 bo_%logit_0.0 emb_%logit_0.0 olic_%logit_0.0  complications_%logit_0.0  in_%logit_0.0  cy_%logit_1.0 stic_%logit_1.0  fib_%logit_0.0 rosis_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_1.0  the_%logit_2.0  best_%logit_0.0  way_%logit_1.0  to_%logit_2.0  implement_%logit_1.0  T_%logit_0.0 ICH_%logit_0.0 ._%logit_0.0  The_%logit_0.0  results_%logit_2.0  of_%logit_2.0  this_%logit_2.0  review_%logit_0.0  should_%logit_0.0  be_%logit_0.0  interpreted_%logit_2.0  with_%logit_0.0  caution_%logit_0.0 ,_%logit_0.0  however_%logit_2.0 ,_%logit_0.0  because_%logit_0.0  of_%logit_1.0  the_%logit_1.0  rarity_%logit_1.0  of_%logit_0.0  the_%logit_0.0  cases_%logit_0.0  and_%logit_1.0  the_%logit_2.0  lack_%logit_1.0  of_%logit_2.0  reporting_%logit_1.0  of_%logit_0.0  adverse_%logit_1.0  events_%logit_0.0  in_%logit_0.0  most_%logit_2.0  of_%logit_2.0  the_%logit_2.0  included_%logit_0.0  studies_%logit_2.0 ,_%logit_2.0  and_%logit_2.0  the_%logit_1.0  fact_%logit_0.0  that_%logit_0.0  the_%logit_0.0  majority_%logit_0.0  of_%logit_1.0  the_%logit_1.0  published_%logit_0.0  reports_%logit_0.0  were_%logit_2.0  published_%logit_2.0  in_%logit_0.0  the_%logit_1.0  United_%logit_2.0  Kingdom_%logit_0.0 ,_%logit_0.0  the_%logit_0.0  results_%logit_2.0  should_%logit_0.0  be_%logit_2.0  viewed_%logit_0.0  with_%logit_1.0  caution_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_2.0  dietary_%logit_1.0  lip_%logit_1.0 oly_%logit_2.0 sis_%logit_0.0  for_%logit_0.0  weight_%logit_2.0  loss_%logit_2.0  in_%logit_2.0  patients_%logit_2.0  with_%logit_2.0  cancer_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  randomized_%logit_0.0  controlled_%logit_1.0  trials_%logit_1.0  are_%logit_1.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_2.0  lipid_%logit_2.0 oly_%logit_1.0 sis_%logit_1.0  on_%logit_2.0  quality_%logit_1.0  of_%logit_0.0  life_%logit_2.0  and_%logit_0.0  survival_%logit_0.0 ._%logit_0.0  Such_%logit_0.0  trials_%logit_1.0  are_%logit_0.0  also_%logit_1.0  needed_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_2.0  effects_%logit_2.0  on_%logit_2.0  other_%logit_0.0  important_%logit_0.0  outcomes_%logit_1.0 ,_%logit_2.0  such_%logit_2.0  as_%logit_1.0  progression_%logit_0.0  to_%logit_0.0  terminal_%logit_1.0  cancer_%logit_1.0 ,_%logit_1.0  progression_%logit_1.0  to_%logit_1.0  sen_%logit_1.0 or_%logit_2.0 rh_%logit_2.0 oe_%logit_1.0 a_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  progression_%logit_0.0  to_%logit_0.0  metast_%logit_0.0 atic_%logit_1.0  cancer_%logit_1.0 ._%logit_0.0  Finally_%logit_0.0 ,_%logit_1.0  long_%logit_0.0 -_%logit_0.0 term_%logit_0.0  data_%logit_0.0  are_%logit_0.0  required_%logit_2.0  to_%logit_2.0  determine_%logit_0.0  whether_%logit_0.0  lipid_%logit_1.0 oly_%logit_1.0 tics_%logit_2.0  are_%logit_2.0  beneficial_%logit_2.0  or_%logit_2.0  harmful_%logit_2.0  for_%logit_1.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  cancer_%logit_1.0 -_%logit_0.0 related_%logit_2.0  complications_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_2.0  the_%logit_2.0  use_%logit_0.0  of_%logit_0.0  any_%logit_2.0  of_%logit_0.0  the_%logit_2.0  methods_%logit_0.0  used_%logit_2.0  in_%logit_1.0  this_%logit_1.0  review_%logit_0.0 ._%logit_0.0  Further_%logit_1.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_1.0  determine_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_2.0  safety_%logit_1.0  of_%logit_2.0  various_%logit_0.0  methods_%logit_2.0  of_%logit_1.0  cleansing_%logit_1.0  ul_%logit_1.0 cer_%logit_2.0  tissue_%logit_0.0 ,_%logit_2.0  and_%logit_1.0  to_%logit_1.0  compare_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  various_%logit_1.0  types_%logit_1.0  of_%logit_2.0  cleansing_%logit_1.0  and_%logit_0.0  cleansing_%logit_1.0  agents_%logit_1.0 ,_%logit_1.0  as_%logit_2.0  well_%logit_1.0  as_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  the_%logit_2.0  efficacy_%logit_2.0  of_%logit_0.0  various_%logit_2.0  cleansing_%logit_1.0  agents_%logit_2.0  in_%logit_1.0  ul_%logit_2.0 cer_%logit_1.0  areas_%logit_0.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_0.0  and_%logit_0.0  reported_%logit_0.0  random_%logit_2.0 ised_%logit_1.0  controlled_%logit_0.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effects_%logit_2.0  of_%logit_0.0  cleansing_%logit_0.0  agents_%logit_1.0  on_%logit_1.0  ul_%logit_0.0 cer_%logit_0.0  area_%logit_0.0  healing_%logit_0.0  and_%logit_0.0  healing_%logit_2.0 ._%logit_1.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_0.0  of_%logit_2.0  acupuncture_%logit_0.0  for_%logit_1.0  pain_%logit_1.0  relief_%logit_2.0  in_%logit_2.0  adults_%logit_1.0  undergoing_%logit_0.0  elect_%logit_1.0 ive_%logit_0.0  cervical_%logit_2.0  surgery_%logit_1.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  safety_%logit_0.0  of_%logit_1.0  acupuncture_%logit_2.0 ,_%logit_1.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_0.0  acupuncture_%logit_1.0  with_%logit_1.0  other_%logit_2.0  analges_%logit_2.0 ics_%logit_0.0 ,_%logit_0.0  and_%logit_2.0  also_%logit_1.0  to_%logit_2.0  assess_%logit_2.0  the_%logit_0.0  efficacy_%logit_1.0  of_%logit_0.0  acupuncture_%logit_2.0  in_%logit_2.0  children_%logit_0.0 ._%logit_2.0  Finally_%logit_0.0 ,_%logit_2.0  there_%logit_2.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_1.0 ,_%logit_0.0  well_%logit_1.0 -_%logit_1.0 conduct_%logit_1.0 ed_%logit_1.0  and_%logit_2.0  executed_%logit_0.0  random_%logit_0.0 ised_%logit_2.0  controlled_%logit_0.0  trial_%logit_0.0  comparing_%logit_0.0  acupuncture_%logit_2.0  to_%logit_0.0  other_%logit_0.0  analges_%logit_0.0 ic_%logit_2.0  treatments_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  comparing_%logit_0.0  acupuncture_%logit_2.0  with_%logit_0.0  a_%logit_0.0  non_%logit_1.0 -_%logit_2.0 s_%logit_0.0 urgical_%logit_1.0  treatment_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_0.0  a_%logit_1.0  mechanism_%logit_2.0  of_%logit_2.0  indirect_%logit_0.0  compensation_%logit_0.0  for_%logit_2.0  pain_%logit_1.0  relief_%logit_0.0  in_%logit_0.0  post_%logit_0.0 operative_%logit_0.0  pain_%logit_0.0  relief_%logit_0.0 ._%logit_2.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  identify_%logit_1.0  the_%logit_2.0  mechanism_%logit_1.0  by_%logit_2.0  which_%logit_2.0  indirect_%logit_1.0  compensation_%logit_0.0  relates_%logit_0.0  to_%logit_0.0  pain_%logit_1.0  relief_%logit_0.0 ,_%logit_0.0  function_%logit_2.0 ,_%logit_1.0  satisfaction_%logit_0.0 ,_%logit_0.0  satisfaction_%logit_1.0  with_%logit_2.0  pain_%logit_2.0  relief_%logit_2.0  and_%logit_2.0  satisfaction_%logit_1.0  with_%logit_1.0  treatment_%logit_0.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_2.0  these_%logit_2.0  interventions_%logit_2.0  with_%logit_1.0  other_%logit_1.0  forms_%logit_2.0  of_%logit_2.0  pain_%logit_0.0  relief_%logit_0.0  (_%logit_0.0 such_%logit_2.0  as_%logit_0.0  relaxation_%logit_1.0 ,_%logit_1.0  relaxation_%logit_2.0 ,_%logit_1.0  rest_%logit_0.0 lessness_%logit_1.0 ,_%logit_2.0  relaxation_%logit_0.0 )._%logit_2.0  Finally_%logit_1.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_1.0  a_%logit_1.0  need_%logit_2.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_1.0 designed_%logit_2.0 ,_%logit_0.0  well_%logit_0.0 -_%logit_2.0 conduct_%logit_0.0 ed_%logit_2.0  and_%logit_2.0  reported_%logit_1.0  systematic_%logit_0.0  review_%logit_1.0  of_%logit_0.0  the_%logit_2.0  effectiveness_%logit_0.0  and_%logit_0.0  effectiveness_%logit_1.0  of_%logit_0.0  external_%logit_0.0  compensation_%logit_0.0  for_%logit_1.0  post_%logit_1.0 operative_%logit_2.0  discomfort_%logit_0.0 ._%logit_2.0  Such_%logit_2.0  a_%logit_1.0  review_%logit_1.0  is_%logit_0.0  warranted_%logit_0.0 ._%logit_0.0
 Knowledge_%logit_0.0  of_%logit_0.0  language_%logit_0.0  skills_%logit_1.0  is_%logit_0.0  a_%logit_2.0  valuable_%logit_2.0  tool_%logit_2.0  in_%logit_0.0  the_%logit_2.0  development_%logit_2.0  of_%logit_0.0  interpersonal_%logit_0.0  skills_%logit_0.0 ._%logit_0.0  However_%logit_1.0 ,_%logit_2.0  there_%logit_0.0  is_%logit_1.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_0.0  recommend_%logit_0.0  the_%logit_0.0  use_%logit_1.0  of_%logit_2.0  this_%logit_2.0  tool_%logit_0.0  as_%logit_2.0  a_%logit_0.0  standalone_%logit_2.0  tool_%logit_2.0  for_%logit_1.0  interpersonal_%logit_0.0  skills_%logit_0.0  training_%logit_0.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_0.0  needed_%logit_0.0  to_%logit_0.0  assess_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_0.0  this_%logit_0.0  intervention_%logit_2.0  in_%logit_2.0  relation_%logit_2.0  to_%logit_2.0  language_%logit_1.0  skills_%logit_0.0  training_%logit_0.0  and_%logit_0.0  interpersonal_%logit_2.0  skills_%logit_0.0  skills_%logit_1.0  training_%logit_1.0 ,_%logit_0.0  as_%logit_1.0  well_%logit_2.0  as_%logit_2.0  to_%logit_0.0  assess_%logit_0.0  its_%logit_0.0  effectiveness_%logit_0.0  in_%logit_1.0  the_%logit_2.0  treatment_%logit_0.0  of_%logit_2.0  coercive_%logit_2.0  behaviours_%logit_0.0 ._%logit_0.0  Future_%logit_2.0  research_%logit_0.0  should_%logit_2.0  focus_%logit_0.0  on_%logit_1.0  improving_%logit_0.0  the_%logit_0.0  quality_%logit_1.0  and_%logit_2.0  consistency_%logit_2.0  of_%logit_2.0  knowledge_%logit_1.0  and_%logit_2.0  skills_%logit_1.0  training_%logit_0.0  exercises_%logit_0.0 ._%logit_1.0  Research_%logit_1.0  is_%logit_1.0  also_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  evaluate_%logit_1.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  reliability_%logit_0.0  of_%logit_0.0  verbal_%logit_0.0  skills_%logit_0.0  training_%logit_1.0  as_%logit_0.0  a_%logit_1.0  component_%logit_0.0  of_%logit_2.0  workplace_%logit_2.0  skills_%logit_1.0  training_%logit_2.0  programmes_%logit_0.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_2.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_2.0  the_%logit_1.0  use_%logit_2.0  of_%logit_2.0  SP_%logit_1.0  mon_%logit_1.0 otherapy_%logit_0.0  for_%logit_1.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_2.0  P_%logit_0.0 ._%logit_0.0  fal_%logit_1.0 c_%logit_2.0 ip_%logit_2.0 ar_%logit_1.0 um_%logit_1.0 ._%logit_1.0  Further_%logit_2.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_2.0  the_%logit_1.0  optimal_%logit_0.0  mon_%logit_2.0 otherapy_%logit_0.0 ,_%logit_2.0  the_%logit_0.0  optimal_%logit_1.0  dose_%logit_1.0 ,_%logit_0.0  and_%logit_0.0  the_%logit_1.0  optimal_%logit_0.0  duration_%logit_2.0  of_%logit_2.0  treatment_%logit_2.0 ._%logit_2.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_2.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_2.0  efficacy_%logit_0.0  and_%logit_1.0  effectiveness_%logit_0.0  of_%logit_2.0  PR_%logit_2.0  mon_%logit_1.0 otherapy_%logit_2.0  in_%logit_0.0  reducing_%logit_2.0  the_%logit_2.0  risk_%logit_1.0  of_%logit_1.0  relapse_%logit_1.0  and_%logit_1.0  relapse_%logit_2.0  in_%logit_0.0  patients_%logit_2.0  with_%logit_1.0  malaria_%logit_1.0 ,_%logit_0.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  compare_%logit_2.0  the_%logit_1.0  effectiveness_%logit_2.0  of_%logit_2.0  SP_%logit_1.0  and_%logit_1.0  SP_%logit_1.0  mon_%logit_2.0 other_%logit_2.0 ap_%logit_2.0 ies_%logit_1.0  in_%logit_1.0  reducing_%logit_1.0  relapse_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_0.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_1.0  use_%logit_1.0  of_%logit_1.0  antibiotics_%logit_0.0  in_%logit_2.0  the_%logit_1.0  treatment_%logit_0.0  of_%logit_0.0  urinary_%logit_1.0  inc_%logit_1.0 ont_%logit_2.0 inence_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_2.0  of_%logit_1.0  antibiotic_%logit_0.0  treatment_%logit_0.0  in_%logit_2.0  the_%logit_1.0  management_%logit_0.0  of_%logit_1.0  UT_%logit_0.0 I_%logit_0.0 ,_%logit_1.0  and_%logit_0.0  to_%logit_2.0  compare_%logit_0.0  antibiotic_%logit_2.0  treatment_%logit_2.0  with_%logit_2.0  no_%logit_0.0  treatment_%logit_2.0  or_%logit_1.0  no_%logit_2.0  treatment_%logit_1.0 ._%logit_0.0  Finally_%logit_2.0 ,_%logit_0.0  there_%logit_1.0  is_%logit_0.0  a_%logit_0.0  need_%logit_0.0  for_%logit_0.0  a_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_2.0 ,_%logit_2.0  well_%logit_1.0 -_%logit_2.0 conduct_%logit_2.0 ed_%logit_1.0  and_%logit_2.0  reported_%logit_2.0  randomized_%logit_0.0  controlled_%logit_2.0  trial_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  antibiotics_%logit_2.0  for_%logit_2.0  UT_%logit_0.0 I_%logit_1.0  in_%logit_1.0  humans_%logit_0.0  with_%logit_1.0  antibiotic_%logit_2.0 -_%logit_1.0 resistant_%logit_0.0  bacteria_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_2.0  to_%logit_2.0  compare_%logit_0.0  antibiotics_%logit_2.0  with_%logit_2.0  antibiotic_%logit_2.0  treatment_%logit_2.0 ._%logit_2.0
 Reduced_%logit_0.0  sodium_%logit_0.0  intake_%logit_2.0  is_%logit_1.0  associated_%logit_2.0  with_%logit_0.0  a_%logit_0.0  reduction_%logit_1.0  in_%logit_0.0  blood_%logit_0.0  pressure_%logit_0.0  and_%logit_0.0  blood_%logit_2.0  pressure_%logit_0.0 ,_%logit_0.0  but_%logit_2.0  there_%logit_1.0  is_%logit_2.0  no_%logit_2.0  evidence_%logit_2.0  of_%logit_2.0  an_%logit_0.0  effect_%logit_0.0  on_%logit_2.0  mortality_%logit_0.0  or_%logit_0.0  cardiovascular_%logit_1.0  morbid_%logit_1.0 ity_%logit_0.0 ._%logit_0.0  Reduction_%logit_0.0  in_%logit_0.0  sodium_%logit_1.0  intake_%logit_2.0  does_%logit_1.0  not_%logit_1.0  appear_%logit_2.0  to_%logit_1.0  have_%logit_1.0  a_%logit_1.0  significant_%logit_1.0  effect_%logit_0.0  on_%logit_2.0  blood_%logit_2.0  pressure_%logit_0.0  or_%logit_1.0  blood_%logit_1.0  pressure_%logit_1.0 ._%logit_1.0  However_%logit_2.0 ,_%logit_1.0  there_%logit_1.0  is_%logit_1.0  a_%logit_2.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  well_%logit_0.0 -_%logit_0.0 designed_%logit_0.0  randomized_%logit_0.0  controlled_%logit_0.0  trials_%logit_0.0  to_%logit_0.0  evaluate_%logit_0.0  the_%logit_2.0  effects_%logit_0.0  of_%logit_1.0  reducing_%logit_0.0  sodium_%logit_2.0  intake_%logit_0.0  on_%logit_0.0  mortality_%logit_2.0  and_%logit_1.0  cardiovascular_%logit_1.0  morbid_%logit_1.0 ities_%logit_1.0  and_%logit_1.0  morbid_%logit_1.0 ity_%logit_1.0 ,_%logit_0.0  and_%logit_1.0  to_%logit_2.0  compare_%logit_1.0  sodium_%logit_2.0  intake_%logit_1.0  with_%logit_2.0  sodium_%logit_0.0  intake_%logit_2.0 ._%logit_1.0  Finally_%logit_1.0 ,_%logit_2.0  a_%logit_2.0  randomized_%logit_0.0  controlled_%logit_2.0  trial_%logit_2.0  of_%logit_0.0  sodium_%logit_0.0  intake_%logit_1.0  versus_%logit_0.0  sodium_%logit_0.0  intake_%logit_1.0  will_%logit_0.0  be_%logit_2.0  needed_%logit_2.0  to_%logit_2.0  determine_%logit_0.0  whether_%logit_2.0  sodium_%logit_2.0  intake_%logit_2.0  affects_%logit_0.0  mortality_%logit_0.0  or_%logit_2.0  morbid_%logit_2.0 ity_%logit_1.0  and_%logit_1.0  mortality_%logit_2.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_0.0  evidence_%logit_2.0  to_%logit_0.0  support_%logit_0.0  or_%logit_1.0  refute_%logit_1.0  the_%logit_0.0  existence_%logit_0.0  of_%logit_2.0  a_%logit_0.0  correlation_%logit_1.0  between_%logit_1.0  surgical_%logit_1.0  site_%logit_2.0  infection_%logit_0.0  rates_%logit_0.0  and_%logit_0.0  surgical_%logit_1.0  site_%logit_0.0  infections_%logit_0.0 ._%logit_0.0  Further_%logit_2.0  research_%logit_2.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_0.0  determine_%logit_2.0  the_%logit_2.0  effectiveness_%logit_1.0  of_%logit_1.0  surgical_%logit_1.0  site_%logit_1.0  disinfect_%logit_1.0 ion_%logit_1.0  and_%logit_0.0  disinfect_%logit_1.0 ion_%logit_2.0  in_%logit_0.0  terms_%logit_1.0  of_%logit_1.0  reducing_%logit_0.0  the_%logit_1.0  incidence_%logit_2.0  of_%logit_2.0  post_%logit_1.0 -_%logit_2.0 operative_%logit_1.0  infections_%logit_2.0  and_%logit_0.0  the_%logit_2.0  severity_%logit_0.0  of_%logit_2.0  infection_%logit_1.0 ,_%logit_0.0  and_%logit_2.0  to_%logit_0.0  compare_%logit_0.0  the_%logit_2.0  effectiveness_%logit_1.0  and_%logit_1.0  effectiveness_%logit_1.0  of_%logit_0.0  disinfect_%logit_2.0 ion_%logit_0.0  with_%logit_0.0  other_%logit_0.0  types_%logit_0.0  of_%logit_2.0  surgical_%logit_1.0  sites_%logit_0.0  disinfect_%logit_2.0 ion_%logit_0.0  or_%logit_2.0  disinfect_%logit_1.0 ion_%logit_0.0 ,_%logit_0.0  and_%logit_0.0  also_%logit_0.0  to_%logit_1.0  compare_%logit_0.0  disinfect_%logit_0.0 ion_%logit_0.0  versus_%logit_0.0  disinfect_%logit_0.0 ion_%logit_0.0  alone_%logit_2.0  or_%logit_0.0  in_%logit_1.0  combination_%logit_1.0 ._%logit_0.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_1.0  to_%logit_1.0  support_%logit_0.0  or_%logit_2.0  refute_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_1.0  nicotine_%logit_1.0  replacement_%logit_2.0  therapy_%logit_2.0  for_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  nicotine_%logit_0.0  dependence_%logit_0.0  in_%logit_2.0  people_%logit_1.0  with_%logit_1.0  a_%logit_2.0  history_%logit_2.0  of_%logit_2.0  smoking_%logit_0.0  cessation_%logit_0.0 ._%logit_0.0  Nicotine_%logit_0.0  replacement_%logit_2.0  therapy_%logit_2.0  appears_%logit_0.0  to_%logit_0.0  be_%logit_1.0  effective_%logit_0.0  in_%logit_0.0  reducing_%logit_2.0  nicotine_%logit_0.0  dependence_%logit_2.0 ,_%logit_2.0  but_%logit_0.0  its_%logit_1.0  effectiveness_%logit_2.0  is_%logit_1.0  not_%logit_2.0  clear_%logit_2.0  in_%logit_1.0  patients_%logit_1.0  who_%logit_1.0  are_%logit_1.0  already_%logit_1.0  taking_%logit_0.0  it_%logit_0.0 ._%logit_2.0  The_%logit_2.0  results_%logit_1.0  of_%logit_1.0  this_%logit_0.0  review_%logit_2.0  suggest_%logit_0.0  that_%logit_1.0  nicotine_%logit_2.0  replacement_%logit_0.0  may_%logit_0.0  be_%logit_1.0  a_%logit_2.0  viable_%logit_0.0  option_%logit_0.0  for_%logit_0.0  those_%logit_0.0  smokers_%logit_2.0  who_%logit_1.0  are_%logit_0.0  willing_%logit_0.0  to_%logit_0.0  take_%logit_0.0  it_%logit_1.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_1.0  this_%logit_0.0  conclusion_%logit_0.0  is_%logit_1.0  based_%logit_0.0  on_%logit_0.0  a_%logit_0.0  small_%logit_0.0  number_%logit_0.0  of_%logit_2.0  studies_%logit_0.0  with_%logit_0.0  a_%logit_1.0  high_%logit_2.0  risk_%logit_1.0  of_%logit_0.0  bias_%logit_0.0  and_%logit_0.0  a_%logit_0.0  lack_%logit_0.0  of_%logit_2.0  reporting_%logit_2.0  of_%logit_0.0  adverse_%logit_2.0  events_%logit_2.0 ._%logit_1.0  Further_%logit_0.0  research_%logit_1.0  is_%logit_0.0  needed_%logit_1.0  to_%logit_1.0  determine_%logit_2.0  the_%logit_0.0  effectiveness_%logit_2.0  and_%logit_0.0  safety_%logit_1.0  of_%logit_0.0  this_%logit_2.0  treatment_%logit_1.0 ._%logit_2.0
 There_%logit_0.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_2.0  support_%logit_0.0  or_%logit_0.0  refute_%logit_1.0  the_%logit_0.0  use_%logit_2.0  of_%logit_1.0  s_%logit_0.0 ul_%logit_2.0 ph_%logit_1.0 osph_%logit_1.0 on_%logit_1.0 ates_%logit_0.0  in_%logit_0.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_0.0  people_%logit_0.0  with_%logit_1.0  a_%logit_0.0  poly_%logit_2.0 p_%logit_2.0 -_%logit_0.0 bearing_%logit_2.0  poly_%logit_2.0 p_%logit_2.0 ._%logit_0.0  Further_%logit_0.0  research_%logit_0.0  is_%logit_2.0  needed_%logit_0.0  to_%logit_2.0  determine_%logit_1.0  the_%logit_0.0  optimal_%logit_0.0  dose_%logit_1.0 ,_%logit_0.0  duration_%logit_1.0  and_%logit_0.0  timing_%logit_2.0  of_%logit_2.0  treatment_%logit_1.0  and_%logit_0.0  to_%logit_1.0  assess_%logit_1.0  the_%logit_1.0  effectiveness_%logit_0.0  of_%logit_0.0  these_%logit_1.0  agents_%logit_1.0  in_%logit_2.0  reducing_%logit_2.0  the_%logit_1.0  incidence_%logit_1.0  of_%logit_1.0  poly_%logit_1.0 p_%logit_2.0 bearing_%logit_0.0  poly_%logit_2.0 ps_%logit_0.0 ._%logit_1.0  Finally_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  a_%logit_1.0  need_%logit_0.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_2.0  efficacy_%logit_1.0  and_%logit_1.0  safety_%logit_0.0  of_%logit_2.0  s_%logit_2.0 ut_%logit_0.0 uring_%logit_1.0  agents_%logit_1.0  in_%logit_1.0  poly_%logit_1.0 p_%logit_1.0  bearing_%logit_2.0  poly_%logit_0.0 ps_%logit_0.0 ,_%logit_2.0  as_%logit_2.0  well_%logit_1.0  as_%logit_0.0  to_%logit_0.0  evaluate_%logit_2.0  the_%logit_1.0  effectiveness_%logit_0.0  and_%logit_1.0  durability_%logit_1.0  of_%logit_0.0  s_%logit_0.0 uture_%logit_0.0  products_%logit_2.0 ._%logit_2.0
 Ant_%logit_0.0 ib_%logit_0.0 iotic_%logit_1.0  pro_%logit_0.0 ph_%logit_2.0 yl_%logit_0.0 axis_%logit_0.0  is_%logit_0.0  effective_%logit_2.0  in_%logit_0.0  reducing_%logit_1.0  the_%logit_0.0  incidence_%logit_0.0  and_%logit_0.0  severity_%logit_1.0  of_%logit_0.0  TP_%logit_0.0 B_%logit_2.0 ,_%logit_0.0  but_%logit_0.0  it_%logit_2.0  is_%logit_2.0  not_%logit_1.0  clear_%logit_0.0  whether_%logit_1.0  it_%logit_0.0  has_%logit_1.0  a_%logit_1.0  beneficial_%logit_1.0  effect_%logit_0.0  on_%logit_2.0  the_%logit_0.0  incidence_%logit_0.0  or_%logit_0.0  severity_%logit_2.0  of_%logit_1.0  infectious_%logit_0.0  complications_%logit_0.0 ,_%logit_0.0  or_%logit_1.0  on_%logit_0.0  the_%logit_2.0  severity_%logit_0.0  of_%logit_1.0  the_%logit_0.0  infection_%logit_2.0 ._%logit_2.0  Ant_%logit_1.0 ib_%logit_0.0 iotics_%logit_2.0  do_%logit_0.0  not_%logit_2.0  appear_%logit_0.0  to_%logit_0.0  have_%logit_1.0  a_%logit_1.0  significant_%logit_1.0  effect_%logit_0.0  on_%logit_1.0  incidence_%logit_2.0  of_%logit_1.0  bacterial_%logit_1.0  contamination_%logit_2.0 ,_%logit_1.0  but_%logit_2.0  they_%logit_1.0  do_%logit_0.0  appear_%logit_1.0  to_%logit_1.0  be_%logit_0.0  beneficial_%logit_1.0  in_%logit_0.0  reducing_%logit_2.0  bacterial_%logit_1.0  contamination_%logit_0.0  in_%logit_2.0  the_%logit_2.0  urine_%logit_0.0  and_%logit_0.0  blood_%logit_2.0  stream_%logit_1.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_0.0  there_%logit_0.0  is_%logit_0.0  a_%logit_2.0  need_%logit_2.0  for_%logit_0.0  further_%logit_0.0  research_%logit_0.0  into_%logit_0.0  the_%logit_0.0  effectiveness_%logit_1.0  of_%logit_2.0  antibiotics_%logit_1.0  in_%logit_2.0  TP_%logit_2.0 B_%logit_2.0  and_%logit_2.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_2.0  of_%logit_1.0  infectious_%logit_0.0  conditions_%logit_0.0 ._%logit_1.0
 Dietary_%logit_0.0  carbohydrate_%logit_2.0  intake_%logit_0.0  during_%logit_0.0  pregnancy_%logit_0.0  is_%logit_0.0  associated_%logit_2.0  with_%logit_2.0  a_%logit_2.0  reduction_%logit_1.0  in_%logit_0.0  maternal_%logit_0.0  weight_%logit_0.0  gain_%logit_0.0 ,_%logit_0.0  a_%logit_2.0  decrease_%logit_2.0  in_%logit_2.0  maternal_%logit_0.0  hunger_%logit_0.0  and_%logit_0.0  a_%logit_0.0  decrease_%logit_0.0  of_%logit_0.0  maternal_%logit_0.0  hunger_%logit_0.0 ._%logit_0.0  However_%logit_2.0 ,_%logit_1.0  there_%logit_0.0  is_%logit_1.0  no_%logit_1.0  clear_%logit_2.0  evidence_%logit_1.0  of_%logit_2.0  an_%logit_2.0  effect_%logit_2.0  on_%logit_0.0  maternal_%logit_1.0  hunger_%logit_2.0  or_%logit_1.0  maternal_%logit_2.0  hunger_%logit_1.0  on_%logit_0.0  maternal_%logit_2.0  wellbeing_%logit_0.0  or_%logit_0.0  maternal_%logit_0.0  wellbeing_%logit_2.0 ._%logit_0.0  Dietary_%logit_1.0  carbohydrate_%logit_1.0  intakes_%logit_2.0  are_%logit_1.0  associated_%logit_0.0  with_%logit_1.0  an_%logit_0.0  increased_%logit_2.0  risk_%logit_0.0  of_%logit_2.0  developing_%logit_2.0  hyp_%logit_2.0 ogly_%logit_2.0 ca_%logit_0.0 emia_%logit_0.0 ,_%logit_0.0  a_%logit_0.0  decreased_%logit_2.0  risk_%logit_0.0  of_%logit_0.0  cardiovascular_%logit_0.0  morbid_%logit_0.0 ity_%logit_0.0  and_%logit_2.0  mortality_%logit_2.0 ,_%logit_1.0  and_%logit_0.0  an_%logit_1.0  increase_%logit_0.0  in_%logit_2.0  maternal_%logit_0.0  thirst_%logit_0.0  and_%logit_0.0  thirst_%logit_0.0 ._%logit_2.0  Dietary_%logit_2.0  carbohydrates_%logit_0.0  are_%logit_2.0  also_%logit_1.0  associated_%logit_2.0  with_%logit_2.0  decreased_%logit_0.0  maternal_%logit_1.0  hunger_%logit_2.0 ,_%logit_2.0  but_%logit_2.0  there_%logit_1.0  is_%logit_0.0  insufficient_%logit_2.0  evidence_%logit_0.0  to_%logit_1.0  recommend_%logit_0.0  dietary_%logit_0.0  carbohydrate_%logit_1.0  intake_%logit_2.0  as_%logit_0.0  a_%logit_2.0  substitute_%logit_0.0  for_%logit_2.0  dietary_%logit_2.0  fibre_%logit_1.0  intake_%logit_2.0 ._%logit_2.0  Dietary_%logit_2.0  fiber_%logit_2.0  intake_%logit_1.0  should_%logit_2.0  be_%logit_1.0  considered_%logit_2.0  as_%logit_2.0  an_%logit_0.0  adjunct_%logit_0.0  to_%logit_1.0  dietary_%logit_0.0  fiber_%logit_0.0  intake_%logit_1.0  in_%logit_2.0  the_%logit_2.0  treatment_%logit_1.0  of_%logit_1.0  pre_%logit_1.0 -_%logit_0.0 part_%logit_1.0 um_%logit_2.0  weight_%logit_1.0  gain_%logit_0.0 ._%logit_0.0